invention other than ones featuring *E. coli*. The Office Action states that "no description is provided, for example, for tRNA genes corresponding to rarely used codons in plant cells or protozoa, two large classes of cell types embraced by the claims (i.e., rarely used codons)." The Office Action also states that the prior art does not appear to provide teachings as to which of the many known tRNA genes correspond to "rarely used" codons for the many different cell types encompassed by the claims, and that there is no evidence of record that rare codon patterns have been established for a sufficient number of cell types for one of skill in the art to be able to envision a sufficient number of specific embodiments of the invention to describe the very broadly claimed genus. Finally, with respect to Written Description, the Office Action states that there remains no evidence of record to indicate that a sufficient number of tRNA genes obtained from different cell types corresponding to rarely used codons of different cell types were known in the prior art for one of skill in the art to envision a sufficient number of embodiments of the claimed vectors and host cells to describe the broad genus of host cells and vectors encompassed by the claims. Applicants respectfully disagree.

Under the law, in order to satisfy the written description requirement, a patent specification must describe the claimed invention in sufficient detail that one skilled in the art can reasonably conclude that the inventor had possession of the claimed invention. Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563; M.P.E.P. §2163. Further, under both the written description and enablement requirements, one need not describe in detail that which is well known in the art. M.P.E.P §2163, citing Hybritech v. Monoclonal Antibodies, 802 F.2d 1367, 1384. The Office Action states that "the critical elements of applicant's invention are the tRNA genes corresponding to rarely used codons on the claimed vectors which are determined by the combination of host cell type (i.e., rarely used codons), the corresponding tRNA genes and the protein to be expressed." Applicants submit that patterns of codon usage were well known to those skilled in the art at the time of filing. For example, Nakamura et al., 1996, Nucleic Acids Res. 24: 214-215 (Exhibit A) provides codon usage tabulated from the GenBank international DNA sequence databases for 4,805 species. Applicants submit that these species include prokaryotes, protozoa and fungi, and a wide variety of higher eukaryotes, including animals and plants. The codon usage tabulation of Nakamura necessarily details low, as well as high codon usage in each of the thousands of species examined.

_

Further, Zhang et al., 1991, Gene 105: 61-72 (Exhibit B) details low usage codons in species as diverse as E. coli (prokaryotic), yeast (S. cerevisiae; protozoan), Drosophila and eleven species of primates. The paper describes the unique combination of least-used codons for the species examined.

In addition, Saier (1995, FEBS Lett. 362: 1-4; Exhibit C) describes rare codon usage in species including *Rhodobacter capsulatus*, *R. spheroides*, *Clostridium acetobutylicum*, *Streptomyces coelicolor* and *E. coli*. Saier relates the rare codon usage to the regulation of metabolically sensitive genes.

In view of these sources of information, particularly in view of the comprehensive nature of the Nakamura database before the filing of the subject application, Applicants submit that a sufficient number of rare codon usage patterns have been established in the prior art for a sufficient number of cell types for one of skill in the art to readily envision a sufficient number of specific embodiments of rare codon usage patterns to describe the claimed genus.

With regard to tRNA genes, Applicants submit that a wide variety of tRNA genes was also known in the art at the time of filing. For example, as early as 1984, Sprinzl & Gauss described a compilation of 353 sequences of tRNA genes including cellular and mitochondrial tRNAs from bacteria and phage, plants, yeasts and fungi, insects, amphibians and mammals, including rats, mice, cows and humans (Nucleic Acids Res. 12 Suppl.: r59-131; Exhibit D). Further, there was available on the World Wide Web as of the end of 1998 (before filing), a compilation of tRNA sequences and genes including 3279 sequences. This number is taken from documentation on the current WWW compilation at www.uni-bayreuth.de/departments/biochemie/trna (see Exhibit E). The thousands of tRNA genes described include those for rarely used tRNAs. Additional rare tRNAs are described in, for example: Kawakami et al., 1993, Genetics 135: 309-320 (Exhibit F), which describes a rare Arg-tRNA-CCU in *Saccharomyces cerevisiae*; and Clouthier et al., 1998, J. Bacteriol. 180: 840-845 (Exhibit G), which describes the rare Arg-tRNA-AGA in *Salmonella enteritidis*. Applicants therefore submit that there was known in the art, at the time of filing, a large number of tRNA genes, including those encoding rare tRNAs, from a broad cross section of species.

The Office Action states that the prior art does not appear to provide teachings as to which of the many known tRNA genes correspond to "rarely used" codons for the many different cell types encompassed by the claimed invention. Applicants submit that given the extensive data on codon usage available in the art (e.g., Exhibits A-C), one of skill in the art would know if a given tRNA gene, e.g., one described in any of Exhibits D, F or G, corresponds to a rarely used codon.

In view of the above, and given the description provided in the specification, Applicants submit that the invention of claims 1-16 and 18-44 is described in sufficient detail to enable one of skill in the art to envision a sufficient number of embodiments of the claimed vectors and host cells to describe the full scope of the claimed genus of vectors and host cells. Applicants respectfully request the withdrawal of the §112, first paragraph written description rejection of claims 1-16 and 18-44.

Rejections under 35 U.S.C. §103:

All claims remain rejected under 35 U.S.C. §103 as obvious over Del Tito et al. in combination with one or more of Makoff et al., the 1997 Novagen catalog, and Wnendt. The Office Action rejects the evidence of commercial success as an objective indicator of non-obviousness because "there remains no meaningful background against which the sales figures presented in Paper No. 10 can be weighed to determine if the demonstrated sales are so indicative of commercial success as to make the claimed invention unobvious." The Office Action further states that there needs to be a showing that the commercial success is commensurate with the claimed invention, and that "A demonstration of commercial success for a couple of specific embodiments useful in E. coli cannot be considered as evidence of nonobviousness commensurate with the full, broadly claimed genus of host cells and vector of the instant invention." Applicants respectfully disagree.

First, Applicants submit that the law does not absolutely require evidence of market share in order for commercial sales of a product of an invention to be persuasive of nonobviousness. The Federal Circuit has held that in order to demonstrate non-obviousness, the commercial success of the product must be due to the merits of the claimed invention beyond what was readily available in the prior art. *Richdel, Inc., v. Sunspool Corp.*, 714 F.2d 1573 (Fed. Cir.

invention, in J.T. Eaton & Co., Inc. v. Atlantic Paste & Glue Co. the Federal Circuit held that a primary showing of commercial success limited to sales, coupled with a demonstration that the commercial success of the product derives from the claimed invention and is attributable to something disclosed in the patent that was not readily available in the prior art is entitled to the presumption that that the commercial success of the product is attributable to the patented invention. J.T. Eaton & Co., Inc. v. Atlantic Paste & Glue Co., 106 F.3d 1563, 1571 (Fed. Cir.1997).

Applicants submit, and the Buchanan Declarations support the conclusion, that the products sold are embodiments of the claimed invention, falling plainly within the scope of claim 1. This claim requires a host cell containing a recombinant DNA molecule which comprises an array of three of more tRNA genes, wherein the tRNA genes correspond to codons that are rarely used in the host cell. As stated in Ms. Buchanan's first Rule 132 Declaration, *each* of the competent cell products for which sales figures are reported contains three tRNA genes corresponding to rarely used codons. Applicants submit that the prior art *does not* teach cells with three or more tRNA genes corresponding to codons that are rarely used in the host cell. Further, the first Buchanan Declaration states that the commercial success of the claimed invention is not the result of heavy promotion or advertising, noting that Stratagene spent no more on promotion or advertising of this product than it did on any other competent cell product it sells. The product also sells for a considerably higher price than non-codon-enhanced cells sold by the same company. Thus, the commercial success of the product is attributable not to heavy promotion or lower price, but to something disclosed in the patent that was not readily available in the prior art.

Under J.T. Eaton, having shown the necessary correspondence between the commercial success and the claimed invention, Applicants are thus entitled to the presumption that the commercial success of the product is attributable to the claimed invention. Under these circumstances, also in accord with J.T. Eaton, Applicants submit that sales alone, in the absence of market data, are indicative of non-obviousness. In view of this, and, where, as in the instant case, there are no data regarding market share because there were no competing products at the

time of the sales reported (itself a strong indicator of non-obviousness), Applicants submit that the sales figures provided are evidence of non-obviousness.

With regard to the assertion that "A demonstration of commercial success for a couple of specific embodiments useful in E. coli cannot be considered as evidence of nonobviousness commensurate with the full, broadly claimed genus," Applicants submit that the prior art cited is drawn to expression in E. coli, as is the evidence of commercial success of the claimed invention. Thus, the scope of the demonstrated commercial success of the claimed invention is directly relevant to the non-obviousness of the claimed invention over the cited prior art. Thus, giving proper weight to the commercial success of the embodiments sold (as discussed above), E. coli embodiments of the claimed invention are non-obvious. Further, if E. coli embodiments, for which the prior art appears to be most relevant, are not obvious, Applicants submit that there is no reason to conclude that embodiments encompassing other cell types, for which there is a lack of relevant prior art, would also be non-obvious. Applicants therefore submit that the scope of the invention encompassed by the commercial embodiments is sufficient to overcome the alleged obviousness of the claimed invention.

In view of the above, Applicants submit that the invention of claims 1-16 and 18-44 is not obvious over the combination of references cited. Applicants respectfully request that the rejection of these claims under §103 be withdrawn.

Applicants submit that in view of the preceding remarks and the Exhibits provided, all issues raised in the Office Action have been addressed herein. Applicants respectfully request reconsideration of the claims.

Respectfully submitted.

Dated: September 26, 2002

Kathleen M. Williams, Ph.D.

Mak J. Fitzber 12 Reg. No. 48,928 for Kattler M. Williams

Registration No. 34,380 Attorney for Applicant

PALMER & DODGE LLP

111 Huntington Avenue Telephone: (617) 239-0451

Telecopier: (617) 227-4420

Codon usage tabulated from the international DNA sequence databases

Yasukazu Nakamura, Ken-nosuke Wada¹, Yoshiko Wada, Hirofumi Doi², Shigehiko Kanaya³, Takashi Gojobori and Toshimichi Ikemura*

National Institute of Genetics and The Graduate University for Advanced Studies, Mishima, Shizuoka 411, Japan, ¹ATR Limited, Seika, Kyoto 619-02, Japan, ²Fujitsu Laboratories Ltd, Chiba 261, Japan and ³Yamagata University, Yonezawa, Yamagata 992, Japan

Received August 31, 1995; Revised and Accepted October 4, 1995

ABSTRACT

Codon usage in 87 602 genes has been calculated using the nucleotide sequence data obtained from the GenBank Genetic Sequence Data Bank (Release 90.0; September 1995). The database is called the CUTG Database; the complete form of the database can be obtained by anonymous ftp from DDBJ and a part of the database, which lists the frequency of codon use in each organism, is made searchable through our World Wide Web server.

SOURCE AND METHODS

Codon usage in individual genes has been calculated using the nucleotide sequence data obtained from the GenBank Genetic Sequence Data Bank (Release 90.0; September 1995). The compilation of codon usage is synchronized with each major release of GenBank. The resulting database is called the CUTG database (1-5).

In selecting protein coding sequences we relied on the FEATURES tables of GenBank, and only complete genes without unambiguous bases were used in the analysis. In GenBank, a group of consecutive genes whose entire region had been sequenced were registered under one LOCUS name. To distinguish the different genes belonging to a single LOCUS, the symbol # followed by a number is added after the LOCUS name; the numbers represent the order of the CDS registered in the FEATURES table of GenBank. When introns of a gene have not been completely sequenced, some of its exons are registered in separate entries (LOCUS) in GenBank. These exons, belonging to the same gene but having different LOCUS names, were combined into one entry and the first LOCUS name is added.

For the biological significance of codon usage, see Ikemura (6) and Aota and Ikemura (7,8).

FILES

Files of the present database, containing codon usage of 87 602 CDSs of 4805 species, are available by anonymous ftp from

DDBJ. Files named as gb***.codon list the codon use in each gene registered in the GenBank Sequence files (gb***.seq). The LOCUS names given in GenBank were used to designate individual genes. Each LOCUS name is followed by fields of information extracted from the FEATURES of each CDS for defining each open reading frame analyzed here. The order of the codons in the table is the same as the previous compilation (see the CODON_LABEL file or REFERENCES).

To reveal the characteristics of codon use of a wide range of organisms, as well as viruses and organella, the frequency (per 1000) of codon use in 461 organisms for which >20 genes are available was calculated by summing up numbers of codon used. World Wide Web clients, such as NCSA Mosaic and Netscape, may be used to query this file. A user can display a codon usage table by clicking an anchor for selecting species or searching with species' name (Fig. 1).

DISTRIBUTION AND ACCESS

Complete form of the database is available by anonymous ftp from DDBJ:

ftp://ftp.nig.ac.jp/pub/db/codon/GB90.

The file README contains the latest information on the database in plain text format.

The frequencies of codon use in 461 organisms for which >20 genes are available can be accessed on the following WWW server:

http://tisun4a.lab.nig.ac.jp/codon/CUTG.html.

Comments on the database can be sent to cutg@lab.nig.ac.jp by e-mail.

ACKNOWLEDGEMENTS

The authors wish to thank Dr Y. Ugawa at the DNA Information and Stock Center, National Institute of Agrobiological Resources, for help in constructing the database. This work was supported by a grant-in-aid for creative basic research (Human Genome Project) and for scientific research on a priority area (Genome Informatics) and by a grant-in-aid of scientific research from the Ministry of Education, Science and Culture of Japan.

^{*} To whom correspondence should be addressed






Figure 1. Snapshot of the CUTG home page.

REFERENCES

- 1 Maruyama, T., Gojobori, T., Aota, S. and Ikemura, T. (1986) Nucleic Acids Res., 14, r151-r197.
- Aota, S. Gojobori, T., Ishibashi, F., Maruyama, T. and Ikemura, T. (1988) Nucleic Acids Res., 16, r315-r402.

 Wada, K., Aota, S., Tsuchiya, R., Ishibashi, F., Gojobori. and Ikemura, T.
- (1990) Nucleic Acids Res., 18, 2367-2441.
- 4 Wada, K., Wada, Y., Doi, H., Ishibashi, F., Gojobori, T. and Ikemura, T. (1991) *Nucleic Acids Res.*, **19**, 1991–1986.
- (1991) Nucleic Acias Res., 19, 1991—1900.

 5 Wada, K., Wada, Y., Ishibashi, F., Gojobori, T. and Ikemura, T. (1992) Nucleic Acids Res., 20, 2111–2118.

 6 Ikemura, T. (1985) Mol. Biol. Evol., 2, 13–24.
- 7 Aota, S. and Ikemura, T. (1986) Nucleic Acids Res., 14, 6345-6355.
- 8 Aota, S. and Ikemura, T. (1986) Nucleic Acids Res., 14, 8702.

GENE 06001

Low-usage codons in Escherichia coli, yeast, fruit fly and primates.....

(Recombinant DNA; GenBank; codon bias; Saccharomyces cerevisiae; Drosophila melanogaster; Homo sapiens)

Shiping Zhang**, Geoffrey Zubay* and Emanuel Goldman*

^a Fairchild Center for Biological Sciences. Columbia University, New York, NY 10027 (U.S.A.) Tel. (212)854-4578; and ^b Department of Microbiology and Molecular Genetics, UMDNJ - New Jersey Medical School, Newark, NJ 07103 (U.S.A.)

Received by W.M. Holmes: 12 September 1990 Revised/Accepted: 17 April/31 May 1991 Received at publishers: 18 June 1991

SUMMARY

Codon usage is compared between four classes of species, with an emphasis on characterization of low-usage codons. The classes of species analyzed include the bacterium Escherichia coli (ECO), the yeast Saccharomyces cerevisiae (YSC), the fruit fly Drosophila melanogaster (DRO), and several species of primates (PRI) (taken as a group; includes eleven species for which nucleotide sequence data have been reported to GenBank, however, greater than 90% of the sequences were from Homo sapiens). The number of protein-coding sequences analyzed were 968 for ECO, 484 for YSC, 244 for DRO, and 1518 for PRI. Three methods have been used to determine low-usage codons in these species. The first and most common way of assessing codon usage is by summing the number of time codons appear in reading frames of the genome in question. The second way is to examine the distribution of usage in different genes by scoring the number of protein reading frames in which a particular codon does not appear. The third way starts with a similar notion, but instead considers combinations of codons that are missing from the maximum number of genes. These three methods give very similar results. Each species has a unique combination of eight least-used codons, but all species contain the arginine codons, CGA and CGG. The agreement between YSC and PRI is particularly striking as they share six low-usage codons. All six carry the dinucleotide sequence, CG. The eight least-used codons in PRI include all codons that contain the CG dinucleotide sequence. Low-usage codons are clearly avoided in genes encoding abundant proteins for ECO, YSC and DRO. In all species, proteins containing a high percentage of low-usage codons could be characterized as cases where an excess of the protein could be detrimental. Low codon usage is relatively insensitive to gross base composition. However, dinucleotide usage can sometimes influence codon usage. This is particularly notable in the case of CG dinucleotides in PRI.

INTRODUCTION

Amino acids (aa) that are represented by more than one codon usually do not use synonym codons equally (e.g., Grantham et al., 1981; Gouy and Gautier, 1982). Indeed, the differential use of codons is most striking and species-

specific and raises many interesting possibilities and concerns (Andersson and Kurland, 1990). Studies on ECO and YSC have shown that high abundance proteins show a sharp avoidance of codons that are in low usage in the overall gene population (Post et al., 1979; Ikemura, 1981; 1982; Bennetzen and Hall, 1982), a finding that has led to

Correspondence to: Dr. E. Goldman, Dept. of Microbiology, New Jersey Med. School, 185 S. Orange Ave., Newark, NJ 07103 (U.S.A.) Tel. (201)456-4367; Fax (201)456-3644.

Current address: Biology Department, Brookhaven National Laboratory, Upton, NY 11973 (U.S.A.)

Abbreviations: as (a.a. in Tables), amino acid(s); bp, base pair(s); DRO, Drosophila melanogaster; ECO, Excherichia coli; PRI, primates; r, ribosomal; STP, stop codon; YSC, yeast Saccharonyces cerevisiae. The second secon

the suggestion that low-usage codons may be more difficultto translate (Grosjean and Fiers, 1982; Konigsberg and Godson, 1983; Kurland, 1987). This suggestion is supported by the observation that cognate tRNA abundance is roughly proportional to codon usage for most codons (Ikemura, 1985) and that rates of translation can vary with concentrations of charged tRNA, at least in ECO (Rojiani et al., 1990). Direct assays of translatability lend some support to this view (Robinson et al., 1984; Bonekamp et al., 1985; Carter et al., 1986; Hoekema et al., 1987; Sørensen et al., 1989; Curran and Yarus, 1989; Chen and Inouye, 1990). Further, expression of at least one heterologous protein in ECO required oligodeoxynucleotide synthesis of the entire gene with high usage synonym codons of ECO, since message containing the naturally occurring codons of the gene (very rich in ECO's low-usage codons) failed to support measurable translation (Abate et al., 1990; T. Curran, personal communication).

Whereas papers summarizing codon usage have appeared sporadically (e.g., Grantham et al., 1981; Ikemura, 1985; Sharp and Li, 1986; Sharp et al., 1988; Wada et al., 1990), the amount of information keeps increasing at the rate of about 2 x 106 bp per year. This necessitates periodic reevaluation and updating of codon usage. There is also the need for new ways of looking at codon usage which requires new perspectives and new computer programs. For example, Gutman and Hatfield (1989) have considered the problem from the perspective of frequency of appearance of codon pairs.

For the purpose of this study and to stay within reasonable practical limits, we will confine the information presented in this paper to ECO, YSC, DRO, and PRI. Mitochondrial genomes are not included in this analysis. Here, we shall describe different ways of estimating codon usage for these four classes of organisms. In addition to serving as an update of previous papers, a new way of evaluating codon usage is introduced and the relationship between codon usage and dinucleotide frequency is addressed. A major purpose of this paper is to give an accurate assessment (as of September 1990) of low-usage codons in different species. A second and more clusive goal is to seek explanations for the evolutionary choices that have been made.

RESULTS AND DISCUSSION

(a) Criteria for identifying low-usage codons

We shall define codon usage as the number of times a codon is translated per unit time. This has not been measured directly in vivo, so estimates of codon usage are obtained by indirect observations. It should be appreciated that codon usage is likely to be different under different

conditions of growth. For example, under conditions of rapid growth when there are plenty of nutrients, the overall rate of protein synthesis will be maximal and the synthesis of proteins that are needed for rapid growth should be favored. By contrast, under conditions of nutrient limitation, a new set of proteins is most likely to dominate metabolism and the overall rate of protein synthesis would be reduced (Ingraham et al., 1983). We will describe three ways of estimating codon usage. Each of them has its advantages and drawbacks. Fortunately, they all give approximately the same answer as regards the hierarchy for most used and least used codons within each synonymous codon family.

(1) Sums of codon appearance

The most common way of measuring codon usage is by summing the number of times codons appear in the reading frames of the genome. This approach is summarized in Table I for four different types of organisms under discussion. This method should over-estimate codons used infrequently and under-estimate codons used frequently. The reason for this is that, when averaging over the entire genome, no weight is given to the number of times different reading frames are used, which is reflected in the variable quantities of protein products. This weighting is a complex resultant of transcriptional efficiency, message stability, and translational efficiency. In general, this weighting is not precisely known but frequently it can be roughly estimated from the amount of gene-encoded protein product.

(2) Absence of particular codons in genes

A second way of estimating codon usage is to examine the distribution of usage in different genes. We have done this by scoring the number of protein reading frames in which a particular codon does not appear. In Table II, these data are directly compared for the four species under consideration. A large number indicates a narrow distribution for the codon in question. No attempt has been made to weight this method by scoring the number of times a codon appears in a gene. Only the presence or absence of a codon within a gene has been scored. This approach to measuring codon usage is based on the prediction that the most used codons should have the broadest distribution and the least used codons should have the narrowest distribution. The data in Table II are presented in a way that is most convenient for making comparisons of relative usage between different organisms. For this purpose, the numbers have been normalized to those actually observed for DRO. The normalization factors are given in the footnote of Table II.

(3) Combinations of excluded codons-

The third way in which we have estimated codon usage starts with a similar notion to that used in the second

TABLE I

A comparison of codon usages* among four different species*

	ECO; total o										DRO: töt	at code	ds: 12 50	27, t o	al prot	eins: 24	4		
_				<u> </u>		A		G			-		•						
t	6089 (Pb		382	(Ser)	487		155	(Cys	Ü			U		C	_	A		G	
•	1838 (Ph		048				196	l (Cys)	Ö		1472	(Phe)	776	(Ser	192	7 /71	, -	- (-)	-
	3897 (Le		105	(Ser)		(STP	25	(STP)	A	, (Phe				7 (Tyr 4 (Tyr	7 71	e (Oya)	
	3659 (Le	1) 7	549	(Ser)	- 61	5 (STP)	416	(Trp)	G	•		(Lea)				7 (STP		2 (Ors)	
	3204 (Le	$\overline{}$										(Leu)		(Ser		7 (SII		(SIP)	, .
C	3135 (Le	., 2	133	(Pro)		Hia)	798	(Arg)	U					100.		. (p.11	1 120	8 (Trpj	
~	980 (Let		104	(Pro)		(His)	6946	(Arg)	C		924	(Leu)	719	(Pro)	120	4 (Hia	100	. (41	_
	17477 (Let		72.4	(Pro)			989	(Arg)	A	C	1600	(Leu)	2393			5 (His		7 (Arg) 7 (Arg)	
_	21171 (DE	, ,	134	(Pro)	9589	(Gla)	1491	(Arg)	G			(Leu)		Pro		G(n)		(Arg)	
	8809 (11:) .	400	(Thr)							4606	(Leu)	1992	(Pro)		Gin		(Arg)	
Α	8719 (11		138	(Thr)	5265	(Asn)	2380	(Sar)	U			<u> </u>		<u> </u>		,		- famel	
-	1272 (11			(Thr)		(Asa)		(Ser)	C			(lic)	1088	(Tbr)	2601	(Asn)	121	(Ser)	
	8507 (Mar		250	(Thr)	12104	(Late)		(Arg)	A	A		(He)	2084	(Thr)	3318	(Asa)	2369	(Ser)	
	(1,10)	, 1		fret	3831	(Lys)	428	(Arg)	G			(11e)		(Thr)	1909	(Lys)		(Arg)	
	6716 [Val) 5:	70	(Ala)	10000	(Asp)		400.3			2997	(Met)	1704	(The)	5320	(Lys)	777	(Arg)	
G	4632 [Val			(Ala)	7116	(Asp)	V702	(Gly)	U		4222								_
	\$896 (Val		60	(Ala)	14134	(Clus		(Gly)	Ç	G		(Val)	1900	(Ala)		(Asp)	1981	(Gly)	
	7972 [Val	106	41	(Ala)	R140	(GIu)		(Gly)	A	G		(Val)		(Ala)		(GIA)	3834	(Cly)	
YS	C: total code		_			<u> </u>	3710	(Gly)	G 		3424	(Val)		(Alaj	5773	(Glu)	599	(Gly)	_
YS	U	ns: 24	C 1091), tota		ps: 484	3710	```	G	D. I	7424 PRI: total	codons	1714 :: 608694	(Ala) , total	5773 protei	(Qlu) 1518	599	(Gly)	_
	U \$559 (Phe)	ns: 24	C C), tota	l proteir	DB: 484		:		D. I	3424	codons	1714	(Ala) , total	5773 protei	(Clu)	599		_
	U \$559 (Phe) 4813 (Phe)	59 35	1099 C 54 (Ser)	l proteir A	(Tyr)	1842	(Oys)	U	D. 1	3424 PRL: total	(Val)	1714 s: 608694	(Alzi)	5773 protei	(Qlu) 15: 1518 A	599	(Gly)	
	5559 (Phe) 4813 (Phe) 5887 (Leu)	59 35: 37:	1090 C 54 (35 (Ser) Ser) Ser)	A 3982 3998 256	(Tyr) (Tyr) (Tyr)	1842 900	(Oys)	U C	D. I	3424 PRI: total U	(Val) codonz (Phe)	1714 :: 608694 C	(Alz) 4, total (See)	5773 protein 7504	(Au) 1518 (Trr)	599 5082	(Cly)	_
	U \$559 (Phe) 4813 (Phe)	59 35: 37:	1090 C 54 (35 (Ser)	A 3982 3998 256	(Tyr)	1842 900 136	(Oys) (Oys) (STP)	U C A		3424 PRI: total 9684 13718 3279	(Val) codous (Phe) (Phe) (Leu)	1714 E 608694 C B052 10677	(Alm) 4, total (Ser) (Ser)	5773 protein 7504 11198	(Qu) 1515 (Tyr) (Tyr)	599 5982 8522	(Cly) (Oya) (Oya)	-
	U \$559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu)	59 35 37 15	1090 54 (35 (12 (Ser) Ser) Ser) Ser) Ser)	A 3962 3982 3998 258 92	(Tyr) (Tyr) (Tyr) (STP) (STP)	1842 900 136 2490	(Oys) (Oys) (STP) (Trp)	U C		3424 PRI: total U 9684 13718	(Val) codous (Phe) (Phe) (Leu)	1714 E 608694 C B052 10677 5766	(Alm) (Ser) (Ser) (Ser)	5773 protein 7504 11198 442	(Qu) 15: 1518 (Tyr) (Tyr) (STP)	599 5982 8522 774	(Cyn) (Cyn) (Cyn) (STP)	•
;	U 5559 (Phe 4813 (Phe 5887 (Leu) 7776 (Leu) 2297 (Leu)	59 33: 37: 15:	1099 C 54 (35 (12 (15 (Ser) Ser) Ser) Ser) Ser)	3982 3982 3998 258 92	(Tyr) (Tyr) (Tyr) (STP) (STP)	1842 900 138 2490	(Oys) (Oys) (STP) (Trp)	U C A		9684 13718 3279 8870	(Phe) (Phe) (Len)	1714 E: 608694 C 8052 10677 5766 2448	(Alm) (Ser) (Ser) (Ser) (Ser)	5773 protein 7504 11198 442	(Qu) 1515 (Tyr) (Tyr)	599 5982 8522 774	(Cly) (Oya) (Oya)	_
;	U 5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 981 (Len)	59 35 37: 15:	1090 54 (35 (12 (15 (Ser) Ser) Ser) Ser) Pro)	3982 3998 256 92 2977 2017	(Tyr) (Tyr) (STP) (His)	1842 900 136 2490	(Oys) (Oys) (STP) (Trp) (Ars)	U G A G	U	3424 PRI: total U 9684 13718 3279 8870	(Val) codoux (Phe) (Phe) (Leu) (Leu)	1714 6: 608694 C B052 10677 5766 2448	(Alm) (Ser) (Ser) (Ser) (Ser)	5773 protein 7504 11198 442 302	(Qu) IS 1518 (Tyr) (Tyr) (STP) (STP)	599 5982 8522 774 8390	(Cys) (Cys) (Cys) (STP) (Trp)	
YS	U \$559 (Phe 4813 (Phe 5857 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu)	59 35 37: 15: 30: 138 51:	1090 54 (35 (35 (15 (18 (18 (12 (Ser) Ser) Ser) Ser) Pro)	3982 3982 3998 256 92 2977 2017 7098	(Tyr) (Tyr) (STP) (SIP) (His) (Gla)	1842 900 138 2490 1801 467 531	(Oys) (Oys) (STP) (Trp) (Arg) (Arg)	U G A G		3424 PRI: total U 9684 13718 3279 8870 6538 12177	(Phe) (Phe) (Phe) (Leu) (Leu) (Leu)	1714 K 608694 C 8052 10677 5766 2448 9352 12138	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro)	5773 protein 7504 11195 442 302	(Qu) (Qu) (Tr) (Tr) (Tyr) (STP) (STP) (His)	5999 5982 8522 774 8390	(Cys) (Cys) (STP) (Trp)	
;	U 5559 (Phe) 4813 (Phe) 5857 (Leu) 7776 (Leu) 2297 (Leu) 981 (Len)	59 35 37: 15: 30: 138 51:	1090 54 (35 (35 (15 (18 (18 (12 (Ser) Ser) Ser) Ser) Pro)	3982 3998 256 92 2977 2017	(Tyr) (Tyr) (STP) (SIP) (His) (Gla)	1842 900 136 2490	(Oys) (Oys) (STP) (Trp) (Arg) (Arg)	U C A G	U	3424 PRI: total 9684 13718 3279 8870 6538 12177 3871	(Phe) (Phe) (Phe) (Leu) (Leu) (Leu) Leu)	1714 8 608694 C 5052 10577 5766 2448 9352 (12138 9007	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro)	5773 protein 7504 11195 442 302 5843 8815 6861	(Glu) (Tyr) (Tyr) (STP) (Hia) (Hia) (Cln)	5992 5982 8522 774 8250 2818 6945	(Cly) (Cyn) (Cyn) (Syp) (STP) (Trp) (Arg) (Arg)	
;	U 5559 (Phe 4813 (Phe 5887 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu) 2003 (Leu)	59 35: 37: 15: 30: 13: 51: 98	C C 54 (Ser) Ser) Ser) Ser) Pro) Pro) Pro)	3982 3998 258 92 2977 2017 7048	(Tyr) (Tyr) (STP) (STP) (His) (Gla) (Gla)	1842 900 136 2490 1801 467 531 255	(Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg)	U C A G U C A	U	3424 PRI: total U 9684 13718 3279 8870 6538 12177	(Phe) (Phe) (Phe) (Leu) (Leu) (Leu) Leu)	1714 K 608694 C 8052 10677 5766 2448 9352 12138	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro)	5773 protein 7504 11195 442 302 5643 8815	(Glu) (Tyr) (Tyr) (STP) (Hia) (Hia) (Cln)	5999 5982 8592 774 8290 2818 6945 8258	(Cys) (Cys) (Cys) (STP) (Trp) (Arg) (Arg)	
,	U \$559 (Phe 4813 (Phe 4813 (Phe 1887 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu) 2840 (Leu) 2003 (Leu) 7454 (IIc)	59 35 37: 15: 30: 51: 98	C C 54 (122 (135 (138 (138 (139 (139 (139 (139 (139 (139 (139 (139	Ser) Ser) Ser) Ser) Pro) Pro) Pro) Pro)	3982 3982 3898 256 92 2977 2017 7098 2500	(Tyr) (Tyr) (STP) (His) (Gla) (Gla)	1842 900 136 2490 1901 467 531 255	(Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg)	U C A G U C A G	U	3424 PRI: total 9684 13718 3279 8670 6538 12177 3871 26245	(Phe) (Phe) (Phe) (Leu) (Leu) (Leu) Leu)	8052 10577 5766 2448 9352 12138 9007 3201	(Alz) (Ser) (Ser) (Ser) (Ser) (Pro) Pro)	5773 protein 7504 11195 442 302 5843 8815 6861	(Glu) (Tyr) (Tyr) (STP) (Hia) (Hia) (Cln)	5992 5982 8522 774 8250 2818 6945	(Cys) (Cys) (Cys) (STP) (Trp) (Arg) (Arg)	
;	U 5559 (Phe 4813 (Phe 5887 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu 2003 (Leu) 7454 (IIc) 4494 (IIc)	59 33 37 15 301 138 516 98	1000 C	Ser) Ser) Ser) Ser) Pro) Pro) Pro) Phro)	3982 3982 3898 256 92 2977 2017 7098 2500	(Tyr) (Tyr) (Tyr) (STP) (His) (Gla) (Gla) (Asa)	1842 900 136 2490 1801 467 531 255	(Oys) (Oye) (STP) (Trp) (Ars) (Ars) (Ars) (Ars) (Ars) (Ars)	U C A G U C C	v c	3424 PRI: total U 9684 13718 8870 6538 12177 3871 20245 9159 (9159)	(Val) codons (Phe) (Phe) (Leu) (Leu) Leu) Leu) Leu)	1714 8 608694 8052 10877 5766 2448 9352 (12138 9007 3901 7770	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro)	5773 protein 7504 11198 442 302 5843 8815 6861 20956	(Glu) SE 1518 (Tyr) (Tyr) (STP) (STP) (His) (Gln) (Gln) (Asn)	5982 5982 8522 774 8250 2818 6945 2258 6354	(Gly) (Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Ser)	_
;	U \$559 (Phe 4813 (Phe) 5887 (Leu) 7776 (Leu) 981 (Leu) 2297 (Leu) 981 (Leu) 2400 (Leu) 7454 (Ile) 4494 (Ile) 3054 (Ile)	59 35 37 15 30 138 516 98 342 370	1000 C 54 (135 (135 (135 (135 (135 (135 (135 (135	Ser) Ser) Ser) Ser) Ser) Pro) Pro) Pro) Pro) Phr)	3962 3988 258 92 2977 7098 2500 7587 6235 9104	(Tyr) (STP) (His) (Gla) (Gla) (Asa)	1842 900 136 2490 1801 467 531 255 2802 1782 5791	(Cys) (Cys) (STP) (Trp) (Ars) (Ars) (Ars) (Ars) (Ars) (Ars) (Ars)	U C A G U C A G	v c	3424 PRI: total 9684 13718 3278 8870 6538 12177 12277 26255 9159 (14619)	(Phe) (Phe) (Phe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu)	1714 K 606694 8052 10677 5766 2448 9352 12138 9007 3901 7776 (13820)	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr)	5773 protein 7504 11198 442 302 5843 8815 6861 20956	(Glu) EF 1518 (Tyr) (Tyr) (STP) (His) (Gln) (Gln) (Asn) (Asn)	5992 5982 8522 774 8390 2818 6945 2258 6354	(Cly) (Cys) (Cys) (STP) (Trp) (Arg) (Arg) (Ser)	
	U 5559 (Phe 4813 (Phe 5887 (Leu) 7776 (Leu) 2297 (Leu) 981 (Leu 2003 (Leu) 7454 (IIc) 4494 (IIc)	59 35 37 15 30 138 516 98 342 370	1000 C 54 (135 (135 (135 (135 (135 (135 (135 (135	Ser) Ser) Ser) Ser) Pro) Pro) Pro) Phro)	3982 3982 3898 256 92 2977 2017 7098 2500	(Tyr) (STP) (His) (Gla) (Gla) (Asa)	1842 900 136 2490 1801 467 531 255	(Cys) (Cys) (STP) (Trp) (Ars) (Ars) (Ars) (Ars) (Ars) (Ars) (Ars)	U C A G U C C	v c	3424 PRI: total 9684 13718 8870 6538 12177 3871 20245 9154 (14619 13605	(Val) codous (Phe) (Pbe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu)	8052 10677 5766 2448 9352 12138 9307 3301 7778 (13820)	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Pro) (Pro)	5773 protein 7504 11138 442 302 5843 8815 6861 20956 10115 18569 13636	(Glu) (Tyr) (Tyr) (Tyr) (STP) (His) (Gln) (Asn) (Asn) (Lye)	5992 5982 5982 774 8290 2818 6945 2258 6354 5747 11285 6086	(Gly) (Cys) (Cys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	
	U \$559 (Phe 4813 (Phe 4813 (Phe 5887 (Leu) 7776 (Leu) 981 (Leu 2297 (Leu) 981 (Leu 2003 (Leu) 7454 (IIc) 4494 (IIc) 5180 (Met)	59 35 37 15 30 516 98 528 342 370 158	1090 C C 54 (122 (135 (138	Ser) Ser) Ser) Ser) Pro) Pro) Pro) Pro) Phr) Thr) Thr)	3982 3998 258 92 2977 2017 7098 2500 7587 6235 9104 8536	(Tyr) (Tyr) (STP) (His) (Gla) (Gla) (Asa) (Lys)	1842 900 136 2490 1801 407 531 255 2802 1782 6791 1814	(Oys) (Oys) (Oys) (STP) (Arg) (Arg) (Arg) (Arg) (Ser) Arg)	U C A G U C A G G	v c	3424 PRI: total 9684 13718 3278 8870 6538 12177 12277 26255 9159 (14619)	(Val) codous (Phe) (Pbe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu)	1714 K 606694 8052 10677 5766 2448 9352 12138 9007 3901 7776 (13820)	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Pro) (Pro)	5773 protein 7504 11198 442 302 5843 8815 6861 20956	(Glu) (Tyr) (Tyr) (Tyr) (STP) (His) (Gln) (Asn) (Asn) (Lye)	5992 5982 8522 774 8390 2818 6945 2258 6354	(Gly) (Cys) (Cys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	
;	U \$559 (Phe 4813 (Phe) 5887 (Leu) 7776 (Leu) 981 (Leu) 2297 (Leu) 981 (Leu) 2400 (Leu) 7454 (Ile) 4494 (Ile) 3054 (Ile)	59 35 37; 15; 30; 13; 51; 98 528 342 370 158	1096 C 54 ((55 () 13 () 13 () 15 () 15 () 17	Ser	3982 3998 258 92 2977 2017 7098 2500 7587 6235 9104 8536 8962 8962	(Tyr) (Tyr) (STP) (His) (Gla) (Gla) (Asa) (Lys) (Lys)	1842 900 136 2490 1801 1801 407 531 255 2802 1782 5791 1814 8376	(Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) Arg) Ser) Arg)	U C A G U C A G U C A G	v c	3424 PRI: total 9684 13718 3279 6870 6538 12177 20245 9154 14619 13605 13572 13572	(Phe) (Phe) (Phe) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Leu) (Met)	8052 10577 5766 2448 9352 12138 9007 3907 3901 7776 (13920 8768 4084	(Ata) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Pro) (Thr) (Thr)	5773 protein 7504 11138 442 302 5843 8815 6861 20956 10115 18569 13636 21516	(Glu) (Tyr) (Tyr) (STP) (STP) (His) (Gln) (Gln) (Asn) (Asn) (Lys)	5982 8522 774 8290 2818 6945 2358 6354 5747 11285 6086 6627	(Cys) (Cys) (Cys) (Cys) (STP) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg)	
;	U \$559 (Phe 4813 (Phe 5887 (Leu) 7776 (Leu) 981 (Leu 2297 (Leu) 2297 (Leu) 2494 (Ile) 4494 (Ile) 5180 (Met) 6485 (Val)	59 33 37 15 300 133 516 528 342 370 158	1000 C 54 (122 (135 (Ser) Ser) Ser) Ser) Pro) Pro) Pro) Pro) Phr) thr) thr) thr)	3982 3998 258 92 2977 2017 7017 7587 6235 9104 8536 8962 5418	(Tyr) (Tyr) (STP) (SIP) (His) (Gla) (Gla) (Jan) (Asn) (Asp) (Asp)	1842 900 136 2490 1801 467 531 255 2802 1782 1782 1782 1814 1814 18376 2146 2146	(Oys) (Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg) (Arg) (Gly) (Gly)	U C A G U C A G U C C A G	v c	9684 13718 8670 6538 12177 3871 20245 9154 (14619 3695 (13572 (13572	(Phe) (Phe) (Phe) (Leu)	1714 8052 10577 5756 2448 9352 12138 9007 3901 7770 (13820 4064 (1788 (4064)	(Ala) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Pro) (Thr) (Thr) (Thr)	5773 protein 7504 111.95 442 302 5843 8815 6861 20956 10115 18569 13636 21516	(Glu) (Tyr) (Tyr) (STP) (STP) (Hia) (His) (Gln) (Asn) (Asn) (Lye) (Lye)	5982 8522 774 8290 2818 6945 2258 6354 5747 11285 6086 6627	(Cly) (Cys) (Cys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Arg) (Ser) (Arg) (Cly)	- 1
<u> </u>	U \$559 (Phe 4813 (Phe) 5887 (Leu) 7776 (Leu) 981 (Leu) 981 (Leu) 2297 (Leu) 981 (Leu) 981 (Leu) 5840 (Leu) 6484 (IIe) 5180 (Met) 6485 (Val) 3622 (Val)	59 35 37; 15; 30; 13; 51; 98 528 342 370 158	1009 C 54 (655 (755) 13 (755) 13 (755) 14 (755) 15 (755	Ser	3982 3998 258 92 2977 2017 7098 2500 7587 6235 9104 8536 8962 8962	(Tyr) (Tyr) (STP) (STP) (His) (His) (Gia) (Gia) (Asa) (Lys) (Lys) (Lys)	1842 900 136 2490 1801 1801 407 531 255 2802 1782 5791 1814 8376	(Oys) (Oys) (Oys) (Oys) (Oys) (Oys) (Arg)	U C A G U C A G U C A G	C A	3424 PRI: total 9684 13718 3279 6870 6538 12177 20245 9154 14619 13605 13572 13572	(Phe) (Phe) (Phe) (Leu)	8052 10577 5766 2448 9352 12138 9007 3907 3901 7776 (13920 8768 4084	(Ala) (Ser) (Ser) (Ser) (Ser) (Pro) (Pro) (Pro) (Thr) (Thr) (Thr) (Ala) (Ala)	5773 protein 7504 11138 442 302 5843 8815 6861 20956 10115 18569 13636 21516	(Glu) (Tyr) (Tyr) (STP) (STP) (His) (Gln) (Gln) (Asn) (Asn) (Lys) (Asp)	5982 8522 774 8290 2818 6945 2258 6354 5747 11285 6086 6627	(Cly) (Oys) (Oys) (Oys) (STP) (Trp) (Arg) (Arg) (Arg) (Arg) (Ser) (Arg) (Gly)	

^a DNA sequences analyzed were from GenBank version 63 (15 March 1990). Reading frames were based on 'pept' labels (or 'CDS' labels in the current GenBank format) in the FEATURE sections. Repeating sequences were excluded. Computer programs used are written in C and run on a Sun3.

The species analyzed include the bacterium E. coli (ECO), the yeast S. cerevisias (YSC), D. melanogaster (DRO), and several species of primates (PRI) (taken as a group; includes eleven species for which DNA sequence data have been reported, however, greater than 90% of the sequences were from man).

method but instead considers combinations of codons that are missing from the maximum number of genes. The assumption here is that combinations of low-usage codons should be excluded from the most active genes, because the more low-usage codons present in a gene, the greater the potential reduction in the amount of translated product. Although this remains to be experimentally tested in a rigorous fashion, there are a number of reasons to predict this result (see INTRODUCTION). The program searches for combinations of codons (two or more) that are excluded from the maximum number of reading frames of the species in question. To make the computer calculations practical, only the 20 least used codons defined by method 2 above were used in the pool to determine combinations of least-

used codons. In Table III, results are presented for combinations of up to eight codons with the least favored incidence; the number of protein reading frames that exclude the combination is given at the left in the table. Frequently, there is little difference between first, second and third (not shown) choices, indicating a degree of uncertainty in giving priority to the choices.

For ECO, there is a stepwise addition of a new low-usage codon at each stage as the size of the combination increases. This is also true for YSC except after stage 7 (combinations containing seven codons) where GGG is eliminated and AGG and ACG are simultaneously added. For DRO, a similar stepwise pattern of addition is seen as for ECO: The situation is far more complex and intriguing for PRI. The

TABLE II

Relative numbers of proteins not using a particular codon in four species

codon (a.a.) EGO YSC DRO PRI coden (a.a.) EGO YSC DE	O PRI
	_
UUU (Phe) 17 15 39 35 AUU (Be) 10 4 1	. /
UUC (Phe) 17 8 12 14 AUC (Ile) 10 8 1	
UUA (Leu) 48 8 125 110 ATTA (TIA) 124 65	,
UUG (Lett) 37 4 28 35 ATK2 (Met) 1	
000 (ac) { 33 5 49 26 ACTIONAL (an)	1 -
000 (Ser) 42 11 14 10 AOC (The) 18 24	
UUA (Set) 68 30 68 40 ACA /The 66 66 6	
UOG (Ser) 80 60 19 64 ACC (mail)	
UAU (Tyr) 30 30 37 78 AATIŽA(An 12 12	
UAC (Tyr) 1 80 5 19 18 AAC (Am) 10 1	
UAA (STP) 82 115 117 178 AAA (Lvs) 4 5	
UAU (STP) 228 198 177 195 AAC /1 vel 95 A	2
0G0 (073) 83 44 76 48 ACTI (c) ar	40
OGC (Cys) 76 89 19 38 AGC (Ser) 20 51 15	14
COR (SLP) 179 175 104 100 ACA (A) 401	45
UGU (Trp) 43 31 30 28 ACC (Arr) 100 70	23
ODO [Len] 41 48 48 35 CHET (V-1) 10 -	38
OUC (Lett) 39 85 20 19 CHIC (IGH) 69 14	16
CUA (Lett) 127 25 69 50 CILL (Cr.) 10 50 21	79
CUG (Let) 9 54 16 6 6 cmc iv. ii 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1 7
CCU (Pro) 58 25 54 21 GCU (Ala) 15 7 74	10
CCC (Pro) 98 65 17 16 GCC (Ala) 18 10 1	4
OCA (Pro) 49 7 27 34 GCA (Ala) 11 30 40	18
CCG [Pro] 20 97 31 73 GOG (Ala) 13 73 99	64
CAU (His) 38 35 41 46 GAU (Asp) 11 8 14	18
GAC [Asp] 41 28 25 21 GAC [Asp] 16 5 12	5
OAA (Gin) 28 5 52 43 GAA (Giu) 7 2 93	17
CAG [Gin] 10 48 11 4 GAC (OL.) 10 10 10	1 4
OGU (APR) 19 37 31 or April Arti (82
CGC (Arg) 21 128 20 47 GGC (CC)	10
CGA (Arg) 124 144 67 68 CCA (Clark) 48 72	25
OGG (Arg) 110 167 72 45 GGG (Gly) 49 70 86	18

^a Normalization factor for each species is the ratio of total DRO proteins to the total proteins of the species. Total proteins used are (normalization factors in parentheses): DRO, 244 (1); ECO, 968 (0.252); YSC, 484 (0.504); PRI, 1518 (0.161). To obtain the actual (instead of relative) number of proteins in each species not using a particular codon, multiply the numbers in the table by the reciprocal of the normalization factor. For example, out of the 968 ECO proteins analyzed, the actual number of ECO proteins not using the CUA codon is 127 (from the table) times 3.968 (reciprocal of normalization factor 0.252) = 504.

four codons at stage 4 are eliminated at stage 5 never to reappear as part of the favored low-usage combination at higher stages. It should be noted that these four codons are

all of the UA type. At stage 5, all four codons ending in CG emerge along with one codon, CGU, carrying a CG in the first two positions. At all future stages, codons containing

TABLE III

Numbers of proteins not using a codon or combination of codons^a

A I	ECO to	otal p	roteins	: 988					В. Т	YSC L	otal pr	oteins:	484						
	AGG								882	CGG									
	AGC .								243	OGG	CCA								
352	AGG .	лga	AUA							OGG									
255	AGG .	AGA	CUA	AUA						CGO									
203	AGG .	∧GA	CUA	ALIA	OGA					ÇÇG									
L59	AGG .	AGA	CUA	AUA	CCGA	OGG			45	CCC	CYZA	(Y27)	COS	C# 101	000				
120	AGG .	AGA	CUA	AUA	CGA	CCC	CCC	*****	80	COC	CCA	AGC.	000	CETO	CCC	~~			
									-	~~~	OCH.	V.		COO	CO.C.				
83	AGG .	AGA	CUA	AUA	CCGA	CGG	CCC	uoc	79	α	CCA	CCC	α	74177	~~		400		
	nung (AUA.	CUA	AUA	OGA	CGG	CCC	UOG	72	CGG	OGA.	CGC	COG	CUC	GOG	AOG	AGG		
	AGG . RO to	AUA.	CUA	AUA	OGA	CGG	CCC	uoc	72	CGG TI to	OGA.		•	CUC	GOG	AOG	AGG		
C. D	RO to	AUA.	CUA	AUA	OGA	CGG		UOG	72 _. D. 1	CGG PRI to	OGA tal pro		•	CUC	GOG	ACG	AGG		
0. D 125	RO 60	tal pr	CUA	AUA	OGA	CGG		uog	72, D. 1 687	CGG PRI to UUA	OGA.	teins:	•	COC	GOG	AOG	AGG		
7. D 125 46	RO to	alai pr AGA	oteins	244	OGA	CGG		uog	72 D. 1 687 380	CGG PRI to UUA UUA	OGA. tnl pro	teins :	•	COC	GOG	AOG	AGG		
C. D 125 46 70	PRO to	aga Aga Aga	otcins	244	CLEA	CGG		vog	72 D. 1 687 380 219	CGG PRI to UUA UUA UUA	OGA tnl pro AUA AUA	teins:	1218	COC	GOG	AOG	AGG		
C. D 125 46 70 55	PRO to UUA IUUA IUUA IUUA I	aga Aga Aga Aga	oteins AUA GGG	244 AUA	OLA	CGG		uog	72. D. 1 587 380 219 116	CGG TIL 10 TILA TILA TILA TILA TILA TILA	CGA tal pro AUA AUA AUA	teins:	CUA 1518		GOG	AOG	AGG		
C. D 128 40 70 55 40	PRO to UUA UUA UUA UUA UUA UUA UUA UUA UUA UU	AGA AGA AGA AGA AGA	AUA GGG GGG	AUA AUA	COG	CGG		uog	72 D. 1 587 380 219 110 80	TIL 10 UUA UUA UUA UUA UUA UUA	AUA AUA AUA AUA OUAU	GUA GUA COG	CUA GOG	AOG		AOG	AGG		
C. D 125 40 70 55 40 35	PO to UUA UUA UUA UUA UUA UUA UUA UUA UUA UU	AGA AGA AGA AGA AGA	AUA GGG GGG AUA	AUA AUA CGG	OOG	CGA	-	. UOG	72 D. 1 587 380 219 110 80 50	PRI to UUA UUA UUA UUA UUA UUA UUA UGG	OGA AUA AUA AUA OGU OGU	GUA GUA CCG CCG	CUA GOG 2518	ACG ACG	OGG				
70 55 40 55 40 35	PRO to UUA UUA UUA UUA UUA UUA UUA UUA UUA UU	AGA AGA AGA AGA AGA AGA	AUA GGG GGG AVA GGG	AUA AUA AUA CGG AUA	OGG AGU CGG	CGA AGU	. OGA	. UOG	72 D. 1 587 380 219 116 80 50	CCGC PRI to UUA UUA UUA UUA UUG CGA UCG	AUA AUA AUA AUA AUA AUA AUA	GUA GUA COG COG	CUA GOG GOO	AOG AOG	OGG	000			

a The indicated codons are absent from the listed number of proteins on the same line, for each species.

a CG in either their first two or last two positions dominate. At stage 8, we find all of the codons that carry the dinucleotide sequence CG.

From the standpoint of computer programming this third method of picking low-usage codons is the most complex. However, with the program in hand it is easy to apply. For purposes of comparison, in most of the remainder of this paper we will use combinations of eight low-usage codons determined by the third method. These codons for the different species are presented together in Table IV. Each species has a unique combination of eight codons, but all species contain the Arg codons CGA and CGG. The agreement between YSC and PRI is particularly striking as they share six low-usage codons. All six carry the dinucleotide sequence CG. It is appropriate to mention at this point that CG is the dinucleotide sequence that is most avoided in PRI. This may be related to the fact that the C in a CG sequence is susceptible to methylation (e.g., see Razin and Riggs, 1980) and is therefore reserved for special situations. In YSC there is no methylation of C residues in CG sequences. Despite this we shall see below that this dinucleotide is also the most unpopular in YSC.

(b) Large codon families are more likely to contain low-usage codons as modulators of expression

There is reason to believe that, if codon usage plays a role in modulating gene expression, it is more likely to do so in the larger codon families that contain three of more synonymous codons. Two aa, Trp and Met, are represented by

TABLE IV

Low-usage codons**

3.8.	PRI	DRO	YSC	ECO
Arg			AGG	AGG
Arg		AGA		AGA
Ile		AUA		AUA
Len				CUA
Arg	CGA	CGA	CGA	CGA
Arg	CGG	CGG	CGG	CGG
Pro				CCC
Ser	UCG			UCG
Arg	CGC		CGC	
Pro	COG		CCG	
Leu		.]	CUC	
Ala	GCG		GCG	
The	ACC		ACC	
Len		UUA		
Gly		GGG		
Ser		AGU		
Сув		UGU		[
Arg	CGU			

The eight least used codons for each species, as determined by the 'combinations of excluded codons' method (see text and Table III).

single codons. The two-codon families include Phe, Tyr, His, Gin, Asn, Lys, Asp, Glu and Cys. In most of these cases, both codons are believed to be capable of recognition by a single cognate tRNA (or anticodon) in ECO (Sprinzi et al., 1987, and references therein). This does not exclude the possibility that some of these codons are used as modulators of gene expression for example, because of the different strengths of anticodon-codon interactions (Grosjean et al., 1978; Yarus et al., 1986). In the cases of all the remaining codon families, where three, four or six codons are involved, at least two tRNAs are found for every aa. Most frequently in ECO and YSC (sufficient information is not available for DRO or PRI), as indicated above, there is a correlation between the abundance of the tRNA and the abundance of the codon (Ikemura, 1981; 1982). There are notable exceptions as in the case of the CGA codon for Arg. This codon is recognized in ECO by the same tRNA that recognizes the two high-usage codons CGU and CGC (Murao et al., 1972). It seems reasonable that we should focus our attention on the major codon families to gain an appreciation of the significance of lowusage codons.

In Table V, we have compared the three methods for assessment of codon usage for the nine major codon families. In this table, codons representing the same aa are grouped together. For each species, the % is given for codon usage determined by abundance in the genome as in Table I. In parentheses, the normalized number is given of proteins of the species that do not contain the codon as in Table II. A large number in parentheses should correspond to a small % if the two methods are consistent. Inspection of Table V indicates that the two methods are in quite good agreement for most aa. With only five exceptions (Val and Ala in ECO, Val in YSC, and Ser and Thr in DRO), the least abundant codon is excluded from the most proteins. With only five exceptions (Val, Ala and Gly in ECO, and Ser and Arg in PRI), the most abundant codon within the aa codon family is excluded from the lowest numbers of proteins; that is, it has the broadest distribution. In Table V, the % use of codons designated as low-usage codons by the combination of excluded-codons methods described above (see Tables III and IV) are underlined. Only in DRO do we have a codon designated by this latter method that does not appear in Table V (the UGU coden for Cys). Simple inspection of Table V suggests that additional codons might be designated as low-usage codons. However, we have chosen to focus our attention on eight codons from each species which we think are most likely to represent bona fide low-usage codons. If we were to attempt to expand this list we would run the risk of selecting codons that may not possess the most important properties of low-usage codons. Until such time as reliable quantitative estimates on rate of translatability can be given, we prefer to make comparisons

with a smaller subset of low-usage codons that we can be relatively sure of.

TABLE V
Synonymous codon usage for major codon families

=			ECO		YSC	_	DRO		PRI
	UUA	11	a (46)b	27	(8)	1	3 [¢] (125) в	
	UUG		٠,	36	.,	18		, II	(35)
Lea	CUU	10	, ,	11		1	Y 7	11	(35)
Lou	, and	10	(39)	5		15	. ,	21	(12)
	CUA	1 =	(127)	13		8	17	7	(59)
	CUG	55	(9)	9	(54)	44	• •	45	(5)
	AUU	47	(10)	50	(4)	33	(18)	33	(58)
Пe		46	(10)	30		53		53	(14)
	AUA	7	(124)	20	(55)	14		13	(88)
	GUU	29	(10)	44	(6)	19	(22)	15	(38)
Val	GUC	20	(23)	25	(12)	26	()	25	(16)
• 64	GUA	17	(19)	16	(52)	9	· · ·	8	(79)
	GUG	34	(17)	15	(43)	48	(15)	49	(7)
	UCU	18	(33)	31	(5)	8	(49)	18	(26)
	UCC	17	(42)	18	(11)	26	(14)	24	(10)
Ser	UCA	12	(68)	19	(30)	8	(68)	13	(49)
	ŲCG	14	(60)	8	(69)	22	(18)	6	(94)
	AGU	13	(85)	15	(40)	12	(69)	13	(40)
	AGC	26	(20)	9	(51)	24	(18)	26	(14)
	CCU	15	(58)	29	(26)	11	(54)	27	(21)
Pro	CCC	10	(88)	13	(66)	36	(17)	35	(16)
	CCA	19	(49)	49	(7)	23	(27)	26	(34)
	CCG	56	(20)	9	(97)	30	(31)	11	(73)
	ACU	20	(29)	38	(6)	16	(50)	23	(28)
Thr	ACC	45	(16)	24	(14)	42	(13)	40	(9)
	ACA.	12	(66)	26	(38)	17	(61)	25	(27)
	ACG	23	(36)	<u>11</u>	(63)	25	(46)	12	(60)
	GCU	19	(15)	44	(7)	19	(24)	28	(10)
Ala	GCC	24	(18)	24	(10)	49	(3)	42	(4)
	GCA	22	(11)	24	(30)	15	(40)	20	(18)
	GCG	35	(13)	8	(73)	17	(28)	11	(84)
	CGU	43	(1.9)	17	(37)	19	(31)	9	(81)
	CGC	37	(21)	4	(128)	33	(20)	22	(47)
4rg	CGA	5	(124)	<u>5</u>	(144)	1.3	(67)	10	(68)
٠.	CGG	8	(110)	2	(187)	14	(72)	20	(45)
	AGA AGG	4 2	(161)	54	(7)	8	(95)	19	(45)
			(180)	17	(58)	12	(67)	21	(23)
	GGU	38	(13)	60	(6)	22	(20)	15	(32)
Лy	GGC	40	(14)	15	(34)	43	(11)	36	(10)
•	GGA	9	(88)	15	(47)	28	(15)	24	(25)
	GGG	13	(49)	8	(70)	7	(86)	25	(18)

^{*} Numbers in each column indicate % use of synonymous codon (derived from Table I). For example, in ECO we counted a total of 31832 Leu codons of all types in Table I. Of these, 17477 were CUG codons; thus, the % use of CUG is 17477 \div 31832 \times 100 = 55% (in sixth line).

(c) Low-usage codons are preferentially avoided in genes for abundant proteins in ECO, YSC and DRO

Implicit in the consideration of low-usage codons is the notion that such codons are more slowly translated and therefore avoided in genes for proteins required in large amounts. This notion is supported by a comparison of proteins containing small and large numbers of low-usage codons (e.g., Ikemura, 1985). For combinations of eight excluded codons, the distribution of proteins according to the number of low-usage codons they contain is given in Table VI.

It is informative to inspect those proteins that fall into the 'zero class', which uses none of the eight designated lowusage codons, and perhaps equally informative to inspect those proteins at the other extreme that use an abnormally high concentration of these low-usage codons. In spite of the fact that the precise molar amounts of each of these proteins are not available, the trends are unmistakable. Thus for the 93 proteins that are in the zero class for ECO, 35 r-proteins are found. Most of the remainder are major proteins involved in protein synthesis initiation and elongation, enzymes involved in intermediary aa metabolism and carbohydrate metabolism and the major outer membrane proteins, OmpR and OmpF. In YSC the zero class also abounds with r-proteins. The zero class in YSC also contains some histones, enzymes involved in aa biosynthesis and fermentation, actin, alcohol dehydrogenase and several ubiquitins. Of the 25 proteins in the DRO zero class the same trend continues with a strong representation of major proteins or at least proteins that are major in some tissues some of the time. Thus, we see some r-proteins, metallothionein, myosin, major heat-shock proteins, alcohol dehydrogenase I, cytochrome c, tropomyosin and a tubulin appearing in the zero class. Only in PRI is the trend unclear. Thus, we do not find r-proteins, histones or major enzymes in the zero class. Rather we find some globins, interferons, interleukins and metallothionein. It may be that these proteins are needed in large amounts in special situa-

TABLE VI

Distributions of proteins with respect to the percentage of low-usage codons they contain

% of low codons	ECO	YSC	DRO	PRI
0%	63°	72	25	43
above 0% to 8%	443	168	48	307
above \$% to 6%	278	190	94	539
above 6% to 9%	102	46	48	862
above 9% to 12%	30	5	16	158
above 12% to 15%	12	2	8	73
above 15%	10	1	5	39

Numbers refer to number of proteins containing the indicated % of low usage codons.

Numbers in parentheses indicate normalized number of proteins lacking the codon (taken directly from Table II).

Ounderlined are numbers of low-usage codons determined by 'combinations of excluded codons' method (see Tables III and IV).

tions and therefore it is beneficial for their translation to avoid the designated low-usage codons. Alternately, it may be that translatability plays a smaller role in the selection of low-usage codons in PRI than it does in the other species considered here.

(d) Proteins that contain a high percentage of low-usage codons in their genes belong to classes where an excess of the protein could be detrimental

It has been argued that only high-usage codons are selected in abundant proteins, and there is no selection for low-usage codons in low-expression-level proteins (Sharp and Li, 1986; Andersson and Kurland, 1990). Nevertheless, an examination of the trends seen in classes with high frequency of low-usage codons raises the possibility of selection for low-usage codons. For example, reading frames found on transposable elements abound in classes with high frequency of low-usage codons. Indeed, transposition of the YSC Ty1 transposon has been reported to be regulated by the concentration of the cognate tRNA for one of YSC's low-usage codons, AGG (Xu and Boeke, 1990). It seems likely that transposition would be under very tight control in most species. The remainder of the proteins found in the ECO list with greater than 9% lowusage codons include some toxins and lesser known regulatory proteins. YSC in the 6% or greater low-usage class contains several regulatory protein genes and nuclear genes that encode products for mitochondria. The DRO proteins with greater than 9% low-usage codons are most notable for the large number of transposable element genes. They also contain the Shaker genes which are believed to be essential for potassium channels in the nervous system (Pongs et al., 1988). The PRI with greater than 12% lowusage codons abound in proto-oncogenes, growth factor genes, several hormone genes and, strangely enough, several histone genes. The finding of histone genes in the class with high frequency of low-usage codons in PRI contrasts with the findings in YSC where several histone genes are found in the zero class. It may be argued that primate cells are held in check by an abundance of low codon usage genes including those likely to lead to rapid growth. Rapid uncontrolled growth often spells disaster in PRI, in contrast to unicellular organisms, and our findings can be rationalized in this way. Alternately, as noted above, low-usage codons may not play the same role in PRI as they do in the other species discussed here.

(e) Codon usage by 'zero class' proteins is more selective than for average proteins

It has been pointed out that proteins in the abundant class have a more restricted codon usage. We have seen that for ECO, YSC and DRO, the zero class also correlates reasonably well with proteins found in the most abundant group. We have engaged in the reciprocal process of selecting the abundant proteins first and then determining their codon usage from the available information in GenBank (results not shown). This reciprocal approach is similar to that taken by Sharp and Li (1987), in which these authors used abundant proteins in ECO and YSC to determine a 'Codon Adaptation Index'. This approach gives very similar results for ECO and YSC, but is more difficult to apply in dealing with organisms that have differentiated cells. Our approach of selecting combinations of excluded codons is more systematic and subject to computer analysis with a minimum of preparation.

Codon usage for zero class proteins is compared with codon usages for all proteins in Table VII. Only data for the major codon families are presented. It can be seen that the most used codons are usually the same in both cases. Exceptions (a total of eight; marked with asterisks) are usually close calls. In many cases for ECO, YSC, and DRO but not PRI, the differences between the most used codons and other codons are more extreme. Indeed, there are more codons in the low-usage group (5% or less) in the highly restricted zero class collection: nine additional in the case of ECO, 14 additional in the case of YSC, eight additional in the case of DRO, but only one additional in the case of PRI. Many of these additional codons in the 5%, or less groupings may be low-usage codons in the sense that they may translate more slowly under some or all conditions of growth. This would be a reasonable explanation for their being more scarce in proteins that are synthesized in larger amounts. To decide this, as in all cases, actual measurements of translation rates will have to be made for each of the codons individually.

(f) Choices of low-usage codons are relatively insensitive to gross base composition

To begin a consideration of the origin of varying lowusage codons in different species, we might first examine the relationship between codon usage and base frequencies in reading frames. This information is presented in Table VIII as the ratio of the observed number of codons vs. the expected number of codons calculated from base frequencies within reading frames on the coding strand. The most relevant relationships are for synonym codons.

A ratio greater than one indicates a codon that appears at a higher-than-expected frequency based on the observed base composition of the reading frames. Similarly, a ratio of less than one indicates a codon that appears at lower-than-expected frequency. In almost all cases, the numbers presented in Table VIII reflect the absolute numbers presented in Table I. For example, the ratios of 0.21 and 3.43 for the ECO Leu codons CUA and CUG in Table VIII reflect the much lower (960) and much higher (17477) numbers for these codons in Table I. Thus, the extreme numbers

TABLE VII

Comparison of codon usage a for all proteins $(T)^b$ and for zero-class'-proteins $(Z)^a$ for major codon families

							<u>.</u>		T	
		•	ECO	2	YSC		ORO		PRI	
		 I	<u>z</u>	T	Z	T	Z	T	Z	
	UUA	111	3	27	17	6	0	8	8	
	DUG	11	5	36	75	18	14	11	11	
Leu	CUU	10	4	11	2	_	6	11	8	
	CUC	10	5	5	٥		17	21	18	
	CUA CUG	55	0 83	13			2	7	7	
		1 55	83	9	1	44	61	45	49	
_	AUU	47	26	50	51	33	30	33	25	
Пė	AUC	46	74*	30	47	53	70	53	58	
	AUA	7	Q	20	1	14	0	13	18	
	GUU	29	47*	44	58	19	18	16	19	
Val	GUO	20	9	25	41	26	38	25	18	
,	GUA	17	24	16	1	9	2	9	4	
	GUG	34	19	15	3	46	42	49	59	
	UCU	18	3 6*	31	53	8	12	18	28*	
	UÇC	17	32	18	32	26	51	24	26	
Ser	UCA	12	3	19	6	8	2	13	11	
Ju	UOG	14	0	8	1	22	18	6	0	
	ACU	13	4	15	4	13	0	13	11	
	AGC	28	25	9	4	24	17	25	23	
	CCU	15	14	29	14	ш	10	27	43*	
Pro '	CCC	10	0	13	2	36	65	35	40	
	COA	19	14	48	84	23	19	26	17	
	CCG	56	72	8	0	30	5_	11	0	
	ACU	20	38	38	51	16	13	23	32	
Thr	ACC	45	52	24	45	42	80	40	35	
	ACA	12	3	26	3	17	3	25	32	
	ACG	23	7	11	0	25	4	12	_0	
	GOU	19	40*	44	72	19	27	28	33	
Ala	GCC	24	10	24	24	40	68	42	46	
	GCA	22	24	24	3	15	4	20	22	
	GCG	35	25	8	0	17	3	11 -	0	
	CCU	45	67	17	13	19	44	9	0	
	ogc	37	33	4	0	33	50	22	ă	
Arg	CGA	5	ا ت	5	0	13	a	10	0	
	CCC	8	0	2	0	14	0	20	0	
	AGA	4	0	54	87	ð	٥	19	48_	
	AGG	2	0	17	0	12	6	21	52*	
	GGU	38	53*	60	93	22	31	15	16	
Ily	GGC	40	42	15	4	43	42	38	40	
7	GGA	9	8	15	2	28	26	24	38	
	CCG	13	3	8	1	7	0	25	8_	

Numbers are % of listed codons for the same aa. The numbers for each as add to 100%. Asterisks indicate cases where most-used codon is different in zero class proteins.

observed for these codons cannot be explained by gross base compositions of the reading frames. This does not mean that gross base compositions have no influence on differential codon usage. For example, consider the case of the Lys codons AAA and AAG in YSC. Table IB shows that there are more AAA than AAG codons (9104 vs.

8536). Nevertheless, AAA codons are closer to the expected ratio than AAG codons (1.18 vs. 1.66), raising the possibility that the more favored base composition of the AAA codon influences the higher frequency of usage of this codon. YSC probably have more examples like this than the other species we are considering here because the base frequencies for YSC differ most from the equimolar value (cf. top of Table VIII, A through D). Analyses of species with more extreme base compositions would be interesting in this regard. Our main conclusion from Table VIII is that low-usage codon choices are only influenced in a minor way by the gross base composition. Other workers have reported analyses indicating that overall codon usage patterns are influenced by gross base compositions (e.g., Bibb et al., 1984; Osawa and Jukes, 1988); however, these analyses primarily reflect codon usage patterns of average and high-usage codons.

(g) Low codon usage appears to be influenced by dinucleotide usage in some cases

In the previous section we saw that the choice of lowusage codons in the four groups of organisms we chose to consider is not influenced to any appreciable extent by the gross base composition. In this section we consider a related possibility that the choice of low-usage codons is influenced by dinucleotide preferences. It has been argued that dinucleotide preferences govern to a large extent codon choices in eukaryotes (Nussinov, 1981; Alff-Steinberger, 1987). Dinucleotide frequencies for the different species are presented in Table IX, together with the ratio of the observed-to-expected frequencies based on gross base composition. If there is a strong bias against the use of certain dinucleotide sequences it should show up in this ratio. Inspection of Table IX shows seven cases (underlined) where this ratio is 0.73 or less. The UA dinucleotide ratio is low for all species (0.71 ECO; 0.69 YSC; 0.58 DRO; 0.53 PRI), the CG ratio is low for both YSC (0.72) and PRI (0.48) and the AG ratio is low for ECO (0.73). As was seen in Table IV, ECO contains two low-usage codons, AGG and AGA, with the AG sequence, and two low-usage codons, CUA and AUA, with the UA sequence. YSC contains six low-usage codons, CGA, CGG, CGC, CCG, GCG, ACG, with the CG sequence. DRO contains two low-usage codons, AUA and UUA, with the UA sequence. Finally, all eight of the low-usage codons in PRI contain the CG sequence. On the basis of these correlations alone we must consider the proposition that there is some unknown pressure or pressures that cause certain dinucleotide sequences to be underrepresented which in turn results in an underrepresentation of the related codon or codons. However, in the process of attempting such an analysis we must be careful to distinguish cause and effect. Therefore, we must try to determine whether low dinucleotide fre-

b Values taken directly from Table V.

Zero class proteins' are those proteins that contain no residues encoded by any of the designated eight low-usage codons listed in Table IV.

TABLE VIII

Ratios of observed number of codons vs. expected number of codons

	numbers 1	V . 220060 ():	sum of reading 9 238372 A: 23	8580 G: 26546	18	C. 1	DRO Gross bas	composition for	erm of reading (r	ames;	
	U	C	A	~~ G			U	U: 78309 C;	103080 A: 93	751 G: 103441	3
	1.47 (Phe)	0.78 (Ser) 1.12 (Tye)	0.82 (Cys				c	^	G	
Ų	1.84 (Phe)	0.87 (Sec) 0.94 (Tye)	0.38 (Ora) ti	•	1.41 (Pb) 1.04 (Tyr)	0.50 (Cys)	
	0.78 (Len) 0.75 (Len)	0.45 (Ser) 0.14 (STP)	0.08 (STP	A	<u>.</u> . u	1] 1.45 (Tyr)	0.93 (Oys)	
_	0.70 (Dett)	0.50 (Ser	0.01 (317)	0.78 (Trp)	G		0.48 (Le: 1.29 (Le:			0.03 (STP)	i
3	0.74 (Leu)	0.46 (Pro)		1.57 (Arg)	U					0.66 (Trp)	
•	0.69 (Leu)	0.28 (Pro)	0.72 (His)	1.30 (Arg)	č	^	0.65 (Let			0.66 (Arg)	
	0.21 (Leu) 3.43 (Leu)	0.55 (Pro)		0.18 (Arg)	Ă	C	(154,			0.88 (Arg)	
_	0.44 (DEB)	1.44 (Pro)	1.79 (Gln)	0.25 (Arg)	Ĝ		0.47 (Let 2.41 (Let			0.87 (AFR)	
	2.02 (Ile)	0.78 (Thr)	1.15 (Asn)	0.47 (Ser)	U				1.99 (G)n)	0.35 (Arg)	
	1.90 (IIe)	1.54 (Thr)	1.54 (Ash)	0.90 (Ser)	Ö		1.55 ([] e		1.05 (Asn)	0.70 (Ser)	
	0.28 (Ilc) 1.67 (Met)	0.44 (Thr)	2.52 (Lys)	0.13 (Arg)	Ä	A			1.50 (Asa)	1.01 (Ser)	
	1.07 [8181]	0.76 (Thr)	0.72 (Lys)	0.07 (Arg)	Ĝ		0.56 [Ile 1.72 (Met		0.58 (Lys)	0.29 (Arg)	
	1.38 (Val)	1.12 (Ala)	2.04 (Asp)	1.62 (Gly)	U			,	2.49 (Lys)	0.38 (Arg)	
	0.80 (Val)	1-40 (Ala)	1.33 (Asp)	1.85 (Gly)	č	_	D.97 (Val		1.95 (Asp)	1.03 [Gly]	
	0.76 (Val)	1.28 (Ala)	3.84 (Glu)	0.38 (Gly	Ă	G	1.02 (Val		1.38 (Asp)	1.47 (Gly)	
	1.40 (Val)	1.79 (Ala)	1.03 (Clu)				0.37 (Va)	0.81 (Ala)	1.08 (G) u)		
SC	Gross base con numbers U:	eposition for an	m of 11 4	0.47 (Gly)	<u> </u>	D. PR	1.78 (Val	0.66 (Ala)	2.45 (Glu)	1.04 (Gly) 0.23 (Gly)	
SC	Gross base con numbers U:	eposition for an		nes: 77 G: 152556		D. PR	1.78 (Val	O.66 (Ala) composition for au J: 391431 C:	2.45 (Glu)	0_23 (Cny)	_
SC	U U	oposition for sm 200820 C: 1	m of reading fran 40270 A: 2288	mes; 77 G: 152556 G		D. PR	1.78 (Val	O.66 (Ala)	2.45 (Glu)	0_23 (Cny)	
SC	U 1.08 (Phs) 1.34 (Phs)	oposition for an 200820 C: 1	m of reading fram 140270 A: 2296 A 0.67 (Tyr)	nes: 77 G: 152556 G	<u>u</u>	D. PR	1.78 (Val	O.66 (Ala) composition for au J: 391481 C:	2.45 (Glu) m of reading fram 190849 A: 46110	0.23 (Cny) les: 03 G: 492738.	
SC	1.08 (Phs) 1.34 (Phs) 0.99 (Leu)	000820 C: 1 000820 C: 1 0 1.65 (Ser) 1.40 (Ser)	m of reading fram 140270 A: 2296 A 0.67 (Tyr) 0.97 (Tyr)	G 47 (Cys) 0.33 (Cys)	n C	D. PR	1.78 (Val	O.66 (Ala) composition for au J: 391431 C: 4 C 1.09 (Ser)	2.45 (Glu) m of reading fram 190849 A: 4611(A	0-23 (G)y) les: 03 G: 492738. G 0.79 (Oys)	
SC	U 1.08 (Phs) 1.34 (Phs)	000820 C: 1 000820 C: 1 0 1.65 (Ser) 1.40 (Ser)	m of reading fram 40270 A: 3298 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (5TP)	G G G G G G G G G G G G G G G G G G G	U C A		I.78 (Val U Gross base o numbers U U I.52 (Phe) I.88 (Phe) 0.46 (Leu)	O.66 (Ala) omposition for au J: 391451 C: C 1.02 (Ser) 1.18 (Ser) 0.65 (Ser)	2.45 (Glu) m of reading fram 190849 A: 46110 A 1.06 (Tyr) 1.29 (Tyr)	0.23 (G)y) les: 3 G: 492738. G 0.79 (Oys) 0.92 (Oys)	
SC	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu)	200820 C: 1 200820 C: 1 C 1.65 (Ser) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser)	m of reading fran 40270 A: 2286 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP)	G .47 (Cya) 0.33 (Cys) 0.04 (Trp)	n C		I.78 (Val II Gross base o numbers I U I.52 (Phe) I.86 (Phe)	0.66 (Ala) composition for au J: 391431 C: C 1.09 (Ser) 1.18 (Ser)	2.45 (Glu) m of reading fram 190849 A: 4611(A	0-23 (G)y) les: 03 G: 492738. G 0.79 (Oys)	U, C
50	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.84 (Leu)	200820 C: 1 200820 C: 1 C 1.65 (Ser) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 1.42 (Pro)	m of reading fran 40270 A: 2286 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His)	G 47 (Cys) 0.33 (Cys) 0.03 (STP) 0.84 (Trp) 0.66 (Arg)	U C A Q		1.78 (Val.) U Gross base of numbers U 1.82 (Phe) 1.88 (Phe) 0.46 (Leu) 0.88 (Leu)	O.66 (Ala) composition for au J: 391451 C: C 1.02 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser)	2.45 (Glu) m of reading fram 180849 A: 4611(A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP)	O.23 (Gly) Lesi D3 G: 492738. G O.79 (Oys) O.92 (Cys) O.99 (STP) O.88 (Trp)	U C
sc	U 1.08 (Phz) 1.34 (Phz) 0.99 (Leu) 1.98 (Leu) 0.54 (Leu) 0.39 (Leu)	200820 C: 1 C C 1.65 (Ser) 1.40 (Ser) 0.50 (Ser) 0.57 (Pro) 0.79 (Pro)	m of reading fran 40270 A: 3226 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 0.70 (His)	G G 152556 G G 1.47 (Cys) 0.33 (Cys) 0.03 (STP) 0.84 (Trp) 0.66 (Arg) 0.24 (Arg)	U C A G		1.78 (Val.) If Gross base of numbers of the control of the contro	O.66 (Ala) composition for au J: 391451 C: 4 C 1.02 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser)	2.45 (Glu) m of reading from 190849 A: 46110 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.85 (His)	0.23 (Gly) lesi 3 G: 492738. G 0.79 (Oys) 0.92 (Oys) 0.09 (Cyr) 0.88 (Trp) 9.30 (Apg)	U C A G
sc	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.84 (Leu) 0.39 (Leu) 0.59 (Leu)	1.65 (Ser) 1.40 (Ser) 0.57 (Ser) 0.57 (Ser) 1.42 (Pro) 0.79 (Pro) 1.78 (Pro)	m of reading fran 40270 A: 3298 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 1.51 (Gra)	G 152556 G 1.47 (Cys) 0.33 (Cys) 0.03 (STP) 0.84 (Trp) 0.66 (Arg) 0.24 (Arg) 0.17 (Arg)	U C A G	U	1.78 (Val. U Gross base of numbers U 1.82 (Phe) 1.88 (Phe) 0.48 (Leu) 1.85 (Leu) 1.85 (Leu) 1.85 (Leu) 0.45 (Leu)	O.66 (Ala) composition for au J: 391451 C: C 1.09 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser) 1.03 (Pro) 1.03 (Pro)	2.45 (Glu) m of reading from 190849 A: 46110 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.55 (His) 0.83 (His)	O.23 (Gly) O.23 (Gly) O.36: 492738. G O.79 (Oys) O.92 (Oys) O.09 (STP) O.88 (Trp) O.30 (Arg) O.61 (Arg)	U C
	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.64 (Leu) 0.59 (Leu) 0.73 (Leu)	200820 C: 1 C 1.65 (Ser) 1.40 (Ser) 0.50 (Ser) 1.52 (Pro) 0.79 (Pro) 1.72 (Pro) 0.52 (Pro)	m of reading fran 40270 A: 3228 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 0.70 (His) 1.51 (Gla) 0.80 (Gla)	G G 152556 G G 1.47 (Cys) 0.33 (Cys) 0.03 (STP) 0.84 (Trp) 0.66 (Arg) 0.24 (Arg)	U C A G	U	1.78 (Val.) If Gross base of numbers of the control of the contro	O.66 (Ala) composition for au J: 391451 C: 4 C 1.02 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser)	2.45 (Glu) m of reading from 190849 A: 46110 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.85 (His)	0.23 (Gly) lesi 23 G: 492738. G 0.79 (Cys) 0.92 (Cys) 0.99 (STP) 0.88 (Trp) 0.30 (Arg) 0.61 (Arg) 0.50 (Arg)	U C A
-	U 1.08 (Phz) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.54 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He)	1.65 (Ser) 1.40 (Ser) 0.50 (Ser) 0.57 (Ser) 1.72 (Pro) 1.72 (Pro) 1.72 (Pro) 1.72 (Pro) 1.72 (Pro)	m of reading fran A 2226 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 0.70 (His) 1.51 (Go) 0.80 (Clo)	G G 152556 G G 1.47 (Cys) 0.33 (Cys) 0.03 (SIP) 0.84 (Trp) 0.66 (Arg) 0.17 (Arg) 0.12 (Arg) 0.63 (Ser)	U C A G C A G U	U	1.78 (Val.) II Gross base of numbers of the company of the compan	O.66 (Ala) composition for au J: 391451 C: C 1.09 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser) 1.09 (Pro) 0.85 (Pro) 0.54 (Pro)	2.45 (Glu) m of reading from A 1.06 (Tyr) 1.29 (Tyr) 0.03 (STP) 0.03 (STP) 0.85 (His) 0.83 (His) 0.55 (Gln) 1.92 (Gln)	O.23 (Cfly) Lesi 23 G: 492738. G O.74 (Oys) O.92 (Cys) O.92 (Cys) O.95 (Trp) O.88 (Trp) O.30 (Arg) O.54 (Arg)	U C A G G G
	U 1.08 (Phs) 1.34 (Phs) 0.99 (Leu) 1.98 (Leu) 0.98 (Leu) 0.39 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He) 1.09 (He)	200820 C: 1 C 1.65 (Ser) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 1.72 (Pro) 0.73 (Pro) 1.78 (Pro) 1.78 (Pro) 1.78 (Pro) 1.128 (Thr) 1.19 (Thr)	m of reading fran 40270 A: 32286 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 1.51 (Gla) 0.86 (Gla) 1.12 (Ash) 1.32 (Ash)	G G 152556 G G 152556 G G 152556 G G 152556 G G G G G G G G G G G G G G G G G G G	U C A G U C C	U	1.78 (Val. U Gross base e numbers U 1.82 (Phe) 1.88 (Phe) 0.46 (Leu) 0.83 (Leu) 0.89 (Leu) 1.85 (Leu) 0.45 (Leu) 2.83 (Leu) 1.30 (He)	O.66 (Ala) composition for au J: 391451 C: C 1.09 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser) 1.03 (Pro) 0.65 (Pro) 0.54 (Pro) 0.90 (Thr)	2.45 (Glu) m of reading fram 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.55 (His) 0.83 (His) 0.85 (Gln) 1.92 (Gln) 1.22 (Asn)	0.23 (Gly) 0.23 (Gly) 0.25 (Gly) 0.79 (Oys) 0.92 (Oys) 0.09 (STP) 0.88 (Trp) 0.30 (Arg) 0.51 (Arg) 0.54 (Arg) 0.65 (Ser)	U C A G G U
_	U 1.08 (Phs) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.54 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He) 1.09 (He) 0.45 (He)	200820 C: 1 C 1.65 (Sar) 1.40 (Ser) 0.57 (Ser) 0.57 (Ser) 1.22 (Pro) 0.74 (Pro) 1.78 (Pro) 1.79 (Pro) 1.19 (Thr) 1.19 (Thr) 0.75 (Thr)	m of reading fran 40270 A: 3228 A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.70 (His) 1.51 (Gra) 0.80 (Gla) 1.12 (Asa) 1.32 (Asa) 1.38 (Asa) 1.38 (Lys)	G .47 (Cys) 0.53 (Cys) 0.03 (STP) 0.84 (Trp) 0.24 (Arg) 0.17 (Arg) 0.12 (Arg) 0.55 (Ser) 1.13 (Arg)	U C A G U C A	U C	U 1.82 (Phe) 1.88 (Phe) 0.46 (Leu) 0.83 (Leu) 1.85 (Leu) 2.83 (Leu) 1.30 (Ile) 1.69 (Ile) 1.69 (Ile) 1.42 (Ile)	O.66 (Ala) composition for au J: 3914S1 C: C C 1.09 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser) 1.09 (Pro) 0.65 (Pro) 0.54 (Pro) 0.90 (Thr) 1.30 (Thr)	2.45 (Glu) m of reading fram 1.06 (Tyr) 1.29 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.05 (His) 0.83 (His) 0.55 (Gln) 1.92 (Gln) 1.22 (Asn) 1.33 (Asn)	0.23 (Gly) lesi 3 G: 492738. G 0.79 (Oys) 0.92 (Oys) 0.09 (STP) 0.88 (Trp) 0.30 (Arg) 0.51 (Arg) 0.54 (Arg) 0.55 (Ser) 1.03 (Ser)	U C A A G G U C
	U 1.08 (Phz) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.54 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He) 1.09 (fie) 0.45 (He)	1.65 (Ser) 1.40 (Ser) 0.50 (Ser) 0.57 (Ser) 1.22 (Pro) 0.75 (Pro) 1.79 (Pro) 1.28 (Thr) 1.19 (Thr) 0.75 (Thr) 0.51 (Thr)	m of reading fran A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 0.70 (His) 1.51 (Glo) 0.60 (Clo) 1.12 (Ash) 1.32 (Ash) 1.18 (Lys) 1.66 (Lys)	G G 152556 G G 152556 G G 152556 G G 152556 G G G G G G G G G G G G G G G G G G G	U C A G U C C	U C	1.78 (Val. II Gross base of numbers 1 1.82 (Phe) 1.88 (Phe) 0.46 (Leu) 0.83 (Leu) 0.89 (Leu) 1.85 (Leu) 2.83 (Leu) 1.30 (Ile) 1.69 (Ile)	O.66 (Ala) composition for au J: 391451 C: C 1.09 (Ser) 1.18 (Ser) 0.65 (Ser) 0.25 (Ser) 1.03 (Pro) 0.65 (Pro) 0.54 (Pro) 0.90 (Thr)	2.45 (Glu) m of reading from A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.85 (His) 0.85 (Gln) 1.92 (Glb) 1.22 (Asn) 1.33 (Asn) 1.39 (Lys)	O.23 (Cfly) 1cs: 25 G: 492738. G O.74 (Oys) O.92 (Cys) O.92 (Cys) O.93 (Arg) O.61 (Arg) O.54 (Arg) O.54 (Arg) O.65 (Ser) 1.03 (Ser) O.65 (Arg)	U C A A G G U C
	U 1.08 (Phs) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.39 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He) 1.09 (He) 1.10 (Met) 1.16 (Met)	1.65 (Ser) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 1.92 (Pro) 1.79 (Pro) 1.79 (Pro) 1.79 (Pro) 1.19 (Thr) 1.19 (Thr) 1.19 (Thr) 1.28 (Thr) 1.29 (Thr)	m of reading fran A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 0.70 (His) 1.51 (Gla) 0.80 (Gla) 1.12 (Asa) 1.32 (Asa) 1.18 (Lys) 1.66 (Lys) 2.00 (Asp)	G G 152556 G G 152556 G G (Cys) 0.33 (Cys) 0.03 (SIP) 0.66 (Arg) 0.24 (Arg) 0.17 (Arg) 0.12 (Arg) 0.63 (Ser) 1.13 (Arg) 0.55 (Arg)	U C A G U C A	U C	1.78 (Val. U Gross base of numbers 1 1.82 (Phe) 1.88 (Phe) 0.46 (Leu) 0.83 (Leu) 0.89 (Leu) 1.85 (Leu) 0.45 (Leu) 2.83 (Leu) 1.30 (IIe) 1.50 (IIe) 1.53 (Mrs)	O.66 (Ala) composition for au J: 391431 C: C 1.09 (Ser) 1.18 (Ser) 0.25 (Ser) 0.25 (Ser) 1.03 (Pro) 1.08 (Pro) 0.54 (Pro) 0.90 (Thr) 1.30 (Thr) 0.36 (Thr)	2.45 (Glu) m of reading fram 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.55 (His) 0.83 (His) 0.55 (Gln) 1.92 (Gln) 1.22 (Ann) 1.33 (Agn) 1.39 (Lys) 2.05 (Lys)	O.23 (Gly) O.23 (Gly) O.30 G: 492738. G O.79 (Cys) O.92 (Cys) O.99 (STP) O.88 (Trp) O.30 (Arg) O.54 (Arg) O.54 (Arg) O.65 (Ser) 1.03 (Ser) O.63 (Arg) O.59 (Arg)	U C A G G A A G A
	U 1.08 (Phs) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.54 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (Ile) 1.09 (Ile) 0.45 (Ile) 1.16 (Met) 1.55 (Val) 1.32 (Val)	200820 C: 1 C 1.65 (Ser) 1.40 (Ser) 0.90 (Ser) 0.57 (Ser) 1.22 (Pro) 1.72 (Pro) 1.73 (Pro) 1.74 (Thr) 1.19 (Thr) 0.75 (Thr) 0.75 (Thr) 0.51 (Ala) 1.97 (Ala)	m of reading fran A 0.67 (Tyr) 0.97 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.72 (His) 0.70 (His) 1.51 (Glo) 0.86 (Glo) 1.12 (Ash) 1.13 (Lys) 1.16 (Lys) 2.00 (Asp) 1.73 (Asp)	0.47 (Cys) 0.33 (Cys) 0.33 (Cys) 0.03 (StP) 0.84 (Trp) 0.66 (Arg) 0.17 (Arg) 0.12 (Arg) 0.63 (Ser) 1.13 (Arg) 0.55 (Arg) 2.81 (Gly) 1.03 (Gly)	U C A G U C A G	C A	1.78 (Val.) II Gross base of numbers of the company of the compan	O.66 (Ala) composition for au J: 391451 C: C 1.02 (Ser) 1.18 (Ser) 0.65 (Ser) 1.09 (Pro) 1.09 (Pro) 0.54 (Pro) 0.90 (Thr) 1.30 (Thr) 0.36 (Thr) 1.27 (Ala)	2.45 (Glu) m of reading fram [80849 A: 46110 A 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.83 (His) 0.85 (Gln) 1.92 (Gln) 1.92 (Gln) 1.22 (Asn) 1.33 (Asn) 1.39 (Lys) 2.05 (Lys) 1.49 (Asp)	0.23 (Cfly) lesi 23 G: 492738. G 0.79 (Oys) 0.92 (Oys) 0.09 (STP) 0.88 (Trp) 0.30 (Arg) 0.61 (Arg) 0.54 (Arg) 0.55 (Ser) 1.03 (Ser) 0.65 (Arg) 0.65 (Arg) 0.69 (Arg) 0.70 (GLy)	U C A G U C A G U
	U 1.08 (Phs) 1.34 (Phe) 0.99 (Leu) 1.98 (Leu) 0.54 (Leu) 0.59 (Leu) 0.73 (Leu) 1.26 (He) 1.09 (He) 1.16 (Met) 1.55 (Val) 1.28 (Val) 0.53 (Val)	1.65 (Ser) 1.40 (Ser) 0.50 (Ser) 1.75 (Pro) 0.79 (Pro) 1.78 (Pro) 0.52 (Pro) 1.28 (Thr) 1.19 (Thr) 0.79 (Thr) 1.29 (Thr) 1.29 (Thr) 1.29 (Thr) 1.20 (Thr) 1.21 (Thr) 1.22 (Thr) 1.23 (Thr) 1.24 (Thr) 1.25 (Thr) 1.26 (Ala) 1.27 (Ala) 1.27 (Ala)	m of reading fran A 0.67 (Tyr) 0.97 (Tyr) 0.04 (STP) 0.02 (STP) 0.70 (His) 1.51 (Glo) 0.80 (Clo) 1.12 (Asn) 1.32 (Asn) 1.18 (Lys) 1.66 (Lys) 2.00 (Asp) 1.73 (Asp) 2.31 (Glo)	G G 152556 G 0.33 (Cys) 0.03 (STP) 0.84 (Trp) 0.066 (Arg) 0.12 (Arg) 0.12 (Arg) 0.15 (Ser) 1.15 (Arg) 0.55 (Ser) 1.15 (Arg) 0.55 (Arg) 2.81 (Gly)	U C A G U C A G U C	U C	1.78 (Val. U Gross base of numbers 1 1.82 (Phe) 1.88 (Phe) 0.46 (Leu) 0.83 (Leu) 0.89 (Leu) 1.85 (Leu) 0.45 (Leu) 2.83 (Leu) 1.30 (IIe) 1.50 (IIe) 1.53 (Mrs)	O.66 (Ala) composition for au J: 391451 C: C 1.09 (Ser) 1.18 (Ser) 0.25 (Ser) 0.25 (Ser) 1.03 (Pro) 1.08 (Pro) 0.54 (Pro) 0.90 (Thr) 1.30 (Thr) 0.36 (Thr)	2.45 (Glu) m of reading fram 1.06 (Tyr) 1.29 (Tyr) 0.05 (STP) 0.03 (STP) 0.85 (His) 0.85 (His) 0.85 (Gln) 1.92 (Gln) 1.92 (Gln) 1.33 (Asn) 1.39 (Lys) 2.05 (Lys) 1.49 (Asp) 1.61 (Asp)	O.23 (Gly) O.23 (Gly) O.30 G: 492738. G O.79 (Cys) O.92 (Cys) O.99 (STP) O.88 (Trp) O.30 (Arg) O.54 (Arg) O.54 (Arg) O.65 (Ser) 1.03 (Ser) O.63 (Arg) O.59 (Arg)	U C A G G A G G

a Observed number of codons is taken from Table I; expected number of codons is calculated from base frequencies within reading frames on the coding strand, assuming bases were randomly associated to form codons. The 'gross base composition for sum of reading frames' is the actual number of each base counted in coding sequences. For example, in all surveyed reading frames of ECO, there were 226989 U, 238372 C, 238380 A and 265468 G, for a sum of 969209 total bases (the sum may not be a multiple of three because we omitted unidentified bases in some sequences). The expected number for a codon is calculated from the probability that any base will occur at a specific position of the codon. In the calculation, the base frequencies are used as the probabilities. In ECO, for example, the probability that a base occurs at a specific position of the codon is 226989 + 969209 = 0.23420 for U; 238372 + 969209 = 0.24594 for C; 238380 + 969209 = 0.24595 for A; 265468 + 969209 = 0.27390 for G. The probability at which a codon is expected to occur is the product of the probabilities of the bases in the codon. The probability of the AGG (Arg) codon of ECO, for example, is calculated as 0.24595 x 0.27390 x 0.27390 = 0.01845. This number means that approx 1.8% of all codons in ECO would be expected to be AGG (also, another approx 1.8% would be GAG and still another approx 1.8% would be GGA). Since a total of 323059 codons were counted in ECO (Table I), the expected number of AGG codons is therefore 323059 x 0.01845 = 5960. The actual number of AGG codons counted was 428 (Table I). Thus, the ratio of observed to expected numbers of codons for AGG in ECO is 428 + 5960 = 0.07.

quency is the cause of low codon frequency or the other way around.

Let us first consider the AG case for ECO. The two Arg codons AGA and AGG are both low-usage codons in ECO. If we examine the AGX box in which they occur (Table I), we find that this box is shared by two Ser codons and two Arg codons. The Ser codons are well represented

compared to other Ser codons. Based on this comparison alone we cannot make a case for saying that these low-usage codons for Arg in ECO are the result of the avoidance of the AG sequence. Other factors must be involved.

Next let us consider the UA case for DRO. Two codons, AUA for Ile and UUA for Leu, have been designated as low-usage codons. If we look at the other codons contain-

TABLE IX

Prequencies of dinucleotides in exons

	T		т		 _		,	
-	E		Y	SC	Di	RO	PI	
w	56879ª	^d (80.1)	84409	(1.16)	16404	(1.07)	88987	(1.01)
UC	51707	(0.93)	40845	(1.04)	22614	(1.08)	103345	(1.00)
UA	39532	(0.71)	43974	(0.69)	11023	(0.58)	52063	(0.53)
UG	77688	(1.25)	51154	(1.21)	25971	(1.24)	150278	(1.43)
CU	53439	(0.96)	39507	(1.02)	20708	(0.99)	130750	(1.27)
CC	50942	(0.87)	29845	(1.10)	26884	(0.95)	143974	(1.14)
CA	57884	(0.98)	49444	(1.11)	30348	(1.19)	143161	(1.18)
CG	76396	(1.17)	21381	(0.72)	25081	(0.89)	62330	(0.48)
ΑU	59307	(1.07)	58264	(0.92)	21265	(1.13)	91864	(0.94)
AC	54289	(0.93)	41907	(0.94)	22519	(0.88)	104960	(0.87)
AA	75435	(1.80)	81823	(1.13)	23885	(1.03)	122009	(1.06)
AG	47506	(0.78)	48775	(0.97)	25689	(1.00)	140078	(E.13)
GU	56386	(0.91)	38151	(0.90)	17688	(0.85)	83357	(0.79)
ÇC	81433	(1.25)	27873	(0.94)	31082	(1.10)	128562	(0.99)
GA	63548	(0.98)	53207	(1.10)	27902	(1.08)	140390	(1.13)
GG	83482	(0.87)	38017	(1.03)	25586	(0.94)	138971	(1.05)
nim	965833		721376		375606		1820027	

Numbers to the left refer to totals for all reading frames.

ing UA (see Table I) we see that these are low, even though they have not been designated as low-usage codons. The other box containing the UA sequence contains the two Tyr codons and two of the stop codons. Since stop codons are always underrepresented this will be a constant factor in reducing the UA frequency. The same is true for other species. If we look at the other species we find that there is a tendency for the NUA codons to be underrepresented in the family boxes (except for UUA and CUA in YSC). Whether the UA sequence is influencing the codon usage or vice versa is hard to say.

To get some further indication on this point we may turn to the dinucleotide frequencies in the intron regions. These are recorded for YSC, DRO, and PRI in Table X for the UA and CG sequences. In all cases the UA dinucleotide ratio is higher for the introns than for the exons. Thus when the coding pressure is lifted, as in the noncoding regions of the introns, the UA sequence gravitates towards the statistically most probable ratio of 1.00. This comparison clearly favors the argument that the low UA dinucleotide frequency in the coding regions is probably caused by the coding pressure.

The CG sequence is associated with six low-usage

TABLE X
Ratio of observed to expected frequences of UA and CG dinucleotides

		Exons ⁸	Introns
YSC	UA	0.69	0.80
130	CG	0.72	0.86
DRO	UA	0.58	0.86
DRO	CG	0.89	0.97
PRI	UA	0.58	0.78
PRO	CG	0.48	0.29

^a Exou ratios are taken from Table IX (b).

codons in YSC and all eight in PRI. Since in both of these cases most of the designated low-usage codons contain most of the dinucleotide sequences in question we must carefully scrutinize the possibility that the low value for the CG sequence results from the low frequency of codons using this sequence.

b Numbers in parentheses refer to ratios of observed over expected where expected is calculated from gross base composition of the reading frames. Ratios of 0.73 or less are underlined. As an example, for the GA dinucleotide in ECO, the expected number would be calculated as follows. The probability that any position will contain a G is 0.27390, or an A is 0.24595 (see footnote to Table VIII for derivation of these values). The probability of finding this dinucleotide is the product of these two individual probabilities (0.27390 × 0.24595 = 0.06737). Thus, out of 965333 dinucleotides, the expected number of GA dinucleotides is 65034 (0.06737 × 965333). The observed number of GA dinucleotides was 63548. Therefore, the ratio of observed over expected is 63548 + 65034 = 0.98.

b Intron ratios are computed from 7582 dinucleotides for YSC, 56497 dinucleotides for DRO, and 686152 dinucleotides for PRI. The calculation is similar to that of the exon ratios (see Table IX, footnote b), however, the gross base composition in this case is taken from the overall base composition, not just the base composition in reading frames.

Inspection of the intron frequencies for YSC and PRI gives different indications for the CG frequency. Thus in YSC the frequency of CG moves closer to the expected (0.72 vs. 0.85), whereas for PRI it moves even further from the expected (0.48 vs. 0.29). Similarly, in YSC the overlapping intercodon C/G dinucleotide in coding sequences also moves closer to the expected, while in PRI the intercodon C/G is found at much lower frequency than expected (data not shown). It would be hazardous to draw any firm conclusions from this comparison. However, taken at face value this would argue that the low codon usage in PRI is dominated by considerations of avoidance of the CG sequence. A possible reason for this avoidance, as already indicated, is that the CG sequence is a site for methylation in PRI (Razin and Riggs, 1980). In YSC, it remains possible that coding pressure influences the dinucleotide frequencies in the coding regions.

(h) Other factors influencing the selection of low-usage codons

Shepherd (1981) noticed that the coding sequences of most reading frames have a bias for the sequence RNY (R = purine; Y = pyrimidine; and N = purine or pyrimidine). We have done extensive analysis of this and the results (unpublished observations) support the view of Shepherd (1981) which was based on a much smaller data base. It is notable that of the designated low-usage codons (Table IV) there is only one example of a RNY sequence. This correlates with the Shepherd view and suggests that the codons selected as low-usage codons in various species may have evolved from less popular sequence arrangements.

(i) Conclusions

(1) We have presented new approaches to identify lowusage codons in a reliable fashion. (2) We have been able to assign with reasonable confidence (with the possible exception of PRI) up to eight of the lowest-usage codons in several organisms (Table IV). (3) Gross base composition and dinucleotide frequencies in general cannot explain choices of low-usage codons; however, dinucleotide usage does show some influence on codon usage in PRI. (4) Lowusage codons are clearly avoided in abundant proteins; those proteins containing a high % of low-usage codons are generally cases where an excess of protein could be detrimental. (5) In a subsequent paper, we shall propose a model by which low-usage codons may affect translation rates. Also, a more detailed review of our data on codon usage in primates has recently been published (Zhang and Zubay, 1991)

ACKNOWLEDGEMENTS

We acknowledge support by the American Cancer-Society, grant No. MV-313A to G.Z., and the National Institutes of Health, grants Nos. GM27711 and 2 SO7 RR05393 to E.G.; the computer resource is supported by the National Institutes of Health, grant No. 2P41 RR00442-20.

REFERENCES

- Abate, C., Luk, D., Gentz, R., Rauscher III, FJ. and Curran, T.: Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly. Proc. Natl. Acad. Sci. USA 87 (1990) 1032-1036.
- Alff-Steinberger, C.: Codon usage in Homo saplens: evidence for a coding pattern on the noncoding strand and evolutionary implications of dinucleotide discrimination. J. Theor. Biol. 124 (1987) 89-95.
- Andersson, S.G.E. and Kurland, C.G.: Codon preferences in free-living microorganisms. Microbiol. Rev. 54 (1990) 198-210.
- Bibb, M.J., Findlay, P.R. and Johnson, M.W.: The relationship between base composition and codon usage in bacterial genes and its use for the simple and reliable identification of protein-coding sequences. Gene 30 (1984) 157-166.
- Bennetzen, J.L. and Hall, B.D.: Codon selection in yeast. J. Biol. Chem. 257 (1982) 3026-3031.
- Bonekamp, F., Andersen, H.D., Christensen, T. and Jensen, K.F.: Codon-defined ribosomal pausing in Escherichia coli detected by using the pprE attenuator to probe the coupling between transcription and translation. Nucleic Acids Res. 13 (1985) 4113-4123.
- Carter, P.W., Bartkus, J.M. and Calvo, J.M.: Transcription attenuation in Salmonella typhimurium: the significance of rare leucine codons in the leu leader. Proc. Natl. Acad. Sci. USA 83 (1986) 8127-8131.
- Chen, G.-F.T. and Inouye, M.: Suppression of the negative effect of minor arginine codons on gene expression; preferential usage of minor codons within the first 25 codons of the Excherichia coli genes. Nucleic Acids Res. 18 (1990) 1465-1473.
- Curran, J.F. and Yarus, M.: Rates of an-tRNA selection at 29 sense codons in vivo. J. Mol. Biol. 209 (1989) 65-77.
- Gouy, M. and Gautier, C.: Codon usage in bacteria: correlation with gene expressivity. Nucleic Acids Res. 10 (1982) 7055-7074.
- Grantham, R., Gautier, C., Gouy, M., Jacobzone, M. and Mercier, R.: Codon catalog usage is a genome strategy modulated for gene expressivity. Nucleic Acids Res. 9 (1981) r43-r74.
- Grosjean, H.J., De Henau, S. and Crothers, D.M.; On the physical basis for ambiguity in genetic coding interactions. Proc. Natl. Acad. Sci. USA 75 (1978) 610-614.
- Grosjean, H. and Fiers, W.: Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes. Gene 18 (1982) 199-209.
- Gutman, G.A. and Hatfield, G.W.: Nonrandom utilization of codon pairs in Escherichia coli. Proc. Natl. Acad. Sci. USA 86 (1989) 3699-3703.
- Hockema, A., Kastelein, R.A., Vasser, M. and De Boer, H.A.: Codon replacement in the PGK1 gene of Saccharomyces cerevisiae: experimental approach to study the role of biased codon usage in gene expression. Mol. Cell. Biol. 7 (1987) 2914-2924.
- Ikemura, T.: Correlation between the abundance of Escherichia coli transfer RNAs and the occurrence of the respective codons in its protein

- genes: a proposal for a synonymous codon choice that is optimal for the E. coli translational system. J. Mol. Biol. 151 (1981) 389-409.
- Ikemurs, T.: Correlation between the abundance of yeast transfer RNAs and the occurrence of the respective codons in protein genes. J. Mol. Biol. 158 (1982) 573-597.
- Ikemura, T.: Codon usage and tRNA content in unicellular and multicellular organisms. Mol. Biol. Evol. 2 (1985) 13-34.
- Ingraham, J.L., Maalæe, O. and Neidhardt, F.C.: Growth rate as a variable, In: Growth of the Bacterial Cell. Singuer Associates, Sunderland, MA, 1983, pp. 267-315.
- Konigsberg, W. and Godson, G.N.: Evidence for use of rare codons in the dnaG gene and other regulatory genes of Escherichia coli. Proc. Natl. Acad. Sci. USA 80 (1983) 687-691.
- Kurland, C.G.: Strategies for efficiency and accuracy in gene expression,
 The major codon preference: a growth optimization strategy.
 Trends Biochem. Sci. 12 (1987) 126-128.
- Murao, K., Tanabe, T., Ishii, F., Namiki, M. and Nishimura, S.: Primary sequence of arginine transfer RNA from Escherichia coli. Biochem. Biophys. Res. Commun. 47 (1972) 1332-1337.
- Nussinov, R.: Eukaryotic dinucleotide preference rules and their implications for degenerate codon usage. J. Mol. Biol. 149 (1981) 125-131.
- Osawa, S. and Jukes, T.H.: Evolution of the genetic code as affected by anticodon content. Trends Genet. 4 (1988) 191-198.
- Pongs, O., Kecskemethy, N., Mueller, R., Krah-Jentgens, I., Baumann, A., Kiltz, H.H., Canal, I., Llamarzares, S. and Ferrus, A.: Shaker encodes a family of putative potassium channel proteins in the nervous system of Drosophila. EMBO J. 7 (1988) 1087-1096.
- Post, L.E., Strycharz, G.D., Nomura, M., Lewis, H. and Dennis, P.P.: Nucleotide sequence of the ribosomal protein gene cluster adjacent to the gene for RNA polymerase subunit β in E. coll. Proc. Natl. Acad. Sci. USA 76 (1979) 1697-1701.
- Razin, A. and Riggs, A.D.: DNA methylation and gene function. Science 210 (1980) 604-610.
- Robinson, M., Lilley, R., Emtage, J.S., Yarranton, G., Stephens, P., Millican, A., Eaton, M. and Humphreys, G.: Codon usage can affect efficiency of translation of genes in *Escherichia coli*. Nucleic Acids Res. 12 (1984) 6663-6671.

- Rojiani, M.V., Jakubowski, H. and Goldman, E.: Relationship between protein synthesis and concentrations of charged and uncharged tRNA^{Trp} in Escherichia coli. Proc. Natl. Acad. Sci. USA 87 (1990) 1511-1515.
- Sharp, P.M. and Li, W.-H.: Codon usage in regulatory genes in Escherichia coli does not reflect selection for 'rare' codons. Nucleic Acids Res. 14 (1986) 7737-7749.
- Sharp, P.M. and Li, W.-H.: The codon adaptation index a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 15 (1987) 1281-1295.
- Sharp, P.M., Cowe, E., Higgins, D.G., Shields, D.C., Wolfe, K.H. and Wright, F.: Codon usage patterns in Escherichia coll, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens: a review of the considerable withinspecies diversity. Nucleic Acids Res. 16 (1988) 8207-8211.
- Shepherd, J.C.W.: Method to determine the reading frame of a protein from the purine/pyrimidine genome sequence and its possible evolutionary justification. Proc. Natl. Acad. Sci. USA 78 (1981) 1596-1600.
- Sørensen, M.A., Kurland, C.G. and Federsen, S.: Codon usage determines translation rate in *Escherichia coli*. J. Mol. Biol. 207 (1989) 365-377.
- Sprinzl, M., Hartmann, T., Meissner, F., Moll, J. and Vorderwulbecke, T.: Compilation of tRNA sequences and sequences of tRNA genes. Nucleic Acids Res. 15 (1987) r53-r188.
- Wada, K.-N., Aota, S.-I., Tsuchiya, R., Ishibashi, F., Gojobori, T. and Ikemura, T.: Codoo usage tabulated from the GenBank genetic sequence data. Nucleic Acids Res. 18, Suppl. (1990) 2367-2411.
- Xu, H. and Boeke, J.D.: Host genes that influence transposition in yeast: the abundance of a rare tRNA regulates Tyl transposition frequency. Proc. Natl. Acad. Sci. USA 87 (1990) 8360-8364.
- Yarus, M., Cline, S.W., Wier, P., Breeden, L. and Thompson, R.C.: Actions of the anticodon arm in translation on the phenotypes of RNA mutants. J. Mol. Biol. 192 (1986) 235-255.
- Zhang, S. and Zubay, G.: The peculiar nature of codon usage in primates. In: Setlow, J.K. (Ed.), Genetic Engineering, Vol. 13, 1991, pp. 73-113.

Minireview

Differential codon usage: a sateguard against inappropriate expression of specialized genes?

Milton H. Saier, Jr.*

Department of Biology. University of California at San Diego, La Jolla, CA 92093-0116. USA
Received 2 January 1995; revised version received 14 February 1995

Abstract Recent work has suggested that rare codons are somefines used for the regulation of specialized gene expression in
bacteria. Moreover, the cellular levels of certain tRNAs may
fluctuate with growth conditions. Evidence implicating such
mechanisms in the control of photosynthesis in Rhodobacter,
solventogenesis in Clostridium, sportulation in Streptomycez, and
finishrial phase variation in E. coli is summarized. It is suggested
that such mechanisms will prove applicable to the control of
numerous additional specialized functions, and that the empirical
tools for testing this possibility are currently available.

Key words: Codon usage; Bacterium; Translation; Gene expression; Sporulation; Photosynthesis; Solventogenesis; Fimbria

1. Introduction ,

can

Ding.

dam,

razi),

pt of urnal

522

In 1989, Brinkman et al. noted that eukaryotic proteins such as the human tissue type plasminogen activator, prourokinase, and the gp41 protein of HIV, which have a high content of rare codons in their respective genes, are poorly expressed in *E. coli* [1]. Moreover, induction of the expression of any one of these beterologous, plasmid-encoded genes was found to inhibit cell division and cause plasmid instability. Most remarkably, when the bacteria were simultaneously provided with a plasmid bearing the dra Y gene, encoding a rare tRNA (tRNA**GAAGO), production of the enkaryotic proteins was increased while plasmid stability and cell viability improved [1].

While these observations were of considerable practical significance to the bioengineer, they foreshadowed observations and experiments that would suggest that the use of rare codons for specialized or differentiation-specific functions in bacteria might provide a general mechanism to ensure proper temporal and spatial expression of the encoding genes. Although this hypothesis is still far from established, work in several laboratories has provided indirect evidence suggesting that rare codon usage is of functional significance in restricting or specifying appropriate gene expression. In this minireview I summarize the evidence concerned with this issue and reiterate the suggestion that the complement of tRNAs found in a particular bacterium under one set of growth conditions may differ from that found under another set of growth conditions.

*Corresponding author. Fax: (1) (619) 534-7108. E-mail: msaier@ucsd.edu

2. Codon usage and gene expression

All living organisms possess characteristic GC contents and preferred sets of codons used for protein biosynthesis. GC content is a major determinant of codon usage, and codon adaptation indices (CAI values) have proven to provide a reliable, empirically determined estimate of gene expression level for specific groups of organisms [2-4]. tRNA availability during the evolution of an organism may play a significant role in determining its characteristic preferred codon usage. However, genes obtained by horizontal transmission from a phylogenetically divergent organism with GC content and codon usage different from those of the recipient bacterium approach the values characteristic of their newly acquired host only after hundreds of millions of years [5]. This fact suggests, first, that differences in codon usage must have arisen relatively early during prokaryotic evolution, and, second, that the pressure for a newly acquired gene to assume the codon usage of the host organism is minimal. The fact that certain genes exhibiting a relatively high level of specific rare codons can nevertheless be expressed at high levels when cloned behind a strong promoter (see, for example, [6]) has led some investigators to suggest that the use of rare codons does not in fact serve a regulatory function [4]. It should be pointed out in this regard that the inability to demonstrate a regulatory effect with one set of genes expressed under a given set of experimental conditions does not rule out the possibility of an analogous regulatory function for another set of genes expressed preferentially under a different set of conditions. Below I summarize evidence suggesting that various specialized functions, expressed in a variety of bacteria, may be regulated at the translational level by selective use of rare codons in relevant structural genes (see Table 1).

3. Rare codon usage is phototrophic vs. heterotrophic genes in *Rhodobacter*

In 1991, Wu and Saier noted that genes encoding proteins of the photosynthetic apparatuses (reaction center and light harvesting proteins) of the Gram-negative purple bacteria, Rhodobacter capsulatus and R. spheroides, differed in codon usage from that of genes encoding enzymes of the fructose utilization pathway [7]. While most codons occurred with similar frequencies in these two groups of genes, a few were found to predominate, or be present exclusively in one or the other group (see Table 2 for representative examples). Moreover, other genes, such as those involved in nitrogen utilization or carotenoid biosynthesis, that were expressed under both

他们们,他们们的一个人。

様ははいけ

Table 1
Selective use of rare codons postulated to control specialized functions in bacteria

Punction	Organism	Codon	Amino Acid
Photosynthesis	Rhodobacter capsulatus	GCU	Ala
Fructose utilization	Rhodobacter capsulatus	AAU UGU	Len Asn Cys
Solventogenesis	Clostridium acetobutylicum	ACG	Thr
Arial mycelium development	Streptomyces coelicolor	UUA	Len
Fimbrial production	Escherichia coli	ÙUG	Leu

heterotrophic and phototrophic conditions, exhibited rare codon usage frequencies that were intermediate between those found in the photosynthetic and fructose-catabolic genes (Table 2). These differences were shown to be statistically significant. It was suggested that different tRNA pools were present under phototrophic vs. heterotrophic growth conditions, and that growth conditions might influence the relative rates of transcription of the tRNA genes and their cognate amino acyl tRNA synthetases. Differences in codon usage might generally allow operation of novel post-transcriptional regulatory mechanisms. It seemed reasonable to suppose that charged tRNA availability and codon usage could provide a safeguard against expression of specialized genes under inappropriate conditions [7].

Rare codon usage as a potential regulator of solventogenesis in Clostridium

Sauer and Dürre noted in 1992 that a mutational defect preceding the gene thr A encoding a rare tRNA, tRNA trop in the low GC Gram-positive bacterium, Clostridium acetobutylicum, gave rise to the absence of solventogenesis [8]. This strict anaerobe is a spore-forming bacterium that produces acetone and butanol only during a late stage in the growth cycle. The shift to solventogenesis is accompanied by a series of morphological and physiological changes in motility, shape, and granulose content, culminating in endospore formation. Sauer and Dürre noted that the ACG codon is rarely used and is largely restricted to genes either expressed at the end of exponential growth or involved in the inducible uptake or metabolism of minor carbon and nitrogen sources [8]. Because these investigators did not conduct statistical analyses, it was not possible to state that the observed differences in codon usage reflected a

unique characteristic of specific groups of genes encoding specialized functions rather than depressed levels of expressivity, [4]. Nevertheless, the potential implications of the observations were clear. As in the case of phototrophic vs. heterotrophic gene expression in *Rhodobacter*, codon usage in *Clostridium* may provide a safeguard to insure proper expression of certain stationary phase vs. log phase genes.

5. Codon usage as a determinant of the differentiated state in streptomyces

Species of the high GC Gram-positive genus Streptomycer undergo fungal-like differentiation with the sequential formation of vegetative and aerial mycelia [9,10]. The fact that only the latter structures contain spores reflects the spatial and temporal constraints imposed upon the process of terminal differentiation within this genus. The industrial importance of these organisms is related to their capacity to produce an array of antibiotics and useful secondary metabolites during the post-exponential growth phase. Although these strict aerobes have many of the enzymatic attributes of their low GC Gram-positive cousins, their regulatory mechanisms appear to be remarkably different [11–13].

Leskiw et al. [14] and Fernández-Moreno et al. [15] first observed that, in Streptomyces coelicolor, a genetic defect in the gene bldA, encoding a rare tRNA, tRNA_{UUA} [16,17], blocked aerial mycelium formation and prevented efficient phenotypic expression of several genes containing the rare UUA codon. bldA mutations (including deletions) did not interfere with vegetative growth but did prevent aerial mycelium formation and antibiotic production (see [18] for a review). It was suggested that this rare codon occurred preferentially in genes concerned with differentiation and antibiotic production as contrasted with those required for vegetative growth.

More recently, evidence was presented suggesting that mature tRNA accumulates in ever increasing amounts as S. coelicolor cultures age, and that the temporally regulated accumulation of this mature tRNA species correlates with an increase in efficiency of UUA-containing messenger RNA transcription and/or translation ([19]; but see also [20]). It seemed to exert regulatory effects on events occurring during late growth, including morphological differentiation and antibiotic production.

Rare codon usage and the control of fimbrial production in E. coli

A recently noted example of potential rare codon control of

Examples of differential codon usage in photosynthetic versus heterotrophic genes in Rhodobacter

	Codon	Amino acid	Fractional	codon usage for	sage for each amino acid		
			fru	pho	nif	Total	
Elevated codon usage in pho genes	GCU	Ala	0.02	0.11	0.03	0.05	
Elevated codon usage in fru genes	CUC AAU	Leu Asn	0.11 0.44	0.35 0.05	0.16 0.18	0.19 0.18	
	UGU	Суз	0.25	0.00	0.13	0.12	

Data were taken from [7]. Numerical values provide the fractional codon usage for each of the four amino acids (Ala, Asn, Cya, and Leu) in the four catagories indicated with abbreviations as follows: fru, fructose utilization (heterotrophic) genes, total of 1724 codons analyzed for R. capsulatus; pho, photosynthetic genes, total of 1976 codons analyzed for R. capsulatus; nif, nitrogen utilization genes (mostly concerned with nitrogen fixation), total of 3824 codons analyzed for R. capsulatus; Total, all available sequenced genes for Rhodobacter species at the time of analysis [7].

avif

tion

phil

Ttain

**yc*e

rma

only

temise

liffer

thèse

ay of

post-

have

posi

nark

i first

in the

rcked

typic

odon

1 vcg

n and

ested

crned

asted

t ma-

1CS 25

dated

th an

tran-

amed

; late

biotic

ai o

trol of

.: الأول

;

specialized gene expression concerns the production of type 1 simbriae in the Gram-negative enteric bacterium, Escherichia coll strain F18, which is able to colonize the mouse colon [21]. Burghoff et al. [22] isolated a 6.5 kb E coli sequence that enhanced the colonizing ability of strain F18 and simultaneously stimulated synthesis of type I funbriae. The gene responsible for this stimulation proved to be the leuX gene, encoding 2 tRNA specific for the sare leucine codon UUG. This gene is in single copy at 97 min on the E coll chromosome, and the encoded tRNA species (LeuX) is apparently dispensable for growth [23]. No effect on growth rate was observed when leuX was mutated [24]. Another tRNA LeuZ, specific for the UUA leucine codon, presumably recognizes UUG by 'wobble', and can thereby substitute adequately for LeuX, at least with respect to the expression of genes encoding functions required for vegetative growth.

The mechanism by which leuX gene expression influences type 1 fimbrial production is probably complex. The fim A gene, encoding the principal type I fimbrilin, lacks UUG codons altogether [25]. However, synthesis of type 1 fimbriae is subject to phase variation due to inversion of a 314 bp DNA segment that includes the find promoter ([26]; but see also [27]). The ratio of the products of two fim genes, fimB and fimE, determine the frequencies of inversion in the two opposing directions with high levels of FimB favoring the 'off' to 'on' transition. Since fimB has six UUG codons while fimE has only two [28], it has been proposed that LeuX influences type 1 fimbrial production by controlling fimB expression more stringently than that of fimE [29]. In this regard it is interesting to note that leuX expression is apparently regulated by two proteins (of 22 and 26 kDa) encoded by genes adjacent to leuX. Deletion analyses have suggested that the 22 kDa protein is a transcriptional activator while the 26 kDa protein is a repressor of leuX expression. These proteins may therefore be indirect regulators of type I fimbrial phase variation, and consequently of net fimbrial production.

Various E. coli strains are collectively capable of producing at least six distinct virulence-related fimbrize, each exhibiting specificity for and mediating adhesion to a specific marumalian cell surface macromolecule [30,31]. Expression of these fimbriae is often subject to phase variation in agreement with the belief that successful colonization of the host depends on the timely expression and subsequent silencing of specific virulence-related genes, depending on the stage of infection. A recent analysis has revealed that the leuX gene of uropathogenic E. coli strain 536 encompasses one of several sites responsible for genetic instability [32]. Internal to leuX is one of two 18nucleotide direct repeats that serve as functional sites for excision of a 190 kb DNA segment. This segment encodes, among other functions, P-related fimbrine. Excision of this DNA segment silences expression of leuX (possibly controlling type 1 fimbrial synthesis, as noted above) as well as expression of the genetic apparatus encoding P-related fimbriae. As bacterial cells lacking 'excess DNA baggage' and incapable of making fimbrine divide with increased growth rates, it may be that timely excision provides the bacterium that has already established itself in the host organism with pathogenic advantage [32]. Based on the proposed regulatory role of rare tRNAs in controlling fimbrial production, we suggest that it was not accidental that tRNA loci have come to serve as sites of virulence-associated DNA insertion/deletion phenomena.

7. Conclusions and perspectives

How important are the postulated regulatory mechanisms giving rise to codon-controlled phenotypic gene expression? Are they generally operative for the control of starvation-induced or stress-related vs. vegetative gene expression in E. coli and other bacteria [33]? Do they function to safeguard proper temporal expression of sporulation (spo)-specific genes at any one stage or during several different stages in the well-defined programs of differentiation of various Bacillus species [34]? Do they play a role in the control of growth phase-specific or condition-selective gene expression, e.g. expression of genes concerned with bioluminescence in Vibrio species [35,36], bacteriorhodopsin-mediated photosynthesis in archaebacteria [37], or induction of virulence-specific genes in bacterial pathogens of plants, animals and other bacteria [38-41]?

The first step towards answering these important questions would seem to be to analyze functionally related groups of bacterial genes for statistically significant differences in codon usage, as reported by Wu and Saier [7] for the photosynthetic vs. heterotrophic genes of Rhodobacter. A second step would be to measure variations in the cellular concentrations of specific rare tRNA species made under relevant but differing physiological conditions. The third step would be to establish a causal relationship between rare codon occurance, tRNA level and gene expressivity. Such studies may lead to recognition of novel codon usage-mediated mechanisms for ensuring the proper expression of temporally and spatially regulated genes in prokaryotic microorganisms. The relevance of such mechanisms to eukaryotic organisms, including protozoa, fungi, plants and animals, could then be ascertained by the application of straight-forward comparative approaches.

Acknowledgements: I thank Lisa Preble for expert assistance in the preparation of this manuscript. Work in the author's laboratory was supported by Public Health Service Grants 5RO1AI21702 and 2RO1A114176.

References

- [1] Brinkman, U., Mattes, R.E. and Burke, P. (1989) Gene 85, 109-
- Holm., L. (1986) Nucleic Acids Res. 14, 3075-3087.
- Sharp, P.M. and Li, W.H. (1987) Nucleic Acids Res. 15, 1281-
- [4] Andersson, S.V.E. and Kurland, C.G. (1990) Microbiol. Rev. 54,
- [5] Groisman, E.A., Sturmoski, M.A., Solomon, F.R., Lin, R. and Ochman, H. (1993) Proc. Natl. Acad. Sci. USA 90, 1033-1037.
- [6] Robinson, M., Lilley, R., Little, S., Emtage, J.S., Yarranton, G., Stephens, P., Millican, A., Easton, M. and Humphreys, G. (1994) Nucleic Acids Res. 12, 6663-6667.
- [7] Wu, L.-F. and Saier Jr., M.H. (1991) Res. Microbiol. 142, 943-949
- [8] Sauer, U. and Dürre, P. (1992) FEMS Microbiol. Lett. 100, 147-154.
- [9] Chater, K.F. (1989) in: Genetics and Molecular Biology of Industrial Microorganisms (Hershberger, C.L., Queener, S.W. and Hegeman, G. eds.) pp. 99-107, American Society for Microbiology, Washington, DC.
- [10] Chater, K.F. (1993) Annu. Rev. Microbiol. 47, 668-713.
- [11] Kwakman, J.H.J.M. and Postma, P.W. (1994) J. Bacteriol. 176,
- [12] Titgemeyer, F., Walkenhorst, J., Cui, X., Reizer, J. and Saier Jr., M.H. (1994) Res. Microbiol. 145, 89-92.

in the ulatus: ation).

象据计

...

T

A!

de

ĊII

of

ρŅ al in 0 in fo I 87 £λ K 0

1.

in sţ **a**

S

tr dı T es se te Ь C ic V: al

tł SĪ

E

Ot 5

.

- [13] Titgemeyer, F., Walkenhorst, J., Reizer, J., Stuiver, M.H., Cui, X. and Saier Jr., M.H. (1995) Microbiology 141, 51-58.
- [14] Leskiw, B.K., Lawlor, E.J., Fernandez-Abalos, J.M. and Chater, K.F. (1991) Proc. Natl. Acad. Sci. USA 88, 2461-2465.
- [15] Pernández-Moreno, M.A., Caballero, J.L., Hopwood, D.A. and Malpartida, F. (1991) Cell 66, 769-780.
- [16] Ribb, M.J., Findlay, P.R., and Johnson, M.W. (1984) Gene 30, 157-166.
- [17] Wright, F. and Bibb, M.J. (1992) Gene 113, 55-65.
- [18] Leakiw., B.K., Bibb, M.J. and Chater, K.F. (1991) Mol. Microbiol. 5, 2861-2867.
- [19] Leskiw, B.K., Mah, R., Lawlor, E.J. and Chater, K.F. (1993) J. Bacteriol. 175, 1995-2005.
- [20] Gramajo, H.C., Takano, E. and Bibb, M.J. (1993) Mol. Microbiol. 7, 837–845.
- [21] Cohen, P.S., Rossoll, R., Cabelli, V.J., Yang, S.L. and Laux, D.C. (1983) Infect Immun. 40, 62-69.
- [22] Burghoff, R.L., Pallesen, L., Krogfelt, K.A., Newman, J.V., Richardson, M., Bliss, J.L., Laux, D.C. and Cohen, P.C. (1993) Infect. Immun. 61, 1293-1300.
- [23] Yoshimura, M., Inokuchi, H. and Ozeki, H. (1984) J. Mol. Biol. 177, 627-644,
- [24] Komine, Y., Adachi, T., Inokuchi, H. and. Ozeki, H. (1990) J. Mol. Biol. 212, 579-598.
- [25] Klemm, P. (1984) Eur. J. Biochem. 143, 395-399.

- [26] Abraham, J.M., Freitag, C.S., Clements, J.R. and Eisenstein, B.J. (1989) Proc. Natl. Acad. Sci. USA 82, 5724-5727.
- [27] McClain, M., Blomfield, I.C., Eberhardt, K.J. and Eisenstein, B.J. (1993) J. Bacteriol. 175, 4335-4344.
- [28] Klemm, P. (1986) EMBO J. 5, 1389-1393. [29] Newman, J.V., Burghoff, R.L., Pallesen, L., Krogfelt, K.A., Kris. tensen, C.S., Laux, D.C. and Cohen, P.S. (1994) FEMS Microbiol. Lett. 122, 281-287.
- [30] Van Rosmalen, M. and Saier Jr., M.H. (1993) Res. Microbiol. 144
- [31] Klemm, P. (1994) Fimbrian: Adhesion, Genetics, Biogenesis, and Vaccines, CRC Press, Boca Raton, FL.
- [32] Blum, G., Ott, M., Lischewski, A., Ritter, A., Imrich, H., Tschäpe, H. and Hacker, J. (1994) Infect. Immun. 62, 606-614.
- [33] Matin, A. (1990) FEMS Microbiol. Ecol. 74, 185-196. [34] Losick, R. and Stragier, P. (1992) Nature 355, 601-604.
- [35] O'kane, D.J. and Prasher, D.C. (1992) Mol. Microbiol. 6, 443.
- [36] Meighen, B.A. (1993) FASEB J. 7, 1016-1022.
- [37] Kuan, G. and Saier Jr., M.H. (1994) Res. Microbiol. 145, 273-285. [38] Thomashow, M.F. and Cotter, T.W. (1992) J. Bacteriol. 174,
- 5767-5771. [39] Gross, R. (1993) FEMS Microbiol. Rev. 104, 301-326.
- [40] Briggs, S.P. and Johal, G.S. (1994) Trends Genet. 10, 12-16.
- [41] Saier Jr., M.H. (1994) FEBS Lett. 337, 14-17.

Meleichchds Research

AEC: 60 SO-BUA-6S

+Department of Chemistry, Max-Planck-Institut für experimentelle Medizin, Hermann-Rein-Strasse 3, D-3400 Gottingen, FRG *Department of Biochemistry, University of Bayreuth, P.O. Box 3008, D-8580 Bayreuth, and

INTRODUCTION

In the compilation of tRNA genes the sequences have been aligned and displayed tides following nuclectide residus 73 and the intervening sequences (see footnotes) have been excluded from the compilation. The compilation is deposited with the Nucleotide Sequence Data Library of EMBL, Heidelberg, and available compilation). The nucleotides preceding nucleotide residue 1 and the nucleoas has been done in the case of the tHMA sequences (Fig. 1 in accompanying there on magnetic tape upon request. The compilers would welcome any information regarding missing material or erroneous presentation. Acknowledgements: We thank Hedwig Gaißler, Thomas Bartmann, Werner Beubepk and Rudolf Jung for skillfull cooperation and the Fonds der Chemischen Industrie for financial support.

_	
-	
7	
q	
ō	
q	
α	
-	
-	
C	
4	
C	
Œ	
7	
=	

425-433 L.GRAF, H.KDESSEL, E.EIUTZ (1980) HATURE 286, 903-910; E.A.OROZCO, 18, K.E.BUSHOW, J.K.OGOG, K.B.MALLICK (1980) J. 810L. CERR. 326, 10977-11003 S.D.BOMITZ, A.TRABOLOTF (1981) CELL 26, 203-903 S.D.BOMITZ, A.TRABOLOTF (1981) J. 810L. CHER. 263, 9075-9061 A.GROSSCOPF, B.TELDMARM (1981) DUNK, GEM. 4, 191-196 A.GROSSCOPF, B.TELDMARM (1981) DUNK, GEM. 4, 191-196 F.TAHANINA, A.SUBUNKA (1982) NUCL. RCIDS REG. 10, 2663-2676 F.TAHANINA, A.SUBUNKA (1982) NUCL. RCIDS REG. 10, 2663-2676	### 1979 1979
Set Rescricted and resceeded	CHTOGO NEED KERNENEN
	אווט אאאאאא או אווט פונים פונים אאאאאא או אווט פונים
วคลาปาควอกาปุคอกรอุณุวอลต	ATTARTITO GREEN TRAILE GEORGE TRAILER DE COSO
ттяратнраттаратряарянна таа	DIIN
	7.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1
ออวอย่าค้วอาามาวอวมที่วอคยุ่ก เออ	TIBUSING PERBERGIAN SECOND SEC
вез вевстоститеся в в в в в в в в в в в в в в в в в в в	CACAS HE KHAN CACAS
	אונס אונס אונס אונס אאא או אאא אונס בינט פור באנט פאטכורונאים פיפים ביט ביט ביט פינט פינט ביט ביט ביט ביט ביט ב
าอวาศุกดวองานาคองอ่อไวคลศุก taa	רובר הבהפתובוש אומער. מה הכנה ההופודוף א כז הידוף א כז
annadraserraserrasanan Taa	AMMANAMA MERA
	OOSO BEC SENERY HORE GEGGG TO BE TO TO THE CT C P G D T
_ उद्यापन विषय । ज्यापन । ज्याप	מסצפ תפכ אבת בשמש כש בשפט פ פ פ פ פ פ ני שו שופי ו שוני שוני שוני שוני שוני שוני שוני ש
	ERRENARA MENE
ออควลาคาอาวาราวาสุวอคลุค อออ	TO 8 HOTO SERVICE SUSTRICTS SEE STORY OF
ees appecaltizatidasappecas	ODOS UGC ETHENOCOCCUS UPNI, G G G C C G F R G C T C R G T T
	5 x 2 d 3 x 3 d 1 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5
	зкімы
76 20 BC 25 24 25 25 30 32 34 38 35 40 42	ZI SL EL LL
Ch it and so are as as as as as as	R Br by St Dred (82 b 6 S t
MATERIAL MAT	1 1 1
NST2, STEM NST2C. STEM NST2C. LOOP ANTIC, STEM	I D

									•																															
E		1	### 	T	H NI	Ţ	. 3	9	5 3	1	9	ㅂ	9 :	.	Ι.	4[9	9) £	9 E	j 5														1	. 9	ī	ช	1	9500
t	1 1	:	5	1	9"	73	9	1	ı,	1	9	ㅂ	1	ᆸ.	L (4	9	ט ו	ן ל	פ ג	Ŧ															Ħ	g	Ħ	•	S00
Ħ	3 3	ı	3	U	HERE	,	Ħ	3	1	1	9	B	Ħ	ַ .	1.	1	9	U :	9 .	LE	1															Ħ	Ħ	T	•	-500
8	****		***	T (#+	HERI U	וֹי	2	8	֓֞֞֞֜֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֓֡֓֓֡֓֓֓֡֓֡֓֓֓֡֓֡֓֡֓֡	1	9	U	9	٥.	ı,	1	9	9 :	ם כ	9 6	5														1	. 9	1	Ħ	1	5500
н	3 3		**	1		+:		***) * * ·	1	9	Ħ	9 :	. c	L.	j	Ð	9 :	 J 9	9 H	1,														1	9	1	Ħ		0023
	HHNH		**				1 8	• <u>•</u> •		١.	- 9	- H	- 9 :	.		ŀ	9	n	H -	1						•											ㅂ	1		500
	***		××	ij	i i	+		Ė		1	•			_	•	7	-				7															. 9				906
t	MKEN T		**	١,	NH!) U		. ر	ļ	1	Ħ	y .	. ر	יי	٦	9	= -	e a :		۳									٠					•					
н	HMMH	1	, ***	(22 T	HENNI Henni	1 5) T	1	ַבַּ	1	A	Ħ	Ħ :	3.	Ŀ.	4	9	י פ			1-			٠												9	1	1		08S2
t	20	1	3	9	9 t	1	כ	9	ב ב	כן	T	Ħ	9	Э.	L.	4	9	9 :	2 9) t	13														T	9	9	Ħ	(3100
d	ב כ	1	Đ	Ð	9 :	₫ ⊃	9	כ	3 =	1	Ħ	Ų	Ħ :	. כ	1.	4	9	9 !	9 1	1 9	2														כ	9	9	Ħ	,	5800
						İ										1															3	N 1	N	Ħ	٦	Η				
						l				İ						ı																								
84 \$4 84 \$4		04		19	8	F3	9 3	 29	:9 LS	9	 65	S	9	9	94		z	5 L!	09 9	5	39	-	0	 N	₩ -) 1	۲	1	н !	9	9	<u>a</u>	5	e	۲ <i>۲</i>	97	 57	rr		
	MB12	٦.	↓⊒ £	SCIN	I HE	1	Ю	315	, di	j		a 0	07	넒.	L	ļ	H	3115	5 .	11								W	18 B	BL I	X3									

MOISTERN ENTER THE SECUENCE ATTENTION OCCODER THE THE PROFILE HOUSE OF THE THE PROFILE OCCUPANT OF THE PROFILE OCCUPANT OF THE PROFILE OCCUPANT OF THE PROFILE OCCUPANT OCCUPA

0053/34 AFTER RESIDUE 14.77 OR 14 INTERPENDING SECUENCE. 1. SHEMBLING SECUENCE. 16. 1771-1780

œ

ĕ
Œ.
æ
ĕ
α
W
2
ਹ
∢
U
•=
ਹ
⊃

	0091/0 ALEGNERY 15 ARBITRA 0091/0 ALEGNERY 15 ARBITRA	0055/0 ALIGNERT 15 ARBITEARY
TIAIRDA Kakesesaharea	qrarogradatiləəqiqi meseeses	\$ 1.1 OS+0
	3 8 7 3 7 8 8 8 7 3 7 7 8 8 8 7 3 7 7 8 8 8 7 3 7 7 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	TADA DETO
A T R D D D J	ฮูออลว วาลอวา ที่ออ้าววา	0150 C @ @
8 18 28 88 8	<u>ราวาวราวตอวา </u>	Taan ono
		BREININE

1 <u>144444 1884 1888</u> 21 T T 3 D T F I	13 a T T T T D T T D T R D T R T D T	a a t èebo
******* **** 	# 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2	9 3 7 · \$600
计算代理程式的存款的 有效 原	1)	ម១ ម ១ ៩០០
h exx maxamax m\tijioidi	#=====================================	A D T 8200
A D D T D D B I	120221000211002012	1910 (200
		.ines MINRAIN
94 74 24 04 89 99	<u> </u>	
	29 29 96 95 95 125 25 05 10 N X	19375 9* ** H = 0
HELS TADEONING	MBT2 3T MBT2 3T	EXTRA PRINCE

En. 206. 291-294 12. Ened Junaral 1, 21. Ened Junaral 1, 22. Ened Junaral 1, 23. Ened Junaral 1, 24. Ened Junaral 1, 25. Ened Junaral 1, 26. Ened Junaral 1, 27. Ened Junaral 1, 28. Ened Junaral 1, 29. Ened Junaral 1, 20. Ened Jun	C.J.GRCEN, B.S.VELD (1923) NUCL. ACIDG RES. 71, C.J.GRCEN, B.S.VELD (1923) HUCL. ACIDG RES. 71, C.J.GRCEN, B.S.LUMKETT, U.H.RCCLARR (1951) PRU RAPAZZAN, G.P.LUMKETT, U.H.RCCLARR (1952) R.E.GRES, A.E.GREEL, A.FELDRARR (1952) R.C.GRETTAN D. A. SAN-242 R.C.GLL 19, 237-242 R.C.GRUNTIZ, A.T.RGOLOFF (1920) J.BIOL.GREEN, 235 R.C.GRUNTIZ, B.C.RARTIR (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1920) C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) CURR, GERETICS 4, C.G.GRUNTICEN, B.C.RARTIRE (1921) C.G.GRUNTICEN, B.C.RARTIRE (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICEN, GERETICS (1921) C.G.GRUNTICS (1921) C.G.GRUNTICEN, GERETICS (1921)	4979-2004 A.L. SERENGE G. P. S.
attranato: nanojenao;	~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~	OSTO OSTO PHOSE T4 6 TO TO TO THE TRANSPORMENT TO TO TO TO TO TO TO TO TO TO TO TO TO
1862118281 1862118281 1862118281	. 119 8 1 1 9 8 2 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	COD
H3T2.3ITNF 900J.3IT	. L. a len en les 10 00 5	a ar are arear

AE2:60	20-6ny-62 9271220
` ¢	05 9271220
Nucleic Acids Research	
60	1
'n.	1
g	i
ij	l
ည်	i
<u> </u>	İ
ر څ	
~	1

CAST/O OLIGINENT IS ARBITRATUM CAST/O OLIGINENT IS ARBITRARY **********************************	TEARTIERA SI THISHMILIA 0/2910 YAMMILERA SI THISHMILIA 0/2910
3	7 8 8 9 9 00 00 00 00 00 00 00 00 00 00 00 00
SY EY IT 60 TO BE ED TO 82 TO BE TO	L H 3 G B 74 24 L H 3 G B 74 24 L H 3 G B C A A A A A A A A A A A A A A A A A A

-	1	1 B C C C C C C C C C C C C C C C C C C	7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	1	11: 10: 10: 10: 10: 10: 10: 10:	T T T T T T T T T T T T T T T T T T T	3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	1 1 2 1 2 1 2 1 2 1 2 2 1 2 2 2 2 2 2 2	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	5 P S P S P S P S P S P S P S P S P S P		5 B B B B B B B B B B B B B B B B B B B	COTTON	T 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5		2 E E E E E E E E E E E E E E E E E E E	1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5	Tanaaa	9 3 3 3	1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	, 13 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	9 8 8 9 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	1. THE THE STATE OF THE STATE O		. 25. 0	10:10:10:10:10:10:10:10:10:10:10:10:10:1	(10) (10) 有比例 10) 年 60 50 1 并 1 50 1 50 1 50 1 50 1 50 1 50 1	1485) 17 20 17 18 20 18 20 20 20 20 20 20 20 20 20 20 20 20 20	TAN TIE	# 6 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	VINE S P P S P P P P P P P P P P P P P P P	R HILL R HILL	enn E enn E enn E enn enn enn	5 6 6 6 6 7 7 8 7 8 8 8 8 8 8 8 8 8 8 8 8	# 11/2/2 1/2	
	TTC. 311	F .	400 GE	_	r	0€ 6	ε,	4 2	7	ente Per	ı	2	A U		 H	٠ د	 5/		£1.2	i () L	6 6	-	-4-	 S		 •		'] uo:	ָּי פ			JH D	חמ	æło		

,		ĺ
	1	ţ
	4	•
	Į	ļ
	4	Į
	•	
	3	١
1	C	l
	•	ŀ
•	1	
	ì	ľ
•	¢	1
	1	
٠	i	
	į	
	٠	•

4+41-4+48 K.SHIBUYA, S.NOBUCHI, S.NISHIHUMA, T.SERIYA (1982) MUCL, ACIOS RES. 10, (1982) MUCL, ARIDA RES. 10, 3279-3219																																											
	v	BIBS'	· F	-PLOF	7.W		403	1271																																		T SZEO	
	•		-			•	٠.										•		- ~					•••		V		•			•••	٠			•••			_	44.12		-4,		
			-,					_				٠,	,- ·			٠,									٠- ١			٠,		Ne	#KI	HK P	52 1	: X II	K #K					OTI	4		
U .	L	9 1	ㅂㅂ	Ħ	Э,	1 9	1	ᆈ.	1 ;	3 8	Ħ	1 t	ďΣ	ㅂ	£ .	ī				Ħ	Ħ	Э.	ιt	1 11	į	Ħ	1 5	3 6) U						3510		9660	
			٦,		_			<u>.</u> †.				٦.	١.	٠	•	_ ا		_							١.`	• • •	١.	J.		г				***						~~~	. 310	55660	
:		2 !	د اد	0	٠.	ı 9	1	1	JE	ביינ עננ		₫:	┞÷	٠.	÷.,			9.	1 5	9		•	Ly	, 0	١:	٠.	Ť.	75	, ,	##	. <u></u>	J	***)] KR	T					3570		5660	
# H	1 1	. J 1	H H	Ħ	J .	1 9	1	₩.	Τē	ם נ	1	1 6	ło	Ħ	u .	վ			E	ı	Ħ	1.	1 f	3 13	b	1	1 5	3 6	4	T	Ħ	Ħ	U t	1 4	H .	UB	DEJ.	l H	HIF))M9	590 0	
			٦.,		_			<u>.</u> }				Ⅎ.	١:	• • •		1					_				١	• : •	• • •	։		**	**		XXI	EXXI	M					OTIV		5650	•
		I	90	0		. 9	+	٠,		, 0	<u></u> .	46	١,	٠,	₽.	40					J	T (2 0	, 0	١.	÷.	٠.;	9	1 6		**	۰.	25 (LINE) LSB	• 0	13176) ,3169]	SAFO	
Ð 9	3	9 !	9	Ħ	נ כ	L 9	1	d :	3 3	9	3	킈ㅂ	(3	9	u !	3 8		1 3	1 9	9		1.	T A		2	1	1 5	o) t	, 1	2	ī	1	U 9	9	g					MNIde		690 0	
			1.					J:			•	ℷ.	Ľ			1 11			19						١. ا		•	Ί.		××	. *	×	441		*			211	UZSKA	SH3.365		49£ 0	
			17	•		ı y	_	٦.	1 3	10		45	ŀï	₽.	÷.:	40		•	LY	2		9	1 3	, 0	٠.	٠	• • •	1	, 4		- H		ر ر 188		73	HALK	3 30					2.560	
A 1	ıı	9 9	3 6	Ħ	3 4	l g	1	4:	כנ) H	Ħ	T F	כו	ㅂ	1.	L					Ħ	¥,	T R	ď				je	1 1	1	H	I	U S	H	9					* 195	enci	99E0	
	•		1.		٠.			.t:				٦.	١	• • •		1									•	• • •		J.												OTIN		LCCC	
3 5		Ri	1 -	D	ו נ	נט	1	4:	- 1			36	ŀ÷	.۲.	ė.	٩.		-	1 9	0		-	. 0	ם נ	١.	÷.	۽ ب	10		23				1 9 HHE						15031		PSEQ	
J :	9	1 5	j s	Ð	3	. 9	Ţ	Д:) 9	בו	9	9 9				1 8	:	5 .	۱9	g			LE	9 8				ıje	1 1	Н	9	1	9 :	3	Ţ					12031	. Э ПЭ	ESE0	
		-=-:	J_			_	_	上:				Ⅎ.		• • •		J.,		_		_						• • •		.l.,						HH									
9 5	9	3 8	77	В	ו כ	. 0	1	7) 9	כי	3	77	1	Ħ	1 !	9		9 .	L 9	9		1	. 9	טי	1	Ħ	ŤΕ	기비	1 T	1	Ð	3	T 3	כי	ī					1105		Z9E0	
			ı					1				ı	l															1							. 30	93	Œ	ษ :)II	15450			
			l					1				ı	ı											Ì	ĺ			1															
			1_					╌			·	1.	L.,			L.,									L.,			l.		L													
	, ,		æ							: 6		92			22										E																		
E	LÞ	66	4	Œ	Sé	: 1		μ		Œ	Z	4	SZ	ε	Z	z	(Ħ	61		Ħ	91		٠Ļ	į	:1	01	. [6	9	[4	8	S	₽ €	Z	ı								
MET	٠	37.14			п3.	71	ı kı-	ı,	.	e	771	MH I	١.	.	s t	1				-	1 0	,				,,e	π	1	ļ	٠,	316		17-	ONI	ш								
-431	-	11	~	30	. .		40		e T	<i>-</i>		w	•	111	3 L	_				لىپ							- L	•	,		-47	•	~		~								

CEFF 147-140	
ALLEIBS, RALVAN ETTEN, CLILURIBHT, ILLIANDERE, D.A.CLAYTON (1991)	0264
J.ELOCINET, J.D.ANARDINGCIPAGET MUCL. RCIDS RES. 11, 1761-5/75	9420
4511-1333	
D.G.CLARY, D.R.WOLSTEINHOLME (1943) MICL. ACIDS NES, 11,	PEEO
M.M.C.DE ERULINGIPES) WATURE 304, 234-24;	CALC
E-MOLECHEM, W. 101103/ET. P. R. WHITE ELD(1943) MUCL. ACIDS RES. 11, 6547-8554 MUCL. ACIDS RES. 10, 467-500	9124
TIMPO NYMBER' TECHNAN' ETEMBAN' NYKANADA' DIZDERF (1485) (1485) MNCF' BEIDZ WER' IO' 1538-3584	ŒĒŪ
ASIBS.3 , S.LAMANE, B.FEPE, TURNALIANISLLÖ, C.SACCURE, E.SBIBA	

P.CANTATORE, C.DE BENEDETTO, G.GBORLETA, B.BALLERANI, A.M.KRUGH,	0222
0.L.ATLLER, N.C.NANTIN (1981) CURR, 65%, 4, 135-143	
TTCO-+CTC , AZZ , KEND, JEIE, L	
O.L.ATELER, D.R.MAJARIFAR, J.A.FOLSE, M.C. GARTIK (1781)	
5.6.80MITZ, A.TZARGLOFF (1989) J. BIOL. CHEM, 253,9035-9981	TOTO
192-E82 ,S .L 9883 (E891)32141141,1,2314380A 30.8,3,634342.L	
(1980) NATURE 287, 750-752	
O.SCHOLDT. J.AMO, R.OGDEN, J. PECKRANH, H.SARANG, J. ABELSON, D.EDELL	ESEO
8777-1777	
"SEE SCION '10MM (2841) WILESELLY 'SERVINGER'S 'SHORBOR'S 'VARRERS'N	
SATT FORTY, SATURATED TRANSPORTS WHITE WAS SAUTURED OF SAUTURED SUITERS	PPPA

"NI	איתיגאם	" CHARALLAG. 8	.AT3JAGAB.B	*011303k3	TATORE, C.DE
		4° 132-143	CURR. SEX.	ILIK (1681)	ונרכעי איכיעא
					דייםאפאי צפיף
					AN,A.O ,ABLIS
					MAXI_A , XIIMO:
	165-185	.5 .L 9893 ()	[861)3844[7]		MA 30.0.3, FEM
					.SBS BAUTAN (

0125/75 IS REPORTED TO BE C IN A.OSCORP, A.FEEDRAWN (1781) CURR, CAN. (1782) ANCHARAT IS REGITUMEN 11, 1604-8424 (1782) OSCORP OF C IN A.OSCORP, A.FEEDRAWN (1781) CURR, CAN.

<u>0</u>	**	61 6 Mari) 1 	## 9	### 	H 6	E		כ 	1	1	1	8	9	,	1	5 5	9 (L #	1															. t		0398 0392	
-	k W H	NAM.	1	##	HÄH	•			-;-	-	•	•	н	•	<u> </u>	7		60: H				ı			4-1-F	; ,										. 8		2050	
	ī	L	L L	1	T.	1	. 6	Ħ	<u></u>	3				_	ī	7		E 2			1				,											ט	_	5960	
g	3)))) T	9	7. F.	1	9	3	2	<u> </u>	9	ㅂ	9	כ	1	4	9 !	9 6		9	1													:	9	B	a	6960	
9	U,	9 t) O	9	0 ***	1	9)	כ	Ī	Ħ	Ħ	9	ב	1	4	9	9 9))	2														9	B	2	496 0	
8	1	#; T :	HEN:	ㅂ	1	4	ᇤ]	1	Q	ŭ	Ħ	1,	د ,	기	H :	9 t	1 1	H	1														1	9	Ħ	9SE0	
9	J	*** T 1		9	U.	4±		9	Τ.	∄ +	Ħ	Ħ	Ħ	3	9	4	9 ()]	9	1													•	9	9	Ħ	1/SED	
	- H M	8 £	בינ י	9	J.	40	••		3	3 +	Ţ	Ħ	Ħ)	1	4	9 9	9 E	2 (] ==	1								•						Ħ	9	A	6960	
*5	8	2 6	9	9) C	19	כ))	11	1	8	9	כ	1	4	9 1	2	9	כו	כ														Ħ	9	Н	2320	
										<u> </u>																		. 11	200	(כזל	8 2)1T5	1249	ă				
27 £7 87 }7	۲. کلا	02 4	CO (79	19	333	+9	2	:9	99	9	7S	\$		5	9	29 S	19	09	5)	₽₩	a	0 6	H	1	K	r	I	9	4	3	2	B.	٥,	8) Sr	*		
į	O 1	\$ 7	K)	O.	IN	4	И	315	3.	J		æ		4	1	ı	M3	115	. 4	ıμĺ								WEL	1 15	AT)	(3								

0344/0 PTJENNENI IR ORBITHURI 0364/0 PTJENNENI IR WEBILHURI 0365/0 PTJENENI IR WEBILHURI 0365/0 TST-120

ع
7
=
ũ
Œ
- 4
. 4
Œ
_
-9
7
-
•
Œ
9
=

T TAART 1008T	045/0 ALIGNERIT IS ARBITATION OF THE CONTROL OF ARBITATION	. H. Pelonaristi (Urr. 65%.	VANTIERS SI THEMENT O-VTCO THANTIERS SI THEMENT O-VTCO THANTIERS SI THEMENT O-VTCO THE STATEMENT SI SI SECULIARION THE STATEMENT SI SI SI SI SI SI SI SI SI SI SI SI SI
******		p	
11362694	38737 37884	1 2 2 2 4 1 2 1	998 86M
ที่ 1 วิดอิตต ปี	3811 111	r	9 5 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9
	38111	TBARTER	998 S8*0
Maraana manar	อออหฐาคคควา	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	see carps
MANAGAMAN AND	*****		1 1 B 6S+0
KHHHHHHHHHHHH			888 8840
717388888	2 a t 2 1201202 2 a f	a aa	0424 RGG ,
	3 A T 3 T D T 2 T P F	ยคอดายา	998 2500
4 T D T D T D T D T D T D T D T D T D T	TTDTTTTP001	TORORAT	141 1510
l i		77-	- · · · · · · · · · · · · · · · · · · ·
			CYSTEIME
	EEEFF II	== =====	
RANNA ******	T D T J J T D A A A D	ที่อัคคว <i>ล</i> ุ่า	19 t 68to
AII 3 1 A I A	TRIDD THRRI	3554141	1 H H Z660
! !			Jaco Mide Strenge
			4 411711 %17001020
		- 	
24 E4 14 E29 48 E2 84 ≯4 \$4 04 69 88	+9 239 108 975 89 8 C9 L9 65 ∠5 926		
HEITS TAXOUTHE	M3T2 चा। च्याध्य वा	I NOTE OF I	AR GRING

A.TARAA.E.YDGMIDA.A.KUBARAMI,Y.YAMIRUMA.K.XOIKEK1943> MUCL.ACIDB REE. A.L. AGGS-4445 A.L. AGGS-4445 A.L. AGGS-4445 A.L. AGGS-4445 A.L. AGGS-4446 A.L. AGGS-4446 A.L. AGGS-4445 A.L. AGGS-4445 A.L. AGGS-	0397 S.ANDERSON ET AL. (1981) MAIGNE 290, 457-445 0399 S.ANDERSON S.R.ALLESBELLY A.R.A.R.COLDENT (1970) MUCL. ACIDS 0451 J.G.YOUNG (1982) J.ANDLESDEL, 154, 625-712 0452 J.E.EELANI, C.PERTELLA, B.RACINO, A.TANDLOFF (1970) MUCL. ACIDS 0453 A.NDLINDP, C.ANTECTER, B.RACINO, A.TANDLOFF (1980) J. INCT. 0454 O. ANDLINDP, C.ANTECTER, B.RACINO, A.TANDLOFF (1980) J. INCT. 0455 A.TSG-1075 A.DEC-1075 E.EADALETA, A.M.RADDN, 0456 A.TSG-1075 A.
R D D T T A A A D D T T A D D T T A D T	тат пата а паттотара тазыск пов вело тат пата а паттотара тазыск пов вело миничиним ртін
Ratifica at 2 and 2 1 4 1 6 2 4	A A T R R D T T D T D B * PERLIN R D T T D B S + 00 T T D T D B S + 00 T T D T D D D D D D D D D D D D D D
ลอา การกลวอกวุลคควา สุดเลือกล	онео сели из в сели из в сели и по
Troofagaatagaagaaga Taa	T B R S C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C C B C C C B C C C B C C C B C C C B C C C B C
8 3 1 2 1 8 6 6 2 8 T 1 8 8 8 2 2 8 1 6 2 6	B I I DI SS E EL STATE CHEATS , SU C C L E E E L L L L
na	RITIA 2 T a 2 H RITI 2 D 2 B R THOTOTHEN EIRBON IR RO +2+0
a a o o o o o o o o o o o o o o o o o o	PROMOREN DITE
	RATITIATTA TABRA 12827 ROS (2NO 12827 ROS (2NO 12827 ROS (2NO 1282 ROS 1282 ROS (2NO 1
	CYSTEINE
	3,1,313,2
	OLIM
<u> </u>	ควกสุดที่ใปลาโาอิเออกอ *SMIVOE CLES
ดาาอดุดถวาธาปุราคดปุควารท	ควาดคุศตลอไดกับถูก ออูกูล * พลูพูพู่ อนอ จอะย
	הפוימולונ הכום בפחל.
18 SD B SS S4 SE S9 30 35 34 38 40 45	
EN TH BE TE BE EE FE ES TS ES S R P. E.	B B + 1 Z 1 O1 G G 4 8 5 + E Z 1
רססף נים אוני אוני האוז ב-גמוא אינו האוז ב-עסטי אינו ב-גמוא אינו אינו אינו אינו אינו אינו אינו אי	UNICHEAST IN SEED IN SEED IN SEED IN
•	

0229\0 HTERGERI 12 WHITEVELL 0229\22 LHE 2.END UR LHE (ENW NEW NOL RELEWINED

Nucleic Acids Research

YARATISMA SI THEMESTA 0/7040 YARATISMA SI THEMESTA 0/7040 YARATISMA ZI THEMESTA 0/2020

£
5
9
98
<u> </u>
ğ
Ų
3
Ď
ਹ
ź

'56'-155' רם" כ'59נכנטאנ" ("פונטא" "פארדפטאנו" עישיגאטטא"	71, S.E.BONITZ, G.COBUZZI, M.WOBRE 15 KES. 6, 2017-2030 ES. C.OR EKROETIO. G. GADALETA. B. E.LANAVE, G.PEPE. E.GUNOLITARIELI B.L.CARGOR(1962) 14, 1379-2289 J.A.CARGOR(1962) 14, 1379-2289 L. ACIDS RES. 14, ACIT-MAIL. E.MMAI	101514 - 10.01.01.01.01.01.01.01.01.01.01.01.01.0	(1091) 2517 32° 320-346 10° 903-317 1° 903-317 1° 508-608° 1°C-646808° 1°204668°	0499 S.AMDERSON, N.H.L.DERKHIJN, A.R. 110.7304 (1982) J.ADL.BIDE. 19 110.73040 (1982) J.ADL.BIDE. 19 0520 W.AMARJINA, H.OZERI, Y.SHIRUKA 0520 W.AMARJINA, H.OZERI, Y.SHIRUKA 0521 H.DERGENES, G.A. LAZANUS, W.SE 1980 (1980)
	188211128218 11888812828	1199 194 14914	7 8 7 8 7 7 7 7 3 9 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	
T	18888383838		10100011 18 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	* TRH BULL ESSO DTIM
	1		A D A B A T B D T B A B T	OTIN TERRY JULY SOED BITIN
8833TTR8TTT	100003455988		RIDD BOT RIBBOT	OSSO CUG REPERBITUALS WIDLE
	7 1 2 2 2 4 4 2 2 2 4 4 4 4 4 4 4 4 4 4 4	1	HANNENSHERSERSERSERSERSERSERSERSERSERSERSERSERSE	1,000.3 &U.D 0f20
012313031.11	9966	Tab ITah		N I N B 1 1 1 1 1 0 N I N B 1 1 1 1 1 0
8 8 3 7 7 8 8 8 3 8 7 .	7 7-7-7-7-7	7778	ROTO OTO COLOR NAME NAME NAME NAME NAME NAME NAME NAME	OTIN
да Эття в в э эт	11 8 8 3 1 1 1 1 1 2 1		a a f a a a a a a a a a a a	CYSTEINE Cont.
24 04 BE BE 46 21 Et 14 68 26 SE 68	8 22 25 25 29 30 3 8 22 24 28 29 30 3	02 61 51 31 5	ZL 01 6 9 2 9 5 + 6 Z L	
HST2C.LODY RIVITIC.STEM	I NSTE. STEM MSTE U	±001 ¤	MSTE 8 HST2 JYZHONING	

				•	
	MARRAGENERS	H eresters w			
	FATET REF			я <u>ант</u>	8550
-	* 336336T	ลอออาวารคอวา	1 1 9 9 3 3 3 3	3 883	>550
	B R T D D T.0 T	татэзттваэт	108815	<u>រ</u> ១១៥	6880
	R B 2 T T R B 2	BAAR 21 AR8 3 1	101111	, i e i	Z990
	A B I B D B B D	2222213027	101000	1 181	LSSO
	8 0 2 2 2 2 T T	B D T D D T D D D T	TBBRB1:	3 1183	0250
	a 6 2 2 2 2 B T	D D R D D T R R B D T	7 9 2 7 2 3	_ _ _ _	OLSD
	a a a a a a a a a	11133189837	108884		LOSO
				3 N I N U L T T T T T T T T T T T T T T T T T T	
	11399993	38737 TAAST	7 3 9 9 3 9 9	, , , , , , , , , , , , , , , , , , , ,	66+0
	π် <u>၂၂၅၂</u> ခု ခု <u>၅၂၅၂</u>	ратро яввот	120000	- · · · · · · · · · · · · · · · · · · ·	∠E†D
]	CYSTEINE cont.	
	1				
92 > 2 54 E		19 29 09 95 95 1 19 69 19 65 29 95	S 25 05 P		
	[ES 15 6	45 47 B D F H J L H P	
	HBT2 JYCHONINF	HBT2 TI 900.1 TT	HETE TI	няя вяткэ	

OSSZIO ALIGNAENT IS ARBITRARY

. 148, 107-127 148, 107-127 148, 107-127	. AGL. BTGL AAMEFEA RI ES. 11.	40158 8 60 18:0 90 18:0 13	.coulson. Loa, Lob. Spring Mar Maring Mar Maring Mar Maring Mar Maring Maring Maring br>Maring M	#100. EFTER; PUBT,A LGGLD : URA E3:	ין עמר ין מוצט'דינין מוצט'דינין אינטאנגי אינטאנגי	11963) 1.1261 1.1361 1.1361 1.1963 1.1963	15-3642 PETRON'I PUBLICAN'I PUBLISHINE S'AGOME.	100 1'4 08' 1'7 1'1 40' 1'1	70	19413 NG1187	4"CF\$ 85KE 41¢	380' f23-f92 12 "EE" 11' G403-EETE' 0'' 1"EE" 11' G403-EETE' 0'' 1"EE" 11' G403-EETE' 0''	G.D.KARADIN, R.D.HOLLICE (1953) H.GEMD.R.GHOUNGHIPED WUCLETC & R.J.ALBER, R.A.VAN ETTEM, C.T.WI R.J.ALBER, R.A.VAN ETTEM, C.T.WI R.J.ALBER, R.A.VAN ETTEM, C.T.WI R.A.MESON, ET M. 13961. MATURE S.A.MESGON, ET M. 13961. MATURE S.A.MESGON, ET M. 13961. MATURE R.A.MESGON, R. 13961	0261 0271 0271 0221 0227
9 0 0 0	כטנ	111:	: פככ	<u> </u>) b s	4 4	113	9	296	8 D T &		66CCC61	מאוכ פטכנוריה? פחמנורנ?	0180
99399	כטכ	7 7 7 ;	2 2 2 2 3	5 = d	3 # 8	១ ១	פככו	9	H 9 t	1318	ם כ	STECCET STREET	טוטל פיכטרז	E090
			ł									arse	BLUTAMIC	
11311	899.	T T T 1	9 4 9 1	 	.	ยีย	9 9	9 1	THE			TTCABRI MH MMMMMMMM	SHIADE DUU	6690
98331	មម១.	7 2 7 3	899.	1 3 1	כאכ	9 B	110	9	TRE	TOTE				965Û
31311	ម១១.	T T T 1	8 8 9 1	9 9	ָבָ,טָיָב	9	a t	996	1188	1915	9 9	**************************************	OTEM F MANUN GUD OTEM	ZES 0
11311			h	-		-1-	T D	_	A T T	*****		AN WANGERNAN GIRBBRT	01(M 32U0M 3UU	9650
11311			999	- 7 7	288	_ _	T 0	_	T 1 A	******		#### #################################	CHOCKD	49 50 65 50
20222			999	- 77	3 9 9		19		188	-, - ,-,-,-	-	8	CHCARO	9930 0229
19133	. פפכ	TTT	999) H H	2 9 9	8 8	1 3	9	198	פבכש		REMARKAUKHANA	כארסונס חרופ בחפרופאט פאטכורונ	49 50
												<u> </u>	SLUTHTINE cant.	
***						<u> </u>					ļ			
64 14 86 SD 04	96 96 76 31		1		53 54 53 55	-2 -2 -8	oz (St or	6 9	782455r		
HETZ. STEH	רסטש ל	CATTIC.	METZ. 31	mb l	HBIS]	ď	ם רסב		NETZ C		HEIR JUSTINE		

EXTRA DRIVE (ATT) A 46 P C E G 1 X H C 46 SI S 52 S 52 S 55 S 54 S 50 S 50 X O X O X O X O X O X O X O X O X O X		 + #	•	нн	神風	NA.	HH	P==	===	==1	5 2 5	Ť						۴.				==1																				
25. EX FX BY BY BY BY BY BY BY BY BY BY BY BY BY	•	13	Ţ	9	9 !	9 3	1	Ţ	9 :	3 :	3 3	1	U	R	9	, כ	L.	Ľ	2	9	ב ו	법	٥															Ħ	ฮ.	1	018	JO
1	Ε	ſΞ	Ħ	9	9	ם פ	F 1	1	3	J :	3	Ţ	ㅂ	ы	9 :	ו כ			1 9	. 9		'n	7								•											
25. EX FX BY BY BY BY BY BY BY BY BY BY BY BY BY		1										ı -		_			•	1`	•	_	_	٦	_															0 ;	a ,	ī	505	D
25. EX FX BY BY BY BY BY BY BY BY BY BY BY BY BY		l																1				-1						- (1	ב	Ħ	כ	1	H I	4 T	រា	٦ 9	í				
25. EX FX BY BY BY BY BY BY BY BY BY BY BY BY BY		L				_												L				1																				
25. EX FX BY BY BY BY BY BY BY BY BY BY BY BY BY	9	LE,	l L	** ``			**	٠.	H	,		١.						Ì٥	==	25	==	_									٠											
25. EST F C E G T S 29 E3 E3 E3 E3 E3 E3 E3 E3 E3 E3 E3 E3 E3	_	-	ı##	**	au.		**	.		•••		+	Ţ	0	υ.	3 1		L	9	-	 E2:0	3	a															9	9 t	5	665	O
25 ES T	Ŧ	[2	2	Ä	H E	9	14	9	9 :) T	. =	T	Ħ	8 (# :	3 1	. 1	9	H	9	J	ä	1															н,	g -	1	PRO	Λ
44 46 B C E G I K H O 46 50 52 54 56 56 66 65 56 56 66 67 70 70 70 70 70 70 70 70 70 70 70 70 70	9	8	I	3	77. [[ы	1	H.					.	n -			٦,		FE	== ±	Ί.	_																			
25 ES T L E G T K H G 42 SS SS SS SS SS SS SS SS SS SS SS SS SS	j	HE	**	××	K HE H	**	**	-				-	_			•	•	-		20	-	٦	3															9 9	9 H	,	26 S	0
25. EX FX 9. D F H 2 L H 2 L B 55 55 55 55 56 66 66 56 76 75 75 75 75 75 75 75 75 75 75 75 75 75	59		1) 	7 T	9	4	1	# J	נו	3	Ţ	ΤI	9 (1	1	ı	2	9	Ħ	Τ	9	1														•	9 1	3 6	1	869	D
27 57 75 28 58 58 58 58 58 58 58 58 58 58 58 58 58			1	5	֪֞֞֞֞֞֞֞֞֞֞֞֞֝֞֞֝֞֝֞֝֞֞֝֞֝֞֝֞֝֡֡֡	e	ור	1	ן ט	בו	3	1	1 1	.		1	1	. 9	9	H	•	al																	-			•
27 57 75 29 29 59 59 59 59 59 59 59 59 59 59 59 59 59			42	***		**	빵	=	. **	•	-5	-				_	٦	þē	3E	•=	^=	=	•															3 5	10	,	299	D
25 E5 F7 B B F M J L N P 48 51 52 52 53 58 87 69 62 62 62 76 75 75 75 75 75 75 75 75 75 75 75 75 75			18 18 18	HHH	1 T	. 9 9	3	J.	7 = E		.3	1	A 1	9 5)]	Ţ	4	9	9	U	9_	Ы.	2														1 1	Lŧ	1 1		659	٥
25 E5 F5 B B F H J L N P 49 S7 S9 S9 F8 E8 E8 F8 E8 E8 F8 E8 E8 F8 E8 E8 F8 E8 E8 E8 E8 E8 E8 E8 E8 E8 E8 E8 E8 E8	9	Ħ	: כ) :	1	9	3	Э.	TI	נו	7	1	u :	, ,	, ,	1	لا	9	Ð	ъ.	9 1	<u>.</u>	3																			
45 47 8 10 F M J L M P 48 58 56 56 58 64 58 58 64 58 58 70 75 75 75 75 75 75 75 75 75 75 75 75 75		HKK H	**	***	t XX KE	***	**	==:		2	==						7	==	Z = :		-	┛`	_														1.	. 10	, 1	•	453)
82 PZ ZZ 0Z PR 88 +9 Z9 D9 65 95 Z5 05 D+ D H X I D 3 D H 8+ PF SZ SZ LZ 65 E9 E8 E5 E5 E5 E5 E5 LA D LA D LA D LA D LA D LA D LA D LA	1	•		٠.	, ,	ט	1	٠.	7 1		7	T	0 :	1	כי	1	4	9	9	b	9 !	9 :	3														1 1	L	, ,)	Z99	3
82 PZ ZZ 0Z PR 88 +9 Z9 D9 65 95 Z5 05 D+ D H X I D 3 D H 8+ PF SZ SZ LZ 65 E9 E8 E5 E5 E5 E5 E5 LA D LA D LA D LA D LA D LA D LA D LA	Í						ŀ										- 1															. 20	٥>	9	NTL	94 F	070					
S4 54 F3 E3 E3 E3 E3 E3 E3 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5							1				- 1						ľ															•		-	••••	~-						
S4 54 F3 E3 E3 E3 E3 E3 E3 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5 E5							+										-4					-																				
Male 11 paration mark at 1002 of 1002							-1																•	1	0	¥	1	×		1	9	9	3		ב כ	H	B)	,	++			
EXTING GRAH TE STEM TE LEGP TE STEM DAILHORGYL STEM	i		-	_			Г	J	-3	•	- 2	6	3	٤5		25	ı		•	5	61	7	•	ď		¥	٦		r		н	3		Œ	€		24	SÞ				
	H	(31)	5 7	K	UD	NIN		н	1311	5 :	шl		d	DQ	٦,	4L	Ī	3	431	5	٩T	l								101	,	SHL)	G									

_
**
Υ
=
- 50
9
ຜ
es
Œ
4=
v
7
Ų
⋖
U
.≖
Ψ
_
S
=
~

8	T J	• 19	TUN (12 24 13 143 143	(/8· (†) (1)	- TP - SS 1 - TE - TE - TE - TE - TE - TE - TE - TE		**************************************	2° 8° 981 981 552		96 '3' '3'	,2 AN HT IC3	.W. 1A1 3R2 4	- Y:	. A.M. 3717 4 A.M. 14 A.M.	22) 23) 20) 20) 20)	61: 861 861 101	100 173 14 14 184	10: 40: 40: 10: 10:	3 N 1484 1484 1484 1484 1484 1484 1484 148	AY. 20. 10. 1.	17 17 17 17 17 17 17 17 17 17 17 17 17 1	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	717 73) 70, 11, 11, 10)	(3") (3") (30) (30)		5	69(29) 59(59(101		1/ S62	-13 4-5	53 174 54¢	• · · · · · · · · · · · · · · · · · · ·	1E C E T	# 51 /11: -25 773:	1010 112° 12° 10) 100 100	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	12F EV8 12F 2-1	N (1 N 1 1 1 1 1 1 2 7 N (1 N (1)	11, : CAR B L B E	(18421) (1848) (1848) (1848) (1860) (1831) (1831)	THS: (18) (18) (18) (2 () (18)	3"HI 102" 102" 102" 102"	1 (1) 1024 1024 1034 1034 1034 1034 1034 1034 1034 103	SACO SALL SALL TING TILL	30 4" "9 4" "8 "4 "6 "1 "1334"	TEM TEM TEM TEM TEM TEM TEM TEM TEM TEM	14-552 1-737 1-737 1-409 1-409 1-409 1-160	H.A H.A H.A H.C A A A A A A A A A A A A A A A A A A A	2590 2590 2690
8558748748748748748787878787878787878787																						OTI																														
			<u></u> .	-	1 6	3 .	J .	T 1	נו		1		, 5	3 ,		15	ŀ	3.8		: פ	1						Ħ	Ţ	T	a	A	9	Ŧ.	+.	9	u .											* :	95710	M .	חחכ		9690
	9 :	ב כ	9	Ξ	J 6	!	ο.	1 :	ו נ	ו ב	Ŀ) :	9	2 (1	4	١.١	1 !	9 5	1	3	1	. 1	9	9			1	Ω	ㅂ	T	5	Ļ	9	9 .											3	1500	M :	ota		9680
	R .) 6	Þ	╡	J t	d :	J .	L	L	. :	1	9	1 (2	נו	l	į,		3 9	9 9	ŀ	1	1	,	9	9			1	9	ᆸ	T	כ	1 1	9	g .	1 6	ine J l	ä	3	2))	T .OM	d'E	н (נרם	Heli	190 8	ia :	m		0290
	9	ט נ	9	1) E	1 :	. כ		Li	. =	l.	,	1) :	١.	١,		1 9	 3 · §	١.	1	1	2	9	9			_	В	Ч	ב		1!	او	A .	1 2	**** 1	* * 1	ener Si		***: 	T SIESHE N	ы 5	an.	lus.	128-8	лтн	rs .	חמר		299 0
				1							ı					4	۴.	• •	•	• • •	1		_	_	-	_			_	_	ŀ	• • •	• • •		•		24	-	111	eus.	H	*				april,		OTI	H			
				֡֟֟֟֟֝֟֟֝֟֟֝ <u>֚֚</u>			, ,		. 1	. 1	1		E			1:	ŀ			,	4						U	T	ī	H	٩	Ω,	÷.	Ť.;		.	Ų	1 T	2	Ţ	Ţ	T :	₿				гъ	40.1H 12		200		9590
	9 6		9	9) E	1]	ו נ	LI	1	. 3	L	1	1	. 3	1	Ŀ	(:	, \$	1	9	ł	1)	כ	9	9			Ħ	9	ㅂ	1	7	į į	9 1	J .		1 3	_	_	-			ורו	JU	49		תפר		T I		9980
	9 :	כו	9 .	: c) t	1 2	,		1	3	9	1 3	9	9	1 3	4	1	L t	, ,	9	ų e	1	1	Ţ	9	9			1	9	님	1	Э,	1 9	9	5 J		e e										18	H :	כחב		290
	A 1	ī	9	īl.) t	1 7	١,	, 1			t,		H				Ι:	, , ,		3 P	١.				9				ш		J		-		١.		•	ENN!	H	911	**	# U !		~* b		~-		945 D11				~~~
•			_	-							├-					1	ŀ٠	• • •	•	•	1		_	_	_	_		•	U	2	٦	٥.	٠.	•	1	9 ,	h	HH	ĘK)			F		fi Tal	3			OTI		, 0 1	٠ '	E S 90
	A S			ๆ ·	L t	בו) 3	LI	. 3	1	13	בי	 R			י	13	Ė	. 5	בנ	۱	,	1	T	9	9			1	H :	뉙		₽.		4:	נ כ		i T					S.VBAB	3 5	30	VIO		שכנו	\$:	תונו	i	2580
;	A 3	9	Э:	3:) H	כו	Ţ	L I	ı	ב	9	9	בי	כ	1	ย	4	L	2	9	t	,	1	1	9	Ð			1	Ð	þ			1.5			Ų H	1	۲,	,	3	- 1	L 'ON	۴ú	H t	ЛI	HUC	501	s :	כת		LS80
	9 9	1	9 :	3 :	3 6	כו	, 1				9	כ		5	1	ᆸ		ם נ	1		Ŀ	ŀ	1	3	9	9			ב	H 1	┛	-			1			I T									ı	943	u :	m	ı	OEEE
				1													ŀ				ĺ										1				1]															
																	ı														ı				1		1						. fras	uI	-10	Ji	×.	11 E)				
				╬.													Ļ.				Ļ.										1				ļ.		ļ.															
•	> >	 Lb	}} G€	P	Æ	96		PS	Œ	ᄹ			_(ZZ				02		ìL	4		S			ı.			I.		١.		_													
		•		1									ΕZ		1	١ ١	۴	;	•	•	ř	i	0	١	iL		Ħ	8	L	•	۲	Z		01	Ή	i B	14	8	¥	7	E	6 1	٠									•
	HBŢ	5'.	III	AR	q	00	٦.	J1.	TW	B	H	31	5":) T.	1N	8 I	l	Ю	TZ	α	1				ď	XI.	1 0				ı	HB	15	0	ł		K	ar.	, T	כא	HÜ	ΝI	et.									

SMULTATUM MULTER DALICATING UNITE DELETION AUTRIDISC YAMATHAMAY	IN YEVENTING UNITS C TRADES GENE II HAS T	
	22.2 24.7 26.2 26.2 26.2 26.2 36.2	\$250 \$250 \$250 \$250 \$250 \$250 \$250 \$250
5 8 8 8 3 7 7 6 7 2 7 2 7 2 7 2 7 2 7 7 8 8 8 8 7 7 7 8 8 8 8	е-итямис яси; я е в в е е в т е	0630 1230 2280 6230
ST EST IN GRINDIAN METERN THE STEM PRINDIANT STEM SATURE OF 18 69 69 69 69 69 69 69 69 69 69 69 69 69	2 2 2 4 44 G E E	

THANTIBAA BL TUGMENIA 0177840

_
7
a
a
a
à
ñ
ш
0
-
C
Ā
~
.=
•
=
Ü
-
$\overline{}$

P'ATBURITS: W'12VEOFORE (1689) "" BIOF" CREW" 522° 6052-6087 62° 7101-1108	
, NAMADIEL (SAPE) DEISAN, T. ARUMANN, N. ABANAT. T. ATOZOY-T. APLICATIO. A.	G699 G. ANDERSOM, R.H.L. DESKULIN, A.R. COULSON, E.C. EPERDN, F. SANGER,
ryandadir 1.80251, A.Candy (1981) Kalure 294, 422-427 B.Ak.J.D.Friend A.Candy (1981) Kalure 294, 422-427	
J.BACT, 152, 775-779	
	•
	•
פפד הפהכדב הוב ביובר בחום בפחח	ספר אקר ארווא אומער, אין פאר ביר און אוא פיר ואר אר און אוא פיר ארווא פיר ארווא פיר ארווא פיר ארווא איין אייר א אנדער
	ENWERNMENNINK OTIM
	a traditable in 1870 1870
- катоыряроттороворијовтив тове	סאלס עכר בובטבו בכב ב ב ב ב ב ב או ב ל מד או דו פ
Set Heachpeacriseccanberce	- 0705 + GCC E.COL.1 6 G G G G G G G G G G G G G G G G G G
	Account of the property of the
<u> </u>	a tar[jīta]ar[aarabbja zvirtsuz zulline zoa 8070
датоняносторовопория пов	B TORITTER TOTA OF DO SIJITALE SULJITAR DO SOTO
	***** 图
คอาวทุดความากลดกาที่ปุ่วกาทีค าออ	в тяфтятар датаара — +тээнчэг rovo
	. פרגכואה
	HERMANNER OUTH
1837475777788743	คอาคดูอาวาอดาโอ⊤าวารอ "avtvos ว∪ง esso
Baararcaceceritcade Taba	0250 UCH2H3N TCCCTGGTGGCTCTGGT 6
	OF IN
. + ค ± + ศ + ค ≥ + + + † + อ อ † คุ่ อุ ว ค ศ ⊃	атдарттајаттотта жижин⊐ии ∨880
	הנוחדאוב הכום כסהל.
]]
18 20 B 22 24 28 28 20 22 34 36 40 42	
Es Te BE TE BE EE EE ES TS BE ES IS A BE	A Br by St Orle 8 1 8 2 b E S r
מספ עונכיבופא אונכיבופא אונכידוסט אונכיבופא אונכיבופא	אוואסאבער צובא א פונבא א מיני

and the state of t	
	•
	·
	9704 S.D.TUCKER, B.S.GOYALBKRISHAR, R.SOLLIMGER, W.GOWHAN, E.J. ALKGOLA(1782)
952-932	E-E-TRUMBUMBEX" 1"K-WERREN (1892) 1" BIOT" CHEM* S29° 181-188
M.G.KDECHEL, C.A.LAZARUS, R.SASAR, H.KUENTZEL (1981) CELL 23,	0302 C'1'88EEM' B'2'ADED (1805) MREF' VC108 8E2' 11' 2142-2134 0325
D.L.MILLER,M.C.ARMIIN(1503) CURR.GEN. 4, 135-143	OLOS C"T'EMEEN' 8-2'AQFD (1482) MBET' VCIDS MEE' 11' 2592-21)
5.8.304112. A.TZAGOLOFF (1980) J. BIOL. CHEN. 255, 9075-9061	1200 Tablusan, Janel Sen (1960) Janel, 6101, 125, 351
921-1101-1104	1.6.YOUNG (LY62) J. NOL. BIOL. 15A, 683-717
NAMED TELL (SAPE: DAISAN, T. ARDRANN, N. ARBANT, T. ATDROY. T. ANLLAY CA.A.	G459 S.ANDERSON, P.H.L.DESKUILN, A.R.CODLSON, E.C.EPERON, F.SANGER,
L'HUDSOUL J.ROSSI, A.LAUDY (1981) MAILIRE 294, A22-427	NES. 11, 2231-2562
0.8ACT, 132, 773-779 G.AN.J.D.FRIESEN(1960) GENE 12, 33-37	0450 LT.P. EERDERES, M.STEREZ, J.D. SMITH (1963) MUCL, ACTOS
OLE-ILL CS: 1348	SAST S. NADERSON ET AL. (1991) NATURE 190, 657-665
	·
	''''' MARKERNERSHARA (1774)
reading the contraction of the c	סייב של הבאפונות אומתר פופחנו שו פונושו באום מפונושו ב
	DITH COLUMN THE PROPERTY OF TH
TADAIAADSTTATATOTAAATDAAIA TOO	TIARTIES ARTRES TA TERM TENSY 200 (200

しゅてつ しゅうつきてつしゅ しょうけいしゅく ガー・カー・カー・カー・カー・カー・カー・カー・カー・カー・カー・カー・カー・カー	סאס עכר 3. במבנו פכ פ פ פ ב פ ב בון בן פור און ביו בו
ізты ардорот тозвод до образів	070+ 6CC E.COL1 6 C G G G R R H R R G C T C R G T T
	NAME OF STREET STREET,
อรอสุคควายาทุวาทุววฤศาสตายค าออ	Tarataintabanaaaa 2010 tarata 2010 1000 1000
9139443311334484 (68)	1111111111111111111111111111111111111
อราชิยควารเมืองควาปวัวที่คุดค เอง	Toptition at a second s
PIDIO HILITORIA DE LICCEBRICTE	PRESENTANTE
อาวที่คอววารปลอควที่ป่วคาปค าออ	тя фітата јо тата а о о о о от эзем от о
	1 1 1 2 2 2 2 2 2 2

	_						-														_	s =	= =	-=1																										
	ſ	1		Ι.	Ξ,	9	Ы.		3	8	9	3	4	1	Ħ	U	9	-	1		ք	Ħ	9	5	ī	5	1																		£	3 ,	T	9	25	Z D
	ľ	¥#.i Lt	3		*** 3	EM L	H MH) .	# *		T •=	3	1	1	Ħ	9		ı		J	9	Ľ	9	 _	 9	1																		ŧ	1 6	H	9	ιs	ZD
	×	# HI			M M	KH			•	**			\$				_				ŀ	•	:	=	=	==	١.																				_			-
1	١,	⊒ : ¥X1) (4)	J .] 	**	9 . **	١.	י •	52 F)	_		4	ī	1	U	Ð	-	•	•	1	9 ••	9 =:	2 :=:	3	5	1*																		-	, ,	9	1	OZ.	20
1	Ł	2 6	:	2	2 :)	L	刂-	1.5	9)	1	Ė	T	9	t	9	7	1		Ų:	9	ď	g	5	9	9 3																		1 5) !	9	ā	۲Q	Z 0
1	ſ	3 E	١.) :))	L.	1	3 .	ָיַ ו	9	: כ	5	3.	ı	ď	ש	9	3	Ţ		Ţ	9	9	9	כ	9	5																		Ł	, ,	9	9	£0.	20
	۲		×	101	×	**		f,		==	3 :		7			н	ๆ	,		1	Ė	= = 9	= = 0	9	ī	9	١,																			•	9 .		ZO.	/n
•	k		1		*	**	K#1	1	•	-			7	•	•		2	_	•	1	ŀ					-	-																							
1	ŀ	2 (1	:)	LI	ן צ	4 1	L t	H :	. כ	Τ :	7	1	1	Ħ	9	2	1	. 1	1	Đ	Ħ	9	1	5	Ţ																		t	1 5		1	LQ.	ረወ
	l							1					L								ĺ						ı													3 M	1			٦	9					
	l												1								-																													
	l	##	H	(11)	(1)	(*	٠.	Ė	=:	==			•				_				H	==		20		-	١.																		_					
	k	L C F	*	***	ent)		1#1 1	4:				J .	4	1	_	0	9	Ľ	1		Ŀ		9	• •		::	1*																		2	, ,	٥.	1	CCI	40
1	۱	1 t		1) t	:	֝֞֞֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֡֓֓֓֡֓֡֓֓֓֡֓֡	Ŀ	9	3	3	ב כ	4	1	Ţ	Ħ	9	Þ	Ţ	1	Ŀ)	9	9	ב	3]																		=) E	9 :	כ	96	30
t	١.	ľ	t		ŀ	,	, ;	Ţ	ננ	. :	9 :	5	₹.	L	9	Ħ	1	9	1	1	Ţ)	9	1	9	3	1																		5	;	Э.	T	ZGS	3 0
								1					1								١																14	03				ΒII		ın.	10					
	۱							ı					ı																								•				~		_							
	L.					_		Ļ.					<u>.</u> .			_				٠.	ļ.						L																	.	. 			-		
	Þ,		04		G 2		88		75		z		þ	9		15	, 22	35	22	P S	E	2			s,		24	_	, (H	_	X	_	I		8		3	a	י.	E (ظ حرد	9>	, St	* !	•		
\$2 E2	١	12		65	1	۷.	,	55	,	E	•	1.	7	-	=	•	-5		25					S				d	•	•	4		١		•		_		3		u	•	1	۷,		יכ	•			
-	H.	ΠZ	•	1	Н	IN!	H	Í	•	Q.	5	J.	ĮĮ			ď	II)	7	11		I	H.	31	S	11											H	ЯÜ	벙	AT.	EX										

TRANTISMA SI THEMBELM 0/0164

ļ	
1	
į	į
į	į
٥	Ċ
÷	
ž	
Acid	
in Article	
Jain Aniste	
Acide	

LENGENGUM ET AL. (1981) MAIURE 299, 457-445 LENGENGUM ET AL. (1981) MAIURE 299, 457-445 LELZA, 167-100 LELZ	2 - 2570	0751 H.G.KOECHEL, C.A.LAZARUS, W.ZASAT, H.ZUENTZEL (1921) CEI 2239-2230 COST T.CEKYTA, Y.KUCHIRO, 9.HISHIMURA (1921) NUCL. MCIDS REG. 7.2249-2250 COST G.D.LARARIN, S.A.HISHIMURA, T.SEKITA (1922) J. SIDL. CHEM. 254 G.D.LARARIN, R.S. HALLICK (1922) J. SIDL. CHEM. 254 G.D.LARARIN, R.S. HALLICK (1923) J. SIDL. CHEM. 255 G.D.LARARIN, R.S. HALLICK (1932) J. SIDL. CHEM. 256 G.D.LARARIN,
эваттавээттэватта тэйтэ	618881618	010 NAKKEERMARKEH 0102 NCC HONON C 1 C 1 C 1 L 1 L B WILD RESERVED CONTROLLER
Tenthensitzeatzehrane	នារាជធារាជាវិសា	
Tanbannorrabarbanan ara		a Ta a T T a T a Sevon Tour Sevon Se
8 1 8 2 1 8 8 2 2 1 1 3 8 8 1 1 1 8 1 8 1 8 8 8 8 8 8 8 8	8841818	RITER THE RECORD RESERVED SOURCE CONTRACT CONTRA
	1962119	סדפס פרכ מהסבסיראז בר אום באים. פר מדיכים פו דים פו דים פו מ
Tanomanootrajaarongana	я э я я я т я т в і	RTTCCCTT * TOP IN 7840 NUMBER STREET OF THE
TO TERRESTICE TO	11942128	OSSS UCC ELECTEN GRACILIS & C & 6 G T H T H PARKANANANA PARKANANANANANANANANANANANANANANANANANANA
	1862138	ער פער פער פער פער אין פאר אין אין אין אין אין אין אין אין אין אין
	า รอครครอ	OTS LECT RETT G C C S T G G G T G G G T G G T G G T G G T G G T G G T G G T G G T G G T G G G T G G G T G G G T G G G G G T G
	1 1 1 1 1 1 1 1	1923 הכב הפהפאנונט איני או מוח איני או היא אווי או אווי או היא אווי או אווי או אווי או אווי אווי
		ELYCINE cont.
St 0t 85 85 55 55 05 85 55 55 8 05 8 8 05 8		B B < 8 3 > € 2 l
אסר אווב. אוובר. אוובר. בופא אוובר. בוספר אוובר. אוובר. אוובר. אוובר. אוובר. אוובר. אוובר. אוובר. אוובר. אוובר.	na hausa	שוואסטכגר פובא

18 EITHER C OR 6 M.ESFWERT 15 ARBITMARY ALLEWRENT 15 ARBITMARY	0/96C0 5/96C0	ETMATUN MOITEIGO ETINU GMITAENEM MI AS OT A CENARCO T TIMU UNITAEREM IL LENARCO T ETINU UNITAEREM TAMATITAENE IL HEMMOLIA ONGEO VARAFILIGMENE I THERMOLIA ONECO
ятраравдовот т	apaaattit	9 8 1 2620
HAMMANAMANAMAN CORRECT	***************************************	
######################################	n q	B 9 B 9620
43838823833311	88311888333	R D T 20070
经验证的证据的证据的证据的证据的证据的证据的证据的证据的证据的证据的证据的证据的证据		
######################################	A 1 A A 1 T A 1 A 1	5 9 H 9940
4 3 8 7 4 8 3 3 8 8 3 3 3 7 7 7	88311888333	9 9 3 \$920
4 7 8 4 8 4 8 4 8 4 8 8 9 7 7 7 7 1		
	n n n n n n n n n n n n n	R R T 7270
ที่วอวววดที่เอวคว่าค	คอวาทุอาอวญก	19 TA 8850
128:27:01:01:01:01:01		
**************************************	a a o o o o de a o o o o o o o o o o o o o o o o o o	3 0 1 ft 32%
a ^p ⊐ 8 ⊃ A A ⊃ ⊃ le e [*] e e la C A A ⊃ S I T 1	a part quae a part a part a part a part a part a part a part a part a part a part a part a part a part a part a	591 ≯ \$20
ロインシンショロインのシフドイロ ロインシンシロインのファイロロ	4034	.
4193336436934181	na httpantalt	Ð TA €2₹0
1 1.	1 1	. Jnos BULTYJO
	1 1	
		*
87 67 17 68 88 88 88 18 68 88 88 88 88 88 88 88 88 88 88 88 88		H N TEE 6 'I K H
	25 ES ES ES EN a N	1 L H 9 0 8 74 24
HBTE JYDRONING HBTE TIT (NOJ ^a T į MBT2 ^{BT} į	HAR CATX3

MANATLEME ST THEFABLIA 0/44%

		1	ı	
	ı	ľ	ı	į
			c	
	•	ì	i	
	٠	٠		
		1		
	۰	١		
		1	L	
	•	1	ì	
,	•	ì		
		١		
١		i		

Vucleic Acids Research

LINGSWONTH, R.B. HALLICK (1982) J. BIOL. CHEM. 257.	### 12795-112. ACTS TREE, 12 - 57-2-12. TAGE TREE, 12 - 57-2-12. TAGE TREE, 12 - 57-2-12. TAGE TREE, 12 - 57-2 TAG	1.6.70 0403 C.J.GR 0459 A.GRUG 0451 J.E.BU RES. 6 RES. 6
personal personal division 1	· WHERPHER BEEF	
атваровататувати д приви	TO SACCHARDINACES PONDEE B C T C P C P T 6 G T C C P G T 6 B T	19 2580
Tanimaalarataradaanan	T D D R R R R D T T T D T D T D T D T D	19 559 0
	כאר פאנפט אייי אייי אייי פפר פפט. אוצב פפר פפטנפט בעל פנר או פט.	19 >90 0
	CHICAGO NAMES SEE	
	UG EUGLENS GRACILIS G G T G T G T G T G C C C A A G C C G T G T G T G T G T G T G T G T G	
<u> </u>	NITO TERMEMBERNAMEN (T. T.	19 Z590
การ การ การ การ การ การ การ การ การ การ	Tea traditification at a temperature of the temperature of temperature of temperature of temperature of the temperature of temperature of temperature of temperature of temperature of temperature of temperature of temperature of temperature of temperature of temperature of temperature of temperatur	19 LSP0
яятэ тяватагарарт тя аря я	A R R R R R R R R R R R R R R R R R R R	9 61-60
	T 9 0 1 9 0 0 0 0 0 1 9 1 1 0 1 0 0 0 0 1 1 1 1	න් දැල්වල
	HISTIDINE	3 2000
	OF IM	
3 and Tracontigues to a quanta	ลรวลลาเลาอโลกีรารวเรล *®wivoel⊐อ	n 6620
	GLYCINE cont.	-
0 B 22 84 36 36 36 36 40 45		
es to get to get get be get th	er a ar M sr orlas Caares r	
мате. этим част. этим _і мате. этим і мэте ај	900∪ α METE α (METE LYDROWING	

	j e:	**	**	***	XXX	×				7						-			*	•											
	Կ [։	9	9 9) T	g .	4 9	9	1:	3 3	ıΤ	1	Ħ	Ð :	3 .	L.	ų s	9	9 b	1	2	⊐							8	9	כ	45790
	-	1 H	7.	•	₩.	٦Fā	_ E	H H	••:	1.		м	n :	٠.		ı.	1	-	-		1.										
		***		**	E1	7 "	┅.			11	•			٠,	•	١.			-	, ,	14							0	1	0	2500
7	٦.	9	<u>.</u> 1	. 1	9 :	3 1	9	2	2 :	1	T	Ħ	8	. כ	ı,	վք	9	9	2	בׁו	9							1	Ħ	3	190 0
. 2	7	8	Ĵ.	. 1	B :	1	g	: כ	J :	6	1	b	9 :	.	L	9	9	9	3	9	١,							11	н	٦.	ES0 0
	. 03	***	WX3	#	WHEN:	+-	-#1	•	er	1				_		١.		-	••		1-								-	•	
	۹.	19	<u> </u>		9 (19	9	<u>ا</u> 5	1 3	1	İ	Ħ	9 :	Ι.	L	45) ⊈	1			כן							ㅂ	Ħ	Ħ	Z990
	- [3	9	<u>ב</u> רב	1	- B	פו		ו כ	. 3	1	1	8	9 :		L	Ę) H	. ด	1	3	ı							н	н	н	1980
	_ +2	***	*	(2)	HHH	+-			•••	-		_			-	}-	=	22			-							_	-	•	
	7.3	1 H	ĨΙ	1	A 1	ļΤ	<u> </u>	נ כ	īī	1	g	A :	b :	3 1	L	į	ı	9	9	R	3							Ħ	Ħ	ב	69-60
			5 i	- H	H		н	5 :	3 3	,	1	н .	9 :	3 1		Γ,	9	9	••	จ	١,							1 1	_		6080
	1			_		7-		•	_	1	_	_			•	1 ~			_		_							11	U	_	COAD
	1					ı										l								ЯВ	I A	I.	L 5	э н			
						l				ĺ						l															
	**	NH K	H#H	###	en a s																										
1	al T	H (פנ	ы	# 6	(H	B !	9 3	בי		1	Ð	5 1	1	1	9	9	⋾	1	Τ	1							9	Ħ	1	66ZQ
	1					ŀ				l										i					juo;		- :				
	1					ı				ĺ						ĺ									4-0,	• •	CIM				
	L					L				L			_			ľ				ı											
8/ F/	22	04	٠.,	89	88		9	29		99	ē	5	94		19	Γ.	 25		75		 20	КИО		9	·		В	95	!	-	
92 ¢	4	LZ	69	2		,	[2		18		Š			55		ES		15		66		ฮัท็ ⊤ีเ	r†н		٠,	ຼັ			3+ "	•	
	L	. ع	12.7	were:	71.50	ļ										Ι.	_								_						
	712	_			THO		R.H.	LS	271			Ю	, ,	4	- 1	. 1	EK	15	đ.	L			NH.	AHT.	Ю						

_
5
ā
•
Ū.
•
Œ
Ġ
ס
-
v
⋖
O
ē
3
=
Z

TANNTIGEN 21 TANNTIAN ONAVOO VANATIGEN 21 TANNTIAN CVCVOO TANNTIGEN 21 TANNTIAN OVCVOO	OSSO/O ALIGNERNI IS ARSITRAN DASO/O ALIGNERNI IS ARSITRAN
АТЭЭЭВРЭТЭВЭТТВВВТЭВТЭВЭЭ МИНИВИНИ МИНИЕ «SERRERA В ТЭТЭЭТТВЭТТТВВТТТВВТТТВВТЭТТТВВТЭТТТВВТВТВТВТВТВТВТВТВТВТВТВТВТВТВТВТВТВТ	ISOLEUCINE 0901 RGGT 0902 RGGT
HENNENHARM STATES OF THE STATE	유유그 8880 유유그 7880 유유그 8880
	887 7880 8 8 7 7880 8 8 7 \$880 8 8 3 \$880
6 2 6 2 6 2 6 2 7 2 2 2 2 2 2 2 2 2 2 2	9870 тр. 2 2580 1 гр. 2 2580 1 гр. 2 2580
**	EXTRA 84

, F.SANGER,	136-226 1 1.C.EFERGN 1 1.C.EFERGN 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	25 - 262 38 - 262	U.K.BROUN.E.N.P. S.AMOERBON, NLK T.G.YOLMG (1962) T.SEHIYA, SLMISI K.FUXADA, JLABEI K.FUXADA, JLABEI	1921 134 000 134 0601 134 074	TEDMC10525 "TIBDT"EGOD" 18" 522-2 TEDMC10855 "TIBDT" 18" 522-2 TEDMC10855 "TIBDT" 18" 523-5 TEDMC10851 "TIBDT" 18" 523-5 VEIDG 862" 10' 4847-4606	u.r.broun,e.r.praeer,a.vand,a.c.ui u.r.broun,e.r.prader.a.urhbja.c.ui u.r.broun,e.r.prader.a.urhbja.c.ui	1880 1880 1880 1880 1880 1880
нноодни		2221882863	1	اسدا	7 7 2 7 8 7 8 7 2 7 2 7 8 8 8 8 8 8 8 8	91 390H J (1513	2060
	ŀ	┝== ' ' ' ' ' ' ' ' ' ' ' ' ' ' '		100	A T T T T T T T T T T T T T T T T T T T		
อาออสิกค	Tabra	2 2 2 4 4 4 5 8 8	я ттэа	7884	าวรอไลก์อุงกรออล	i galu E. Colli	1 08 0
						IZOCENCINE	
	<u> </u>			-	*************************************	OTIM	
A B T 3 T A A	อรอาทุ	ванттировня	j	คควคศ์	TITERTERE		3690
9872198	อาอาปุ	<u>ត ១ ១ ១ ។ ៨ ១ គ គ គ</u>	,	A 3 3 A A	1 1 1 8 6 1 8 1 8 6 8 1 8 1 8 1 8 1 8 1	MITO * GUG HUMAN * NITO	(6 6 0
คอาวาุลล	атат⊐[ត្តក្រុងក្រុង	f (មេខ១ សុំ	TITERIGIAN	# 25NON 9NO F	3 590
8883188	ататт[A 2 A T T A 2 A A A	ਬ 		TITE CALCALANTACE	011M * MDERIƏ QUÐ (011M	2990
ត ១ គ ១ ក គ គ :	อาอาทุ	ត្តក្នុងក្នុងមនុ	н .		TITERTETABLE	* NOTE CHEMIC LITTLE *	5880
8 8 T 3 T R R	อรอาทุ	пвазтизиве	ម .	១១គុម	TITORIA HARANAMAN	אנדט הטפ המפוגבה המפוגבה * הווא	.99 0
A D T D T A R i	отатт <mark></mark>	n	u	ววยฝ	TITER TATERNATES		9980
_ 9 # > 9 # > 9 #	эт эт т[вовтатовта	A TTOD	១១៩	TATBOTABTACOB	פ פתפ אסתפב	190
99193399	grere	פפטבבכטכפ	8 1199	104	GCCGTGPTCGTCTT	ONE DECEMBERS HELFOR	200
1 - 1 - 1	7	7777		7			
Ì	1	[]		ł		. fros BNICITZIA	
		·		+			
27 07 85 81 27 17 66 46							
						_	
Mara, aithe 40	II. SNTIC. LO	METER FINITIC.STEN	- 4001	, a 1	NETTE O NETTE JYDODNING		

PERIFFERENT JAMERIC (1962) HUCCL. MCIGB RES. 10, 1653-1659

Nucleic Acids Research

0950/33 AFTER RESIDUE 34 INTERVENING SEGUENCE OFFICE

_
4
ä
ã
ŭ
ř
-
÷
-3
2
٩
Ų
Œ
ਹ
ַ⊐

	ENGTER	156 115	J (1861) 7	6. H.XIXEBSE	823-433 123-433	7560	*	VCID2 KEST 11' 2542-255	.J.GREER, B.S.VOLD (1983) HUCL.	3 404D
רר גבי	(1841) CE	1321K30K	. B . NABAB.	יירעצשעופי א	אים.אמפכאפר, כינ 1774–177	6623	A1EA-10EA . I	(1685) NACH "MCIDA KER" I (1685) WACH' WCIDA KER'	. ANG ZIHEDY . H. GYI FUHLI. 3 . T SWKEUDJ. 1 AUG ZIHEDY . H. GYI FUH. C. A MANAGA GO	'N
									7730 41-0 A . CONT. 3 . LANDING !	4 1480
a					J			*****		
		F	7 7 0 3	<u> </u>	ын ттаа	199	9 1 2 7 3 8	A 1 1 A T D B B B	GRU MANCYSTIS NITHLANS	7260
991999	ATAB	TTI	그ㅁㅜ뒥	ទទួមម	វម	9 9 1	гывтээ	a Transina	HELDERY RLINYDEORIG URB DT/M	9960
AATERO	8188		2 8 1 1	анвин				**************	DLIW	
				7.7.7.1	1		, ,,,,,	AND THURSDAY	CHU RAT **	2260
១១១១១១២	8 T 8 B	± 7[?	2 2 8 3	리기한번	A 188	Ta	ו או בידים או	ATTATOBBB	azirin nuo	Þ960
គ ក	A T A B	TTI	TTBT	ត្ត ១ ១ ១ ១	я тав	338	нстти	KH KANAKANAKA Gettettu	CHU REPRESELLUS NITH.	***
Recen		}-		h	1		7 7 7 7 7 7 7 7	********	BELL BILLINGSON (ND	£560
		↓		ង់១៦គ	ia TTBB	T T 8	1 (12. †) (1)	MANN ANNEXES	. DNA_EN ALLINOSONE UPPR	022 5
019999	6119	1 1 1 ⊃ :	דמככ	42989	B 1133	119	ярэт э əl	0 1 1 1 1 2 2 2 2	פאר בתפרבאט פאטכורוב פאר בתפרבאט פאטכורוב	1980
202024	H 1 H 1		TOJI	7 2 9 6 5				**************************************		
		J		4.3.3.5.5	a 1700	1 2	d::::	ANTERNATION NO PERSON NA P	Taray vau	0360
313334	RIRB	T 3 3 3	בׁחכפ	១១១៦១	A 1123	139	le c r c bi	6 6 6 6 6 7 1 6 1 1	פטה שטכנררה2 פתקעורו2	2060
319338	H H	1 7 6	9 3 8 9	43989	L			********		
				7	- 	7 T A	d 1.1.1.5	ATTTDJESE	ELLITEUS ZULLIDAR UPD	P060
arabaq	A T A B	172:	9 3 4 7	ឧុទ្ទឧ	A 1133	1 7 9	ופכנכום	T T D T D D D D	פטה פאכורדה2 בתפונדיופ	E080
			- 1				1 1			
							1 1		. 150LEUCINE cont.	
	. 		1				1 1			
25 40 42	96 ¥6	ZE OE	9Z 8	2 62 22	8 02 8L	ZŁ SL	EL IL			
EP LP BE Z	32 32 3	ສີ⊇	62 <i>LZ</i>	PS . CS				5 84 8 8 + E Z L		
				1 1			1 1			
WOTO SITKE	900J.DIT	וצאי סא	ra TITHR	I MOTE (I		Ð	NST2 0	PHINORCYL STEM		
•								•		-

		W.R.ACGEZHSCOM, R.DAVIDGOM (1931) CELL 23, 251-259	
#ES. 11, 225-235		BARDYERAM, S. RHARD, N. YAMADA, D. SUELL (1940) CELL 19, 849-495	
E.E.WILLIANSON, W.F.GOOLITTLE (1983) MUCL, ACTOS	7645	SECTION OF THE PROPERTY OF THE	6590
HOUSE (1962) HUEL, ACTOS RES. 10, 6619-6633		1. AITMARA RIKUWO, Y. OSHIMA (1992) MUEL. ACIDS. RES. 10, 1771-1700	
D.O.CLARY, J.A.CHDDARD, S.C.MARTIN, C.AE. FAURON, D.A.MOLSTEN-		CHFU* \$22* 10861-11003	
"STO day of months in e 1 William 1.2 OHANGED. G. L. YNACL-O.C.	7560	E.M.DROZCO, JR., K.E.RUBHLOW, J.R.DODD, R.B. HALLICH (1920) J. BIDL.	
(1982) NUCL. ACTES RES. 10, 1279-3249		LIGHAT, NIKOESSEL, E.STUTZ (1940) HATURE 244, 104-910:	1545
B.HULTROP, C.LANKIVE, G.FFPC, C.OURGLIAATELLO, C.SACTONE, S.2015A		C.L.? EERLEG.F.GEGERHERALA.A.ABELEGH(1983) GELL 32, 525-534	CEAD
P.CEMTATORE, C.DE REMEDETTO, S.GADALETA, R.CALLERANI, A.G.KROON,	SEAD		CAGP
B'KQCH" E'EDRWERE' H'KDEBEET (1487) CETT 52° 509-519:	568	C-1-CREEN, B-8-VOLD (1983) NUCL. ACIDS RES. 11, 3743-5774	2000
CE9-629		C. J. CREEN, B. S. UID, 14063 MICH. APPEAR DOOR AND ADDRESS AS MICH. 2001 CALL.	7080
H.B.KIRETHEL, C.A.LAZARUS, H.EABAK, H.XUENIZEL (1961) CELL 23,		N. GORSANGER, S. THRITA, H. YDSHIE ARRE1983) NUEL. ACIDS RES. 11, 6301-6316	
italian designate in hange in Shidaya i D 7 (2877271). File	6423	\$ZVI-ZDVI "01 "CRU COTTM "TOTAL (PCAT) BURGURATE "FRONTE" " PROPRIES " PROPRI	

######################################	iller sanco e to	622233444	
4222881	д аводтаниэт	Tagtaga	1994 4960
NAMES AND PARTY OF THE PARTY OF	Massametra 1	11789381 ====================================	H118 8880
M#####################################	Manager C	17 2 4 2 2 T	ATTR 3620
月TコTTTR	์ ที่	រា ៦ ភ ព ៦ ឝ ្ម T	AATA 32220
H P P C C C	# ### ### ## ## ## ## ## ## ## ## ## ##		100H +950
MK MERENDE	##========	Section 2	1000 7360
q 3 T A A B A	4 012A318402T	ทุ่อ รอด 🔄 ก	18 T €269
ATT TO TO THE	goracajoradar	בפרפפע	1994 S280
Kanusia **	EMPER-PERSON		1990 6330
1	4 3881 3 188831	打む日下つ直り	1990 1980
4594831	208222278827	192912	1930 CCE1
******	KM _ b======		
B G C C C	<u>วีราควร</u> เอยอวา	ग् व व म स व 🗅	T 5 2 R 2080
คราวเออย	4 24123184821	1888183	1993 1080
******		*****	
4222988	dronoutere ori	ที่ออรออ่ว	T 8 8 B COCO
	1	THE CONT.	onerosi
	1 1	·	
	<u> </u>		
92 92 82 92 98 9	29 29 D9 95 BS	E E I K H O 48 20 25 R	U Sh bh
57 57 17 58 78	B9 €9 ⊩B €5 ∠\$ \$\$	E IS EN ANT CHAU	8 47 57
NGTZ JYZROVII I	ष्य भञा≳या <u>भण्</u> या या	MRIS THE STEM	

		F []		[****** 接接券 你回收 签男要分布包装装
29332	⊐*3 3 A 2 T :	<u> </u>	, 9 > 7 9 9 9 9 9 9 9	REST CRESULTATION SUPPLIES BED BOOK
01331	888811	<u> </u>) A388 TTA	R B B B B B B B B B B B B B B B B B B B
98131	388211	គ គគក <u>។ ១</u> ៩៦៦៦ គុន) n 2 a a T T A (פספ במה במבוננט בעווווג פר ה ב ה ד ה ה ב ב ב ב ב ב
96334	. בטטפפכ	ที่ 1 ออ 1 วี ฮ ว่ อ อ คุค	T D T B B D D B I	роз ня силия в на в в в в в в т о б б с с с в в на в я в в с с с в в г с с с в в с с с с в в с с с с
a T 3 a T	88871	163884 438846	ataa ttai	ярта е се я в зарычения в на выста в на выста в на выста в на выста в на выста в на выста в на выста в на выст
				rencine
		1 11		
				TIN CARRESPONDENCE OF IN
	គិ	++	8 8 3 1	RESTRICT RESERVANCES OF THE SECOND CONTRACTOR
ARTOR	9818911	17 3 0 7 1 1 6 6 6 6 6		д <u>ат эт</u> ат двааа тинын из а теви
HHION	281831 1	тэнтянаня		1910104 HERRERESERVEN DILK
		}	0010	SESS GRUNDLER MARKHANANAN DTEN (2016)
PR10A	9 9 1 9 9 1 1	7. 3 8 1 4 8 6 8 6 8	9 8 3 1	TO TO THE PROPERTY OF THE PROPERTY OF THE TENTON CONTROL OF THE PROPERTY OF TH
១១១១១១	3 " R T R B T 3	2222828888	199 196	2010 671 1 REPORTED BBB 0309001 1060 0360
	*			CACCAC ********************************
3D3 8 T T	A B T B D T D	ם שם פרב בר ב מ חלב	1199 TR	å a to a la fig a constant a " accestant atogets end esec
		1 1 1		150LEUCINE cont.
ļ				1 }
		╌┠╾╾╾╌╾╾╍╂╌╬╌╌╺╍╌╸╾┟╌	·····	
	E 9E ≯E 2E ∠1E 9E 1DE			EL LL
	LE 35 CE	F 25 72 25 25 15	A Br A Br M	A St Dile al 782 b E S r
אמוזכ, בזפא	PMTIC.LOOP	וו אוצא מאזוב. און	4007 Œ	HETE O NETE JYDRONING

#EI* #8# 40* 3308-3215		Б.АМОЕКЗОМ ЕТ АС, (1961) МАТОМЕ 190, 457-465 Б.АМОЕКЗОМ, М.Ж.С.ОСЕВЦІІМ, А.А.СОСБЕВОМ, Т.С.ЕРЕВОМ, Б.SAMGER.	
GCAD LIAK CODES (1983) PROC. RATL, RCAD	7001	192 173 194-190	
C.J. BAREH. B.S. WOLD (17423) MUEL. ACIDS REG. 11, 5353-5374		ALLETER, R.R. PAR ETTEN, C.T. WRIGHT, N.P. WALRERG, D.A. CLAYTON (1981)	9640
C-1-CREEN' 8-3-MOFD (1493) MUCE, ACIDS RES, 11, 5763-5774	SDCT	o'K'ROTELENHOTUS' C'W'-W'EVNWON' T'W'80000WD (1655) EEKE 50' (2-66	0473
NUCL. ACIDS RES. 10. 7919-7934		F. TOKATUA, A. SUBLUKA (1932) HUCL, ACIDS RES. 10, 2665-2676	
(5661) HTIME.G.L .MDTJE.G .SEFTMDJ.M .AJJIVCKART.A.T	ZDOI	CEIT 12' 112-151	
C.FUKADA, J.ABELEDN (1980) J.NOL.BIOL, 139, 177-391	root	#.e.CEUTS21.A.A., B.A., TTC36384.A.O.(EXBLESEL). B.A.EX3350, A.B., FTC323180.G.W	
1.0.100M0 (1962) J. 70L. #[0L. 156. 663-777		8.4.14880AB.B.S.DUBOCK[1932] J.B1QL,CHEA, 257, 17191-11194	6560

		-	## 1		**	## #	de a				=1										B.)										: :						. 1	1 1			
(d :	9	ב	3	׆ ֞֞֞	3 3	c	, 4	3	> :	ᅿᅩ	법	Ħ	Ħ	ד כ	. 1	. 9	9	9	1 !	9 o	ı						9	Ļ	٦	3	9	9	ש	1	D 1	9	9	1		900L
		HR#H 1 10	9 9	2	1	*** 	ľ	9	9	֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֡֓֓֓֓֡֓֡֓	3.	9	н	н	ו כ		9		""; "		1				ŧ:	•••	יי	H	1	::	н	9	ı	ດ້	: : FI	131 M 1		; ; 0	; ; ¬		1004
	**	MM	KÄ)	××	*	-	1.		23:			_		_		_	_		==] -				_	_	13	* 5		. :	: :	•	•	_	•	7.1	::1	: 1	: ī		
4	١,	9] (34)] **	KK!		Ϋ́		 	. C	3,	9	a	Ø	נ כ	ī	15	9	9	9 !] 1						9	2	1	و.	ij	3	Ħ	Ţ	1	1.:) T	-	ī		E001
~ • • • •	1	Ţ	Ţ	٦.	1	1	} >	ч	3	3 :	1	Ħ	Ħ	9	3 1	1	9	9	9	1 9	c k	ı							9	Đ	9	9	9	3 .	L.	1 3	כנ	ב	1		Z001
,	ľ	X 41	(3H)	1	*#I	4 ** 1 1	1	==:	==: 5	7 2 2	١,	9	н	Đ	- 1		5	 		1 4	١,				•						"		н	9		:::	. 3 1	_	٦.		LOOL
•	1-	_	-	-			1-	_	-	- 1	7-	•	Ĭ	-		_	1-	_	_	•	1-						-	_	•	-	_		•		•		•	•	-		
							l				i																				2	3 h	I	J	n	3	7				
	ı										l										ı																				
	H	4 #1 7	124	##:	**! 1 }	### 4 I	Þ₽ i	EE1	E # 1	7	١,	н	H	н	٠,		•	9	H		١,																1 4		н		6660
	H	HÄ	HH	e e	HH	HK	١.	===	•	7	7-	•	Ŭ	~		•	F			22:	1 ^															٠		•	•	٠	0000
t	Į,	- <u></u> -	Ţ	1,	l t	1 1	Ĺ		3	3	7 7	Ħ	h	Ħ	1 1	3	Ð		9	9 t	1															t	4	Ţ	Ħ		2660
t	(ï		1	Ĩ.	1 6	1	1	2	1	2 :	2	9	Ħ	8	3 I	1	g	9	Ħ	9 t	1															t	ı i	1	Ħ		9860
t) **		(*)*	1	1 F		7	 -	7	==:	١.	н		н	. ,	1	5	- 61	H	9 t	1																ιн		_	٠	296 0
•	**	* #1	· i	•		**	Ι-,	E .		===	7 -	٠.	u	υ.			=	===	==	= -	1 -															C		1	0		2000
ŧ	[]	<u>.</u>	2	9 !	3 1	L	9	9	u	2 :	1	2	Ħ	Ų.	3 7	4	פ	9	1	<u> </u>	ב וּ															1	9	9	b		09 60
t	("⊃	9	Ĩ"	Ü.	9 6	Ţ	[s	Ħ	1	3 :	1	1	Ħ	u :	э т	4	9	9	U	Ţē	3															1	1	8	8		6580
																i														• • •	un:	,	3 14	7 78		NJS	т				
	l										l										ı									•			an		1.3	÷13	٠				
	L-						١.,				Ļ.,								. . .		L.,						.		•-									- -			
	þζ	_	4_	D E		92		19	Z		99		Ś	8		۶4			O		8▶		10	H	ı	ĸ		1		9		3		כ	ŧ	3	ᇡ	٠	-		
SZ 62		12	6	8	4 5	'	59	ε	:9	re	۱ ۱	9	4	S	99	-	25		25	e,	1	4	•	4	٦		r		Н		ď		Œ	•	•	۷,	•	*		•	
	W3	15	٦Ļ	JHC	INC	HU		HE	115	LE	J		æ	רט	41	1	b	431	.5	٦Ľ								н	워버	벙	iT,	(3									

0

102011) WLIEW WERTONG 15 CHLEMACHING REGNEWER 102510 WICHEMENL IZ WHIEMACHING REGNEWER 1040125 WLIEW WERTONE 25 KHIEMACHING REGNEWER

	,	-
•	7	i
	1	
	Ę	į
	5	ij
		į
	2	
ı		L
	6	1
•	ę	1
•	Į,	1
	V	
	A Aniab	֚֓֝֝֜֝֜֜֝֜֜֝֓֜֜֜֝֓֓֓֓֓֓֜֜֜֜֓֓֓֓֜֓֜֓֜֓֓֓֓֓֓֓֜֜֓֜֓֜֓֓֓֡֓֜֜֡֓֜֡֓
	Service Contract	
	oto Anido	֝֝֝֜֜֜֜֝֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜֜
	STORY VIOLO	

L.C.EVERGN. S.ANDERSON. D.P.BYERLICH (1945) WATURE 286, 440-442	
H.G.KOECHEL, C.A.LAZARDS, N.BABAK, N.KUENTZEL (1781) CELL 23,	
тарына антыра ары дары аны а	1050 URR MRYS GEGGRIPHTEE GE
	HIJO NAKKBERBERGE
อากาวแลกกรากโดยกลาส์ว่อว่าปล ลายก	าคคว∋อศุอห์วิอือที่โออือคีโโก - ****** คณ ezor
881217888121288	ו 1056 כמה מאמבסדיוונה אפונאים ברבה מה בנים אפכ פני
	TILL COLUMN COLU
T R T J T J D R R T T T R D A T R R J D T D R	TTR BROSOSHILA NELGNOT TO TAR BROSOSHILA NELGNOT TRA BROSOSHILA NELGNOT TO TARREST TO
- атті дивеятті деввей фрартія - ета а	105-н ижинижен бттяльей кејеснејнесссео
הפדה החכה הדרכ כ הרדי ה הפה מו המח ה	אונם אונם אונסררים אונסררים אונסררים אונסררים אונסררים אונסרים אונסרים אונסרים אונסרים אונסרים אונסרים אונסרים
	MITO HERESTELUS MITOUL, OT B G G T D T G C T G P F P P D G C
аратитараттыратты изиралына өтөө	
earn encecuracentitaents	1060 URB EUGLERA GRACILIS GCA D G C AIT G G C G G R A T T T G G
	he secondaring
ออดวาปรายกราวารเกิดอาวารเกิดอาวารเกิด	to the second of
aarajiaaniinganaaqaaana miaa	1074 URB E.COLI G C G G G G G T B G C G T B I T C I
} }*******	TITLE OF STREET STREET STREET STREET
อดา า ฝายอดวาที่วอดา ว่น ออกอ	іа ття 4 разъріа 1 рак вара за таповита вид сиог
	LEUCINE cont.
20 B ZZ Z4 ZZ Z2 30 3Z 34 3B 3Z 91 4Z	PL ZL SL EL LL
Et 11 9E TE 2E 2E ES TS ES ES TS ES ES	
DETEN PATTC. LOG PATTC. LOG PATTC. LOG PATTC. STEM	DOT O HELS O HELS TARBOUTHUS
M3T2. LINE TOTAL STEM I PATIC, STEM ON TIC, LINE OF 900	DOTIO 1 MELS OF I MELS TADBONIANS
	and the second s

P52-933	,
# "8"10ECHEF" C'4"FVSVENB" K	
CEFF 32' \$12-\$58	3
W. BRD I SUER, U. II. BREENBERG.C.	A
214'0805C2' 18'' 1'8'HVTF1C	3 050
A.L.REWMANH, R.C.OSOEM, J. ASE	j -
\$E1: 33: 249-2495	
U.K.STAMDRING, A.VENEDAS. U	3 876
HIME,Y "IMBEG.M "ARILAMAH.H	# 410
512-1212	Ľ
B'DUESTER, R.K.CANPEN, M.O.	070 E
	6212-1213

################		***	
4 2 2 2 2 1 8	137333188831		3 1 9 A A 1 A 1 T T J A 9 J 680f
MANAMANAN WAN	KM SERBERSE		TODALDITIES TO USE
######################################	<u>"droroo</u> raaaor	ក់ខែ៦ឧឧសុ១	JOLL SSOL
HTHELL	15699766897	1669167	***************************************
*********		100012	a a a a a a a a a a a a a a a a a a a
q a a a t t a	オティッタ アイフィ	q rəaaqı	ย⊥ย S≊n.
MENNYMHENNYH.	##====================================		V + U 225
42 484488444 43 4 4 T T J	<u> </u>	ก็ออดอดีว	1984 1981
# 1 9 3 3 3 H	119113198821	Tankogi	114111 114111
**************************************	(Manage 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	750033	11344431841 5201
4 T R 8 B D T	ゴ TTTB ゴ TARB コT	प्य अस्त ब्रा	1052 TBRC6CAR6TC6
HAMMANAMAN ;	HITTOLDINGTI		1111 1111
CATATANAN TA	Tarara	Terroral	8128141112181 050r
4334439	griciarenesi	<u> โอ ค อ ค ค ว</u>	914948193181 0+or
************	H	7-1-1-11-1	11 1111 1111 11
45555	<u> </u>	ก้อคอาฟา	ataaqqaaaaaa bror
4262122	222222104471	.)	11111111
7	7	า เออสออไร อ	DABBDATTIDITET OPOP
į.]	<u> </u>	LEUCINE CONT.
		1	
		<u> </u>	
92 42 22 02 89 9	4 28 29 D9 PS 95 P	K H O 40 E0 ES E	I 9 3 3 8 8 9b
54 64 14 69 4B	\$8 E9 LB ES 25 SS	ES IS SH H N 7 C	H = 0 & 44 & 44 1
I TO THE TANKS OF			- -
HINDROYL STEN	µ ਅਤਸਟ ਬਸ਼ ਕ 20ਹ∃ ਜਾ	MBT2 RT	MAR RATING

1000/37 ALTER RESIDUE D4 INTERVENING SEQUENCE 1050/37

Nucleic Acids Research

1066/0 ALIGNENENT IS ARBITRARY 1061/0 ALIGNENENT IS ARBITRARY 1065/0 ALIGNENENT IS ARBITRARY

_	
_	
٤	
ā	
q	Į
u	
4	
α	
V	
Ţ	
**	
2	
•	
.0	
đ	١
-	
_	

	081-291 192 773	CANK* CEN* +* 141-139	1024 M.FELDARMA (1931)
(1991) MUTYALD.A.D GRABBLE O.B. THB(RU.			
(1595) MUCE, ACIDS RES, 10.	377-2955		
As 276 BATCA PAIN (C&E)	POL-REST		
LAM.D.GRUNNERRERETATION HUCE.ACTOS ACS. 11.	MOG. 1. N. BAAH. A. A. I NBEG MAN. R.	3 4901	MOST' VCIOS KES' B' 2013-2010
IZA-625, 445 3ApidAt (1981) JSITANII	SAMLE, MAHOFSTETTER, MAL.	I. A.NORREGA, A.TZAGOLGFF (1980) 1026 (TOTA BEDERLANT, S.G. BONITZ, D. CORUZ
(1) 1639 PATED 1330H (DA(1)	113-455) הסרכרשנג' סיטימטרקונאפסרענ		(1492) J.SIGL.CHER. 252, 5503-5
1) 234 DATA MIN (T40)	THI I ON HEAT FIRST AND A TENTON	1 FAA1 SAMURDE, A. RHTHREALL, B. TRANSIZ	1991 A.A.SEERWEIZ, E.I.KREBBERS, E.
	7 (******)	[*******	DTIM
n a b b a q a a a a t T I T a a b T T	∮ધ¦ુરૂરથ છે.	เอคาคศุรคลอุโคปุศารรวรค	#3500M 98 0 ₽801
04371300411400	1 	раниния хини	
ag 2 1 1 2 2 2 1 1 1 1 2 2 1 1	<u>រឿង ប៉ៃ ម៉ា គ</u> ត្ត ក ១ ក ៦ ៖) ១៦៨៦១១៦៨៦។៦១៦៨៣៦	NEWLH 2010 6601
	gapaadutota	วอคอวออก <u>ชูกออการอ</u>	1087 대한 바라 다이트로
	1	AN EMMERNMEN	
a p a b a 1 1 8 8 8 3 1 1 8 5 8 1 3	រថ់១១ខែពុករ១។ខេ៖		SIVER CENTINEX SEC SOOF
Tecontinanctinant	442874	TITESED BE THIRE TO TELEBRISH TELEBRISH TO TELEBRISH TO TELEBRISH TO TELEBRISH TO TELEBRISH TO T	רוספל ערונון ארוניטאר אמיניטאר אמיניטאר אמיניטאר אמיניטאר אויניט
	14.7.8.8.9	DITIONOLUMENTALENCE	DENINGY O ITHERESTED DOLY SAME
- RAJORRBBOTT 3 T D D T T	1 ਫ਼ੈਕੈਕੈਕ ਫ਼ੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕੈਕ	a d n a d t d a a d t f f f f T f T A d	THR DRU AGO!
	1,7222111	PHENERAL STREET	OTIM
p	∄ <i>ᡮ⋽</i> .₹.₩ ¥३	1 a a a a d i a á a a a a a a a a a a a a a a a a a	≈ MOSSIS 5HU €801 ©TIM
na partique en la composición del composición de la composición de la composición del composición de la composición del composición de la composición de la composición de la composición de la composición de la composición del composición del composición del composición del composición del composición del composición del composición del composición del composición del c	при при при при при при при при при при	0.511111999999	* MRTU SAUTE BRU SAUF
	₹ <i>₹₹₹₹₹₹</i> ₹	**************************************	OLIN COLUMN
- กุกวาปคอยกราปรอยรา	∤स्रो⊅ जरम् रः	ត្រុងក្រុង គ្នាស្រុក ស្រុក សស្រុក ស្រុក ספו חשפ פסצורדש פסצורדש	
######################################		CKNNCKIHNGEERN	GIIN
	{aiɔ`ɔ`i al ɔɔɔ	la a o a dit ti si ala afatti i i o a	1000 PEG CHUMBEE *
101810800111713014	leises elecacies	11942271327111322	12937 RRU >502
	13	THE TOTAL STATE OF THE PROPERTY OF THE PROPERT	0903-0
_ อวาวปุกคลลว า ฆ์คอลอว	esta specie	TARRETEET PETT 2 2 B	1061 CRS HELLER
	i i		.fec cont.
			144351
	 		•
29 30 38 3E 3E 40 4S	10 20 B 22 St 28	ZL SL EL LL	
EP LP GE ZE SE EE LE GE ZZ		A 81 41 St 01 6 8 7 8 8 4 5 5 1	
HITC.STEM SMITC.LODP SMIC.SIEM			
WITE TIME CALL TITLE THE TIME	o i wanta ni 900	Ja' "Haye a l hate Jyzhontha	

			
FIDRER.	ฐ <u>คคลว</u> ฐาคลลวอ	7	1 S50L
4238138; 66666		192919 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1	
AXEXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX	136223166821 1	Terecting as a serio 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	1 490L
FICTERIT.	136337FR8337	בדרכים במהמפט ב מוניייי ביייייייייייייייייייייייייייייייי	1088 1
ARBATTA.	TTTTT TTTT	AT B C B C B C B C B C B C B C B C B C B	H SPOL
F T D R R R R T T T B M M M M M M M M M M M M M M M M		fabita and and the fability of	H 1-80f
4 T D A D A D A T		Tabttit RA	H E801
4 T 3 A A A A T	198922129828. 198622129829	Tastit AR	R 2801
1 3 A A A A	88833138839.	100T-TT 7 00	q , raor
FIBERGE	яякээтэвеээ.	7	
ANNARAMENT DE LA COMPANSION DE LA COMPAN	11122100021	_ L	1 4701
A 2 8 8 8 2 1			1 1901
		LEUCINE cont.	
94 14 24 04 199 89 54 24 14 59 49	1 19 28 09 85 95 15 59 69 19 65 45 55	* 48 H C E 6 1 K W D .46 50 52 54 45 45 B D E H J F W 5 46 54 53	P*
HELE TARRENING		EXTRACT PROPERTY OF THE STEM	
		THE HEALT	

TARATIGAR 21 TRARAFAA ONLEGI TRARITERR 31 TRAFINA ONCEGI TRARITERA 31 TRAGRESIA ONEVOJ

_
ਹੁ
Ġ
9
0
œ
07
<u> </u>
Ų
∢
O
Ü
ō

AFTER RESIDUE SO INTERCEMENTS SEQUENCE		THANTIBLE SI THENSELLA ONAPOR TRANTIBLE SI THENSELLA DYAPOR TRANSISSA SI THENSELLA DYAPOR
一日のことをごとなっては、	pasatoastaj	
a 3 5 5 5 7 7 3 5 7 5 5 5 5 5 5 5 5 5 5 5	5 2 1 T 5 5 5 T 5 2	1999 istr
a n a a a a a a a a a a a a a a a a a a	อวาทุอคอวอุ่า	1990 0 SLL
agaagatataaaag	a > 1 1 a a a a fi a	TOTA EMI
A D T D B D T A D T T D D T T D D T T D D T T D D T T D D T T D D T T D T T D T T D T T D T T D T T D T T D T	3 7 1 3 3 A A 3 2	1999 0111 .
TOBBITTESSICE TOBE	D T T D D D D D D D D D D D D D D D D D	1911 2011
		9 N 1 5 L 7
	j '	
MANAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAMAM	8 2 9 1 1 8 8 1 1 1 R R	A A CCOT
40681122112112116	A 2 T T A 3 A 3 A 2	3181 680t
413888888888888888888888888888888888888	A 3 D 1 D 1 T 1 T T	12 H A 1601
ятавтэээтэтээгва	A 2 T T 2 2 A 2 A 2	3311 880f
		LEUCINE con
		•
92 24 24 04 98 98 +9 28 29 99		3 U 9b bb
54 E4 L4 69 49 59 E9 L9 69 .	S, 55 ES IS 6№ 4 N 7 P H 3	Q 8 4+ S+
METE LYDRONING METE TI	0. जा MBTट जी . MBM 9817X	1

67) MUCL-MCTOR 188 - 18, 889-1842 T (1982) PROC. WATL- ACAO. SCI. USA MEX-SATTH,F.YAMAD.B.SOELL(1982) MUCL.ACIOS T (1982) PROC. WATL. ACAO. SCI.US.A. T (1982) PROC. WATL. ACAO. SCI	F.J.DEL REY,T.F.DUMMUE,G.A.F. W. 6134-4142 V. 6434-4142 D.DEFRANCO, G.SCHILDI, D.SDEL P. 3363-7348	TELL 26, TAT-189 1149 1255-727-189 1267 1268) T) T) T
887278877777778877 88877887777777777777	1 4 3 5 4 2 4 1 5 2 4 1 4 3 5 4 2 4 1 1 1 2 2 4 2 4 1 1 1 1 2 3	TOS CLU CRENCRHREDITIS ELEG.6 C C C 6 B T T 8 C T C P 6 T C C C B T T 1 B C T C P 6 T C C C C B T T R C C T C P G T C C C C C B T T R C C T C P G T T B C T C C T C P G T T B C T C C T C P C T C C T C C C C C C C C	il il
8822228881131881	1422114 T.BB	CENTINE CONT. CENTINE CONT. CENTINE CONT. CENTINE	iL IL
MTIC.STEM MITTIC.LOOP PHITIC.STEM 6+ N+ 86 TC 25 E2 E 25 T 2+ 0+ 85 85 N5 25 0c 85 S+ 0+ 85 85 N5 25 0c 85	Z 52 52 2 8 61	A BI PI SI OIB 6 7 B 2 > 5 S I	

WACKLE ACIDS RES. 10, 7919-7734

וס פוצא (מעזבנ,פופא מעדנכ,נוספי אעזנב, פוצא	1 17006	CHINOSCAL STEN D STEN												
er in se de se ce e e e e z'e z														
Z+ 0+ BE BE +E 2E 0E BZ BZ +Z ZZ	R OZ PL ZL SL E	21 11												
	İ		LYSINE cont.											
Trandaarriinaara143449	199 188	11100111170000	יוש אומינים אומינים אומינים											
<u> </u>	Taa Stad	STOURTH RESPONDENCE	NITO NELTHIOSOSHILA NELTHIO.											
	1	T.TTOTTATEMENT	Takay uuu Azhr											
	១ គ ។	Toga A a so strain	* 189 ULU 2211											
	1	3 1 3 3 0 1 0 3 3 1 3 3 3	OTIM BRUT											
0 1 2 1 A A A A A A A A A A A A A A A A A		жж иминини ки В с с с с в в с т т в с т С	THE CLU RAT											
R 3 T 3 T A R 1 T 3 T 3 R 8 H 3 T H 3 B R 8 R),,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1129 CON CHICKEN ENERGO											
7433401131313813413A13		TY TO THE REPORT OF THE PERSON	146S CITI IMIZOLATI'U METUMO'											
Ta3248A17373T32T3HT2AR		"""""	וזפה כבט מאנטבספאזנה אאנטפה -											
RATT BRETTI JORRITA JORB		KANAMAMAKANA GIJA A A B I B I D A D	* SEUDIN ULU BENI											
2011301113001140001		ATJOR REPRESENTATION OF THE PERSON OF THE PE	OTIM * MONUM LARU YELF											
ratartetta ratatatetti (12000)		新新工作的 	DITH											
	1023-207	M. H.KDENIZEL (1981) CELL 21.	1723 M'E'KDECKET' C'U'TYSVKAR' M'8YEI											
Agumineru. Z. Mathaba. Y. Tata. S. Nienimur. Pilos nes. 10. 1411-6419	TTP "VATESTAN" T"													
HILLIG (1883) NATURE 297, 31-36	### ##################################													
.A. WOLETERWOLKE (1963) MUCL. ALIDE RES. 11.														
i.uam ETTEB, C.T. Mitum, M.W.WALBERG, C.A.CLAYTOM (1981)		UAGLIANTELLO, C.SACCONE, E.SSISA												
VI" (1941) WALINKE 540° 421-422			דופף וואיאשא חיסיאשעטנעם (1883) אמבו											

	H 5	1 E	H T	1263 1 H	77		נ כ	7	.		<u>.</u> -			J				ב														
	7 *	HKN	***	HONE					•	-				٩	¥.	9 5	3 0	<u>.</u> 9 .	L											T R	9 t	j
	4 9.	191	R T	l b	<u> </u>	T	<u> </u>	L		Ħ	8 6	1	. 1	4	וכ	9 5	9 6	卣	1											т т	5 6	,
	d 5		A T	. 5	11	٦	R 1	ı	20	. .	9 t	1	. 1	ď	۲.	,	9		L											9 T		
	FE D. 1		*** 11 1	***	**:	262	A 1	-						ŀ				-												, 1		•
	922	CANAL PROPERTY.	*	٦,	삵		 T	-4	שכ	J :	9 0	T	. 1	٩	Ř I	1 F	9	ቭ 1	L										t	9 8	1 1	,
	a 3 8	9 !	ī	1	92	Ħ	ככ	3	3	9 t	8 9	כ	1	4	9 9	פּ) T	9 :	ī										,	L 9	9 9	I
	g 2 g	9 (ŌΙ		g 3	u	כ כ	7	,	٥.	9 9	_	1	٠,١	9 s	2 S		5 :														
	MERE	XXWI	E#5	*	***	***		ᆑ	•	٠.	4	_	_	1	5) :	ee J	===] -	,										J	. 9	9 9	
	9 J 9	N D C		1.	1 9	Ţ	ככ	3	1	9 t	ט נ	3	1	Ą	D E	9	8	<u> </u>											j	2	9 9	
	4 9 T			Ħ.	כב	1	ĴΪ	귙		t	1 11	כ	Н	ц) F	19	H :	9 6												L		
	R D T	***	を開発す 2 ↓	MWW!	* -:	9 1	666. H]	==[_		ŀ	===			•								٠			-		9 0	
	***	HMM	・ 大	*	¥ 70:		===:	-╡	Δ.	ם כ	1 1	J	Ţ	4	9 9	nı		ā Ŧ												۵	ככ	
	a > 8	. 9 9)) 	1 1	<u> 19</u>	Τ.	ככ	Ē.	1 9	9 6	a A	3	1	4	9 9	9	8 :	2 2											1	9	9 9	
	R 1 1	ו כ	9	R F	41.	В.	נו	E	1 9	9 5	e	3		ď.	eee Fo	H	1 1	١.														
	1				1		••	- [_	•	_	_	7		_	• •	1-											7	H	1 3	
	1				1			1						1				1								• ‡	בפע	ΞŅ	I54	7		
	1				1									١				ı														
94 \$4	2	02	29	99	7-5	9	Z8	6		28		s	, ,	+	25	٠٠,	··	t											-			
52 E		-69			29			9			<u>.</u> 25			Ŀ	cs i	, 15	Et C	77	a (0 N	H	וג ר	_	I H	9.	; ∃	a ²	e e	ម ! ∠≽	9¥_	++	
	KETE	21.7		ITI.			s -			_	_							ŀ	_				•		•	,	u	•	LF	51	•	
	~323	17.A		THU	и	W21	.5 -	ш		4	007	=	ΙŢ	1	H3.	15	٦T	1						HE I	RWI	ΣŒ						

TRARTIBAR SI TREMENDA D'ALLI TRARTIBAR EL FREMENDA D'AVIL PARATIBAR ET TREMENDA D'AVIL

125/0 stickents is ambithany by Groskopy, byfelonama (1761) cura, Ben. 125/0 is experty (0 be 1 lw a. Groskopy, byfelonama (1761) cura, Ben. 125/0 is experty (0 be 1 lw a. Groskopy, byfelonama (1761) cura, Ben.

Nucleic Acids Research

86

8

101

TRANSTERN 21 TRANSMILM 0/9911.

######################################	10'KWWYSIN' KTB'HWYTEÏK (16 '3562-13566 '37' KOTTJHGERGKIK' B'8' KW' '32-913	. A251 1 A251 1 A251 1 A251 1 A251	"53" 946-540 "" VCIDE MED" 9" 1526-7589 "17" VCIDE MEE" 17" 2346-2324 "190" 987-213 "" 190" 987-213 "" 100" 100" 100" 100" 100" 100" 100" 1	1018 .uom .t <564f) menor.o.t
1.777	1 7 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		************	CHTOKO
88388381821113811	ក្នុករខ្ពុំភាព ក្រខុ	3 3 2 4 3 7 -	***********	1258 CHICHER OFFERENCE CHICAGO
атээтиятиэт цавая;	∖a[Σែកែ⊒ ខ្មែក រ ៦ រ	a n n n n n n j រ៉ ដ ជ	A 2 4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	4529 대치 환경대당사의 현상HC1 F12 CHTCHO
тэээвятгаттпаааг	គ្រោះ ខេត្ត ខេត្ត ខេត្ត) तबस्टरंड	. <u>6667586</u> 7866	1528 CHI ENGLENH GRACILLI
TIBBIRDIRDICAL	2 2 2 2 4 4 4 4 4 5 5 5 5 5 5 5 5 5 5 5 5	. วาคค _า	CARTATORSAR	אזמב כפט הברופה אזמר אזמר במט הברופה אזמר
99119991931119919	4 T R R B B B B B B B B B B B B B B B B B	. 1 A B 1 1 1	, 6CCABARKANNANA 	אננס אננס שבאפנוזיהפ אנסר
96000661600099913	17		SET SET SET SET SET SET SET SET SET SET	1523 CUT HINKIN
	 }		HARMIN REEXES	
 	ក្នាប់រត់ដែន ឧទ	, aradiii:	**********************************	
ernergerabrahilie:	ត្រាប់ ខែ ខ្លួង ក្រស រ	ภ าาอ ค่'⊃ ำว่	*** ******************************	TADO, SI DED OF OF ST
втардрегерт фарре	อาอออส มาวอย	i Toeppit		TITRIE SULLLIUS SURTIL
			± N €	HEZHIONI
	 	}····	******** ******	DTIM
	(4 3 9 9 T	a 1/4:1:3	Ku kananaka Jahadaatjaa	* BAIVOS ULU CETT
וכ ה פ אב ד ד ד ז א ה א ב ז ב ה פ	ферранов так) prodpre	3 8 R T A B B D D D B	MANNAH UUU BEEFF
		l		CYSINE cont.
1 1		1		
34 05 05 05 55 TO				
EF LF GC ZC SC EC LC GZ ZZ	F		01687881681	
אַדוב. אַדוב. בופא מאדוב. בופא אידוב. אַדוב.	R Hafe of Too	n a leges	נאזואסטכער פובא ם	

	ᆸ	Į.	9	e e) <u>1</u>	72 2	T.	I t	i A	5	3,	. 6	8	Ħ	c	1	1	9	9	1	1	ы :	3													L	9 t	9	ESZL
	7	-	NH.	KR	p k	***	÷		*	•••	Ξ.					_	7	-	••	•	_	5																	
	4	1.) !	9]			Ŀ	1 1	7	₹.	، 5	. 8	6	Ħ	3	T	4	9	ð	<u>в</u>	9	!)													Τ:	9 (8	952L
	ᆸ	ב	5	e t	9	ĭ	3	1 5	1	1	ιE	ш	Ħ	법	2	ī	4	9	ġ	Ħ	כ	u :)													L	9 9	1	9521
	J	491	-	***	**	##	*		-		₫.	_			_		J	-	•																				~~.
	9	<u>.</u>		7 T		486	1	1 1	. T		3 4	. 9	t	Ħ	J	1	4	9	E .			취기	L													9	9 1	Ţ	SSZ L
	괴	์ כ	9	ו פ	1	1	£:	ו כ	. 5	1	ر ل	. 1	Ħ	9	J	1	ᆁ	Ŋ	Ħ	Ð	Ħ	0 1	L														U E	9	ÞSZ1
	J	KXX	No.	H	HH	HR#	*	•••	-	-	┫			_	_		j	-	==:			亅.					•	**	ik :	•									0031
	٩		J :		. J	### T	1:	1 (. 0	. L	₫ "	1 4	0	Đ	3	Ţ	٩	9	9	, <u>.</u>		g :	J													1	9 5	H	ESSI
	ㅂ	ב כ	Ð (2 6	1 8	L	₹:) I	. 3	1:	킈 =	9	¥	9.	3	1	1	9	H	9	Ħ	회 :)													1.3	9 9	8	1521
	J	***	EN		HEN	RHH.	ታ'		<u>'</u>		╛.			_	_		ŀ	===	==	_ •	==	J.																	OLZL
	٦	_	u :	H T	横形	¥.	1:		==:			. ช	법	9	_	1	4	9	121		J.	9-	,														Ð	9	0161
	ㅂ	1	7 !	9 3	J	9	d :	ז כ	. 3	J :	:	1	Ħ	9	3	T	ᆁ	9	9	9	9 !	희그	1													1 9	0 9	8	1503
																													3	N	T I	N C	1	H	1 5	H			
	L		**				L.		===		Ţ						ı					J																	
	Ħ	9	1 9	9 9	Ī	1	1		7	1 ;	1 8	1	Ħ	1	Ų.	5	ⅎ	Ð	В	9	, ה	a 7														1 (9 9	Ħ	2611
	1	**	**		**	. 46	۴.				١.	_			_		ŀ		•	==	==	₫.																_	
	7	J	9 9	ם נ)	1.	4 5) I	J	3 :	1'	9	Ħ	ū	. د		4	9	9	9	0	73	i													1 !	9 5	51	8 811
	1										L						ı															, å n	60	3	NIS	ረገ			
		. <u>-</u> -			. - •						ļ.						1					1-																	
87 87 27		٤۷ ً		E88		95 18	1	73 1	. Z	.9 14	6 9	6\$	75 2		5	* ! S		25	:S	.5	S	₽>	٠	0	, 1 N	4 7	×	۴	I	4 5		3	a :	9	۳,	91	r St	**	
	Į.						1				.1						ı		_	_												_							
	×	(TT	•	W	יונוס	(THE	7	н	2115	. 4.	ш		ď	Ų 7	4	1	1	1	ŒΙ	5	크	ı							HAR.	3 t	MT	(d							

Nucleic Actds Research

YMANTIGMA SI THEMBELM DAVYSE

אואטאביאי אוד בספר דר אודאטאביאי אודאטאביאי אודא

Nucleio Acids Research

FIGURER IS WESTERNED IN THE SERVICE IN THE SERVICE OF THE SERVICE

T 5 3 A 1995

TeeA

888 8 8 8

1989

HETHIONINE cont.

NATH DRITICAL

- Артяттицьэмімотнтэн

ESE I

ZSEL LSEL LOCE

EZ.L ÆZ1

1538

562L 1520

_	ť	
•	Ċ	
	è	
1	ÿ	ļ
1	ÿ	
i	ž	i
í	÷	
L		
-	_	
-	Ų	
•	Ų	
-	ľ	
•	0	
•	Č	
•	֓֞֜֜֜֜֜֜֜֜֜֜֜֓֓֓֓֜֜֜֓֓֓֓֓֓֓֓֓֜֜֡֓֓֓֓֓֜֡֓֜֓֓֡֡֓֜֡֓֜	
•		
•		
•		

#FY-10281 #FR-CTPRESCH(1891) 1-8101 CDHC+ #614-4351 TSAG-584 TRANSCHOUNT TSAGE	1360 M.DERG, A.TAID, A.SHINGZARI, M.SUBIUMA (1982) 1297 SANDERGN A.TAID, A.SHINGZARI, M.SUBIUMA, E.J.GUBRING, L.ADBURNG (1962) 1297 SANDERGRY, E.I.XMEDBERG, J.SONHARZ, E.J.GUBRING, L.ADBURNG (1962) 1297 SANDERGON, A.A.MAL.GERGUIN, B.A.COULSON, F.SANDER, ETC. 23, (67-180) 1297 SANDERGON, A.MAL.GERGUIN, B.A.COULSON, D.C.EPERGN, F.SANDER, ETC. 23, (67-180) 1297 SANDERGON, A.MAL.GERGUIN, B.A.COULSON, D.C.EPERGN, F.SANDER, ETC. 23, (67-180) 1201 C.J.GREGU, B.S.VOLLE (1962) 1202 C.J.GREGU, B.S.VOLLE (1963) 1203 SANDERGON, M.M.L.GERGUIN, B.A.COULSON, D.C.EPERGN, F.SANDER, B.A.COULSON, D.C.EPERGN, B.A.COULSON, D.C.EPERGN, D
באפב פפח אפכפות בישפער בראו אחב בכראפ	T353 CRU XENGRUS LAEVIS R & C R B B B B B C B
	1362 CRU XENDRIG LREVIS A G C A B A B F G G C G
	1361 CAU SACCHARONYCES PONDE T G C G C G G T A G G A
	· · · · · · · · · · · · · · · · · · ·
простисти простинати в в в в в в в в в в в в в в в в в в в	1301 CRU BACILLUS SUBTILIS C G C G G G T G D B G
	APTPITINI-BUINDIHIBN
	MAN KKENNER OLIM
— веродран сордевар и и та фі	1239 CRU BOUTURE ***** TANKERRAND BEAR TO THE C
приня при при при при при при при при при при	าอคา ายออกกรอด * พฤษแนะ แคว 📆 🗂
**************************************	APPLICATION AND REST * SELECTION UPD 8251
	CHURCH PRESERVE CHUTCH
ออบออุวลาควาทาวอาทุศาอักอิด กาออ าอตุว่า	1295 CRU WAYZE 6 C C 1 A C T D
	Taran Tarana a Darentura oasr
	METHIONINE cont.
= 20 00 BE SE 9€ 2€ 0€ 9€ 98 97 52 B 8 02 81 41 SI EI - EV 10 6€ 4€ SE 6€ 1€ 62 42 BZ 6Z 12 U 6I U 8I 01 Z	1 01 6 8 7 8 3 + 6 2 1
	HINDREAF ZIEN D ZI
Mary Title Brit Laris Erick Laris II. Will (M3	U.S. Targette formations

SK FK LK 69 70 E3 E8 F8 62 52 E2 E2 F2 E2 F2 E4 H J L H H G G 79 24

and the			nioje.		Liljan	yd:					**	220		عيب						-,-		eigh, d paglas		د اد چاپ				,		200 200	210040	-	*****	ļ.	.	- A-1-1			—	
																											279) s	te.	1123	(096	רד נו	J305*	6 1 1	.grvi	A35*C	ינושם.	٠,	iset
IAH E				061	-191 450	.u:	יכאנ יכאנ	ינטר ינטר	1.L 151	4114 931	1081 111	HT7:	AA1:	5'G	MI X5 WI X8 B* [X * H*]	201 201 118	A.A	22	£1		111			OKY	ŝ.₹	•	ERQ:	13*:	1.1	72- VH [†]	9 '9 5 'RD 5 H	17" 123 18"C 18" 123	ton' 17N' 11N'	IAUTRI UANTE LOK	P (1 0'7° 1'8	2841 H"W 2411	**************************************	816.U.I 430ka.; 430ka.; 430ka.; 430ka.; 463.U.;		MZI TSSI
. N3.1	13 ()	1.3	110	GH3	12201	اڻو: اڻو:	1" I 1-61	7507 1°3	7 'Y	''N ''!	K30,	N 55:	. JO: 382,	1 (2	0 1 1 2 1 1 1 2	וננו ונט)3.0	25	E t									mo	.t.3	'Z	RAMIS. E	129–221 12°30 120	055 ° '5138 '5138	SC . SES SES	. 1.3 E.1.	נק" ו נק" ו נבצי	17810 18461 2013	,0834.1 8 ,1301 378,4.4 (881)) }	138
	ı				כו	ŀ				ተ ነ	-		•••				9 9				- 1		• •	ì		4	### 0 15 4##	2 4#	U EEX	? C	HEN			Jage /						SEL
	u	Ħ	Τ (9 3	11	4	9 9	9	3 !	9		 Έ	בּ	벟		. u :	99		ı	1 9	ы	5 L	9	9	u .	1	***	** "	HWN G HMN	### D 5 ###) T	38)40. SI	4 5 3		OUT	ΗДЭ	U S 1	נטו	L	SEL SEL SEL
		•	•					_	-							-		-						Į		-	1.	T	I N	I	- 3	N I				. 3 :	H			
	ł				13	ŀ				-1	• • •	• • •	• •								ŀ	•••	• •	•		1	### © @ E ©	H	Ħ	1 E	J U				_ 	HRH DT				159 159
ے : و و	1				1	ı				1 '	•••	•••	•••		1	1	9 9				ŀ	• • •	•••	• • •		4	T 2 444 6 6 444 444	U ##	EN»	L S	8				x C	HOT				5 2 1 521
	1				1				-	-		• • •					99				ľ	• • •	•••	••		þ	1 D	#K	K H H	-	i w ir	.tn	D)	INE			DT (כאו	Ď!	9ZL
 07					 32							 Z						 H	 L	SI		 L	LL		E 6	-	 2 9			 c. 2	 : L									
] '			• 		<u>ַ</u>			۔۔۔	٦		نعن			J	ø	- 		J,	. '	٦		_		•	1			•											

PARTIEN ST THEMMENT OFFEET

ı
5
ŝ
قِ
<u> </u>
Ę
₹
.9
쁡
<u> </u>

8, N.A.HDRBACH, T.SCHNIDT, E.EUGLI, 43-613 MUCL. ACTOS RES. 9. M. C.RR.FHIRON, D.R.HOLBYENHOLRE J.B.GODORND 419823 DENE 20, 63-49	JAPAGERER, P.C.WERSINK, D.COELL ST JAPATHARY, D.DETANNO, M.SILRERIANN JAPATHARY, J.R.EGDZARO, S.C.AMARTIN D.G.CIARY, J.R.EGDZARO, S.C.AMARTIN S.SHATTANDLES, C.AA.FANDOR, J. S.SHATTANDLES, C.AA.FANDOR, J. J.SANTOR, B.ZARLOFF (1981) SELL ST J.SANTOR, B.ZARLOFF (1981) SELL ST J.SANTOR, B.ZARLOFF (1981) SELL ST J.SANTOR, J. J. J. J. J. J. J. J. J. J. J. J. J.	8017 (2008), 1362 8. E. Salan 5. E. Salan	ANDIEROP, C.LAMAVE. G.FEPC, C. DUME IGANIELLO, 8.8ACCIONI TPRED MUCL. GCIOB REB. 10, 7279-7289 REB. 10, 1797-1797 A. UHERGAS, C. GORRALEZ, P. JULL, P. VALENZUELA (173-327 REB. 10, 1797-1797 A. UHERALD, F. SPERCER (1923) FEBS LETTERE 161, 323-327	1229 1222
B 4 3 3 3 4 4 4 4 5 5 5 6 6 6			MMMMAXAXH	
BESCERTRALEGES	at a sa	2 a g 5 a 5 a 6	119 119 119 119 119 119 119 119 119 119	REL.
R822330418233388	9 글 시 네 1. 그 9. 너	R T 3 A A T 3 8 A 2		136r
TA33338183TT888	3 T ១ គ T ប៉ ម៉ គ គ			BEL
843238818333886	этээтэээн нөв	тан зазва.	Б СТО ОРОБОРНІСТЯ МЕСЛИЮ, Я 6 С Я 6 В 6 Й В МЕНТИВИВИВИЕМ В МЕТОВ В В В В В В В В В В В В В В В В В В	DEL
ветрозавтя з э э т в г	ттатара вое	T B R 3 8 3 8 8 .		ecr
Restratestrates	3 7 4 2 1 3 4 9 2 1 9 9	114453434	TOUGH TO BE MUNITED MUSTIFIED OF THE OUT OUT OF THE OUT OUT OF THE OUT OF THE OUT OUT OUT OUT OUT OF THE OUT OUT OUT OUT OUT OUT OUT OUT OUT OUT	9E1
8 6 6 E T C B T B B C C C T G	1 1 2 1 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1	19629399.	MITO MANAGEMEN SHING 6 C.G.C.G.T.B.T.B.T.B.T.B.T.B.T.B.T.B.T.B.T.B.T	SEL
_	3 2 1 4 1 3 8 4	ят <u>эя 4тэёй</u> э.		SE L
- рт во розтвот разтра	га үфтар ар тав	TARTOTA 8	TE COU GERENALLES NITUL. 9 G C G G G T	SE I
			METHIONINE-INITIATOR cont.	
30 35 34 28 38 40 45		LI SI EI II		
ED- 11- BE 78 BE 65 TE ES	; 22 BS ES S A Er 1	a ar bi sr orle	9 4 8 8 6 2 1	
HEITZ. STEM MATTE. STEM METZ.	ज्या का स्वयं न्यात	ia leesal	HELS TACHOUGH	

	1								_														••			-																				
	Н	ī	Ξ	ିଶ		ື້ວ	ī	ι :	•	3	1	8	כ	4	Ħ	Ħ	ㅂ	1	3	1	Ħ	9	9	1	H	9	b)													1	Ð 1	Ð	a	•	78£ L
	. !	-	_	K H	KP	٠.	*1	GR.	宁 :				•	•	_					_		-	•=	٠.		-5	١.																_	_		BEL
	ч	9	1	ᄖ	ī	9		2	Ŀ	2	<u>-</u> -	<u>.</u>	<u> </u>	Ξ	3	В	Ħ	Ħ	Ţ	3	Ţ	9	9	1	<u> </u>	. 9	1															U	2	0	•	REL
	4	ī	1	Ī	7	ì		3	Τ.	ī.	<u>.</u>	<u>.</u>	5	3	ı	Ħ	¥	1	ㅂ	1	1	و	ฐ	.	8	1 8	ı															ㅂ.	i	1	9	38E1
	7	FR	#	5 5	××	##	163	ж	÷		••		4 2	4								⊨≖	==																		_					
	벽	1	2	Đ	1	٦	L	ו ב	1	9 .	1_	Ţ	3	7	Ħ	B	Ħ	Ð	3	1	Ħ	9	9	Ħ	9	3	, ,	l													T	9 !	9	a	9	128
	J	**	ŧ×.	**	HH	**	7.7	131	Г.		. =	==	-	J	8	_	_	q	_		u	75	9				b															9 9	a	H		-OEL
	٩	٠,				-			1		_	:.	٥.	1	0	0	Ģ	2	J	Ţ	9	-3	22 12	==	. S		י ו	•													•	-	•	_	•	
	ᆈ	ב	5	9	בֿ	5	-	1	1.	١.	9	Ţ	כ	3	1	Ħ	Ħ	9	כ	1	1	9	9	8	3	9	1													•	2	e e	9	ㅂ	C	196 L
	Į	!	en	×	×ĸ	ĦR	1	()()(+				•	=												= =	1															_			_	
	벽	T	ב	9	2	9	5	2	1 ') I	9	9	2	7	ď	Ħ	9	Þ	1	R	9	פַ	ַ	1	3	-	1															9 .	L	O	•	æı
	J		7	T T	**	a	**		Γ.	•			_	7		_	н	ь	н		١	 	8	,		6	l٠															۲ i	8	н	9	:SEL
	٦	i	ű	ŭ	×	**	•	**	L		•			7		_	٠	_	٠	•	1		•=		.:	,:	1-															•	-	_		
	ď	1	Э	9	כ)	1	L	įŧ	J (Ħ	L	כ	ゴ	1	2	R	Ħ	2	9	4	9	9	Ħ	1	1	1															U.	1	Ľ	•	SE L
	1								l					l							1																.1 -				-					
	1								ı					1							1						l				ţu	-	1	RIII	Ωŧ	111	AT.	3517	INU	(HT	אכ					
	١								1					ł							1						ì																			
									┝·					t		٠											Ŀ-		 															-		
84 14	r	"		20		12		99		. *		٠z		P			×S		35		۶5		25		05		*			H	_	×		I H	ຸຍ	ر ا	3	Œ) 8	ᆸ	.9	7 51	_	*		
SZ É	٤.		-4		69		۷5	1	2	4	E	B		8	t	S	•	:5	•	دد				15		₽Þ	i	•	M		1	•		н	•	3		u	-	-	•	5 11	•			
	i	a	LS	٦	בו	80	ΝI	K		•	8	15	: 4	ı			ď	טנ	1	11	١	1	EH	15		цΙ	Į						-	2	1 1	ЯIJ	Œ									
		_									_		_							_			_																							
																			•																											

1293\0 WITGHNENT IS ARBITEMMY

		_									-,	٠.			٠,								,			.								***									
8 8	1 0	ᆸ	9 (9 8	9	Τ:	1	1 9	H	1	4 5	ļÞ	9.	Ĥ.	Şt	1	9	9	9	1	. 1	9	ч	.ڊ.	į.	. . 5	U	4	Ü	ä	Ħ	2				פרצות	и R	TIH	9050 1050		689		65¢L
1 1	9	1 4	8	y H	9	τ:	갸	בנ	9	Ħ.	별	9	.9	Ä	٥				Ь.	ו נ	H	Τ	녝	۲.	1.	9	ㅂ	4	9	Ţ	Ц	นู้	1	1 5	1						FF 19		82Þ1
19	13	박ㅂ	9 (ט נ	Ð	T;	7 :	9	H	3	비	ŀ÷	#.	7.	키	1	9	9	9	1	1	9	비	÷.	9 .	. 9	9	4	ä	ď	٦	ขู้))	T 8	3974	2. 6 0	a Ju	KON		3 5	변의		(Sti
9 9	1 3	비비	ו פיי	1 11	9	1 :] t	1 9	H	ב.	<u> </u>	9	9	Ŭ.	키	ı	9	9	9	1	Ŧ	9	4	٠.	ļ.;	9	ŧ	4	1	T	U	8 9	9	9 5	!				OT TER		CU		95≯1
11.		₹.	41		_	-	-				ᄩ	ŀ۶	٠.	Ħ.	7 7		ב	T	: כ	1	ב	ם	볙	÷.	Į.;	9.9	8	4	9	Ţ	Ħ	1	**	19					HEM	Н	25 19		9 5 >1
1 1	¥ 9 .	4	9⋅6	ט נ	9	1 9	ᆝ		Ţ	9 9	9	, 3	9	.	키	I	1	9	9	1	1	8	뼥	₽.	1.	ò	ㅂ	ㅂ	9	Ä	9	1	1	9 5		HIDO	211	Πt	DH <u>R</u>		RS 2		ナミナし
A R	L J	비	9 (1 H	9	1 :	ᆙ	9	_	1.	4 5	ج.	9	t.		١.	9	9	9	T	1	9	볙	₹.	1.:	.9	R	4	U	Ħ	۲,	_	_) 9 ***		51	var.	1 5	UPON	žΧ		-	CS>1
H 9		ų u	9 t	1 U	9	1 :	יו	9	H	٦.	빌	2	9	۲.	9 4	I	9	9	9	T	1	9	벽	Þ.	١.	. 9	A	_	1		_		9	9	u	5958	ם א	104	OT.		FB 5	;	757
1 8	1 1	비비	9 1	3 4	9	1 1	ᄖ	#	H	1 1	9	?.	9	١٣	5 0		1	9	9		1	Ð	벅	4 ,.		9	Ħ			Ţ	1	T.	Ţ	9					15H		HH3		1571
333]] ;	4	H 6	Ħ	9	т 1	ᄖ	9	9	9 9	ᄪ	2	9	U !	7 4		T	9	9	J	1	Ð	₫.	٦.		ā		4	Ħ	9	g		3	9					כםרו	E.	600		2071
. T 0 ;	. כ נ	4 8	Ħ ŧ	1 4	9	7 :	비	9	9	3 (4 4	כ	9	¥ !	ᅨ		T	9	9	ı	1	9	법	J .	1 3	9	a	4	9	Ð	ڌ	Ţ	5	9	5	וזרו	ens	घा	בנוד	鰋	AH3		L0+L
											H											-	1				ŀ	1	İ			3	N	I	ΗН.	18	3 1	N :	3 H 6	i			
		1_					L								L		.												Ĺ		_												
Z# E# LI		Þε	9E		Æ,	25		30	EZ		×		S			E		8	L .	4L	-	št_	F	ı	LL				,														
- 41	•	"		76	•	_	٢٤	'	-		۱ ۱	5Z	E	Z	12	Ħ	Þ	-		• 1	Br	P	4	Z	-	UL	6	٦	-	a	5	7	- 4										
MRIS	, DITI	Ü	400	בירו	ΙI	KH	Ìн	31	5":	ILL	أيف		ΉL	5 (]			ď	רם	α			1	HQ.	ļ5	a		ì	Ю	115	٦	U	Ю	11M	Ħ								

595		
		7" NIBC' CHEW 321" Y50-911
"F# 3722 (1941) 7324N30		A.C. MILLER. B. RALPUT, R.STITH, D.G. TRTLUR, G.N. TENER (1947)
142-123	1424	U.R. ADDISON, C.R. ASTELL, R.D. GELANEY, I.C. BILLAN, B. MATASHI,
KER" 9' TO33-1045		K-G-CHDSSHOLL'H'LEFDUNKHIABI) CSKK'BEN' +' 1AI-1AF
7,77 100. 1 120.	1429	ALE DEALYARNI, T.SEAI, K. YABIMUTA, K. KOLLE (1981) GENE 16, 297-307
DWEFEON (1499) THIEF.	••••	VCING KER* 11' 8273-1215
MCIOS WES 73' 4179-4319	1423	V. GANDLIN. J. AMD, B. APPEL, N. SUMPER-BAITH, F. YARAD, B. 50ELL 1753 MUCL.
. GALLABHER, M. KREUSKERF, R. A. 9.		FACE, MATE. ACRD, SC1, USA 75, 190-194
E102 HEE' IT' SOTS-3042	VENI	1. UALEMZUELA, A. VENEBAS, F. WELMDERG, R. BISHOP, W. J. AUTTER (1978)
455-6945 'II' 839		S"CHERZ'O"VILVEDI(1280) CEFF 16' 32-544

	ANDERBON ET AL. (1991) NATURE 290, 487-465	1422
	E49-529	
	H.G.XOECHEL, C.A.LAZARUS, N.ZABAK, M.XUENTZEL (1701) CELL 24,	7¢2¢
1	F. MUELLER, S.G.CLANCEUM (1940) CELL 19, 145-153	1423
	E.BELKER, C.YANDFSKY (1940) HUCL, ACIDS REE, 8, 1037-1042	1425
11	CHEN 224, 11735-11740 -	
	DICINICLER, W.C.MARTIM, M.D.PMAR, J.E.COMELSOM (1960) J.BIEL.	1571
H	SIDDIGUS, J.F. N. VERGE, B. A. REEC1943) HUEL. ACIÓS RES. 13, 4279-4389	
	.t.a.a.a.a.k.a.a.a.a.a.a.a.a.a.a.a.a.a.a	1405
1	T. TAMANDA, N. COHET, H. ISHIKUHATIYABA) MUCL. ACIDS RES. II, 2027-3045	
	CTTEREEN' BIRTOOFO (1883) MICH WCIDS WEST II' 2293-2256	1011
	•	

	PER	-	HE	- 1		.									ŕ			20	== !																	
t	비그	9 9	כנ	1	1	ป อ	9	9 3	כו	כ	T 6	3 5	ב	1	4	D 1	כנ	Ţ	٦:	3												1	9	e t	t	6 2 ≯↓
	F. F. F.	## P	! (P4	F	n m m	7.) H	(H			н	н	u	╌	1 . 1		9	•5	ı													B 9			95>1
•	 ,	**		-	He	.	٠.	•		1			_		7				E 0	•													ш :	9 (,	03/1
1	ᇦᄀ	¥ 5	1	9	1	1 1	9	9 3	בנ	כ	T \$	9	3	1	4	9 9	9 3	1	벼)												1	9 9	9 1	L	∠9≯ L
	KSH 			**		.	===			_			-		٠,۲,	P = 1			٦.	2													9 9			9561
		- C		e 	t##	W==	2 4.P		, ,	7	Ι,	. 2	_	-	4	9 .		-e:		•												1	9 ;	2 (•	AZEL
t	d o	e t	8 8	1	8	c	3) t	1 7		1	H	2	8	ᅿ.	1 :	9	9	9	3													H !	3 t	Í	55>L
	!	N KI		**;		֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓	054		==				_			5 t			Ţ														۰.			
	, ,,,	483	1 H	¥#)		4 I	=2		===	-	9 (, 0		•	٦.				4	ı												1	9 9	, ,	,	PS+1
ŧ	∮⊃	8 8	כו	1	1.	1 9	Ð	9 3	בי	Þ	, t	9	_	1.	1 1	9) 1	J	킈:	2												1	9 9	3 t	j	ESFL
٠.	*** C L	機関を	**	H		•		~-	==	_			_		Ė	55 S	*		1														9 9			
,	***	=	و. ا	##)		1	8	J = =	==	-	1 .	, ש	_	1	ቈ	2 . 2	. =	1	٦.	3												1	u :	3 6	,	25 p L
	()	9 9	9	Ħ	₽.	4 1	M) T	. =	1	1 t	9	ב	1	4 5	8 t	1	Ð	40	5												כ	u 1	IJ	L	しらっし
E	***	代別者	## 61	4 4)	***	,	- EE	53 7	==			. 9	-			9 6		٠.,	"	3													9 J			ZDÞŧ
	***	272	##	 K a t	H	-:	٠ <u>.</u>	* = = =		-	1 6	י י	_	•	١.		1 ,1 **	٠.	٠.,	,													. u		,	CUPT
E	4 >	פכ	H	B	J :	כוב	1 '	9 2)]	1	1 6	9	J	1 .	Ц!	9 5	כנ	9	9 :)												1	9 J	L£)	LOPL
	i														l									3	N)	N	ㅂ	ם ר	٦	A N	3	На				
	├					⊹									+.				٠+٠																	
91 91 51 E1	۲,	0 2		19 2	.9 .9	59	ε: Ε:	Z8 9		B 28	95 5		95 5	5		25 3		73 E	: P1	•	, 0	N	μ.	נו	r	I	9	4	3 (, ⊃	Ē	1 9 24	S #	*	•	
	M3T	57		DH.	IIW	,	MB.	LS	ᆀ		_	00	1 ±	ц	1	ΗЭ	15	d)								HEE	1 15	ЯŦХ	3							
								_					_			_			-																	

1107

Nucleic Acids Research

TAPATONERNI EB MABITEMBY

1	
3	2
Š	
ğ	į
ů	
7	
Ť	į
Ť	į
4	ĺ
Ç	3
ď	j
₹	1
_	٠

1499/D ALIERRENT IN ARRESTRARY	TEARTION ALICHMENT 15 ALICANIES	ţ
คือาวาคาวาวเกาวายคอวาปอ	אבנו נו אונג אונג אונג אונג אונג אונג אונג	L
POS	H TTO D D D	
######################################		L
F B D D D T T D T D T T F R B D T T D	וב03 ממפד במבות	Į.
222882118822221862118	בבכיפים כוב כיפים	L
######## ## ==========================	#####	
ต ่อคออาคท่อง า ว ว าหลด ว ร ทุ อ	יייסיו אפיבד כלכח אפ	٠
·	PRDLINE	
	.	
阿特斯斯特 斯根斯特特的 □□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□□	hamore .	
######################################	19 6 a 1 88 P 1	•
яряянтарэтит аттяя.	rภอูอ ่⊺	,
ברוחכמהאף פכוכר מוחה פנף -	1968 T R F F F F F F F F F F F F F F F F F F	L
4年 「日本の中国日本の日本日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本の日本		
ผูวออรววที่ รออกว่าคลควาท่อ:	ıppa tere os⊪t	•
	PHENYLPLININE cont.	
	44 48 D E R C I K H D 48 20 E 42 42 B D E H 7 F N 6 48 21	
MGT2 JYDRONINR, NGT2 9T 900J 9T N	TIZ TI NAPA PATXS	

	1302 G.CILISENIO, L.CRNIASPOLI, P.A.MELIDH, R.CORREGE (1983) PROC. MAIL.
MUCE, ACIDS REB. 8, 5007-5016; (1981) MUCE, ACIDS REB. 9, 2421	1201 K.FUZADA, J.MELSCO (1980) J.MDL.9104, 139, 377-391
DANGURAL, M.D. PHAM, K. EMBERREE-LYDM, M.C.MARTER (1980)	1"E-YOUNG (1982) J. MBL. 810L. 136, 683-717
752-922 H'O'KOECHET' C'UTTYSTYDE' M'BYSYE' H'KOEHLISFF (1465) CEFT 52'	1434 274MDENBOM" H'Y'F'DERBORTH' Y'4"CONTROM' I'C'ELEKUN' 1'29NDEK' [22]
E.F. WAMMCDIBER, J. N. NAMMSEN (1953) J. BICE, CHEN. 255, 291-295	1496 M.J.BIUR, R.D.VAN ETTEN, C.I.MKICHT, T.U.MALGERG, D.A.CLEATON (1981)
C.L.GREER, 8.5.VOLD (1993) MUCL. ACIDS RES. 11, 5761-5774:	1905-246b
TALFARMULLA, A.CORTESE. D.AELTON, J.D.SAITN, NUEL. ACIDS REB. 10, 714-7945	1441 "THEN-TORKS" DENEMB 528, 5363-5311 BERT 11983) NUCL. ACTOS RES. 11.
VCVD" 801" ff24 36" 1762-1766	1440 A.A.STEINWETZ, E.T.EREBERE, 2.SCHWARZ, E.J.GURBINS, L.BOSCHAD
	MINN HAMMANAMERAKAN OLIM
อลดดอดออกาที่วาการสมาออลุก รอย	MITO TERMANAMENT OTTH A TERMA SECTION OF TRANSPORT OF TRA
nangataaari qarta qaaa qar taa	1851 UGG ASPENDILLUS NIDIL. CRG 6 TTR BRG CCR B G T
	HANNAKARTKARAP
arandaaarrilaaraddaabaan raa	TSO3 VEG BACILLUS SUBTILIS C G G B A B G B A B C T T
a na a disa a tripa a a tripa a que ta a	Terrate and the base and and settings of the part of the base of the base of the part of t
	1119 4 1 1 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
а а в э травит травто да за в а в в в в в в в в в в в в в в в в	ารายคุ่ว⊺วอ คา[อารอาวาว คาฐอดครออม คอฮเ
	PROLINE
	HERREN MARKE DITH
торы дваритирования в на в на в на в на в на в на в на в н	DELT GAR BOVING 6TA BIT G T TO BELT PACCC
	HELENDER BESTER TOTAL TOTAL SEED SHEET TO THE SE
<u> </u>	HABE GROWNLER* GTTR TETTER TO THE TRIBLE TRIBLE TO THE TRIBLE TO THE TRIBLE TO THE TRIBLE TRIBLE TO THE TRIBLE TRIBLE TO THE TRIBLE TRI
ат за үн на вет ир за ви лет в ет в	AT SERVENCE SELECT SET OF THE SET OF SELECT SERVENCES AND SELECT SERVENCES AND SERVENC
	CHLORO NA KHARANANA KH
_ วาวว่า โดย ค.ค.อาปคลอก ปีสุวอค ปล - ช - ช -	TTอคุวาวอุดบุคออดุวาอ SXIRK ณฑีอ cast
	HENVINERANTE CONT.
ZF OF BE SE WE SE OE BE SE TO TE BL	AL SE EL LL
EP UP BE LE SE DE LE EZ LZ BZ EZ LZ H BI	R SI PI SI OIS 6 7 3 2 4 2 2 1
רסטי מו אווכיבופאן מעוזכירומי אוווכיבופא מו מיווכיבופא	G HEIS O HEIS TACHONIAN

£",

_	
-	
-	
₹	
- 2	
- 2	
_	
_	
_5	
T	
.::	
ij	
Acid	
Acic	
c Acic	
ic Acid	
leic Acid	
cleic Acid	
Icleic Acid	
lucleic Acid	

HULBON- I.C.EYERO, B.A.CLAYTON (1941) O. 437-463 Holon- I.C.EYERON, F.SANGER,	7.SEETYA, R.MIEMIZANA, K.MATSUDA, C1962) MUCC., ACTOS RES. 10, 6412-6 M.J.BIBB, R.A.VAN ETTEW, C.T.UMRIGN M.J.BIBB, R.A.VAN ETTEW, C.T.UMRIGN ELMDERSON, M.M.L.DEBRULING, AS.E.G S.EMDERSON, M.M.L.DEBRULING, BIGL. J.S.TOWNG (1792) J.MOL. BIGL. 156,	7451 74594521 7459- 171	DW, 8.A.RDE (1953) HUCL. ACIDS ALBERGI953) HUCL.ACIDS RES. 11 ALILECTO S.HISHIMURA ALILECTO RUCH S.HISHIMURA RUCH S.HISHIMURA	+005-2269
		1	**	OTIM
A 2 T T 3 B 3 2 2 2 T T T 2 B 1	<u> </u>	a r a a a ti'i'i	ខាត្តក្នុង១១១១	LEGG FRAIME *
A R T D a T T T D B F T T D B F	ล	TTRART'TT	8 A T R R B R B R D	atin * Wayling (S2) Tin
<u> </u>	<u> </u>	वर र ६ व र र र र	อุนาอนคอดคว	. 35 000 990 98\$1
8 8 8 2 8 1 8 8 8 8 1 1 3 8 3	таттката таа	a a n 1 3 î	5 5 1 7 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	TRM 888 2681
a g a o a t a a a a a t t o a a	राज्ञीर वेशीय र बर	B B A T D T	0 9 1 1 9 2 1 3 9 9	1584 520 FG21
a n a 3 a 1 a a a 3 1 1 3 a 3	11112310 133	อ อ ศ า ัว ัก	D D T T D D T D D D	1893 CEG RRT
a n a y a T a a a a T T a a a	rafraeta Tee	อ อ ศ า ว ำ :	D D T T D D T D D	. 2535 CCC MONES
a a o t a o o o o t t t o o o	วากอาคคล ค.		ER RESE SEEN	DLIN SIABUT STUDION DON PSSL
#6ETT1666TT168*		••••	经外租的股份股份	OTIM
1	, , , , , , , , , , , , , , , , , , , ,	0 1 2 2 2 1 1 1 1	ратавнаянэ	* 유럽시1기 1145 8811
] ·	. PROLINE cont.
27 OF 98 38 40 45				
CP 1P GE 2E 3E 5E 1E 6Z	/- The Tan Tan Tan Tan Tan Tan Tan Tan Tan Tan	.21 Si Si ii B Bi bi Zi O	1234587891	•
אבובין שאנוכידסטה מאזוכי216א				
	DITHOUR NOTE OF TOWN	C METTE C	MINORCYL STEM	

£1	MANTIENA 21 THEMBLIA RANTIENA 21 THEMBILA RANTIENA 21 THEMBLIA	PRINCH (1982) CONR. SEN. 5, 221-225 1597/9	VARATIOM OLIOMENT IS ARBITRARY CSSV42 IS BEVENEY IS BARITMEN CSSV42 ALIGHEYT IS BARITMEN
jennu munuk	Kapres erre	P446 4625	
FEBRUARE DESCRIPTION 1	## 7 = = = = = = = = = = = = = = = = = =	к э а т э	9 9 T 882f
4 3T2T2T	ींगररे⊃वे स	ត្នក្នុក គឺ គឺ គឺ គឺ គឺ គឺ គឺ គឺ គឺ គឺ គឺ គឺ គឺ	9 9 T 588F
f 2 T T D T T	: דבכייב	3 A T B A B B B B T	991 889L
Cebect Representation of the central section	Respondents	18211888122	
**************************************	#### === ###	etres sr	T Đ Đ R ĐĐS
	##	1 8 3 7 7 8 8 8 7 3 3	1994 ▶651
2223882	488333 188	1 A D T T B B B D D D	1998 E65L
2 2 2 2 8 8 2	ค ืออ ว ว ว 1 ช ช	R 3 T T 8 8 8 3 3 3 3	. 1998 ZSSI
FICTCE BHNN WASS M	73773778 164 - 25 - 24		
**********	## =====		5 0 1 6227
a a T T D T T	317334 78	នារឧត្តឧខឧ៦ ខាំ	8 8 1 \\ \text{7551}
			PROLINE CONT.
84 P4 24 04 89 49 84 P4 24 04 89 8		K H D 46 20 25 24 28	I 9 3 3 11 84 94 H 3 11 8 24 S9
MINORCYL STEN	เค หมายาก ซ	DOJ TI MESTE AT	HEN CHILKS

1	
ı	c
ı	_

	Common transfer of the second		•		
EC 1130 (1941) 13	455-433 Pre-Koecher, Clalearuug, Rubsak, Mikuexize	FCPE	•	R.MOEBE (1983) PROC. WATL. ACMS.	
715-40	D-L-Miller, M.C.MARTIK (1961) CELL 21, 50 D-L-Miller, M.C.MARTIK (1961) CELL 21, 50	7091	9831137 S034 (EMED, A-9. EALINAM, A.A. BAYEV (1912)	127°159+151 1202 a'u'xblokoa'a'n'keens
1809-ECOT ,225	S.B. S. B. S. S. S. S. S. S. S. S. S. S. S. S. S.	1590	1268	1893) MINEL, ACIDS RES, 11, 5763-5	TPOY C'TEMEEN' B'S'NOFD (I
1885) ERRO TONKOVE E*	8.8.FAGE, 8.0.KALL (1941) RIGL, ASTDS RET. 9 P.E.BAKER, A.EIGEL, D.VOEGTEL, N.FELDARIN (1 291-293		FEBS LETTERS	MEG. A. U. EAL INAN, A. A. BAYEVELPEZ>	120°152-153 1965 A'U'EMANKON'N'H'KEENSE
	**************************************			HADR.JTAN.DORY CETYLLANDERNAME.	6-7-16-278. 449-472 78, 449-472
192011120 11 1144 1154	R.C. DGDEN ET AL. (1980) INC TRANSFER RMA, D. 56	4791		16E-71E- (92)	LAGE A.FURADA, J.ABELSON C.

TORITIOSOTI	า <u>ฮอลา ว ค</u> ือ ว ฮ ฮ ศ ห	1 9	491299	TERRESERVE	DITH CONTRACT
яятэтя"яярээт			1	MAN HANNAKANA	ULU 1879-1990 RESST
	TTTATTENTER TRA TO B		1	TAT DAD TO BENDER 232	STIN
				MA paanamaa an Tirriro	1583A (139 (59)
			1	******* ** ** 1736838	18891 ABA 18881
	h	191	q a b b a a	APDRINGARANA APDRICAL	Takay Rad enat
	7 3 2 2 2 7 3 2 2 2 2 2 4 2 3 2 4 2 3 4 2	ופכ	49.3.3 49.	5 50LFRIR, 6 C C G G G B	50 8070 37 05 8091
	The Soo ⊐articities as a s	T) (piairithn:	384444	2T 32PH- ADD 2081
3133388139T			1	าอลคอดออ etitreus	JEDN CEN BHEIFTRE
		T D T B 6	4633344	ARTILIS GGR BELITTER	SULLINE REAL ECENT.
2 A T D R A R R D T T	. जुरु विस्ति विस्ति विषय ।	1991	1929996	T 1 3 3 A A 3 8 TA 4 A A A A A A A A A A A A A A A A A	1602 UGA PHREE 15
B B D D A A A A B T T	. 719979797871199	TDF	គ ១ ឝ ១ ជ ១ រ	AMARKKANAKKA Sengecel	AT 98AFF ROU FORF
ŧ				1	ZEELI NOO DOOL ZEELI
					11035
S 34 36 36 40 45	25 06 62 32 54 22 8 02 91	ZI SI	ᡶ ::-	· · · · · · · · · · · · · · · · · · ·	
Elt it be de se de			Er it	1234551	
HEIZ.SITHA MULLSTAN	HEITZ-JITHR HEITZ G 400-	α	Hare o	WELLS TATHERNIUM	
•					

	þe	<u> </u>	**	元並	k M)		#=			200		ч						-	F۵			===	:=)								::	: ;	: :		,		;	: 1	**		: •		
	9	1 3	I	כ	Ţ	7	벽.	1 1	5 ,	Lt	5 3	1	Ħ	U	Ð	J	1	ų	9	1	Ħ	1	ᅥ	3						J	. 1	1	3	법	병	Ħ	Ħ	1	1 9	9 4	H	1	CS91.
	*ر	***	##	WWI 1	# W 51	9*	Ŧ	10	9			١,	н	Ħ		٠,		d	<u> </u>		-:	••• 5	' ጋ	_							_	::	::	<u></u>			_	. '	• • •				
	٦,			MW.	2) 1917	E 4	4		12 و	1 . 586	; e E	1 *	ø	0	0	J	_	4					3	_							::	::	::	۲.	9	1	٦,	١.	3.5	99	.9	1	258 L
	의 :	-	1	Τ	T	1	ᆸ.	Τí	# :	נ כ	כו	1	H	Ħ	9	J	1	긔	9	Ħ	9	1	비	T					1	נו	ΙŢ	1	Ħ	B	Ħ	1	9	i.	1 6	3 6	9	1	1991
-	. "	٠.	**	##1		E K	**		PE:		**=	1.	_		_	_		.1	•	••	•=:	•	=	_								::								111	-	_	
	٦,		**	٠,	T		u :) <u> </u>	٠.	ַ ב	,	1	9	6	១	J	1	٦	9	_] -	7	7							9	7	2	3	9	Ţ	Ţ	1	3 8	9	9	1	029 f
	9		9	9	1	9	4:	5 5	9 .		כו)	1	Ħ	B	_	1	1	9	9	1	7	9	2							9	כ	כ	כ	9	1	3	1	5 C	9	g	1	6781
		***	**	##I	*	-	*	:				١.	_	_	_	_						-	1	_						* 1			1 6 1	11	_	_	-			111			
	1		E SI	, 181		##	<u>.</u>) :		,		1	A	•	0	J	+	4	-	9 ==:	_	_	9	כ					č	ב י	Ð	9	a	9	3	J	1	Э.	L	3 2	9	1	909L
	열 :	כנ	1	Ţ	T	1	ⅎ.	l t	, :	כו	ı 5	T	J	Ħ	Ħ	3	Ŧ	1	9	9	9	1	ы	1	: c	5 5	3 .	L	. t	1	Н	Ħ	3	9	U	1	8 1	u .	ı E	9	9	1	209L
	۳.	***	HH	1911	***		宁:		•			١.				_		ŀ	==		•		-	_		_		11:	::	• !	_		_	-	_	-	ī	,	1 1			-	
	١.	, , 44	ᄣ	, L	-#- -	i.	1:	י נכ				1	Ħ	Ħ	8	7	Ť	4	9	9	9	ָ שַׁ	~	כ		5	9 7		2		9	Ħ	Ħ	Ţ	9	1	9	ַ,	1 5	-	A	Ŧ	P031
	d :	בכ	1	3	כ	Ī,	ı :	נ כ	. ;) 3	Ū	1	H	Ħ	9	כ	1	1	9	9	9		-1	_			1	כנ			9	t	Ħ	Ħ	כ	1	9			9	ㅂ	3	EOB!
		**	K# 3	***	HEX	××	4	•			==	١.	_		_	_		ŀ	•	•••	•••]	_										_						_		_	
	٦;) J	***	1] ! ***	H 1	1 1]		1	ב	A	9	3	ī	4	3	9	. T	Ħ :	9	1		5	9 9	-	֚֓֞֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡֓֓֡֡֓֡֓	Ţ	Ġ	9	Ţ	9	8	_	9.	Ϊ.	2 5	.,	J	כ	2091
!	<u>Θ</u> .	כו	1	Ĵ	ב	9	2		,	. 3	3	1	Ħ	ㅂ	U	ב	1	J	9	9	н	Ţ	9	2			J	ני				9	9	_	ב		י נכ				н	5	LOGIL
	1						1				J							-					1	_				_			_	_	_	_	-	_	_			_	_	_	
	1						1											İ					ı												3	N	I	A	3	S			
	1						1				- 1							1																									
E 4 - 4 - 4	t			***			+-											+					t										•••									٠.	
94 \$4 94 £4		12			9 2	຺ຘ	58 58	, H 9	€8	Z9	۲a	BE	s	S		iS S		9		'S	្តឲ	21 13	₽			֓֞֝֞֞֜֞֜֝֝֡֝֝֡֡	,	١,	ĸ	_	I		9	,	₹,		ַכ	_ t		8Þ,		+	
	Ţ	- 1.			•	-	٦	,			٦,	-	2	-	7	=	-	ľ	_	٠	.3	-		•			•	•		T.		н		=		α	'	B	۷,	•	*		
	ΗB	ţS	٦	Ju	ON	H	j	Н	Ð١	5	ग			ď	07	4	1	ı	į.	131	.5	ᅶ	ı								Hž	В	W	ΙX	3								

1735/35 WIEW WESTONE 35 INLEWAGHING REDDENCE 1946/55 WIEW WESTONE 35 INLEWAGHING REDDENCE

Nucleic Acids Research

1602/0 EN ERTUROV ET.AL. ALLEGERENT DEVIATING 1606/37 FUSSIBLE SITE OF INTRON CLEAVACE

_
ũ
Č
S
ğ
20
7
œ.
ਹੁ
_

jen se	*****	- M M M M 1	•	EDE 5	J				.1				1.											
7 -		####H		4 1	4	7	8	e r	4	2020		9 : ==	1 .									Ħ	2 A	
E 2 1	1 7 1	1,1,1	<u>4</u> ⊥⊐	1 2 :	1	TД	9	3 T	4	9 2	9	9 5	9									Ħ	T 0	
5 3 1	*****	(M. 94) T. T. I.	9 0	ט כ	2	1 1	U) T	4	16	9	T :	9				: ! ! .	ı		1			i A	
a 3 1	≥288 8	991		133	₫ r .	ם ם	u :) T	4	9 9	Ţ	3 9	† =		9	ב נייי	2 5	1	כ	1,3	2 0		9 1	
a[j ≀		991	פכ	1 3 3	1	4 4	u :	ו כ	1	D 8	Ţ.	D 5	5		-	ככ			3				91	
1 A 1	TI		3 3	11;	1	a A	9 :)*T	4	9 9	9	9 8	ם									1	Ð 1	
a 3 T	T 1	113	9 9	I B 1	фu.	FR	u .	r D	4	ΩŢ	Ħ	2 3	ב								1	3 9	D T	
42.1	. D I	Li	9 9	1 U	.	9 8	u ,	LJ	1	0 T	1	ב כ	2									: כ	9	
5 3 3 8 3 3 3	T C	T T C	T 3	T A :	1 1	5 W	9 :	э т	1	9 1	A	9 8	Τ) A			1	Τć	::- כי			
1					i				1			•					٠,	uo:		-254 I	אפר			

D. WALL [1901] NATURE 291, A64-467 D. WALL [1901] NATURE 291, A64-467 D. WALL [1901] NATURE 291, A64-467 D. WALL [1901] OR THE PROPERTY OF THE	14.5 12.21
	TIETTI MANAGEMENT AND THE PROPERTY OF THE PROP
A T A D A A A A A T T T T T T T A T B D B A A D	RRETT DE RETTER TOUR RUINFURDIN FOU ESST
Ranjianaarijaarjanjaira Ta	TESZ VERNENDYS LAEVIS RRERENENNEN TEGECR 6 DG T G C
1 198 1 1 8 8 1 3 9 1 2 8 8 1	THE MEMORIAN CLICK
	TSS1 GCU XENDPUS LAEVIS * 6 A R C T T G P C T G G R C C C
า อาวากุกคอา การคอกวาศ ฮาวออ คุศ การ	ы тапарданита веспетания свят
Torotafa de a ca ca ca ca ca ca ca ca ca ca ca ca c	TOPA CONTENSI GGCRCIANT GGCCGC 60
	MAKH WH DILIN
Tan Dan and Transfer and Transfer Ta	
ี้ดู ทั่วที่ทุดดาว อ r by ด ถ อ ค q by	อากา ออกกลกอ "SNIVOS USO YSSI เหม่ามหมายเหม
трэтэкатэатэна	HILD MAKHARAKANAN OTT.
	CTIN SHERRENMENNERS * MENUNTELLED BESST
ттатыры тээтүг агырын агары бары	
	SERINE cont.
	JA1035

FE 15 64 46 46 46 47 12 12 12 12 12 12 12 12 12 12 12 12 12	RL ZL SL SL LL
	A 81 AN ST OF B S A S A E S F
HETE, DITHR MITE, STEM MITE, LIDER RATE 0	שאנאסטבער בענאו ווו מבונאו וווי מורסס
	·

Research
Nucleic Acids
_

	0155 .((7)5) .DD#9.d33 (6891)308.A.A.WCLIX.M.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.A.
CEIT 59° 193-180	
ALLEGES, R.A. VAR ETTEN, C.T. USTENT, S.E. UALBERS, D.A.CLAYTON (1951)	
PUR. 18, 225-239 FUDE: 18, 225-239	
EAGF" 10' 332-334	
E.M.BARMAL E.M.PRAGER, A.CANO. A.C. MILSON (1742) J. HOL.	11429)
U. N. BRONKS. F. A. SANDER, A. C. UTLEOK(1942) - J. A. LOLL, EVOL. 18, 225-239	8 4/91 "RODRING TO STREET TO SCHOOL STREET TO TREET TREET TREET TREET TO COOT
*. A. SROWH, E. A. PROER. A. MANG. A. C. WELSON (1982) J. M. L. EUOL, 18, 225-239	TYPY GOD EVENUELD WERNHUTTICK (1983) 7' BIOC CHEW SOR' 2215-2218 1939 #
D D R R R D T T D D D T T R D R D T H T P D	BSS GOUNDS TEAGRANAM MAINTE ACTOR COO SEST
}	MAKEMBHANAMAN MATTO
	DIT S GEU GIBBON " MOBBI DO GES!
<u>अप्रमाधिक अधिक श्रीत कर सम</u> ्जात	STEP GET * METER BARRAN BARRO ULD 8781
	KMANANNANAN OTIM
7 A 2 T I A A T J D T I D A D A A T	פטפורלט פטפטטטפע בו בפ פטפטטט בו בפ פטפטטט בו בפ
10011001001300001	MANNHAMANAN CTIM
	HA HANNERS TOTAL US STATE
T _ A _ T _ A A T _ D & T _ A A A A A A A A A A A	רופה הכע אבועסויש באביעוב" המחכרוז מוח כוד ה הפוף כי כי ב
TabbathaabadabanAtraea	א א א א א א א א א א א א א א א א א א א
	CHOLPE NAMER WANTER DESCRIPTION
_ _{7 อิว} าทุคถาวอาทุคออาปุลายกฤกาวคออ	
TROTT	а та та на на на на на која 798 г тря 100 г. 798 г.
	מוד באוני באוני באוני פרנכ פפאל פארכנ ודכא באוני אוני באוני אוני אוני אוני אוני אוני אוני אוני
***************************************	СЕТЫ икканивиний
_ aroayonnaarinnaanigoaanportaa	
	CHLOND ANARAMANANA
_ อดอบปุลกรวองปุลอง เปลี่ยอดดูตอบรอย	าอคู่อาวาาอาไอคลอดออ 21.1.1756 คล <u>-อาฮบสามา</u> อ
	SERINE cant.
20 B 22 24 36 36 34 36 37 40 42	ZI BI BI II
	ช อเ รน์ เว๋า เเธย 2 9 5 + 6 2 เ
בססף מאוזכיבובאן האוזכיבעט אוזכיבעט אוזכיבאר פאוזכיבאר d	LI O HEITE OF HEITE LYCHONGINA

1	6 M 16 M	***	Heimm	# = 4		=	7					p :				9											;:	::			::	
4	#####¥ ¥#¥###	. Ç.	E***	#3	C	L 1	퀴	1	Ħξ	כנ	1	식	9 9	B	9 !	털병	ı										1	1.	īΤ	Ħ	Ħ	2631
ьf) T]	1.	LI	9	9	L tt	₩)	8	1	Ħ	1 5) Т	ы	: כ	c F													1	8	1	6/91
ц	T T C	1 J	L I	3,0	9 ,		٦.,	3	u <u>e</u>	1 Т	9	1 5	} 1	7 W Z		╡.															_	829L
	2 T C 84888	424	e ne w	9			_	_			-	77	7			7 -														-	0	ACHL
	****	***	HERR	#:	2	. 8	70	3	a 5	. т	7	٦:	1	. T	⊋_;]													3)	ש	449 L
4	HHMAN.	** T 1	ز الما استا	3 5		. U .	ш)	8 9	T	ב כ	<u> 1</u> 9	1 1	B :	3 _3	i >													3	1	Ħ	9291
	7 T C	ר פ	LI.	9	9 :) H :	ъ	1	8 8	2	Ι,	J 9	1	9.	1 :	9													7	Ħ	1	6991
<u> </u>	REAL C	1 J		75	T :		1.	8 1	ня	3			9		H C	j		_	Н.		_						_					
1.	****		HEN	ŀΞ:	-	325	₹ _			_	* .	23	==:			1-		,	о.	1 3	J	7 6	9 19	1	1 :	9 8	9	J 6	3 I	9	Ţ	4881
¥ .	*****	K### T T	. C .	¥2.	1 2	:] ⊥	B 1	9 9	3	1.	1 5	. <u>9</u>	9 1	A 6]]		3	B .	19	כ	1 t	ט נ	Τ	1 9	9 5	9	3 6	1 1	9	1	4881
ર્ધું.	113	11	1	9	9 T	U 3	ψœ	# 1	ם כ	Ţ) :	ט כ	1	U :	2	2													Ħ	3	9	Z991.
d .	299	9 3	L	ī	D 8		1	Li	4 8	3	1 :	5	9	125	9 H	١,				:; H	Ξ.	;;;			ш	.::	:::	:::	:::	_		~~.
_1	*****	**	HEN	†;	===	I Z Z Z				_		==			===	Ī		:	:::		٦,	1 (1			υ.	•::	::	3,1		9 (•	8381
ļu:	****			7 -	465 T 7	. L.	1	U 1	פנ	3	1 3	12	9 ===	9 (9 9	12) t	-	Ϊ.	įĘ	i.	1	Ι.	י _י ָּ	Ħ,	9 6	1 1	9.	T	5881
4:	3 2 1	2 t	1:	Ţ	7 2	2 :	1	A f	ם נ	כ	1 1	9	9	9 t	9 5] =			=	ט ט	ם ו	u t	u	1	8 (1		1	1884
1				l			ı									ı) UI	כנ	344	EKI	ĸ			
				ĺ																									_			
B4 94 24	02						<u>t-</u> -																								_	
S4 E4					9 ; 29		P∃ G	s						DS S			_ 0	i N	H -	ĸ	_	I	9	3 4	3 (. "	. (ម្ល	48	. "	>	
ļ M=	אר פונ	"H-16	a I Lin		LIST I	5 ALL	1					Γ.			-		-	••	,	•	•	,		•	-	•	•	4.	>			
~-			-170	•	43L)	. at		•	00-	· 4	T		43L	SA	11						,	מאא	D.	ITX3	3							

Traftsera Traftser	81 89	atene ugul Atene ugul Atene ugul 184 solines	0/4991 0/4991

TRANTISNA BI Thantisna bi Trantisna ci	TRANSPIRM	0/9/91 0/6991
	23414U2 A2U	0/299I 0/9991

-5
٤
ã
q
u,
•
α
÷
. =
Ų
⋖
43
٠5
40
\overline{a}
3

## J.ROSSI, #.LANDY (1931) BRIUME 294, 422-427 ## J.ROSSI, #.LANDY (1931) BRIUME 294, 422-427 ## J.ROSSI, #.LANDY (1931) BRIUME 294, 422-427 ## J.ROSSI, #.LANDY (1931) ## J.RASIRO(1943) J.BIOCHER. ## J.ROSSI, #.LANDY (1931) J. BIOL, CHER, 724, 721-295 ## J.HOLOF (1993) J. BIOL, CHER, 724, 731-295 ## J. WORSEL, ## J. J. J. BIOL, CHER, 724, 731-295 ## J. WORSEL, ## J. WORS J. J. BIOL, CHER, 725, 791-295 ## J. WORSEL, ## J. WORS J. J. BIOL, CHER, 726, 791-295 ## J. WORSEL, ## J. WORS J. J. BIOL, CHER, 726, 791-295 ## J. WORSEL, ## J. WORS J. J. WORS J.	MOZDUH.J +071 MILMAIR.A 1011 "EF .0.L.MA.B .0.L.MA.B .1.383.L.J 2071	290, 457-462 COULSON, 1.C.EFERON, 7.SANGER, 64, 657-717 STEL, ADDIE REE, 8, 3797-2402	1496 R.J.SIEB, B.B.UAN ETIEM, C.I.IMRIG CELL 26, 145-140 1497 B.AMDINGUN ET PL. (1981) WATURE: 16-EMBRO (1983) J. NOL. BIOL. 25 1702 E.L.OMESTER, W.A.HOLIES (1980) WATURE: 1702 K.L.UARSARA, J. ROLL BIOL. 25 1704 K.FUKARA, J. ABLEIGN (1980) J. NOT C.P. AMBRON, J. ABLEIGN (1980) J. NOT C.P. A
nta o araaar iirraara faraa aa	199 18	***************************************	(QT.ZM
а на ве с постисти в в в в в в в в в в в в в в в в в в в	T 3 3 4 3 8 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4	A PARTITION TO THE PROPERTY OF	ירסים הפט מאמנונעם איני איני איני איני איני איני איני אינ
	Tab fia	4 7 7 7 2 8 4 1 8 1 8 8 7 7 3 8 4 1 8 1 8 8 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8	ואספ חפרו אמבוררופ פרופגורוב
1983		, A D T D D A T A T A D T D D	1,00.3 UBB NOT!
9940144101			1703 REN E021
919999		1421238144444444444444444444444444444444	1702 CENT TANKE TA
			THREOKINE 1701 GGU E.COLI
	TTabAa	The state of the s	* BNIVD& ARU 6881 OTIN
TROTTARTOSTARABRA 		CHREATH STATE	S MONTH RELL SEST OTIN
	2 9	. Тярвяявяя	* SELON LOS 6081
			SERINE conf.
	S OF SE	EL LL	
M STEM FAITC. STEM FAITC. LOOP FAITC. STEM	90 00 1 0 81	Sr or ea Care st	
The second secon	AUU I L	HATE OF THEM I DISTEN	

ARERE, S. ANDEDY, T. ATOZOY, T. SEE	C IN A.NITAJIAR, KI-1011 , C IN A.NITAJIAR,	A 28 GT G3780434 21 IA.L (ZAVI)CHISAX.Y	74\ 6 071	yaariilaa et The Taariilah et The Taariilah et The	TOASTO WITEMEN
	*********	No Cottebased	015555		
t	A D A T T T A '	gaarrate		1 м	11 1871
	KHMMHHKKMMH		*********	-	1.1 125.1
	, e e b a e c	1,1000000	ุล <u> </u>	J 18	9 U 8021
•	2000000	1313318	ห ค ⊃ т า อ อ อ อ อ	1 9	D H 90ZL
	《长河外米外米市市市市大 市	7272722000	======================================		5 0 BUZF
	Manamanananan Taton-bandaranan	12287218	ล อ.ว∙		D U _ 104L
8	1911666		R 8 2 T T 8 R 2 2 F	ם ב	9 U EOLL
				_	
	KERKKANAKANAKA Bulluk		8 5 5 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	3 19	1 A SOC1
	JBR J T R T		8 5 7 T 5 8 2 2 2	3 19	99 1021
	ļ	1	1		3 ,021
		ł		3 M I M O 3 A H T	
		[
,	TTTTTT	== ====	1 7 7 4 1 7 7 7 7		
•	######################################	5 T T 3 3 T T 1	าอาหาอืออื่อสุ	g Ti	a a eear
1	STTTTT	3 DIT 20TT (1031100000	9 1.	1 1 Z69:
	日本 日 一 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日 日				
7		33107000	, 0 + + 4 9 + 0 - 4	T :) 9 96BL
				. Jrnoo BMIMBS	
i					

94_+4_	Z4 04 99 98		1 85 MS 25 05 P	46 A K H O 4	bb
52 EZ	14 69 49	39 t3 t6 e2	45 SS ES IS GH	E A I C H E I E ZF St	•
	HETZ LYDRONIKA	MBIZ AT	DOUGHT HOUSE HT	EXTRICT FRM	
				אסט טפאלט	
	وعترها أحانا	China Control of the			

r121

·	· - -		eurase o A 1871930 7 744 1630 3 4 ffft
9 4 2 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4	اعتونها سنعام	ен минимини	QTIM
	त ^{ो में क} े भे थे वास्त्र म	12013013111213	# 3MIYOR UBU BEST
- aaaaqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqqq	ਕ੍ਰਿਸ਼ਤ ਸਾਸ਼ ਸਾਹਮਸਥ੍	1 4 1 9 4 1 9 1 1 7 7 1 9	OLIH AMMIN MEN ZEZI
B T 3 2 R R R T B T 1 J T B B T J		MARAMARAMARAMARA	OTIM SEE
	 	This and an I start	# 3500H NON 964L
- ppjowyratertatraeta	тэатта ная-п	TATARTECCCGATA	ABVIJ TRA USU BRYN OTIM
B9339HRIBILT(007)	[**************************************	GTIM SET
<u> </u>	मूं <u> प्रेड</u> का राप्त स्	,	JUZO NON XENDENRO FUENTE
я в в в в т я я т в т т я т в э э э т т	дэаяа ттаа наң	STORULT NAMES	GMCTHC)
9929188181181		MERCHANGE AND A STORY OF THE ST	의 기관 기관 기관 기관 기관 기관 기관 기관 기관 기관 기관 기관 기관
aaaa a q q q q q q q q q q q q q q q q	ជុំរដ្ឋមន្ត្រី ខេត្ត ខេត្	コイコ語ロガキエエエココヨ	1228 nen enerenu enuciriz
19393881391833378	ค รอดอด รออ รอค	DHENNORM WANTER	DEIO"HD
	7	DIDAG TITODOD	IDUNIAS NEED FELL
R B B D T R R T B T T T T B D D T	व्राच्याच्या । व्यवस्था	TADBETTABETTABETTABETTABETTABETTABETTABE	TATE USD STATEMENT OF THE STATEMENT OF T
gaabitantatitabit	P*****	MAKENERSHERM	OTIM
400040012114127114	ผ่วอกญิด รออ ราคคุ	T1388171717171	1752 USU SICONIMUNCES CEREV
	1 1		יואפרואונאב בפטני
j j j]]	• [, Joos BAINDBAHT
	1 1	1 1	
St 0) 86 86 46 26 06 83 8	2 22 8 02 9L /L GL E		
	7	21 01 68 48 5 + 8 2 L	
1 1 1			
האוזכ, אוז אוזב ונספף האוזכ, אוז אוזכ. אוז אוזכ.	ול הסוסה לו ולוכים	MELLS II APPLIS TATHORISM	

G.GGENT,ALFELDANANITASS) CURA.GEN. 3, 221-225 FLJ.SIEB. A.A.VARE ETTER. C.I.KAIGNI, A.E.DMLBERB, D.A.CLAYTON (1921) S.ANDERSON ET AL. (1921) HATURE 290, 432-445 S.ANDERSON, M.H.L. DE BRULLM, A.M.CEULEON, I.C.EPERON, F.SANGER, I.G.YOUNG (1927) J. MDL. 134, 423-717	6643 4643 9643	ALGUREL, C.A. CAZARUS, W.SASAK, W.EUGHTZEL (1981) GELL 23, EZZ-CZZ, R.E.MASHDAM, B.E.DUDDOK C1982) J. BIOL. CHEM. 258, 5212-5218 G.D.MAGARIM, R.G.HALIGE (1982) J.BIOL.CHEM. 258, 5212-5218 A.A.STEIMWEIZL C.1.MESBERS, Z.SCHMARZ, E.J.GURBING, L.BOGURAD A.A.STEIMWEIZL C.1.MESBERS, Z.SCHMARZ, E.J.GURBING, L.BOGURAD	7621 7621
ATTACHMEN DIFTON RECEIVED BARNER (1963) NUCL. ACTS RES. 11, ACTOR		HIGHTONES CINCARD AND AND AND AND AND AND AND AND AND AN	

	MERNA	****	. **	-	850	.	ı				1	-			-															
	1 3 8	9 8 5	1 1 3	ב כוו	11:	בכ	ו שם		8	1 3	Я	Ħ	9 t	9	9 8	1											t s	Ð		154L
	MHMHM	***	***								7				:=															
1	H 2 H	996	183	ו בלו	Ι.	Li			1	. 3	ı	Ħ	B E	9 8	9 1												4 5	3 6		1585
	ENKK M	*****	N M W W								1	-==																		
1	ᆸᄀᄬ	9 4 5	1 2 1	lo 1		ᄓᅬ	1	J	1.1	. 3	ᅦ	ㅂ	9 t	4 K	a 1			•	~ 4"	••							# t	j t		近八
	MARKET	RSRS									- 1	.==		****	=															
1	436	9,6) 🗅 T	101	. 1 :	2 J	_N	l 9	u :	ΙŢ	덕	Ħ	9 Ł	1 8	8 1	,											# t	J E	•	第 41
		w ##	HH H KN								ŀ	EEE	===		1															
	1 D R	9 8 6	1 2 1	15:	1 1 3	ᇽ) t	שו	# t	ı	4	Ð	9 t	g t	71 7												U \$	9 4	•	19 21
	HNRKE	* **	MICH OF			-==					t		200	====	:=															
	ם כ 🌣	0 D 1	. 9 U	1 1 5	9:	ובכ	TA	Ħ	8 3	1	4	9	9 :	1	ᆸᄀ	l										Ţ	9 5	19	4	1521
	-	744 14	****										===	===	= =															
	וםכוֹו	966	BR	ן כן	9:	כ כ	1 6	Ħ	9 2	ıT	4	9	9 :) T	의 J	•										Ţ	9 9) T		15 <u>7</u> L
	***	****	PERM		***						_f		24:	***																
	ជ១១:	999	9 8	1 7 6	. פו	ובנ	T A	н	6	1	4	9	9 🕽	3 T	벽그	ı										Τ.	9 6	, 0	,	-641
	MAKKA	***	-							_	J.		===		٠ <u>٠</u>															
	4 3 8 4	a a t		ÅΤΞ	1 1 .	- 3	A T	•	9 3	1 9	4	9	8 t	, j	8 8	l											0 1	שׁ		SZI
	PARK	RRARR	No KA	T							.P	==			·- [.															m / I
,	476	RIA	1 #	} ¤ 1	.] :	' ጘ	T R	a	A :	1	4	9	פ פ	9	ᅰᆂ											1	9 S	, 6	•	33/1
						١					ı											, śn	03	BNI	NO:	BAH!	-			
	ļ			ļ]				• • •	4				1.									- 			· -			
		99 ک						9 5			역	S		05	86		Ø	Н	>	•	1	9	3	2				**		
9/ E	4	69	4 8	59	€B	18	65		5	SS	F	S	LS	: 6	Þ	٩		ł	٦	r	Н	ᆵ	(1	Ð	Ź٥	S	•		
	1			Ι.							- [-1															
	STEN	סטכגר	NIHL	l W	312	411		ďÜ	רַס	ЯĬ	١	н	315	لاء ;	. I						HUU	ART	ΧJ							

Nuclaic Acids Research

_
arc arc
õ
S
õ
- 60
ő
. <u>Ħ</u>
ā
ei.
₹
≍
ម

TRANTIBAN BI TUBRNƏLIA OVETEJ T RO 3 SHINTS ET M GIVAZSI YARATIBAN BI TUBUNDIAN OVEMB TRANTIBAN BI TUBUNDIAN OVEMB	1923/30 N IS ELIMEN I OF V 1923/30 N IS ELIMEN I SERVENING SERVENCE 1923/30 N IS ELIMEN I SERVENING SERVENCE 1923/30 N IS ELIMEN I SERVENING SERVENCE
医骨柱间隔壁 机转换器指挥电 电电电电电电	
	- 리Đ링 디뮤니 - 유리 - REBI
TTT TCTTTDDGCCTTD	
NAMES AND ASSESSMENT OF THE PARTY OF THE PAR	pessengers AAA 2001
ar or or part of the series of	. 1
811233133333136371	
ASTITED STRICT THE ST	poceanas .
HADNAKAKAKAKAKA DE DE DE DE DE DE DE DE DE DE DE DE DE	100 A D D D D D D D D D D D D D D D D D D
ब्रा⊒राग्∃ वर्षरागरवर्ष २०६	। स्वाप्त विद्या विद्य
สุวยวอลอศุวคาววากคลอวา	TOORTOR TOTA ARE
MANAME NEEDS	Designation of the state of the
#5188888888888	T 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
8113318111313188831	1922 2 P T B 2 S 2 P T B 2 S 2 P T B 2 P B P T B 2 P P T B P
atrana propertare and the contract of the cont	PRESENTECE
成员业长业长规则分类型权当的 pe acutat	
สุรออออสอรราสาขายคอวร	Tagaaat Tata roor
	MAHGOTAYRI
84 44 24 04 89 88 69 29 ha ca ac a	
84 64 14 68 49 88 88 69 19 65 45 55 84 64 24 04 89 88 69 59 19 65 45 55	PS 23 03 PF 0 W M H B B B B 25 PS PS 13 89 4 7 7 H H D E 24 S9
i i	
NETZ JYDRONINA NETZ TT 900J HT	HETS TI MEN PRINCE

*II *539 5 678	ELL, 1481, 256- MET. 187, 256- MET. 187, 256-	(1881) CUBE: BEP. ¢ THILBANDEEN WAY'D'SO	ERULJN(1983) W. A SPRING HARS., S SPRING HARS., S SPRING HARS., THE CLARACTER AND THE CONTROL THE	7020 N.H.L.DE 1020-1031 ASSE 1020-1031 ASSE 1030-1031 1801 R.A. YOUNG (1979) J.SIGL.CHEA. 234, 12715-12731 25.5. H.O.KOECHEL, C.A.LAZARUZ. R.SADAK, M.RUSETZEL (1981) CELL 73, 25.6. A.C.LARATHE, N.D.HARA, K.LMDESSRIUX-LYDN, D.L.AIZLEA, J.E.DOWZESOW 25.0. A.L.METELLE, M.L.SOBIN (1961) BIOCHEMISTRY 20, 4015-4021 25.0. A.L.METELLE, M.L.SOBIN (1961) BIOCHEMISTRY 20, 4015-4021 25.0. A.L.METELLE, M.L.SOBIN (1961) BIOCHEMISTRY 20, 4015-4021 25.0. A.L.METELLE, M.L.SOBIN (1961) BIOCHEMISTRY 20, 4015-4021 25.0. A.L.METELLE, M.L.SOBIN (1961) A.R.KRON, 25.0. A.L.METELLE, G.DE BENEDETTO, D.DOMARTA, R.GALLERNAI, A.A.KRON, 25.0. A.M.C.LAMAYE, S.T.G.C. C.DUALIDARIELLO, C.SACCOME, E.SAIEA	
18173 18831 18832 2003 2003 2003 2003 2003 2003 2003	0 4 2 2 1 1 1 4 4 4 2 2 1 1 1 1 1 1 1 1 1	7 1 2 1 1 2 4 2 3 1 2 1 2 1 2 1 2 1 2 2 2 2 2 2 2 2 2	A A A A A A A A A A A A A A A A A A A	188 188 188 188 188 188 188 1188 83818	A
	Le se ce	MATTE STEN E 05 25 25 E 06 25 35 4	8 22 8 0	er A at ▶r	St LL D G G S S S S S S L S L C L G G G S S S S S S S S S S S S S S S S

- 4 :

lds H
leic Ac

1899/¢ Alienbent is arbitandy 1991/5 after residue es luteruenias sequence	VERNITIES SI THEMSELS 0/7461
C D D D D D D D D D D D D D D D D D D D	1898 F281
	, , , , , , , , , , , , , , , , , , ,
Paramananan manasasasasasasasasasasasasasasasasasasa	Tabbarantaat soer
######################################	TTJBBBBBBBBBBBBB
42393331113318883118882	TT3R83TA3T83 roer
	TYROSINE
THE CALL TO THE CONTRACTOR OF THE CALL TO THE CALL TO THE CALL TO THE CALL TO THE CALL THE CA	
PRESENT REFERENCE PROPERTY OF THE PROPERTY OF	2 A A 8881
MANAGEMENT REPRESENT	9 do Zegl
атоттовя пояраовера	а н я — 8£61°
	.ina MAHADIAYAT
8/ 4/ 2/ 8/ 8/ 8/ 8/ 8/ 8/ 8/ 8/ 8/ 8/ 8/ 8/ 8/	
SK FK 69 K9 89 F9 K9 89 F9 89 89 85 F5 K5 69 84 N 7 F	1933H8+++
METE STEM TE LOGIE AT METE AT METE AT	HIND DRING

L.WDBOOM, J.MRESS, A.LANDS (1961) MATURE 294, 422-427 L.MDBOOM, J.MRESS, A.LANDS (1962) MATURE 294, 422-344 L.ML.SELMESS, D.L.CHRINGS (1962) WHOLE, MATL, RCRO, SCI, USA L.ML.SELMES, D.L.CHRINGS (1962) WHOLE, MATL, RCRO, SCI, USA L.ML.SELMES, D.L.CHRINGS (1962) WHOLE, MATL, RCRO L.ML.SELMES, D.L.CHRINGS (1962) WHOLE, MATL, RCRO L.ML.SELMES, D.L.CHRINGS (1962) WHOLE, MATL, RCRO L.ML.SELMES, D.L.CHRINGS (1962) WHOLE, MATL, RCRO L.ML.SELMES, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS, D.L.CHRINGS L.ML.SELMESS L.ML.S	88, R.A.VAN ETTEM, C.T.MATOMT, A.W.MALBERB, D.A.CLAVION (1961) 8, 167-180 8, 167-180 8, 167-180 1905 1907 19	2 222 222 2 222 2
อ т т ว ป ศ ค ค т อ		
**************************************		19 taer
	IN ASTERBILLUS MITTLE. REGRAGES TCC 6 TR 1 6 T T	19 ZFGL
Tatatatatatabenadabenga TTab	TO GET A GET A GET A GET A GET TO TO THE TOTAL THE TOTAL A GET A G	19 SDBL
3 0 1 2 1 A A A A T D A B B B B B B B B B B B B B B B B B B	经股份的股份股份股份	
	ANAMANANANANANANANANANANANANANANANANANA	190S C
_ วอ ; ว ปุ ค ค ศ ว ว า ว ค อ ค ว อุ ค อ อ อ ค ค ค ว ว อ อ	a a g a s a s a a a a a a a a a a a a a	D FOET
	TYROSINE	
TODDSSCETTCRSSCCCT	HILD REPRESENTED REPORTED TO THE PROPERTY OF T	
TOJOSUBURCELICEBURCECL	MIND STATEMENT CONTRACTOR OF THE CONTRACTOR OF T	n ESG1
	тяядттаартттяярая "иямын яз	n zeel
_ ⊤ว_วอสุดคดวากว่วอดอนุยุววายุ ค	TRICOLES TRANSPORTED OTTO	5 GD01
		n 9501
	. snos Martiotyky	

C+ ++ GE 4E SE DE LG GZ 4Z SZ ZZ A 02 VI	ZL BL BL AL	
	er by sr original to a b & s.r	
רסטים או קאדוכ, בונטים האדוב, בונטים האדוב, בינטים אורוב, בינטים	C NETE OF NETE ATHORITH	
	· · · · · · · · · · · · · · · · · · ·	

182\0 WIENERERI IS WRILIWELL
182\0 WIENERI IS WRILIWEL
182\0 WIENERI IS WRILIWEL
182\0 WIENERI IS WRILIWEL
182\0 WIENERI IS WRILIWEL
182\0 WIENERI IS WRILIWEL
182\0 WIENERICE
182\0 WIENERICE
182\0 WIENERICE
182\0 WRILIWEL

75
2
Ö
×
ĕ
_
ಹ
-5
×
.9
₾
Ç
2
Z

R. SROSSKUPF. H.FELDMARH (1981) CURM. GEM. 4, 191-194. J.F. H. LONG. D.P. T. M. C. L. L. L. C. C. C. C. C. C. C. C. C. C. C. C. C.	1925 F. MELER, B.D. CHARGOM, A.B. WALLACETTORS OEME 20, 478-478 1925 F. MELER, B.D. CHARGOM, 1990) CELL 19, 145-135 252, 11974-11920 1935 F. CHARGESCHATU, R. B. MALLICK (1923) J. 1101. CHER, 25, 1997 1935 F. CHARTORE, C.DE BENEDETTO, B. BROALETR, R. BRALLERRNI, R. R. R. R. R. S. P. S
а ет э ца в ятат э на ят п д э а я в	DTIH
·····	MITO GET ARBENSERSES GET B B CT I B B C C C B B C C B B C C B B C C B B C C B B C C B B C C B B C C B B C C B B C C B B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C B C C C B C C C B C C C B C
	1957 Быя ніуры — ***********************************
	างค่อำวัญอนุครุกกายล *azuon,คบอ aeer
วอนาวทุดคด การควาคอาการคายคอาคาคา วออ	ээн эээт тааааагаа зиелт тилж чил жеег
	TTBREET GITTES THE THE STATE OF
татэняяятыттаятя аэвя Т	TTBREATTO BETTO RATION OF THE CONTRACT HIS SHELL
Tabbatatabbbatahta	MENNAMEN HA CIIM
A R I D I R R A T B I T A D B I I I I D B A A	DITH DEREMEMBERS OF THE
	19 1 2 1 3 1 3 1 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
	Taria ma marcius e n e 1 Taria e 1 Ecc ca marana rea
กรายาสุดออกสุดวอกอุก าออ	TO BE GIR XENDRES LEAVIS CCTTCBATA BECT C BECT
อาบานสำคนาบานลอนคาสุวออนุตาบาลอ	T T B E E E E E E E E E E E E E E E E E
	TYROSINE CONT.
20 00 BE BE BC 20 00 02 07 47 37	
Ep 17 ED 05 05 05 05 05 05 05 05 05 05 05 05 05	d ar ar ar ar ar ar ar ar ar ar ar ar ar
MAISTATING CONTRACTOR CONTRACTOR	1 1 1
1000 POLITIC STEW PARTIC STEW MATE OF THE	DATABOLI STEM 10 STEM

(* / 864 taan / 800 ta	
1'ersoned (1685) 1' UGF' BIOF' 129' 982-515	
S.AMBERSOM, M.H.L.DEBRUJUM, A.R.COULSON, 1.1.EFEROW, F.SAWGER,	5651
S. RHORRSON ET AL. (1941) HAFURE 290, 457-465	1661
N91-/81 *92 7179	
ALL-818. R.A.URN EIYEN, C.T.MICHT, R.F.MALREGO, D.A.CLAYION (1991)	
The thou the manufacture of the first and the first of th	7447
E.AMAROSHI, S.ALYMANNITAGS) NUCL. ACIDS RES. 11, 3647-3742	1442
D.G.CLARY, D.R. HOLSEENHOLTE (1983) MINCL. ACIDS REB. 11, 6859-6572	7841
N.H.L.OE BAULH(1983) MATURE 504, 234-243	TASE
**************************************	3401
J.F. H. HOMOS. D.F. PAK. M.K. WELSON, B.A. ACC (1983) HUCL. ACIDS RES. 11.	
The state and a state and a state of the sta	1424
M. SKINSSHUPF., H. FELDRANN (1985) CURR, GER. 4, 191-196	

1490/0 WTIGHERI IZ WESTEWEL 1440/0 WTIGHERI IZ WESTEWEL 1440/0 WTIGHERI IZ WESTEWEL

			•	
	MAKKWAK KKX	NA APREZ CACEER	purscarer:	
	433877	<u>ที่นี่ร</u> อกอยุกอดยาก	. 1 อ อ ค อ ค _. T	494 6 661
	RODRII	TTISTE BBRT	. 1999 8 8 B B B B B B B B B B B B B B B B	
	HAMMANAMAN	NAME OF REAL OF STREET		R 9 R TEEL
٠	MXMENXXXXXX		ក្រី១១១១៧០	ਸ਼⊃ੰਸ਼ੇ eeer
	822822	2227722788827	таранево ттонастн	31935 ZEB1
	H H H I L	7		· · ·
	NENEWERSHIPS	###	T 2 G 3 G 2 G 1	PTT 3681
	A □ TRAT	<u> </u>	TIRBARI	914 9 961
	R[JIBIII	<u> </u>	กออหอหว	R 1 2 8281
	HANNARANNA Panarananna	***	Petapenen	R 1 2 6261
	******* *	###======== T	T 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	R 0 R 2521
	RITTO R B	<u>วิติวอควาสาคคอวา</u>	י כמוכדוד באבופקו	1194 + 561
	499449	212665116621	1001342	
	******* *** 4949991	###	=======================================	.998 ESBT
	922339.	ד כ פ א כ ד ונ ה כ כ נ וכ כ	ر ق ق ق ق ق آ	. 825 B B B B
		1 1	HOSINE cont.	J.
	i		1	
D4 N4	-			
94 HZ SK E	27 07 55 7 17 88 71		и ти ти ти ти ти ти ти ти ти ти ти ти ти	9¢ ¢Þ
	1		ES 12 EP 4 N J L H 7 G E 79	S *
	אסאכאר פופא	IHQ HB12 국가 역00J 국가	Hate at Hard ANTX3	

60
Ţ
č
ž
œ
8
정
e
일
Z

search	
Acids Re	
Nucleic	

MOITIEDA 21HT 14 A ONJY TO	TAMATIBAN ET TA ET ETANLEDD ET	SOSTAN MIBBURS AYABBA, B 62\420S	0816-\$116 ,bsc .nsic.,b18.0	IN 8.E. TRALENFELB, A. TZABOLAFF (1986) J SEGUENCE WITH DEVIATING 39-42	D/TS02
NE AKKERK	##personate:	.	h===== ==	•	
HKKKKKKKK	4英本教では今日から。 19 対 T T J コ			1918	190Z
HAMM WAME	4	ភ្លែតឧ៦។	อควาคว	1966	0902
######################################	ядвват	ត្ត "ព្រក្	TADITE	១១	ESOZ
ផ្សារពុធ	g T a T a a	T B B B D B	911111		
HAKHAKAKAKI G B B B C B	*****	3 3 1 8 H 2 1	993333	អ ១ អ	esoz
H T C T D H	Red Expenses	3		2998	P\$02
*******	**************************************	1 3881	A A D T T T	ម១ម	2023
ATTOIT	1 H T D D H ;	켭ㅜㅁㅁㅁㄱㅜ	атаадо	199	ZSOZ
## ####### # T D D T T	191913	3 288927.	884747	1488	LSOZ
я эт я я я	адрват:		963333		
ECTECH CCTCCH CCTCCH	TRIBLE ENGER	ฟ ที่อยยอกเ		1936	D+02
	- 7		99393	. 1999	E005
	1			אטר ז א ב	
87 FY SY 07 88		DS 95 95 MS 55 25 55	K N O 46 80 85	[H = D B Z + S + ++	
METZ LYDROM	IMP METE RI	400J ₹T	MBT2 TT	NAS FATIKE	

H.C.MYLLER, B.RALBUT, B.R.TENIOR, G.G.TEMER (1982) J. BIOL. CHEM. 257, 670-675 J. BIOL. CHEM. 257, 670-675 G.G.CERRY, J.B.GODGAG, S.C.RRITKN, C.RR.FAURON, D.R.UGLBERNIC, G.LEMAPE, G.PEDE G.A.COURE, F.C.RHITKN, C.R.G.REC (1982) BIEL. G.C.BERNICK, G.RESE, G. GADDALERANIC, C.LAMAPE, G.PEDE G.A.COURE, F.C.RHIN SEL, STA-416E A.M.GRORGEN, T.GERI, B.TRARMEN, G.KGINE (1982) PROC, WATL, ACRO. CLE. J.TEGRIS, G.G.C. WATL, ACRO. CLE. G.G.C. G. G.G.C. WATL, ACRO. CLE. J. G.G.C. G.G.C. G.G.C. G.G.C. WATL, ACRO. CLE. G.G.C. G.G.C. G.G.C. WATL, ACRO. CLE. G.G.C. G.G. G.G.C. G.G. G.G.C. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G. G.G.	291-295 2053 HC.EPERGH, G.A.C.ARATIM, J.E.DOMELSON (1940) MUEL. REIDS 2053 HC.EPERGH, G.A.C.ARATIM, J.E.DOMELSON (1940) MUEL. REIDS 2053 HC.EPERGH, G.A.C.ARATIG, N.E.AGAK, H.XUEMYZEL (1961) CELL 23, A. A. A. A. A. A. A. A. A. A. A. A. A.
M. C. M. C.	Partition of the property of
- क्षेत्रच्या सम्बद्धा । स्वत्त्र । स्वत्य । स्वयः । स्वयः । स्वयः । स्वयः । स्वयः । स्वयः । स्वयः । स्वयः । स	SOUT DECEMB GREEKS & STATES OF BELLIS OF THE STATES OF THE
Beredrashermsshaferen ine	SPECIAL DESCRIPTION OF THE PROPERTY OF THE PRO
	a Japi⊐i⊃Apinininaaaa astaw 248 248 248 248
	THE THE PERSON NAMED IN TH
HHMOULANT	* 139 360 GS02
<u> คอดอำ</u> กลวดงาศควรง ชุดีวอลศุล โอ	SOSS 1992 DRONGLICH YRIGIBA CHRITTANA GCTTATTRE
	阿特拉斯阿斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯斯
	2054 SPECIFICA MELPHO, GITTEL BEGIND SPR PEOS
ื่ออกาที่วดวการวุกความควอกๆค	DRDRATTORNATION OF THE PROPERTY OF THE CONTRACT OF THE CONTRAC
# # # # # # # # # # # # # # # # # # #	[
กลอบคาคาคา คายาเปลื่อดลด เอื่อ	NITO PEPERGILLES MIDLE. ARGARANTE AGE CTC AGTT 6
RABDRIATITETTIBCRCBCBRR	MARK MEMMANA DITA
	a traditionantinonaban "Teuar Jan Feux
Rand Anderdate Transpersion Tran	· · · · · · · · · · · · · · · · · · ·
[[[[[[[[[[[[[[[[[ZO40 FULL YEAST B G T T T C G T G G G T C T G G G T C T G
да в за в в в в в в в в в в в в в в в в в	
	STATE THE THE THE COOS
	URINE
25 05 95 9C bc art no early 40 45	
ED 12 SE 25 SE 12 DE 25 SE 8 02 91	LI SI EI LI
	A 81 P1 S1 D1 8 8 7 8 2 P E S 1
עסטי אודוב, אודוב אודוב, אודוב עו אודוב מ	0.0
	LI G NATE LYCHONING
	. 1

	ANVAR EIIEM, CLTJARIGHT, NLULWALI 1809 - ANLLGENBULJA, BLRLCOULEGU, ILC 1887 - I. GOLL IIOL, ISA, GLTLIS, ST	CUAD 2 PARENTH	LDISEAUX,R.NACHE(1982) I. M.SUGIUMA (1781) NUCL. ACIDE RES. INDEAKI, N.SUGIUMA (1782) INDEAKI, N.SUGIUMA (1782)	A-4 -
EF L+ BE ZE SE CE	25 25 28 30 32 25 35 30 32 25 36 30 32 35 36 36 36 36 36 36 36 36 36 36 36 36 36	TANK AN THE REAL PROPERTY.	#### ######## A T D T D D D A ####################################	2005 6PC SPINDO 2008 6PC TOBRCCO 2008 UNC TOBRCCO 2008 UNC TOBRCCO 2009 UNC SPINDO 4110 2009 UNC SPINDO 4110 2009 UNC SPINDO
MTIC.LOOP ANTIC.STEM	R I STEM RATIC.STEM R	acon a Haus a	MATROACY, STEM	

1	ď	ī	1	3	1	H	Ĭ.	Ħ	Н)	L				í	ı	н	ר		Γ,		. 3		•	1 -															Ħ		_		502	
	**	42	Ī	***	-	**	ı			-			-			•	•	_	_			_	-			1 -															u	2	u	-	MOUC	
(틴	Ţ	Ξ,	1	2	Ħ	E	b	. 8	5	, (Lt	1			Ħ	3	3	U	2	1	t	2	1	. 1	T															Ħ	9	Ħ	9	602	
•	ij) (**)	9	Ä	Ĭ,	Ħ	1	2) ;	. [1	9	Ħ	9	כ	T	2	9	9	2	ä	1	כ														ı	9 :	9	Ħ	٠	90Z	
ŧ	## T	2	<u>ک</u>	J	ı,	U MM	4	7	b	9	1	1	9 :	2 !	. פ	8	9	כ	Ţ	1	9	H	2	1	_	ב														L	9 1	ð	Ħ	E	S 02	
t	Ţ	ֹב	<u>ב</u>	כ		Ü	4		Ħ	9	1	:	1	3 (9 (4	9	כ	1	4			2			כ														T.	9	B	Ħ	2	S 02	
																																			. 1	נסע	3	91	117	ĦΛ						
94 E4	7.5 I.E.H	12		38 28 6	۷		ŀ	9		69	Z9 S	L9	!	5		Z		S 2	S	s	:5		 LS		타	3 >	d	Ō	N	H	: 7	X 1	 H	4	9	0	ò	8	٦	9	51	b	•			

TRANTIERA EL 1835MELLA OVYTOS

5040/0 VETOBULENT TO VEDELVERA JAPY/30 VETER VEZIONE TO UN 33 INTERACHISMO SEDDENCE

125

Nucleic Purity States of S

ротовторнатт вотовторнатт вотовторнать при при при при при при при при при при	9913443041	повети повет
IDIE PROMI		MSTZ 0 MSTZ JYCHONIMH Br Pr Sr Ore 8 7 8 2 4 5 2 1

۱,

TOPP/G ALIENSENT IS ARBITARANT

	(11	14 E	*H3	TTA.	i".a i)"ii	'48	1343 1843	9		905	muz	3.A.I	٠.	KLJI	IXA:	***	. H. f.	9 92110 1 40843 91 194 8 1881	Oité.	5 6	605 6405		:29-	-	-86£	S '	8E8.	HE:	VCII					202°U	111	IVZĐA		Y)''	, CH3G.	309¢ H
٠.																																								
t	9	H	Ţ] 2	Ħ	5 (n 1		1 4) H	כו	3] e	ر د ا	9	н (н	_	81		ŗ:	• • •	• • •	1.						***				01	IH		
t	, , ,	н	<u> </u>	٦,	ы	٠,	3 1	-	:				1		• • •	• • •	1			٠	_			1 ፣	•	٠.,	٦°	4	u u								* BNIV		חשכ	2022
			<u>. </u>	77	•	_ (3 1	٦	<u> </u>		1	ו כ	4 6	Į,	.9.	A F	1		8 1	1	Ħ	1 (4 6	Ţ	1	2 5	ol u		9								* 382U OT			
t	19	Ħ	9	z c	벙	. J £	1 T	1.	ء لا	2	1	7 +	ļ	١,	n	не							_	Ι:	• • •	• • •	1		***								ויפנג		JC8 1	960Z
	<u> </u>	-		Ⅎ.	_ `		_		+-				1 "	• ~ •	٠٠.			1	D 8	•	Ţ	T 6		٦.	1.	2.5	a a	丩	U .	נו	9	9 9	9				03368		그러다	\$08€
3	- <u>-</u> -		ы ,	T	9) t	פנ	1.	4 7	בו	Ħ	D 1	9		9		! =	1	9 9)		J 9	э ы	5		JE		d	***	144	***	XXI					רטאט	43	•	
ġ	9	1	9 9	a i	9) t	, 9	1.	בו	2	# #	 ב	9			н п	l e		9 9					•	•••		1	7	**	F	***	***	E MA		•		LORO BACCO		349	2083
]]]	_	-] _	*	פנ			3 5	ם נ	3	1	3 6	16	4	Ħ .	9	Ð	9 £	G				HOMNI		369	2902
									1																			J							٠,	COU	BHI THE	١.		
				L			_		1			i														- '	1	1												
	ZÞ	D	Þ	38	9	F	ÞĒ.	25	7				td										-4				ļ.,													
e,	1	. •	ĊC	₹~,	ŗ	`			1'	Œ	9	۔ ا	24	P	Z	Z2,	8	20	유니	- 4	L	SL	. i	EL	L	t.	ı	ı												

2096/76 AFTER RESIDUE 16 OR 37 INTERVENTING SEQUENCE

.inos SMIJAV

6602

BROZ

₩902

E90Z ZORS

8 8 8

8 8 8 1994

TOBB

1944

30

EXHIBIT E



Compilation of tRNA sequences and sequences of tRNA genes

Mathias Sprinzl*1, Konstantin S. Vassilenko²

¹ Laboratorium für Biochemie, Universität Bayreuth, 95440 Bayreuth, Germany and ² Institute of Protein Research, Russian Academy of Sciences, 142290 Puschchino, Moscow Region, Russia

*To whom correspondence should be addressed

Tel.: +49 921 552420

Fax: +49 921 552432

email:

mathias.sprinzl@uni-bayreuth.de;

kvassil@vega.protres.ru

INTRODUCTION

The new compilation of tRNA Sequences and Sequences of tRNA genes contains in addition to 3279 sequences of the last edition from 1998 (1) the completely new Genomic tRNA Compilation including the sequences of tRNA genes from complete genomes published up to January 2002. The current Database consists of three parts:

- 1. Compilation of tRNA Genes (MS Excel® file, ZIPed)
- 2. Compilation of tRNA Sequences (MS Excel® file, ZIPed)
- 3. Genomic tRNA Compilation (MS Excel® file, ZIPed)

Compilation of tRNA Genes,

is a summary of the sequences of tRNA genes published in the literature and databases up to the end of 1998. It contains tRNA genes of all organisms and organels, but is not updated since January 1999. This table contains about 500 sequences of cytoplasmic tRNA genes that are not included in the Genomic tRNA Database. Most of the tRNA gene entries in this table have references of the publications in which the sequence was communicated.

Compilation of tRNA Sequences,

is a summary of tRNA sequences, including modified bases and references of the publications. The references are restricted to the first publication of the complete sequence unless additional information (e.g. base modification, corrections, etc.) was later obtained. In such cases additional references were added. This compilation is updated up to January 2002. The table contains the known tRNA sequences of all organisms including organells. This is the continuation of the original tRNA compilation first published in 1978.

Genomic tRNA Compilation,

is a new addition to the Database. This is the most complete compilation of the sequences of cytoplasmic tRNA genes derived from complete genome sequences included into DNA databases. Since sequences of tRNA genes originated from cellular organelles frequently can not be processed to the general cloverleaf scheme, they were not included in the Genomic tRNA Compilation. There are specialised databases dealing with these sequences (see links below).

Current Genomic tRNA Compilation consists of about 3700 tRNA gene sequences from 63 organisms covering archaea, bacteria, higher and lower eukarya. The database includes the tRNA genes sequences collected in GtRDB (2) as well as those from the additional complete genomes found in DNA databases. If the genomes of the different strains of the same organism were sequenced, the corresponding tRNA genes were added to the database independently.

PRESENTATION OF SEQUENCES

Compilation of tRNA Genes and Compilation of tRNA Sequences

In order to facilitate a computer analysis an alignment of sequences is used which is most compatible with the tRNA phylogeny and known three-dimensional structures of tRNA (3, 4). The corresponding numbering system is shown in Figure 1. Positions in particular sequence which are not filled (gaps in the generalised structure) are indicated by a dash. All nucleotide insertions are commented and denoted by underlining at the place of insertion.

This compilations use a one-letter code for all nucleotides including modified ones. For standard nucleotides, adenosine, cytidine, guanosine, thymidine and uridine the usual abbreviations, A, C, G, T and U, respectively, are used. To designate modified nucleotides, the other ASCII signs are employed (see table "Intro" in the corresponding MS Excel[®] file). Terminology and structure of the modified nucleosides occurring in tRNAs were used according to (5) and (6).

Sequences are presented as MS Excel[®] files. Each sequence in the compilation occupies two consecutive rows. The first row begins with the unique six-position identification code of the sequence ('D' or 'R' for DNA or RNA, respectively; a one-letter code for the amino acid, X for methionine-initiator, Z for selenocysteine; the three-digit code specifying the organism and one digit for isoacceptor number). After this, the sequence of the anticodon is given, followed by the abbreviated name and the kingdom of organism, and the sequence (99 standard positions). The second line begins with the sign '+' and contains the information about base-pairing (double helical regions only, tertiary interactions are not annotated). Nucleotides involved in Watson-Crick pairs are marked with '=', the GU pairs are indicated with the sign '*'.

The database is organised as an MS Excel® workbook. All the information collected are split into different indexed tables according to the type of data (specificity, sequence, organism, etc.) and the descriptions of certain genes are summarised in the main worksheet that includes the relations between the data tables. The information can be obtained by filling the query form that allows to enter the simple search criteria and to select the type of data to be displayed. The result of search is presented as a table containing the description of the genes found. This includes unique id, amino acid specificity, anticodon sequence, organism name and taxonomy, strain, original database source, position of the gene in genome, literature reference, sequence, basepairing and additional comments. Sequences are aligned in the same way as it was described above for the tRNA compilations.

In addition to the plain text table one can explore the result of search by presenting the sequences in a cloverleaf form (Figure 1). It is possible to scroll the found sequences one by one or to select directly the sequence of interest from the result table. The presentation supports colour code for different structural features in the canonical cloverleaf model.

Simple statistical information on the occurrences of certain bases at given positions and the preferences in basepairing also can be obtained on a special data sheet.

Useful links:

The RNA Modification Database http://medlib.med.utah.edu/RNAmods

A database for plant mitochondrial tRNA genes and molecules http://bio-www.ba.cnr.it:8000/BioWWW/#PLMItRNA

Compilation of mammaliam mitochondrial tRNA genes http://mamit-trna.u-strasbg.fr

GtRDB: The Genomic tRNA Database http://rna.wustl.edu/tRNAdb

ACKNOWLEDGEMENT

This project was supported by Fonds der Chemischen Industrie and Universität Bayreuth. We are gratefull for advise, cooperation and help with data collection to Todd Michael Johnson Lowe, Genetics, Stanford University, California, Dr. Carlos Hoyo-Vadillo, Departamento de Farmacologia y Toxicologia, Cinvestav, Mexico City, Mexico, Yvonne Baberowski, Mark Dürr and Bernhard Thielen, Universität Bayreuth.

REFERENCES

- Sprinzl M., Horn C., Brown M., Ioudovitch A. and Steinberg S. (1998) Nucl. Acids Res. 26, 148-153.
- 2. Lowe, T.M. & Eddy, S.R. (1997) Nucl. Acids Res. 25, 955-964.
- 3. Transfer-RNA: Structure, properties and recognition, P.R. Schimmmel, D. Söll, J.N. Abelson Eds., 1979, Cold Spring Harbor Laboratory, p.518-519.
- 4. Steinberg S.V. and Kisselev L.L. (1992) Biochimie 74, 337-351.
- 5. Limbach P.A., Crain P.F. and McCloskey, J.A. (1994) Nucl. Acids Res. 22, 2183-2196.
- 6. Crain P.F. and McCloskey J.A. (1997) Nucl. Acids Res. 25, 126-127.

tRNA database searching engine

Internet service that allows to find records in the database according to multiple search criteria. Complicated sequence-based queries can be formed (Updated for the data in Compilation of tRNA Genes and Compilation of tRNA Sequences up to the end of 1998).

tRNA-Editor

Researchers who wish to perform an advanced search for tRNA sequences according to several criteria, e.g. anticodon, amino acid specificity, modified nucleoside, or wish to print the requested sequences in the cloverleaf form can <u>download</u> appropriate Windows 3.1 based software as a 900kB ZIPed file (Updated for the data in Compilation of tRNA Genes and Compilation of tRNA Sequences up to the end of 1998).



A Rare tRNA-Arg(CCU) That Regulates Ty1 Element Ribosomal Frameshifting Is Essential for Ty1 Retrotransposition in Saccharomyces cerevisiae

Koichi Kawakami,* Suchira Pande,† Brenda Faiola,‡ Daniel P. Moore,§ Jef D. Boeke,§ Philip J. Farabaugh,† Jeffrey N. Strathern,‡ Yoshikazu Nakamura* and David J. Garfinkel‡

*Department of Tumor Biology, The Institute of Medical Science, University of Tokyo, Tokyo 108, Japan, †Department of Biological Sciences, University of Maryland-Baltimore County, Catonsville, Maryland 21228, ‡Laboratory of Eukaryotic Gene Expression, NCI-Frederick Cancer Research and Development Center, ABL-Basic Research Program, Frederick, Maryland 21701-1201, and †Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Manuscript received February 24, 1993 Accepted for publication June 10, 1993

ABSTRACT

Translation of the yeast retrotransposon Ty1 TYA1(gag)-TYB1(pol) gene occurs by a +1 ribosomal frameshifting event at the sequence CUU AGG C. Because overexpression of a low abundance tRNA-Arg(CCU) encoded by the HSX1 gene resulted in a reduction in Ty1 frameshifting, it was suggested that a translational pause at the AGG-Arg codon is required for optimum frameshifting. The present work shows that the absence of tRNA-Arg(CCU) affects Ty1 transposition, translational frameshifting, and accumulation of mature TYB1 proteins. Transposition of genetically tagged Ty1 elements decreases at least 50-fold and translational frameshifting increases 3-17-fold in cells lacking tRNA-Arg(CCU). Accumulation of Ty1-integrase and Ty1-reverse transcriptase/ribonuclease H is defective in an hsx1 mutant. The defect in Ty1 transposition is complemented by the wild-type HSX1 gene or a mutant tRNA-Arg(UCU) gene containing a C for T substitution in the first position of the anticodon. Overexpression of TYA1 stimulates Ty1 transposition 50-fold above wild-type levels when the level of transposition is compared in isogenic hsx1 and HSX1 strains. Thus, the HSX1 gene determines the ratio of the TYA1 to TYA1-TYB1 precursors required for protein processing or stability, and keeps expression of TYB1 a rate-limiting step in the retrotransposition cycle.

THE Saccharomyces cerevisiae retrotransposon Ty1 is a mobile genetic element that replicates via an RNA intermediate (reviewed by BOEKE and SAND-MEYER 1991; GARFINKEL 1992). The transposition cycle of Ty1 elements resembles several important steps in the replication of retroviruses. Tyl protein maturation by Tyl-protease (PR) and reverse transcription take place within Ty1 virus-like particles (Ty1-VLPs), which appear to be absolutely required for the transposition process. The Ty1 genome contains two genes, TYA1 and TYB1, which correspond to the gag and pol genes of retroviruses, respectively (CLARE and FARABAUGH 1985). As with certain retroviral pol genes (reviewed by HATFIELD et al. 1992), expression of TYB1 requires programmed ribosomal frameshifting (CLARE, BELCOURT and FARABAUGH 1988). Ribosomal frameshifting solves two problems encountered in the life cycle of a retrovirus or retrotransposon. First, since catalytic Pol proteins, such as reverse transcriptase/ribonuclease H (RT/RH) and integrase (IN), are usually found in much lower amounts than the structural Gag proteins, requiring a frameshift event for pol expression is an effective strategy of gene regulation. Second, since Pol proteins function within a particle, creating a Gag-Pol fusion

protein by frameshifting delivers Pol proteins to the correct compartment.

The TYA1-TYB1 fusion protein is synthesized by a +1 frameshifting event in the TYA1 sequence CUU AGG C (Belcourt and Farabaugh 1990). Ribosomal pausing at a rare AGG-arginine codon and slippage of a leucyl-tRNA from CUU to UUA are required for frameshifting. A single-copy tRNA-Arg(CCU) gene that recognizes the AGG codon is located on chromosome X (GAFNER, DE ROBERTIS and PHILIPPSEN 1983). BELCOURT and FARABAUGH (1990) have shown that overexpression of the tRNA-Arg(CCU) gene reduces Ty1 frameshifting. Ty1 transposition is also reduced when the level of the tRNA-Arg(CCU) is increased (Xu and BOEKE 1990). These results suggest that the low abundance of tRNA-Arg(CCU) promotes frameshifting. Recently, we have identified this tRNA gene as the HSX1 gene involved in the heat shock response (KAWAKAMI et al. 1992). Even though there is only one copy of the HSX1 gene (GAFNER, DE ROBERTIS and PHILIPPSEN 1983), an hsx1 disruption mutant is viable. Apparently, the AGG codons normally decoded by the single-copy HSX1 gene are decoded by another tRNA [probably by the near-cognate tRNA-Arg(UCU)

TABLE 1
Yeast strains

Strain	Genotype	Plasmid	Source or reference
DMy51	MATα ura3-167 his3Δ200 leu2Δ trp1Δ1 GAL	pGTy1A-Bneo (pD109)	This work
DMy94	MATa ura 3-52 his 3 \(\Delta 200 \) lys2 trp1-289 GAL	. , , , ,	This work
JC287	Matα ura3-167 his 3Δ200 leu2GB Ty1-146::lacZ Ty1mhis 3A1-263 GAL		M. J. Curcio
JC344	MATα ura3-167 his3Δ200 leu2GB Ty1-146::lacZ Ty1mhis3A1-270 GAL		M. J. Curcio
KK156	JC287: hsx1::LEU2		This work
KK157	JC344; hsx1::LEU2		This work
KK240	MATa ura3 his3 leu2 trp1 hsx1::H1S3		This work
KK242	MATa ura3 his3 leu2 trp1		This work
KD198-16A	MATa his4\D5 ura3 arg11 GAL		K. J. DURBIN
DG1301	JC344	pGAL1-lacZ	This work
DG1302	JC344	pGTy1-H3neo	This work
DG1305	KK157	pGAL1-lacZ	This work
DG1306	KK157	pGTy1-H3neo	This work
DG1333	JC344	pGTy1-H3neo::Sac1-1702	This work
DG1334	KK157	pGTy1-H3neo::SacI-1702	This work
DG1344	JC344	pGTyAlneo(PGK1 ter.)	This work
DG1347	KK157	pGTyAlneo(PGK1 ter.)	This work

gene]. In this paper, we describe the effects of an hsx1 disruption mutant on Ty1 frameshifting, transposition and protein processing.

MATERIALS AND METHODS

Yeast strains, plasmids, general genetic methods and media: The strains used for the Ty1 transposition assays are listed in Table 1. Strains KK240 (MATa ura3 his3 leu2 trp1 hsx1::HIS3) and KK242 (MATa ura3 his3 leu2 trp1) were used to test Ty1 frameshifting. These strains were derived from an hsx1::HIS3/HSX1 diploid strain (KAWAKAMI et al. 1992).

The plasmids pMB38-9merWT and pMB38-9merFusion contain the frameshift heptamer fused to Escherichia coli lacZ gene in the +1 TYB1 reading frame and the 0 TYA1 reading frame, respectively (BELCOURT and FARABAUGH 1990). The plasmid pMB38-9merFusion(w/o AGG) contains the AGG-less 0 reading frame [GAT CCG CTG ACA CTT GGC CAT GAG GTA C (the frameshift region is highlighted)] fused to lacZ. The plasmid pKK67 was constructed by cloning the 230 base-pair (bp) wild-type HSX1 DNA, amplified by polymerase chain reaction (PCR) (SAIKI et al. 1985) into the URA3-based centromere-plasmid YCp50 (Rose, et al. 1987). The plasmid pKK68 carrying the mutant hsx1(MluI*) gene was constructed by digestion of the plasmid pKK67 with MluI, fill-in synthesis with Klenow DNA polymerase, and ligation to a SalI linker. The hsx1::HIS3 and hsx1::LEU2 disruption alleles were constructed by modifying the same MluI restriction site and ligation to a ClaI fragment containing the HIS3 gene, or an MluI-ClaI fragment containing the LEU2 gene (kindly provided by P. ROGAN). The plasmid pKK69 was constructed by cloning the PCR-amplified 112-bp wild-type SUP201-0 gene (THI-REOS, PENN and GREER 1984; MORISHITA and UNO 1991) into the URA3-based centromere-plasmid pRS316 (SIKORSKI and HIETER 1989). The plasmid pKK71 carrying the SUP201-0-1(CCU) gene was constructed by digestion of plasmid pKK69 with MluI and BamHI and ligation to a 63-bp synthetic double-stranded DNA containing the C for T substitution at 3' base of the anticodon. The EcoRI-BamHI DNA fragments containing the mutant and wild-type tRNA genes were prepared from plasmids pKK67, pKK68, pKK69 and pKK71, and subcloned into the TRP1-based centromere-plasmid pRS314 (SIKORSKI and HIETER 1989). These subcloning procedures generated plasmids pKK73 (derived from plasmid pKK67), pKK74 (from pKK68), pKK75 (from pKK69), and pKK76 (from pKK71). The plasmid pGTy1A-Bneo (also known as plasmid pD109), with the Ty1 frameshift correctly removed (BELCOURT and FARABAUGH 1990), was constructed from a transposition-competent pGTy1-H3/Ty1-912 hybrid plasmid by oligonucleotide-bridge mutagenesis (MANDECKI 1986). The frameshift mutation and tRNA sequences were confirmed by chain-terminating DNA sequencing (SANGER, NICKLEN and COULSON 1977) using Sequenase 2.0 (U.S. Biochemical Corp.). The plasmid pGTyAIneo (PGK ter.), kindly provided by P. ROGAN, was constructed by replacing almost all of the pGTy1-H3 TYB1 gene (from a Bglil site located at position 1702 to the end of the element) with the bacterial neo gene and the PGK1 transcriptional terminator. Standard techniques were used for all molecular cloning procedures (SAMBROOK, FRITSCH and Maniatis 1989).

The hsx1::HIS3 and hsx1::LEU2 disruption mutants were constructed by single-step gene disruption (ROTHSTEIN 1991). Plasmids were introduced into cells using the transformation procedure of ITO et al. (1983). All yeast media and standard genetic techniques were those described by ROSE, WINSTON and HIETER (1990).

Transposition assays: TyImhis3Al and TyImade2Al transposition assays were performed as described previously (CURCIO and GARFINKEL 1991, 1992), and will be presented briefly here. For detecting spontaneous TyImhis3Al transposition events, liquid cultures were inoculated at low densities (about 2 × 10³ cells/ml) and grown to saturation at 20° in YPD or in SC-ura (glucose). A portion of each culture was spread on SC-his or SC-his-ura (glucose) plates and incubated at 30°. The cultures were titered on YPD or SC-ura (glucose) plates. For detecting chromosomal TyImhis3Al transposition events in the presence of a pGTyI helper plasmid, cells were grown on SC-ura (galactose) plates for 7 days at 20°, or an overnight SC-ura (glucose) liquid culture was diluted 50-fold into SC-ura (galactose) liquid medium and incubated with aeration for

3 days at 20°. Tylmhis3AI transposition events were detected as His+ papillae by replica plating cells from the SCura (galactose) to SC-his-ura (glucose) plates, followed by incubation at 30° for 3 days. To determine the number of Ty/mhis3AI or Ty/made2AI transposition events in galactose-grown liquid cultures, the cells were concentrated, spread on several SC-his-ura (glucose) or SC-ade-ura (glucose) plates, and incubated at 30° for 3-5 days. Cells were titered on SC-ura (glucose) plates. Tylneo and TylA-Bneo transposition events were detected as described previously (BOEKE, Xu and FINK 1988; Curcio, Sanders and Garfin-KEL 1988) with the following minor modifications. Diploid strains were constructed by mating strains KD198-16A with strains DG1302 or DG1306, or by mating strains DMy51 and DMy92 (Table 1). The resulting diploids were induced for Tyl transposition on SC-ura (galactose) plates as described above. After segregation of the pGTy Ineo plasmid from the strains, the level of resistance to the antibiotic G418 (Gibco) was determined by growth on YPD plates containing a final G418 concentration of 500 µg per ml (for diploids derived from mating strain KD198-16A with strains G1302 or DG1306) or 75 µg per ml (for diploid derived from mating strain DMy51 with DMy94).

Tyl RNA levels and Tylmhis3AI splicing efficiency: We isolated total RNA from hsx1 and hsx1::LEU2 strains by established procedures (CURCIO, SANDERS and GARFINKEL 1988; Rose, Winston and Hieter 1990). Northern analysis was used to analyze Ty I RNA levels (Curcio, Sanders and GARFINKEL 1988; CURCIO and GARFINKEL 1992), and reverse transcription-PCR (RT-PCR) was used to estimate TyImhis3AI RNA splicing efficiency (WANG, DOYLE and MARK 1989). The total amount of RNA transferred to hybridization membranes was estimated by staining with NAQ-STAIN, a reversible fluorescein-based stain developed by Integration Separation Systems. Transcripts from the PYK1 and ACT1 genes were used as internal loading standards. RNA sequences that span the region where the artificial intron (AI) was inserted in HIS3 (CURCIO and GARFINKEL 1991) were amplified using the HIS3-specific oligonucleotide primers CTCCACGCGCCAGTAGGGCC (for DNA amplification) and ATGACAGAGCAGAAAGC CC (for reverse transcription and DNA amplification). The amplified products were separated by agarose gel electro-phoresis through a 2% NuSieve/1% SeaKem (FMC Bioproducts) gel, stained with ethidium bromide, and photographed. The resulting negatives were scanned using an LKB Ultroscan XL enhanced laser densitometer. Relative splicing efficiencies were estimated by the amount of the amplified products. The splicing efficiency is defined as the amount of 334-bp spliced product over the amount of

spliced plus 438-bp unspliced products. Immunoblot analysis: Total yeast protein isolation, polyacrylamide gel electrophoresis, protein transfer, and antibody reactions were performed as described previously (Youngren et al. 1988; Garfinkel et al. 1991). Antibodies were added in at least 10-fold excess, as determined by titration experiments. Ty1-VLP antibodies were previously shown to react with TYA1 and TYA1-TYB1 precursor proteins, but not with TYB1 proteins (ADAMS et al. 1987; Youngren et al. 1988; Garfinkel et al. 1991). Tyl-VLP antibodies did not show a dramatic difference in avidity for TYAI vs. TYAI-TYBI precursor proteins, as determined by titration experiments (A.-M. HEDGE and D. J. GARFIN-KEL, unpublished results). Ty1-VLPs were isolated by the method of Eichinger and Boeke (1988), except the final continuous sucrose gradient was omitted. Equal amounts of protein (approximately 20 µg per lane) were loaded onto SDS-8% polyacrylamide gels. Protein concentrations were verified by staining gels run in parallel with Coomassie blue. Cross-reactivity of immunoblotted proteins with antisera that recognize the mature proteins p54-TYA1 (Ty1-VLP antiserum; ADAMS et al. 1987; YOUNGREN et al. 1988), p90-Ty1-IN (B2 antiserum; YOUNGREN et al. 1988), p60-Ty1-RT/RH (B8 antiserum; GARFINKEL et al. 1991), and their respective precursor proteins were detected using the ECL chemiluminescent detection system (Amersham).

Ty1 frameshifting efficiency: β -Galactosidase assays and the efficiency of Ty1 frameshifting were determined as described previously (Belcourt and Farabaugh 1990). Briefly, six transformants of each plasmid were each assayed in triplicate for β -galactosidase activity. The frameshifting efficiency is measured by determining the ratio of β -galactosidase activity produced from the construct requiring a +1 frameshift to express lacZ (pMB38-9merWT) to that of a construct in which the upstream and downstream genes are fused in frame [pMB38-9merFusion and pMB38-9merFusion(w/oAGG)].

The efficiency of Ty1-H3 frameshifting was also estimated from immunoblot analysis. Strains DG1333 (pGTy1-H3neo::Sac1-1702, HSX1) and DG1334 (pGTy1-H3neo::Sac1-1702, hsx1::LEU2) were constructed by transforming the plasmid pGTy1-H3neo::Sac1-1702, which contains a Ty1-PR mutation (Youngren et al. 1988), into strains JC344 and KK157, respectively (Table 1). Total protein isolated from galactose-grown cultures of strains DG1333 and DG1334 was analyzed by immunoblotting using Ty1-VLP antiserum. To determine the ratio of p58-TYA1 to p190-TYA1-TYB1 protein, exposures of the resulting blots were scanned using a laser densitometer. The efficiency of Ty1 frameshifting equals the amount of p190-TYA1-TYB1 protein divided by the total amount of p58-TYA1 plus p190-TYA1-TYB1 protein.

RESULTS

Tyl transposition is inhibited in an hsxl disruption mutant: We determined whether a disruption mutation of HSX1 affects Ty1 transposition using two assays that monitor transposition of chromosomal elements marked with the his 3AI retrotransposition indicator gene (Curcio and Garfinkel 1991), as well as by monitoring the transposition of plasmid-borne pGTy Ineo and pGTy Imade2AI elements (BOEKE et al. 1985; BOEKE, Xu and FINK 1988; M. J. CURCIO and D. J. GARFINKEL, unpublished results). The his3AI gene is a yeast HIS3 gene interrupted by an artificial intron (AI) in the antisense orientation. The his3AI sequences are inserted in a Ty1 element at a unique restriction site located between the TYB1 gene and the downstream long terminal repeat, such that the intron is on the sense strand of the Ty1 element. Placement of marker genes at this position of a Ty1 element does not severely inhibit transposition. Since splicing and retrotransposition of the marked Ty RNA gives rise to His⁺ cells, the relative efficiency of Ty/mhis3AI transposition can be monitored by plating cells on media lacking histidine. An ade2AI retrotransposition indicator gene has also been developed (M. J. Curcio and D. J. Garfinkel, unpublished

First, the relative efficiency of Ty1mhis3AI trans-

TABLE 2
TyImhis3Al transposition in an hex1 disruption mutant

Genotype	Ty1mhis3A1	His* colonies/ total cells (×10 ⁷)	Relative transposition efficiency
HSX1	TyImhis3AI-263	25/1.6	2.0 × 10 ⁻⁶
		46/1.6	
		40/1.8	
		36/1.9	
		30/1.9	
hsx1::LEU2	Ty I mhis 3A1-263	0/2.3	2.7×10^{-8}
		0/2.3	
		1/2.2	
		2/2.2	
		0/2.1	
HSX1	Tylmhis 3AI-270	28/1.6	2.0×10^{-6}
	•	34/1.6	
		22/1.4	
		32/1.4	
		36/1.6	
hsx1::LEU2	Ty1mhis3A1-270	3/1.7	3.8×10^{-8}
	•	0/2.3	
		0/2.4	
		0/2.1	
		1/1.8	

The Ty1mhis3Al-263 element is present in HSX1 strain JC287 and hsx1::LEU2 strain KK156. The Ty1mhis3Al-270 element is present in HSX1 strain JC344 and hsx1::LEU2 strain KK157. Each measurement represents the results of one of five independent cultures. The relative transposition efficiency is the mean fraction of total colonies that are His⁺. To estimate the efficiency of Ty1 transposition, the relative transposition efficiency should be multiplied by a factor of 8, to account for the splicing efficiency of the Ty1mhis3Al transcript, and by a factor of 11, to account for the effect of introducing the his3Al marker gene into a Ty1 element (Curcio and Garfinkel 1991).

position in isogenic HSX1 and hsx1::LEU2 strains containing single marked chromosomal elements Tylmhis3AI-263 or Tylmhis3AI-270 was determined (Table 2). These unspliced Ty1mhis3AI elements were identified after galactose-induction of a strain containing plasmid pGTy1-H3mhis3AI, and are present at different chromosomal locations (CURCIO and GARFINKEL 1991). There was a 53- or 74-fold decrease in the efficiency of TyImhis3AI-263 or Ty/mhis3AI-270 transposition, respectively, as monitored by the number of His⁺ colonies in a hsx1::LEU2 mutant background. The transposition defect in the hsx1::LEU2 mutant KK157 was complemented by a low copy number plasmid carrying the wild-type HSX1 gene (pKK67), but not by a plasmid carrying a mutant hsx1(M1uI*) gene (pKK68) (Table 3).

The second transposition assay depends upon the ability of a pGTy1 helper plasmid to stimulate transposition of a genomic Ty1mhis3AI element in trans (CURCIO and GARFINKEL 1992). Expression of the pGTy1-H3 helper plasmid increases the frequency of genomic Ty1mhis3AI transposition about 100-fold (CURCIO and GARFINKEL 1992; M. J. CURCIO and D.

TABLE 3

Tylmhis3AI-270 transposition in hsrl mutant KK157 containing plasmid copies of tRNA genes

Plasmid (genotype)	His ⁺ colonies/ total colonies (×10 ⁶)	Relative transposition efficiency
pKK67 (HSX1)	17/5.3 58/2.3	6.4 × 10 ⁻⁴
	16/3.6	
	18/5.3	
	23/4.1	
pKK68 [hsx1(MluI*)]	0/4.5	<4.9 × 10 ⁻⁶
•	0/4.6	
	0/4.4	
	0/2.3	
	0/4.5	
pKK69 [<i>SUP201-0(UCU</i>)]	0/5.7	$<3.5 \times 10^{-6}$
	0/6.5	
	0/5.2	
	0/5.6	
	0/5.9	
pKK71 [SUP201-0-1(CCU)]	4/7.5	1.1×10^{-6}
	3/5.6	
	7/5.3	
	11/5.9	
	8/6.1	

The TyImhis 3A1-270 element is present in the hsx1::LEU2 strain KK157. The designated plasmids were introduced into strain KK157 and single transformants were chosen for further analysis. Refer to Table 2 for more information.

J. GARFINKEL, unpublished results). The pGTy1-H3neo helper plasmid (BOEKE, Xu and FINK 1988) or the control plasmid pGAL1-lacZ (BOEKE et al. 1985) were introduced into isogenic strains JC344 (HSX1) and KK157 (hsx1::LEU2) that also contain the chromosomal Ty1mhis3AI-270 element. Ty1 transposition was induced by growing the cells on SC-ura (galactose) plates and spliced Ty1mHIS3 transposition events were detected by replica plating onto SC-hisura (glucose) plates (Figure 1). The HSX1 strain DG1301 (containing the pGAL1-lacZ control plasmid) gave rise to a few transposition events, while the HSX1 strain DG1302 (containing the pGTy1-H3neo helper plasmid) gave rise to hundreds of transposition events. In contrast, no Ty1mHIS3 transposition events were present in the hsx1::LEU2 strains DG1305 and DG1306, even though strain DG1306 contains a pGTy1-H3neo helper plasmid that was induced for transposition. Since the hsx1::LEU2 mutation is recessive (Table 3), we showed that the pGTy1-H3neo helper plasmid is transposition-competent by testing pGTy1-H3neo transposition in an hsx1::LEU2/HSX1 diploid strain (Table 4).

Several controls were performed to determine whether the hsx1 mutation directly affected the Ty transposition process or whether the hsx1 mutation affected RNA splicing or Ty RNA levels. The splicing efficiency of the Ty1mhis3AI-270 transcript varied

DG1301: pGAL-lacZ HSX1 DG1305: pGAL-lacZ hsx1::LEU2

DG1302: pGTy1-H3neo HSX1

DG1306: pGTy1-H3neo hsx1::LEU2 FIGURE 1.—TyImhis3A1-270 transposition in an hsx1 mutant background, Strains DG1301, DG1302, DG1305 and DG1306 contain the genomic TyImhis3A1-270 element. The relevant plasmids and status of the HSX1 gene are shown alongside the strains. These strains were tested for transposition by growing cells on SC-ura (galactose) plates for 7 days at 20°, replica plating to SC-his-ura (glucose), and incubating the replicas for 3 days at 30°.

TABLE 4
Tylneo transposition in hsxl/HSX1 diploid strains

Relévant genotypé ^a	Relative transposition efficiency (%) ^b	
HSX1/HSX1	42 (15/36)	····
hsx1::LEU2/HSX1	47 (16/34)	

a Homozygous HSX1/HSX1 diploids were obtained by mating strains DG1302 and KD198-16A. Heterozygous hsx1::LEU2/HSX1 diploids were obtained by mating strains DG1306 and KD198-16A.
In this transposition test, the transposition efficiency is the number of G418', Ura plasmid segregants divided by the total number of Ura plasmid segregants.

from 12 to 20% in both HSX1 or hsx1::LEU2 strains as determined by RT-PCR. These splicing efficiencies agree with previous results where it was shown that about 12% of the Ty1mhis3AI transposition events had lost the AI by splicing (Curcio and Garfinkel 1991). However, the overall Ty1 and Ty1mhis3AI-270 RNA levels were between 2- and 8-fold lower in an hsx1::LEU2 mutant background when compared with ACT1, PYK1 RNA or rRNA levels, although these differences were not completely reproducible.

To determine whether this moderate decrease in the level of Ty RNA could account for the more than 50-fold reduction in Ty1 transposition, we assayed the level of pGTy1-H3made2AI retrotransposition (M. J. CURCIO and D. J. GARFINKEL, unpublished results) in an hsx1::LEU2 mutant. In collateral experiments, the level of pGTy1 expression in an hsx1::LEU2 mutant was determined by immunoblotting (see below). The efficiency of Tylmade2AI transposition was reduced almost 70-fold in an hsx1::LEU2 mutant background, while the level of GAL1-promoted Ty1 proteins remained unchanged in the mutant (Figure 2). A similar decrease in transposition was also observed when an HSX1 strain containing a pGTy1A-Bneo plasmid with a mutation that corrects the frameshift was galactoseinduced. Taken together, these results suggest that neither inhibition of splicing nor the lower concentration of chromosomal Ty1 or Ty1mhis3Al RNA can completely account for the reduction of Ty1 trans-




FIGURE 2.—Immunoblot analysis of Ty1 proteins from an hsx1 mutant background. Strains DG1302 (HSX1, pGTy1-H3neo; lane 1), DG1301 (HSX1, pGAL-lacZ; lane 2), DG1306 (hsx1::LEU2, pGTy1-H3neo: lane 3), DG1305 (hsx1::LEU2, pGAL-lacZ; lane 4), DG1333 (HSXI, pGTyI-H3neo::Sacl-1702; lane 5), and DG1334 (hsx1::LEU2, pGTy1-H3neo::Sac1-1702, lane 6) were induced for transposition by growth in SC-ura (galactose) medium and total protein was isolated for immunoblot analysis. Proteins were separated by electrophoresis on an SDS-8% polyacrylamide gel, transferred to a nitrocellulose membrane, and cross-reacted with B2 and VLP antisera. The B2 antiserum detects p90-Ty1-IN and its precursors. The VLP antiserum detects p54 and p58, which are VLP structural proteins derived from TYA1, as well as p190-TYA1-TYB1. The minor bands observed between p90-Ty1-IN and p140-TYB1 are probably caused by cellular proteolysis because they are present in immunoblots prepared from a Ty PR mutant (S. D. Youngren and D. J. GARFINKEL, unpublished results). Tyl protein size estimates (in kilodaltons) are indicated.

position in an hsx1::LEU2 mutant. Previous analyses have shown that increased expression of tRNA-Arg(CCU) (HSX1) negatively regulates Ty1 transposition (Xu and BOEKE 1990). Our results indicate that the HSX1 gene is required for transposition of Ty1 elements.

Mature TYB1 proteins do not accumulate in an hsx1 disruption mutant: To further investigate the inhibition of Ty1 transposition by hsx1::LEU2, we compared the levels and processing of Ty1-encoded proteins in isogenic HSX1 and hsx1 disruption strains (Figure 2). Total protein was isolated from strains DG1302 (HSX1, pGTy1-H3neo; lane 1), DG1301 (hsx1, pGAL1-lacZ; lane 2), DG1306 (hsx1::LEU2, pGTy1-H3neo; lane 3), and DG1305 (hsx1::LEU2, pGAL1-lacZ; lane 4) that were induced with galactose. The proteins were separated on SDS-polyacrylamide gels and immunoblotted. The resulting filters were reacted with B2 antiserum, which reacts with the fulllength 190-kilodalton (kD) TYA1-TYB1 precursor protein, the 160-kD and 140-kD processing intermediates, and mature 90-kD Ty1-IN (GARFINKEL et al. 1991) or Ty1-VLP antiserum, which reacts with the 58-kD TYA1 precursor protein and the mature 54kD TYA1 product (ADAMS et al. 1987; MULLER et al. 1987; YOUNGREN et al. 1988). Wild-type protein patterns were observed when the HSX1 strain DG1302 was analyzed with B2 or Ty1-VLP antiserum (lane 1), or with an antiserum (B8) that detects p60-Ty1-RT/ RH (B. FAIOLA and D. J. GARFINKEL, data not shown). As expected, strains DG1301 (lane 2) and DG1305 (lane 4) containing the heterologous expression plasmid pGAL-lacZ had very low levels of Tyl proteins (GARFINKEL et al. 1985; CURCIO and GARFINKEL 1992).

The hsx1::LEU2 strain DG1305 (Figure 2, lane 3) displayed a different protein pattern when reacted with B2 and Ty1-VLP antisera. Essentially wild-type levels of the 190-kD TYA1-TYB1 precursor protein and 160-kD processing intermediate were detected using B2 antiserum. However, very little of the 140kD precursor or 90-kD IN protein was detected. Similar results were obtained when an antiserum (B8) that detects RT/RH was used: the 190-kD and 160-kD TYB1 precursor proteins were present at wild-type levels, but the 140-kD precursor and the 60-kD Ty1 RT/RH protein were barely detectable (B. FAIOLA and D. J. GARFINKEL, data not shown). When TYA1 proteins were analyzed with Ty1-VLP antiserum, normal levels of mature p54-TYA1 protein were observed in an hsx1 mutant, but very little full-length p58-TYA1 precursor was detected even after extended exposure of the filter. Furthermore, similar protein patterns were observed when partially purified Ty1-VLPs were reacted with B2, B8, or Ty1-VLP antisera (B. FAIOLA and D. J. GARFINKEL, data not shown). These results suggest that the transposition defect observed in hsx1 mutants is related to aberrant protein processing.

Tyl frameshifting increases in an hsxl disruption mutant: We tested whether the observed transposition defect in the hsxl mutant resulted from abnormal

TABLE 5
Translational frameshifting in an hsx1 mutant

Relevant genotype	Frameshift site	β-Galactosidase units	Frameshifting efficiency (%)
HSX1	9merWT	2400	
	9merFusion	6800	35
	9merFusion(w/o AGG)	8900	27
hsx1::HIS3	9m34WT	5100	
	9merFusion	5600	91
	9merFusion(w/o AGG)	6100	84

Strains KK242 (HSXI) and KK240 (hsx1::HIS3) were transformed with plasmids pMB-9merWT, pMB38-9merFusion, and pMB38-9merFusion(w/o AGG). β -Galactosidase activities are the averages from six independent transformants. The frameshift efficiency is defined as the β -galactosidase activity of the 9merWT divided by the β -galactosidase activity of either the 9merFusion or the 9merFusion(w/o AGG) (Bellicourt and Farabaugh 1990).

TABLE 6
Translational frameshifting in an hsx1 mutant KK240 containing plasmid copies of tRNA genes

Plasmid genotype	Frameshifting efficiency (%)
pKK73 (HSX1)	35
pKK74 [hsx1(MluI*)]	98
pKK75 [SUP201-0(UCU)]	90
pKK76 [SUP201-0-1(CCU)]	65

Plasmids were introduced into strain KK240 (hsx1::HIS3) by transformation. Refer to Table 5 for experimental details.

frameshifting using two different frameshifting assays. In the first assay, the HSX1 strain KK242 and hsx1::HIS3 mutant strain KK240 were transformed with pMB38-9merFusion and pMB38-9merWT plasmids in which the 0 (TYA1) and +1 (TYA1-TYB1) reading frames and lacZ are fused, respectively (Table 5). β-Galactosidase activity was determined from at least six different transformants of each plasmid and Tyl frameshifting efficiencies were calculated as described (see materials and methods; Belcourt and FARABAUGH 1990). A frameshifting efficiency of 35% was obtained in an HSX1 background, which is comparable to published values (BELCOURT and FARA-BAUGH 1990). In contrast, the hsx1::HIS3 disruption resulted in 91% frameshifting. The frameshifting efficiency was restored to 35% by a low copy number plasmid carrying the wild-type HSX1 gene (pKK73; Table 6).

We also determined the Ty1 frameshifting efficiency by quantitating the ratio of the unprocessed p58-TYA1 precursor to the p190-TYA1-TYB1 precursor in HSX1 and hsx1::LEU2 strains DG1333 and DG1334, respectively (Figure 2, lanes 5 and 6). To insure that unprocessed precursor proteins accumulated during the galactose induction, strains DG1333 and DG1334 contained a pGTy1-H3 plasmid with a well characterized Ty1-PR mutation, pGTy1-

H3neo::SacI-1702 (YOUNGREN et al. 1988; GARFINKEL et al. 1991; CURCIO and GARFINKEL 1992). Proteins were analyzed by immunoblotting using TyI-VLP antiserum, which recognizes TYA1 proteins and the 190-kD TYA1-TYB1 precursor protein (ADAMS et al. 1987; MULLER et al. 1987; YOUNGREN et al. 1988), and frameshifting efficiencies were calculated by densitometry (see MATERIALS AND METHODS).

The HSX1 strain DG1333 (Figure 2, lane 5) showed the pattern of unprocessed 58-kDa and 190-kDa proteins expected from a Ty1-PR mutant (ADAMS et al. 1987; MULLER et al. 1987; YOUNGREN et al. 1988). A frameshifting efficiency of about 3% was obtained from densitometric scans of various exposures of the immunoblot. In contrast, the hsx1::LEU2 strain DG1334 (Figure 2, lane 6) had much more of the 190-kD TYA1-TYB1 precursor and slightly less of the 58-kD TYA1 precursor than the HSX1 parent strain DG1333 (Figure 2, lane 5). The hsx1::LEU2 disruption mutant had a frameshifting efficiency of about 50%, which is about 17-fold higher than in an HSX1 background. The overall level of Ty1 protein also appeared to be similar in the HSX1 or hsx1 mutant backgrounds. These results suggest that the absence of tRNA-Arg(CCU) enhances ribosomal pausing at AGG and slippage of the leucyl-tRNA from CUU to UUA. Furthermore, the regulation of frameshifting by the HSX1 gene is essential for Ty1 transposition. The reduction in transposition in an hsx1 mutant may be caused by a defect in protein processing that results from an aberrant stoichiometry of Ty proteins.

The capacity to translate an AGG codon does not limit β -galactosidase synthesis in an hsx1 mutant: The lacZ fusion gene in the pMB38-9merFusion plasmid has only one AGG codon and it is located at the fusion site (Belcourt and Farabaugh 1990). That AGG codon is missing in the pMB38-9merFusion(w/ oAGG) lacZ fusion gene. Therefore, the effect of a single AGG codon on β -galactosidase synthesis was determined in an hsx1::HIS3 mutant. Interestingly, β galactosidase activities in the hsx1::HIS3 mutant or the HSX1 parental strain harboring the pMB38-9merFusion and the pMB38-9merFusion(w/oAGG) plasmids were similar (Table 5). These results suggest that the capacity to translate the AGG codon does not limit \beta-galactosidase synthesis in an hsx1 mutant. However, we do not know how the AGG is translated in an hsx1 mutant. Since haploid cells contain more than eight tRNA-Arg(UCU) genes (BECKMANN, JOHNSON and ABELSON 1977), it is possible that tRNA-Arg(UCU) decodes AGG codons by near-cognate recognition when tRNA-Arg(CCU) is absent (YOKOYAMA et al. 1985).

Complementation of hsx1 by a tRNA suppressor SUP201-0-1(CCU): Although tRNA-Arg(UCU) may decode AGG codons, excess tRNA-Arg(UCU) does

not inhibit frameshifting (BELCOURT and FARABAUGH 1990). This may be because of sequence or structural differences between tRNA-Arg(UCU) and tRNA-Arg(CCU) (Figure 3). Alternatively, the information needed to regulate Ty1 frameshifting may reside within the anticodon. To determine if the CCU anticodon is sufficient to regulate Ty1 transposition (Table 3) and frameshifting (Table 6), we constructed a low-copy-number plasmid carrying a mutant tRNA-Arg gene that has a CCU instead of a UCU anticodon. The SUP201-0-1(CCU) anticodon mutation was introduced into the SUP201-0 tRNA-Arg(UCU) gene (THI-REOS, PENN and GREER 1984; MORISHITA and UNO 1991), by oligonucleotide mutagenesis (refer to MA-TERIALS AND METHODS). Functionally active tRNAs were synthesized from these plasmids because a plasmid carrying the same 112-bp segment of DNA with a SUP201 nonsense suppressor complemented the cyr1-2 UGA allele (Morishita and Uno 1991; K. KAWAKAMI and Y. NAKAMURA, unpublished results).

To determine if SUP201-0-1(CCU) could suppress the transposition defect imposed by an hsx1 mutation, strain KK157 containing Ty1mhis3AI-270 and hsx1::LEU2 was transformed with the suppressor plasmid pKK71 [SUP201-0-1(CCU)] or the parental plasmid pKK69 [SUP201-0(UCU)]. The level of Ty1 transposition was partially restored when the pKK71 [SUP201-0-1(CCU)] plasmid was present in the hsx1::LEU2 mutant (Table 3). This result suggests that the CCU anticodon can regulate transposition.

An hsx1::HIS3 mutant strain KK240 harboring plasmids pMB38-9merWT or pMB38-9merFusion was transformed with plasmids pKK75 [SUP201-0(UCU)] and pKK76 [SUP201-0-1(CCU)] and frameshifting efficiencies were analyzed in these transformants (Table 6). The SUP201-0-1(CCU) mutant tRNA resulted in an intermediate level of frameshifting. Interestingly, frameshifting in the pKK76 [SUP201-0-1(CCU)] transformant was higher (65%) than in the pKK73 [HSX1; tRNA-Arg(CCU)] transformant (35%). This result is consistent with the lower level of transposition of the pKK71 [SUP201-0-1(CCU)] transformant (1.1 × 10⁻⁶) when compared to the pKK67 [HSX1; tRNA-Arg(CCU)] transformant (6.4 \times 10⁻⁶; Table 3). Therefore, although SUP201-0-1(CCU) can partially regulate Ty transposition and frameshifting, it does not work as well as tRNA-Arg(CCU) encoded by HSX1. Other aspects of SUP201-0-1(CCU) expression or structure may prevent full complementation of the hsx1 mutation. These results also suggest that base pairing at the third position of the second codon in the frameshift heptamer is essential for regulating Ty1 transposition and frameshifting.

Increasing TYA1 expression restores Ty1 transposition in an hsx1 mutant: Our results indicate that more of TYA1-TYB1 fusion protein is translated in

SUP201-0 GCUCGCGUGGCGUAAUGGCAACGCGUCUGACUUCCUAAUCAGAAGAUUAUGGGUUCGACCCCCAUCGUGACGUG

HSX1 GUUCCGUUGGCGUAAUGGUAACGCGUCUCCCUCCUAAGGAGAAGACUGCGGGUUCGAGUCCCGUACGGAACG

MI UI




FIGURE 3.—Comparison of SUP201-0 and HSX1. Nucleotide sequences of the SUP201-0 and HSX1 tRNAs are shown. Identical nucleotides are indicated by asterisks. Anticodons are in bold lettering. The clover leaf structure of the SUP201-0 and HSX1 genes, and the SUP201-0-1(CCU) mutation are also shown.

the hsx1 disruption mutant, and that this altered stoichiometry of TYA1 to TYA1-TYB1 precursor proteins may inhibit Ty1 transposition. Therefore, providing more TYA1 protein should restore TyI transposition in an hsx1 mutant background. To test this idea, the efficiency of TyI transposition was determined with strains DG1344 (HSX1) and DG1347 (hsx1::LEU2) containing the helper plasmid pGTy-Alneo (PGK1 ter.), and strains DG1301 (HSX1) and DG1305 (hsx1::LEU2) containing the heterologous expression plasmid pGAL-lacZ. The helper plasmid pGTyA1neo (PGK1 ter.) contains a complete TYA1 gene, about 25 codons of N-terminal TYB1 sequence, the neo marker gene, and a transcriptional terminator from the PGK1 gene in place of the downstream long terminal repeat. Liquid cultures of strains DG1301, DG1305, DG1344 and DG1347 were galactose-induced and transpositions of the chromosomal Ty1mhis3AI-270 element were selected on SC-his-ura (glucose) medium (Table 7). Although expression of the helper plasmid pGTyAlneo (PGK1 ter.) did not markedly affect Ty1 transposition in an HSX1 strain, expression of TYA1 stimulated Ty1 transposition 50fold more in an hsx1 strain than in an HSX1 strain. In addition, galactose-induction of pGTyA1neo (PGK ter.) did not affect the level of full-length Ty1 RNA in an HSX1 or hsx1 disruption strain (B. FAIOLA and D. J. GARFINKEL, data not shown). As expected, the level of the TyAlneo (PGK ter.) transcript was the same in the HSX1 and hsx1::LEU2 mutant strains. These results indicate that expression of pGTyAlneo

TABLE 7

Effect of pGTyAlneo(PGK1 ter.) expression on Tylmhis3A1270 transposition in an hsx1 mutant

Strain	Relevant genotype	Relative transposition efficiency
DG1301	HSX1, pGAL1-lacZ	1.3×10^{-7}
DG1344	HSX1, pGTyAlneo(PGK1 ter.)	4.8×10^{-7}
DG1305	hsx1::LEU2, pGAL1-lacZ	<3.7 × 10 ⁻⁹
DG1347	hsx1::LEU2, pGTyAIneo(PGKI ter.)	2.4 × 10 ⁻⁵

These strains contain the genomic TyImhis3AI-270 element. Relative transposition efficiencies were determined from liquid cultures grown in SC-ura (galactose) as described in MATERIALS AND METHODS. The relative transposition efficiency is the number of His⁺, Ura⁺ colonies divided by the number of Ura⁺ colonies. Each measurement represents the mean of four cultures. The total number of colony-forming units was similar within each set of cultures. Refer to Table 2 for more information.

(PGK1 ter.) stimulates Ty1 transposition in an hsx1 mutant background by restoring the proper stoichiometry of TYA1 to TYA1-TYB1 precursor proteins.

DISCUSSION

Our study reveals that the HSX1 gene is necessary for TyI transposition because elimination of this gene causes a significant transposition defect. Our work also shows that TyI translational frameshifting increases dramatically in an hsxI disruption mutant. The hsxI mutant defects in frameshifting and TyI transposition are completely complemented by the wild-type HSXI gene and partially complemented by the

mutant SUP201-0-1(CCU) gene, while no complementation occurs with the SUP201-0(UCU) gene (Tables 3 and 6). Therefore, at least some of the information required for Ty1 frameshifting is provided by the CCU anticodon. The partial complementation activity of the mutant SUP201-0-1 tRNA-Arg(CCU) suggests two possibilities. First, SUP201-0-1(CCU) may be expressed at a lower level than HSX1, thus directly affecting the level of tRNA-Arg(CCU) available for frameshifting. Second, SUP201-0-1(CCU) may not recognize the AGG codon within the context of the frameshift heptamer as well as HSX1, since the SUP201-0-1 and HSX1 tRNA genes differ by 20 nucleotide changes (Figure 3). RAFTERY and YARUS (1987) have shown that the structure of the proximal anticodon stem affects efficiency of a tRNA suppressor of E. coli and suggested that it is a part of the extended anticodon. The 2-bp difference in the anticodon stem between SUP201-0-1 and the HSX1 tRNAs may result in the altered AGG codon recognition activity of the SUP201-0-1 tRNA.

Both -1 and +1 frameshifting mechanisms used by a variety of RNA viruses, retroviruses, and retrotransposons apparently require a translational pause for optimum efficiency (reviewed by Hatfield et al. 1992). For example, the translational pause in retroviral -1 frameshifting is created by a pseudoknot located a few nucleotides downstream of the frameshift, whereas Ty I + 1 frameshifting uses a the rare tRNA-Arg(CCU). Our results are consistent with the +1 frameshifting model proposed by Belcourt and Far-ABAUGH (1990). According to this model, the increase in +1 frameshifting results from a longer translational pause in an hsx1 mutant created by the absence of tRNA-Arg(CCU). The longer translational pause regulates translation of TYB1-pol by allowing more time for the tRNA-Leu to slip from the 0-frame CUU codon in TYA1 to the +1-frame UUA codon in TYB1.

Two different approaches were used to estimate the increase in frameshifting that occurs in an hsx1 disruption mutant. First, frameshifting was measured using the minimal heptamer sequence with lac2 as a reporter gene (Belcourt and Farabaugh 1990). The absence of tRNA-Arg(CCU) increased frameshifting as measured by β-galactosidase activity about 3-fold. Second, frameshifting was measured by immunoblotting using Ty1-VLP antiserum and a Ty1-PR mutant defective in protein processing. The increase in frameshifting at the CUU-AGG-C sequence leads to accumulation of slightly less p54-TYA1 protein and much more p190-TYA1-TYB1 fusion protein. Using this assay, frameshifting increased about 17-fold in an hsx1 background.

We estimate that Ty I frameshifting occurs at about a 3% efficiency in an HSXI background by immuno-blotting. In other words, 3% of ribosomes translating

the TYA1-gag open reading frame undergo a +1 frameshift and continue translating the TYB1-pol open reading frame. It is somewhat surprising that the Ty1 frameshifting efficiency of 3% is about 5-10-fold lower than that obtained by lacZ fusion analysis. It is possible that we have underestimated the Ty1 frameshifting efficiency obtained from immunoblotting because of an inability to detect the p190-TYA1-TYB1 precursor protein. However, control experiments suggest that p58-TYA1 and p190-TYA1-TYB1 are transferred at about the same rate under the immunoblotting conditions used in this study, bind to Ty1-VLP antiserum with comparable affinities, and have similar turnover rates (A.-M. HEDGE and D. J. GARFINKEL, unpublished results; Curcio and Garfinkel 1992). There may also be differences in translation rates of lacZ in yeast, or in the placement of the frameshift heptamer relative to the start of translation that contribute to this apparent discrepancy (P. J. FARABAUGH, unpublished results).

The Ty1 frameshifting efficiency of 3% obtained by immunoblot analysis is comparable to the efficiencies obtained from several viral systems that utilize different mechanisms for translation of the pol gene. Retroviruses that utilize programmed ribosomal frameshifting or read-through suppression undergo translational suppression at an efficiency of about 5% (reviewed by HATFIELD et al. 1992). Yeast Ty3 retrotransposons have a +1 frameshifting efficiency of about 4%, even though these elements use a different frameshifting site (KIRCHNER, SANDMEYER and FOR-REST 1992) and mechanism than Ty1 or Ty2 elements (P. J. FARABAUGH, unpublished results). In addition, the yeast L-A double-stranded RNA virus undergoes -1 frameshifting to express its pol gene at an efficiency of about 2% (DINMAN, ICHO and WICKNER 1991). Even though the molecular mechanisms underlying these expression strategies are quite different, a certain ratio of "structural" (Gag) proteins to "catalytic" (Gag-Pol) proteins may be a general requirement for formation of a transposition/replication-competent particle.

Immunoblot analysis suggested that a processing defect of the TYA1-TYB1 fusion protein is related to the lower level of Ty1 transposition in an hsx1 disruption mutant. The protein cleavages required to form p54-TYA1 and the p160 processing intermediate still occur, while the proteolytic cleavage required to convert the p160 processing intermediate to p23-PR and the p140 processing intermediate apparently do not (Figure 4). Since formation of p140-TYB1 is defective, it follows that low amounts of mature IN and RT/RH are detected in an hsx1::LEU2 mutant. Perhaps Ty1-PR is not completely activated when more of the TYA1-TYB1 fusion protein is produced. Alternatively, normal amounts of p140, IN and RT/RH




FIGURE 4.—Scheme for TYB1 protein processing in an hsx1 mutant (modified from GARFINKEL et al. 1991). p190-TYA1-TYB1, the 190-kD product of the gag-TYA1 and pol-TYB1 genes, is cleaved near the frameshift region (the vertical line separating TYA1 and TYB1). This proteolytic cleavage releases p160-TYB1, which is normally cleaved to form Ty1-PR (23 kD) and p140-TYB1. Cleavage of p140-TYB1 produces IN (90 kD) and RT/RH (60 kD). The dotted lines indicate that p160 and p23 may be encoded by both TYA1 and TYB1. The arrows show that neither the p140-TYB1 percursor nor mature p90-Ty1-IN and p60-Ty1-RT/RH accumulate in an hsx1 mutant. Also shown is the p58-TYA1 precursor and p54 processed product, which are the major structural components of Ty1-VLPs. In an hsx1 mutant, we detect p54-TYA1 but not the p58-TYA1 precursor.

may be synthesized, but are rapidly degraded because of an hsx1-dependent defect in Ty1-VLP assembly.

To prove that aberrant protein stoichiometry is the major reason for the block in Ty1 transposition in an hsx1 disruption mutant, we showed that a pGTy1 plasmid expressing just the TYAI gene not only restores Tyl transposition in an hsxl::LEU2 mutant, but stimulates transposition to a level 50-fold higher than is observed in an HSX1 strain. We also showed that overexpression of TYAI does not alter the level of Tyl RNA in an hsxl mutant. These results suggest that overexpression of TYA1 enhances the utilization of Tyl RNA as a transposition template by rebalancing the level of TYA1 and TYA1-TYB1 proteins required to make transposition-competent Ty1-VLPs in an hsx1 mutant, even though the absolute level of Tyl RNA is somewhat lower in the hsxl mutant. Furthermore, since GAL1-promoted Ty1 transposition decreases about 70-fold without a concomitant decrease in GAL1-promoted Ty1 protein levels in an hsx1 disruption mutant, whatever effect the hsx1 mutation has on Ty1 RNA levels is limited to chromosomal Tyl elements. These results suggest that the hsx1 mutation may affect chromosomal Ty1 RNA accumulation, but we have not investigated this idea further.

The stimulation of Ty transposition that occurs in an hsx1 mutant when TYA1 is overexpressed supports and extends previous biochemical and genetic studies that identified the availability of Ty1-PR, which is

encoded by TYB1, as a rate-limiting step in the Ty1 retrotransposition cycle (CURCIO and GARFINKEL 1992). Since more TYA1-TYB1 precursor protein is made in an hsx1 mutant, the availability of TYA1 protein becomes rate-limiting under these conditions. Therefore, a specific ratio of TYA1 to TYA1-TYB1 precursor proteins is required to form fully processed Ty1 proteins and functional Ty1-VLPs.

Several retrovirus, retrotransposon and endogenous viral mutants in which gag and pol have been artificially fused are defective in particle formation, replication and infectivity. For example, fusion of gag and pol genes blocks production of infectious Moloney murine leukemia virus (FELSENSTEIN and GOFF 1988) and human immunodeficiency virus (PARK and MOR-ROW 1992). In Moloney murine leukemia virus, the Gag-Pol precursor protein is produced, but neither protein processing nor particle formation occurs. In human immunodeficiency virus, the Gag-Pol protein is produced and processed, but particles do not form. A protein processing and transposition defect similar to the one created in an hsx1 mutant is observed when TYA1 and TYB1 are fused by deleting one base at the frameshift site of a pGTy1 plasmid and transposition is galactose-induced in an HSX1 strain. Preliminary experiments suggest that Ty1-VLPs are formed in an hsx1 mutant (B. FAIOLA and D. J. GARFINKEL, unpublished results) or when just the TYA1-TYB1 fusion protein is expressed (J. D. BOEKE and D. J. GARFINKEL, unpublished results). Recently, a Ty3 GAG3-POL3 fusion mutant has been analyzed for defects in transposition and Ty3-VLP formation using a pGTy3 expression system (KIRCHNER, SANDMEYER and FOR-REST 1992). The fusion mutant is transposition-defective, but can be rescued by coexpression of GAG3 or just the capsid domain of GAG3. Protein processing of GAG3 capsid protein and Ty3-IN is altered in the mutants, as is individual Ty3 protein and Ty3-VLP yield. Optimal ribosomal frameshifting and the proper Gag to Gag-Pol protein ratio are also required for L-A virus propagation in yeast (DINMAN and WICKNER 1992). Therefore, Tyl and Ty3 elements seem to be unique in that some particle assembly can take place when excess Gag-Pol precursor protein is synthesized (KIRCHNER, SANDMEYER and FORREST 1992) when only Gag protein is synthesized (ADAMS et al. 1987; Burns et al. 1992), or when PR-dependent protein processing is blocked (ADAMS et al. 1987; MULLER et al. 1987; Youngren et al. 1988; KIRCHNER and SAND-MEYER 1993).

In summary, our work has identified an essential role for HSXI in TyI frameshifting and transposition. This is one of a small but growing collection of cellular genes required for TyI transposition that act post-transcriptionally (reviewed by BOEKE and CHAPMAN 1991; GARFINKEL 1992). The additional defects of an

hsx1 disruption mutant (KAWAKAMI et al. 1992) may allow us to select second-site suppressors that restore Ty1 transposition without affecting Ty1 frameshifting mediated by tRNA-Arg. These suppressors may identify additional cellular genes involved in Ty1 frameshifting or Ty1-VLP assembly.

We thank M. J. CURCIO, K. J. DURBIN, Y. MATSUI, T. MORISHITA and P. ROGAN for plasmids and strains. We thank S. BROWN, D. COURT, M. J. CURCIO and A. REIN for their helpful comments and J. HOPKINS for preparing the manuscript. This work was supported in part by The Ministry of Education, Science and Culture, Japan (K.K. and Y.N.); U.S. Public Health Service grants GM 29480 (S.P. and P.J.F.) and GM 36481 (D.P.M. and J.D.B.); and the National Cancer Institute under contract N01-CO-74101 with ABL (B.F., D.J.G., and J.N.S.). The contents of this publication do not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

LITERATURE CITED

- ADAMS, S. E., J. MELLOR, K. GULL, R. B. KIM, M. F. TUTTE, S. M. KINGSMAN and A. J. KINGSMAN, 1987 The functions and relationships of Ty-VLP proteins in yeast reflect those of mammalian retroviral proteins. Cell 49: 111-119.
- BECKMANN, J. S., P. F. JOHNSON and J. ABELSON, 1977 Cloning of yeast transfer RNA genes in *Escherichia coli*. Science 196: 205–208.
- BELCOURT, M. F., and P. J. FARABAUGH, 1990 Ribosomal frameshifting in the yeast retrotransposon Ty: tRNAs induce slippage on a 7 nucleotide minimal site. Cell 62: 339-352.
- BOEKE, J. D., and K. B. CHAPMAN, 1991 Retrotransposition mechanisms. Curr. Opin. Cell Biol. 3: 502-507.
- BOEKE, J. D., D. J. GARFINKEL, C. A. STYLES and G. R. FINK, 1985 Ty elements transpose through an RNA intermediate. Cell 40: 491-500.
- BOEKE, J. D., and S. B. SANDMEYER, 1991 Yeast transposable elements, pp. 193-262 in *The Molecular and Cellular Biology of the Yeast Saccharomyces: Genome Dynamics, Protein Synthesis, and Energetics*, Vol. 1, edited by J. R. BROACH, J. R. PRINGLE and E. W. JONES. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- BOEKE, J. D., H. Xu and G. R. FINK, 1988 A general method for the chromosomal amplification of genes in yeast. Science 239: 280–282.
- BURNS, N. R., H. R. SAIBIL, N. S. WHITE, J. F. PARDON, P. A. TIMMINS, S. MARK, H. RICHARDSON, B. M. RICHARDS, S. E. ADAMS, S. M. KINGSMAN and A. J. KINGSMAN, 1992 Symmetry, flexibility and permeability in the structure of yeast retrotransposon virus-like particles. EMBO J. 11: 1155-1164.
- CLARE, J. J., M. BELCOURT and P. J. FARABAUGH, 1988 Efficient translational frameshifting occurs within a conserved sequence of the overlap between the two genes of a yeast Ty I transposon. Proc. Natl. Acad. Sci. USA 85: 6816–6820.
- CLARE, J. J., and P. J. FARABAUGH, 1985 Nucleotide sequence of a yeast Ty element: Evidence for an unusual mechanism of gene expression. Proc. Natl. Acad. Sci. USA 82: 2829-2833.
- CURCIO, M. J., and D. J. GARFINKEL, 1991 Single-step selection for Ty1 element retrotransposition. Proc. Natl. Acad. Sci. USA 88: 936-940.
- CURCIO, M. J., and D. J. GARFINKEL, 1992 Posttranslational control of Ty1 retrotransposition occurs at the level of protein processing. Mol. Cell. Biol. 12: 2813-2825.
- CURCIO, M. J., N. J. SANDERS and D. J. GARFINKEL,

- 1988 Transcriptional competence and transcription of endogenous Ty elements in *Saccharomyces cerevisiae*: Implications for regulation of transposition. Mol. Cell. Biol. 8: 3571–3581.
- DINMAN, J. D., T. ICHO and R. B. WICKNER, 1991 A -1 ribosomal frameshift in a double-stranded RNA virus of yeast forms a gag-pol fusion protein. Proc. Natl. Acad. Sci. USA 88: 174-178.
- DINMAN, J. D., and R. B. WICKNER, 1992 Ribosomal frameshifting efficiency and gag/gag-pol ratio are critical for yeast M₁ double-stranded RNA virus replication. J. Virol. 66: 3669-3676.
- EICHINGER, D. J., and J. D. BOEKE, 1988 The DNA intermediate in yeast Ty1 element transposition copurifies with virus-like particles: cell-free Ty1 transposition. Cell 54: 955-966.
- FELSENSTEIN, K., and S. GOFF, 1988 Expression of the gag-pol fusion protein of Moloney murine leukemia virus without gag protein does not induce virion formation or proteolytic processing. J. Virol. 62: 2179-2182.
- GAFNER, J., E. M. DE ROBERTIS and P. PHILIPPSEN, 1983 δ sequences in the 5' non-coding region of yeast tRNA genes. EMBO J. 2: 583-591.
- GARFINKEL, D. J., 1992 Retroelements in microorganisms, pp. 107-158 in *The Retroviridae*, Vol. 1, edited by J. A. Levy. Plenum Press, New York.
- GARFINKEL, D. J., J. D. BOEKE and G. R. FINK, 1985 Ty element transposition: reverse transcription and virus-like particles. Cell 42: 507-517.
- GARFINKEL, D. J., A.-M. HEDGE, S. D. YOUNGREN and T. D. COPELAND, 1991 Proteolytic processing of *pol-TYB* proteins from the yeast retrotransposon Ty1. J. Virol. 65: 4573-4581.
- HATFIELD, D. L., J. G. LEVIN, A. REIN and S. OROSZLAN, 1992 Translational suppression in retroviral gene expression. Adv. Virus Res. 41: 198-239.
- ITO, H., Y. FUKUDA, K. MURATA and A. KIMURA, 1983 Transformation of intact yeast cells treated with alkalications. J. Bacteriol. 153: 163-168.
- KAWAKAMI, K., B. K. SHAFER, D. J. GARFINKEL, J. N. STRATHERN and Y. NAKAMURA, 1992 Ty element-induced temperature-sensitive mutations of Saccharomyces cerevisiae. Genetics 131: 821-892.
- KIRCHNER, J., and S. B. SANDMEYER, 1993 Proteolytic processing of Ty3 proteins is required for transposition. J. Virol. 67: 19-98
- KIRCHNER, J., S. B. SANDMEYER and D. B. FORREST, 1992 Transposition of a Ty3 GAG3-POL3 fusion mutant is limited by availability of capsid protein. J. Virol. 66: 6081– 6092.
- MANDECKI, W., 1986 Oligonucleotide-directed double-strand break repair in plasmids of *Escherichia coli*: a method for site-specific mutagenesis. Proc. Natl. Acad. Sci. USA 83: 7177-7181.
- MORISHITA, T., and I. Uno, 1991 Genetic and molecular analyses of the *SUP201* gene: a tRNA-Arg nonsense suppressor of yeast cyr1-2. J. Bacteriol. 173: 2406-2408.
- MULLER, F., K.-H. BRUHL, K. FREIDEL, K. V. KOWALLIK and M. CIRIACY, 1987 Processing of Ty proteins and formation of Ty virus-like particles in Saccharomyces cerevisiae. Mol. Gen. Genet. 207: 421-429.
- PARK, J., and C. D. MORROW, 1992 Overexpression of the gagpol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production. J. Virol. 65: 5111-5117.
- RAFTERY, L. A., and M. YARUS, 1987 Systematic alterations in the anticodon arm make tRNA-Glu-Su-ochre a more efficient suppressor. EMBO J. 6: 1499-1506.
- Rose, M. D., F. Winston, and P. Hieter, 1990 Laboratory Course Manual for Methods in Yeast Genetics, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- Rose, M. D., P. NOVICK, J. H. THOMAS, D. BOTSTEIN and G. R.

- FINK, 1987 A Saccharomyces cerevisiae genomic plasmid bank based on a centromere-containing shuttle vector. Gene 60: 237-243.
- ROTHSTEIN, R., 1991 Targeting, disruption, replacement, and allele rescue: Integrative DNA transformation in yeast. Methods Enzymol. 194: 281-301.
- SAIKI, R., S. SHARF, F. FALOONA, K. B. MULLIS, G. T. HORN, H. A. ERLICH and N. ARNHEIM, 1985 Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230: 1350–1354.
- SAMBROOK, J., E. F. FRITSCH and T. MANIATIS, 1989 Molecular Cloning, Ed. 2. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- SANGER, F., S. NICKLEN and A. R. COULSON, 1977 DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74: 5463-5467.
- SIKORSKI, R. S., and P. HIETER, 1989 A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122: 19-27.

- THIREOS, G., M. D. PENN and H. GREER, 1984 5'-Untranslated sequences are required for the translational control of a yeast regulatory gene. Proc. Natl. Acad. Sci. USA 81: 5096-5100.
- WANG, A. M., M. V. DOYLE and D. F. MARK, 1989 Quantitation of mRNA by the polymerase chain reaction. Proc. Natl. Acad. Sci. USA 86: 9717-9721.
- Xu, H., and J. D. Boeke, 1990 Host genes that influence transposition in yeast: The abundance of a rare tRNA regulates Ty1 transposition frequency. Proc. Natl. Acad. Sci. USA 87: 8360-8364.
- YOKOYAMA, S., T. WATANABE, K. MURAO, H. ISHIKURA, Z. YAMAIZUMI, S. NISHIMURA and T. MIYAZAWA, 1985 Molecular mechanism of codon recognition by tRNA species with modified uridine in the first position of the anticodon. Proc. Natl. Acad. Sci. USA 82: 4905–4909.
- YOUNGREN, S. D., J. D. BOEKE, N. J. SANDERS and D. J. GARFINKEL, 1988 Functional organization of the retrotransposon Ty from Saccharomyces cerevisiae. Mol. Cell. Biol. 8: 1421-1431.

Communicating editor: A. G. HINNEBUSCH

EXHIBIT G





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

J Bacteriol, February 1998, p. 840-845, Vol. 180, No. 4 0021-9193/98/\$04.00+0

Copyright © 1998, American Society for Microbiology. All rights reserved.

tRNA^{Arg} (fimU) and Expression of SEF14 and SEF21 in Salmonella enteritidis

S. C. Clouthier, 1,2 S. K. Collinson, 1 A. P. White, 1 P. A. Banser, 1 and W. W. Kay 1,2,*

Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia V8W 3P6, and Microtek International Ltd., Saanichton, British Columbia V8X 3X1, Canada

Received 21 August 1997/Accepted 16 December 1997

Abstract of this Article

- Reprint (PDF) Version of this Article
- Similar articles found in: JB Online PubMed
- ▶ PubMed Citation
- This Article has been cited by: other online articles
- Search Medline for articles by: Clouthier, S. C. || Kay, W. W.
- Alert me when:

 new articles cite this article
- Download to Citation Manager
- ▶ Books from ASM Press

▶ ABSTRACT

A Tn10 insertion affecting SEF14 fimbrial synthesis in Salmonella enteritidis was located 13 bp upstream of a gene designated fimU. The 77-bp DNA sequence of fimU from S. enteritidis was identical to that of fimU encoding tRNA Arg (UCU) from Salmonella typhimurium and 96% identical to that of the Escherichia coli argU homolog. Furthermore, the open reading frame adjacent to and overlapping the 3' end of fimU was similar to the prophage

- ▲ Top
- Abstract
- **▼** Introduction
- **▼** Materials & Methods
- **▼** Results
- **▼** Discussion
- References

DLP12 integrase gene. The fimU-encoded transcript comigrated with total cellular tRNA and was predicted to form a tRNA-like cloverleaf structure containing the arginine anticodon UCU. Thus, fimU encoded a tRNA^{Arg} specific for the rare codon AGA. fimU mapped to the SEF21 fim operon located 15 C's from the sef14 gene cluster. Although fimU was located within the SEF21 fim gene cluster, the fimU Tn10 insertion mutant of S. enteritidis was found to be defective in SEF14 as well as SEF21 (type 1) fimbria production. SEF17 and SEF18 fimbria production was not affected. Complementation of this mutant with plasmid-borne fimU restored normal production of the fimbrins SefA and FimA as well as their respective fimbriae SEF14 and SEF21. This is the first description of tRNA simultaneously controlling the production of two distinct fimbriae.

INTRODUCTION

Regulation of fimbria biosynthesis in bacteria is multifactorial and complex. In *Escherichia coli*, the expression of type 1 fimbriae is transcriptionally regulated in part by an inversion-dependent, phase-variable mechanism that

- ▲ Top
- ▲ Abstract
- Introduction
- ▼ Materials & Methods

involves two site-specific recombinases (17, 24, 27) and a tRNA^{Leu} molecule (32). tRNA^{Leu}, specific for the rare leucine codon UUG, stimulates type 1 fimbria synthesis by influencing the switch from phase off to phase on (35). Recently, type 1 fimbria expression in *Salmonella typhimurium* has been

- ▼ Results
- ▼ Discussion
 - References

shown to be regulated by mechanisms that are different from those controlling type 1 fimbria expression in E. coli (41). However, a common regulatory theme does exist in that a tRNA, specific for the rare arginine codons AGA and AGG, is required (40). Swenson et al. (40) suggest that the amount of tRNA arg (UCU) available in S. typhimurium may influence the expression of three genes encoding regulatory proteins of the fim gene cluster, since in each of these genes there is a high frequency of rare AGA codons recognized by tRNA arg (UCU).

Salmonella enteritidis 27655-3b produces at least four fimbrial types: SEF17 (10), SEF18 (6), SEF21 (type 1 fimbriae) (30), and SEF14 (7, 14). Although little is known about how the expression of the operons is regulated, SEF21 and SEF14 fimbriae are produced under similar environmental conditions (5, 12). Thus, the question arises as to whether or not their expression is coregulated. In a previous study, a Tn10 insertion mutant, S. enteritidis 3b-122, was generated which no longer produced SEF14 fimbriae and carried the transposon outside of sefA, the structural gene for these fimbriae (14). Further characterization of 3b-122 in this study indicated that this mutant was also defective in type 1 fimbria (SEF21) production, suggesting that the Tn10 interrupted a gene whose product coregulated the expression of both SEF14 and SEF21 fimbriae. The results of this study show for the first time that the production of two fimbriae is coregulated by the same tRNA.

MATERIALS AND METHODS

Bacterial strains, plasmids, media, and growth conditions. S. enteritidis 27655-3b, originally isolated from human feces, was provided by T. Wadstrom (University of Lund, Lund, Sweden). S. enteritidis 27655-3b-122, a Tn10 insertion mutant of the parent strain, was constructed by Feutrier et al. (14). E. coli DH5α and S. enteritidis 3b-122 were used as hosts for pSFA (11), pLU/TA 4-1, and pGEM-T1. To create pLU/TA 4-1, PCR-amplified fimII was cloped into pGEM-T (Promose Com).

- <u> Top</u>
- ▲ Abstract
- ▲ Introduction
- Materials & Methods
- **▼** Results
- **▼** Discussion
- **▼** References

fimU was cloned into pGEM-T (Promega Corp.), a TA cloning vector containing 3'-terminal thymidines. To create pGEM-T1, the 3'-overhanging thymidines of pGEM-T were filled in with dATP and T4 DNA polymerase prior to ligation (38).

Bacteria were grown at 37°C with shaking in Luria-Bertani (LB) broth (36) supplemented with ampicillin to a final concentration of 250 μ g/ml except where noted. To analyze the production of fimbriae by *S. enteritidis*, the cells were grown in various liquid media under different growth conditions (Table 1). Cultures grown in LB broth and terrific broth (TFB) (38) were transferred to ice 24 h after inoculation, whereas cultures grown in colonization factor antigen (CFA) medium (13) and T broth (10) were transferred to ice 48 h after inoculation. All the cultures were standardized to an optical density at 630 nm (OD₆₃₀) of 1.

View this table: S. enteritidis 3b and S. enteritidis 3b-122 [in this window]

Subcloning Tn10 from *S. enteritidis* 27655 3b-122. *S. enteritidis* 3b-122 chromosomal DNA was isolated by the method of Alm et al. (1), purified by CsCl centrifugation (38), and digested with *Hin*dIII. To subclone the Tn10-containing chromosomal DNA fragment, size fractionated *Hin*dIII fragments (2 to 3 and 3 to 5 kb) were purified from an agarose gel with Sephaglas (Pharmacia Biotech), ligated to *Hin*dIII-digested and -dephosphorylated cloning vector pTZ19R, and then introduced into *E. coli* DH5α by transformation (38). A total of 2,880 colonies grown on Hybond N⁺ membranes (Amersham) were screened by hybridization to the oligonucleotide probe Tn10 IS10L+R (5' GCAGAATTGGTAAAGAGA 3'). This probe, complementary to the sequence located 134 bp inside the insertion sequence of Tn10, was used to identify Tn10-containing clones. The probe, end labelled with [γ-32P]ATP, was hybridized to the membranes at 45°C in prehybridization buffer (38) containing 200 μg of herring sperm DNA (Sigma)/ml. Following hybridization, the membranes were washed in 0.2× SSC buffer (1× SSC is 0.15 M NaCl plus 0.015 M sodium citrate) containing 0.1% sodium dodecyl sulfate (SDS) at 45°C, and the results were recorded by autoradiography on Kodak BioMax film.

DNA sequencing and computer analyses. The Tn10-positive clones and the three fimU PCR products amplified with primers located outside the fimU gene were sequenced with Sequenase version 2 (United States Biochemicals). The custom oligonucleotide primer Tn10IS10L+R was synthesized on a PCR-MATE EP model 391 DNA synthesizer (Applied Biosystems Inc.). The DNA sequences obtained were analyzed with DNA Strider 1.1 (26). Similarity searches of the National Center for Biotechnology Information (NCBI) databases were conducted with the program BLASTN (2).

PCR amplification of fimU. Custom oligonucleotide primers fimULT (TAATAGCGATACGCAGAATTCAAAAATATCCTACACGGCAGG) and fimULB (CAGATATGCTCACCTAAGCTTTAATCATTTAACGGAACACGG) were designed based on the S. typhimurium chromosomal DNA sequence flanking fimU and were synthesized by Gibco BRL. fimU was PCR amplified from a previously prepared cosmid clone, pPB523 (12), with fimULT and fimULB. To facilitate the cloning of the amplified product, the primers were designed to contain an EcoRI site and a HindIII site, respectively (underlined). Amplification was carried out in a 100-μl reaction volume containing 10 μl of pPB523 (0.01 μg/ml), 25 pmol of each primer, the four deoxynucleotide triphosphates (Boehringer Mannheim) at 0.5 mM each, and 2 U of Taq DNA polymerase (Boehringer Mannheim) in reaction buffer consisting of 50 mM Tris-HCl (pH 8.5), 20 mM KCl, 2.5 mM MgCl₂, and 0.5 mg of bovine serum albumin/ml. The Taq enzyme was added after an initial 3-min denaturation step at 95°C (4). Thermocycling was performed in a PTC-100TM Programmable Thermal Controller (MJ Research Inc.) as follows: 1 cycle of 75°C, 1 min; 50°C, 2 min; 74°C, 2 min and 30 cycles of 95°C, 1 min; 50°C, 1 min; 74°C, 2 min, followed by an 8-min elongation at 74°C.

Subcloning PCR-amplified *fimU*. PCR-amplified *fimU* was purified from a 1% agarose gel with Sephaglas, ligated to pGEM-T according to the manufacturer's instructions (Promega Corp.), and then

transformed into E. coli DH5a (38).

Mapping of fimU on genomic restriction maps of Salmonella and E. coli strains. The fimU gene was mapped as previously described for the four fimbrin genes sefA, agfA, fimA, and sefD (8). The fimU probe, prepared by running EcoRI- and HindIII-digested pLU/TA 4-1 on a 1% agarose gel and purifying the fragment with Sephaglas, was labelled with [α^{32} P]dATP (Pharmacia Biotech) by nick translation. The radiolabelled fimU probe was hybridized to nitrocellulose blots containing XbaI- and BlnI-digested E. coli, S. typhimurium, and S. enteritidis genomic DNA separated by pulsed field gel electrophoresis (blots were provided by K. Sanderson and S.-L. Liu; see reference 8).

RNA extraction and Northern blot analysis. Total RNA was prepared from *S. enteritidis* 3b, 3b-122, 3b-122 pGEM-T1, and 3b-122 pLU/TA 4-1 grown statically in LB or CFA broth at 37°C for 45 h by a modification of the procedure of McCormick et al. (28) as described in Clouthier et al. (7). For *fimU* transcript analysis, the RNA was separated on a 10% polyacrylamide gel containing 8 M urea and transferred onto Hybond N⁺ membranes (Amersham) with transfer buffer (0.025 M phosphate buffer [pH 6.5]) and an LKB Pharmacia semidry blotting apparatus. For *sefA* transcript analysis, the electrophoretic separation of total cellular RNA and its subsequent transfer to Hybond N⁺ membranes (Amersham) were performed as described in Fourney et al. (15). The *fimU*- and *sefA*-specific probes used for Northern blot analysis were gel purified from *Eco*RI and *Hind*III digests of pLU/TA 4-1 and pSFA, respectively, with Sephaglas. The probes were labelled with [α³²P]dATP (Pharmacia Biotech) by nick translation and hybridized to the blots at 65°C for 18 h in the presence of 200 μg of herring sperm DNA (Sigma)/ml. The membranes were washed at high stringency (0.2× SSC buffer-0.1% SDS, 65°C), and the results were recorded on Kodak BioMax or X-Omat AR5 film.

SDS-PAGE and Western blot analysis. Whole-cell lysates of *S. enteritidis* 3b or clones of this strain were screened for the presence of four fimbrial types. SEF14, 18, and 21 were solubilized from whole cells with SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer supplemented with 0.2 M glycine (pH 2, 100° C, 10 min), whereas SEF17 fimbriae were solubilized from whole cells with formic acid according to the method of Collinson et al. (9, 10). A portion of each culture (1 OD₆₃₀ unit) was resuspended in 200 µl of sample buffer, and 10 µl (0.01 OD₆₃₀ unit) was loaded per lane. Proteins in these samples were separated by SDS-PAGE, electrophoretically transferred to nitrocellulose, and screened with rabbit polyclonal anti-SEF14 (7), SEF17 (10), SEF18 (6), or SEF21 immune serum (30). Immunoreactive proteins were detected with goat anti-rabbit immunoglobulin G-alkaline phosphatase conjugates (Cedarlane) and visualized with 5-bromo-4-chloro-3-indolylphosphate and Nitro Blue Tetrazolium (Sigma).

Electron microscopy. SEF14 and SEF21 fimbriae on *S. enteritidis* 3b, 3b-122, 3b-122 pGEM-T1, and 3b-122 pLU/TA 4-1 were immunogold labelled with SEF14- or SEF21-specific rabbit polyclonal immune sera followed by incubation with protein A-15-nm-diameter gold particles (Cedarlane). Negative staining was performed as described previously (10).

Nucleotide sequence accession number. The nucleotide sequence reported herein for *fimU* has been submitted to GenBank and has been given the accession number AF013136.


RESULTS

Fimbria production in *S. enteritidis* **3b-122.** Production of SEF14, -17, -18, and -21 fimbriae by the *S. enteritidis* Tn10 mutant 3b-122 grown under various growth conditions was assessed by Western blotting with fimbria-specific antisera, and the results were compared to those obtained with the wild-type strain *S. enteritidis* 3b. The Tn10 mutation in 3b-122 had a pronounced effect on SEF14 and SEF21 production but little or no effect on

- ▲ Top
- ▲ Abstract
- ▲ Introduction
- ▲ Materials & Methods
- Results
- **▼** Discussion
- **▼** References

SEF17 and SEF18 production (Table 1). As previously reported, SEF14 fimbriae were not expressed by 3b-122 grown in static CFA broth at 37°C (Table 1). Further characterization in this study, however, showed that 3b-122 lost SEF14 expression under all the growth conditions in which 3b was SEF14 positive (Table 1). In addition to the SEF14-negative phenotype, 3b-122 was also defective for type 1 fimbria (SEF21) production. The wild-type strain produced FimA under all growth conditions tested, whereas 3b-122 only produced FimA in CFA broth cultures. Thus, the result of the Tn10 insertion was the complete loss of SEF14 expression under all growth conditions and selective loss of SEF21 expression under certain growth conditions. The altered production of SEF14 and SEF21 fimbriae in the Tn10 insertion mutant relative to the wild-type expression patterns suggested that the transposon insertion interrupted a gene whose product was required for both SEF14 and SEF21 fimbria expression.

Identification of the Tn10 insertion site in S. enteritidis 3b-122. To determine the Tn10 insertion site, HindIII fragments of 3b-122 chromosomal DNA were subcloned into pTZ19. Clones containing Tn10 were identified with the probe IS10L+R, which hybridized within the insertion sequence located at either end of the transposon (Fig. 1A). Of the 17 Tn10-positive clones identified, 3 were subjected to DNA sequence analysis. Comparison of the 3b-122 DNA sequence flanking Tn10 to sequences listed in the NCBI databases revealed that the sequence was 99% identical to that of the region located between fimW and fimU of the S. typhimurium type 1 fimbrial gene cluster. Thus, on the basis of DNA sequence comparison, Tn10 was inserted 13 bp upstream of the predicted start site of the gene, which will hereafter be referred to as fimU (Fig. 1A and B).



View larger version (19K):


[in this window]

[in a new window]

FIG. 1. Location of Tn10 on the S. enteritidis 3b-122 chromosome and identification of the genes flanking the Tn10 insertion in S. enteritidis 3b. (A) Schematic diagram of S. enteritidis (S.e.) 3b-122 chromosomal DNA (black line) showing the Tn10 insert and the strategy used to obtain the chromosomal DNA sequence adjacent to one side of this insert. A 3-kb HindIII fragment comprising 3b-122 chromosomal DNA fused to one end of Tn10 was identified by hybridization with the Tn10 oligonucleotide IS10L+R. IS10L+R was also used as a sequencing primer to obtain 240 bp of DNA sequence from the subcloned HindIII fragment. (B) Schematic diagram of the S. typhimurium (S.t.) chromosome (black line) between fimW and fimU of the type I fimbrial gene cluster that was homologous to the 240 bp of S. enteritidis 3b-122 DNA sequence. Two 42-bp oligonucleotide primers, fimULT and fimULB (horizontal

arrows), were made based on the *S. typhimurium* sequence previously deposited in GenBank (L19338) by Swenson and Clegg (39). (C) Segment of the *S. enteritidis* 3b chromosome (black line) amplified by PCR with the primers fimULT and fimULB. This amplified DNA segment was subcloned and sequenced (Fig. 2) to identify the DNA flanking the Tn10 insert. The Tn10 insertion point (vertical arrow) was determined to be between the -10 region and the start of the fimU gene. The presence of fimW, fimU, and the -35 region on the 3b chromosome is also noted.

DNA sequence analysis of fimU subcloned from S. enteritidis 3b. By using primers fimULT and fimULB designed from the sequence flanking the fimU gene in S. typhimurium, a 490-bp fragment was PCR amplified from the cosmid clone pPB523-G containing 35 kb of S. enteritidis 3b DNA (Fig. 1B). The fimU PCR product was subcloned into vector pGEM-T (Fig. 1B). Nucleotide sequence analysis of three clones revealed a potential promoter, but a putative translated protein could not be detected by open reading frame analysis. Comparison of the DNA sequence downstream of the potential promoter to sequences listed in the NCBI databases showed that the sequence was identical to that of fimU of S. typhimurium (Fig. 1C and 2B) and 96% similar to that of argU/dnaY of E. coli (Fig. 2A). These genes encode arginine-specific tRNAs that recognize the rare AGA codon. The nucleotide sequence of fimU from S. enteritidis 3b contained 4 inverted repeats, which were predicted to fold the sequence into the characteristic tRNA-like cloverleaf structure (Fig. 2B) with UCU in the expected tRNA anticodon position. Together, these data suggested that fimU from S. enteritidis 3b encoded an arginine-specific tRNA.




View larger version (22K):
[in this window]
[in a new window]

FIG. 2. Sequence comparison of fimU from S. enteritidis 3b (S.e.) with fimU of S. typhimurium (S.t.) and argU of E. coli (E.c.) as well as the predicted fimU RNA secondary structure. (A) Alignment of S. enteritidis fimU DNA sequence with both the S. typhimurium fimU ($\underline{39}$) and E. coli ($\underline{31}$) argU gene sequences. Symbols: •, DNA sequence identity; −, gaps introduced to maximize homology; *, bases constituting the -35 and -10 boxes; \$\frac{1}{2}\$, bases constituting the anticodon; \$\times\$, position of the Tn10 insertion on the S. enteritidis 3b-122 chromosome. The DNA sequence corresponding to the proposed mature $tRNA^{Arg}$ (UCU) is underlined. (B) Diagram of the proposed secondary structure for $tRNA^{Arg}$ (UCU) from S. enteritidis 3b. The anticodon bases are underlined.

Analysis of the nucleotide sequence downstream of *fimU* revealed an open reading frame oriented in the opposite direction such that the 3' ends of the two genes overlapped. The predicted amino acid sequence was 88% similar to that of the prophage DLP12 integrase of *E. coli*. The sequence further downstream of *fimU* displayed 60 to 88% similarities to those encoding transposases of the IS3 family of insertion elements.

Mapping fimU on the S. enteritidis 3b genome. Like fimA, fimU was localized to chromosomal XbaI and BlnI fragments in the 98.5- to 13.0-C's region of the chromosome in both Salmonella serovars. By using a series of S. typhimurium and S. enteritidis Tn10 mutants the fimU gene was more precisely mapped to between purE884::Tn10 at 12.6 C's and the first XbaI restriction site at 13.6 C's in S. enteritidis or 13.0 C's in S. typhimurium. Thus, fimU mapped to the same region shown previously to contain the fimA gene in the fim gene cluster.


Analysis of fimU transcription. To determine if the fimU transcript was the same size as tRNA, a fimU-specific probe was hybridized to a blot containing total RNA isolated from S. enteritidis 3b, 3b-122, 3b-122 pGEM-T1, or 3b-122 pLU/TA 4-1 grown under conditions optimal for type 1 fimbria (SEF21) production in S. enteritidis 3b (static LB broth, 48 h, 37°C). The fimU-specific probe hybridized to a transcript that was present in total RNA from 3b and 3b-122 pLU/TA 4-1 (Fig. 3). The fimU transcript was consistently difficult to detect on Northern blots of 3b RNA even with excessive amounts of RNA loaded on the gels (25 µg [Fig. 3, lanes 1 to 4] and 50 µg [Fig. 3, lanes 5 to 8]) and extended exposure of the blots to X-ray film. Although the transcript was not found in RNA prepared from 3b-122, trace levels were evident in 3b-122 carrying the vector pGEM-T (Fig. 3), but the transcript was even more difficult to detect than its counterpart in 3b. The transcript detected with the fimU-specific probe comigrated with tRNA, suggesting that the product of fimU from S. enteritidis was indeed a tRNA molecule.



View larger version (29K):
[in this window]
[in a new window]

FIG. 3. Northern blot analysis of tRNA^{Arg} (UCU) production in *S. enteritidis* 3b strains. A *fimU*-specific probe was hybridized to PAGE-separated total RNA from *S. enteritidis* 3b (lanes 1 and 5), 3b-122 (lanes 2 and 6), 3b-122 pGEM-T1 (lanes 3 and 7), or 3b-122 pLU/TA 4-1 (lanes 4 and 8). Lanes 1 to 4 contain 25 μg of RNA, and lanes 5 to 8 contain 50 μg of RNA.

Complementation of fimbrin expression and fimbria assembly in 3b-122. Fimbria expression was examined in *S. enteritidis* 3b, 3b-122, 3b-122 pGEM-T1, and 3b-122 LU/TA 4-1 grown under conditions that promoted production of both SEF14 and SEF21 by the wild-type strain (static CFA broth, 48 h, 37°C). Western blot analysis of whole-cell lysates using SEF14- or SEF21-specific antisera showed that complementation of the insertion mutation in 3b-122 with pLU/TA 4-1 restored SEF14 and SEF21 fimbria expression (Fig. 4). Thus *fimU* affected the production of two fimbrins encoded by genes located on two different gene clusters.




View larger version (49K): [in this window] [in a new window]

FIG. 4. Complementation analysis of *S. enteritidis* 3b-122 Tn 10 mutant with the fim U-containing recombinant plasmid pLU/TA 4-1. Whole-cell extracts were analyzed by Western blotting to determine the presence of SefA (21 kDa) and FimA (14 kDa) fimbrin proteins in *S. enteritidis* 3b (lane 1), 3b-122 (lane 2), 3b-122 pGEM-T1 (lane 3), and 3b-122 pLU/TA 4-1 (lane 4). Numbers at right indicate positions of SefA (21) and FimA (14).

Assembly of SEF14 and SEF21 fimbriae on the cell surface of S. enteritidis 3b, 3b-122, 3b-122 pGEM-T1, or 3b-122 pLU/TA 4-1 was determined by immunogold labelling and electron microscopy performed on cells grown in static CFA broth for 48 h at 37°C. The wild-type strain, S. enteritidis 3b, expressed both SefA and FimA and assembled the respective subunits into SEF14 and SEF21 fimbriae (Table 2). Similar analyses of 3b-122 and 3b-122 pGEM-T1 showed that SEF14 was not produced and that SEF21 fimbriae on the cell surfaces of these two strains were rarely detected (Table 2), a result consistent with the Western blot data (Fig. 4). In contrast, SEF14 and SEF21 fimbriae were evident on the surface of 3b-122 pLU/TA 4-1 (Fig. 5) at levels equal to or greater than that on 3b. Thus, expression of SefA and FimA fimbrins and assembly of their respective fimbriae were restored by complementation of the Tn10 fimU mutation in 3b-122 with a wild-type copy of the fimU gene on pLU/TA 4-1. Cells producing SEF17 were readily seen without immunolabelling on all the grids prepared for electron microscopy (Table 2).

[in this window] [in a new window]


TABLE 2. Detection of assembled SEF14 and SEF21 fimbriae in various View this table: S. enteritidis strains by immunoelectron microscopy with specific antifimbrial sera



View larger version (90K): [in this window] [in a new window]

FIG. 5. Analysis of SEF14 and SEF21 fimbria assembly in S. enteritidis 3b-122 pLU/TA 4-1 by immunogold electron microscopy. S. enteritidis 3b-122 pLU/TA 4-1 was labeled with protein A-gold and negatively stained following incubation with immune serum generated to SEF14 (A) or SEF21 (B). Arrows indicate individual immunogold-labeled SEF14 and SEF21 fimbriae in panel A and B insets. respectively. The average diameter of the gold particles was 15 nm. Bar, 0.5 μm (electron micrograph) or 50 nm (inset).

Analysis of sefA transcription. The effect of tRNAArg (UCU) on sefA transcript production was analyzed by hybridizing a sefA-specific probe to a blot containing total cellular RNA isolated from S. enteritidis 3b, 3b-122, 3b-122 pGEM-T1, or 3b-122 LU/TA 4-1 grown under conditions optimal for SEF14 production in 3b (static CFA broth, 48 h, 37°C). The sefA-specific probe hybridized to a 660base transcript that was present in RNA from 3b and 3b-122 pLU/TA 4-1 but absent from RNA from 3b-122 and 3b-122 pGEM-T1 (Fig. 6). The strains expressing the sefA transcript corresponded to those carrying a functional fimU gene, suggesting that fimU was required for expression of sefA.



View larger version (36K): [in this window] [in a new window]

FIG. 6. Northern blot analysis of sefA transcription in S. enteritidis 3b strains. A sefA-specific probe was hybridized to 10 µg of total RNA from S. enteritidis 3b (lane 1), 3b-122 (lane 2), 3b-122 pGEM-T1 (lane 3), or 3b-122 LU/TA 4-1 (lane 4).

DISCUSSION

fimU, located in the fim (sef21) operon of S. enteritidis 3b, encodes an arginine-specific tRNA that is required for expression of not only SEF21 fimbriae (type 1) but also SEF14 fimbriae. The product of fimU in 3b is a tRNA, since Northern blot analysis of RNA from 3b and 3b-122 pLU/TA 4-1 demonstrates that the fimU transcript comigrates on polyacrylamide gels with tRNA. Furthermore, the 77-nucleotide sequence of the fimU gene of 3b is

- ▲ Top
- ▲ Abstract
- ▲ Introduction
- Materials & Methods
- ▲ Results
- Discussion
- ▼ References

identical to that of fimU of S. typhimurium (39) and shares extensive homology with that of argU encoding $tRNA^{Arg}$ (UCU) from E. coli (18). The fimU-encoded transcript from 3b can be folded into a typical tRNA cloverleaf structure containing the 3'-terminal sequence CCA as well as the invariant or semivariant nucleotides common to tRNA molecules (19, 34). Finally, the DNA sequence 5' to the fimU gene contains features common to the promoters of tRNA operons including the consensus E. coli -10 and -35 promoter elements (16, 21) and a G+C-rich discriminator sequence (16, 42, 43). The regulatory mechanisms controlling fimU expression are unknown. Recently, however, the integration and excision of plasmids, phage, and pathogenicity islands into and out of the chromosomes at tRNA loci have been shown to affect tRNA gene expression (20, 33). As shown with the E. coli tRNA gene argU (25), the open reading frame adjacent to and overlapping fimU is a homolog of the integrase gene (int) from the defective lambdoid prophage DLP12. Integration of prophage DLP12 at this site prevents cotranscription of the int gene with fimU, which may contribute to the regulation of fimU expression in S. enteritidis 3b.

The influence of tRNA^{Arg} (UCU) encoded by *fimU* on SEF14 and SEF21 fimbria production is evident in the Tn10 insertion mutant *S. enteritidis* 3b-122. The transposon, inserted between the predicted promoter and the 5' end of the mature *fimU* transcript, disrupts transcription of *fimU* and thus tRNA^{Arg} (UCU) production. This mutation results in the loss of SefA production and selective loss of FimA production, i.e., the subunits of SEF14 and SEF21 (type 1) fimbriae, respectively. Thus, in *S. enteritidis* 3b, tRNA^{Arg} (UCU) is required for SEF14 production and enhances type 1 fimbria (SEF21) production. In *E. coli*, cross-talk has also been reported to occur between adhesin gene clusters (29), and tRNA molecules have been shown to play a key role in global regulatory cascades (20). However, this is the first study to show that a tRNA-specific locus found on one fimbrial operon influences the production of two fimbrins whose operons are separated by 15 C's on the chromosome.

tRNA^{Arg} (UCU) encoded by *fimU* is required for transcription of *sefA*, the gene encoding the subunit of SEF14 fimbriae in *S. enteritidis* 3b. The regulatory mechanism is unknown, but a direct correlation between the abundance of tRNAs and the occurrence of the respective codons in protein genes (22, 23) has been suggested to control the translation of genes containing rare codons (3, 37). Since AGA, the codon recognized by the tRNA^{Arg} (UCU) species encoded by *fimU*, is one of the least-used codons for arginine, then perhaps the limited availability of charged tRNAs for this minor codon controls the level of translation of the *sefA* transcript or of a transcript whose protein product is involved in the regulation

of sefA transcription. sefA contains neither of the rare arginine codons AGA or AGG recognized by $tRNA^{Arg}$ (UCU), indicating that fimU expression would not have a direct effect on the translation of sefA mRNA. However, sefE, the gene encoding the putative AraC-like transcriptional activator of the sef14 gene cluster, contains 13 arginine codons, including 9 AGA codons and 1 AGG codon (5). Perhaps the $tRNA^{Arg}$ (UCU) encoded by fimU regulates translation of sefE, which would in turn affect transcription of sefA and the downstream genes.

With the exception of the gene *fimA* encoding the subunit of SEF21 fimbriae (12), the remainder of the *sef21* gene cluster has not been characterized in *S. enteritidis* 3b. Thus, the mechanism for regulation of type 1 fimbria synthesis by *fimU* remains to be determined. However, type 1 fimbria (SEF21) production is optimal when *S. enteritidis* 3b is grown at 37°C in a static broth culture but suboptimal when the cells are grown at lower temperatures (21 to 30°C) in shaking broth culture or on solid medium (12). Similarly, expression of SEF14 fimbriae by *S. enteritidis* 3b is environmentally controlled by temperature, medium composition, and aeration, and is optimal at 37°C in static, aerobic CFA broth (5). Thus, the coregulation of SefA and FimA fimbrin production by *fimU*-encoded tRNA^{Arg} (UCU) results in the corresponding fimbriae being expressed under similar environmental conditions, which may give the bacteria a competitive advantage for survival.

ACKNOWLEDGMENTS

This project was supported by operating grants to W.W.K. provided by the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Canadian Bacterial Diseases Network. S.C.C. was the recipient of an Industrial Postdoctoral Fellowship from NSERC, and A.P.W. was the recipient of a Graduate Research Engineering and Technology Award scholarship from the Science Council of British Columbia and a Graduate Research scholarship from NSERC.

We thank S. Lee for helpful discussions on tRNA.

FOOTNOTES

* Corresponding author. Mailing address: Department of Biochemistry and Microbiology, University of Victoria, Victoria, B.C. V8W 3P6, Canada. Phone: (250) 721 7078. Fax: (250) 721 8882. E-mail: wkay@uvic.ca.

REFERENCES

- ▲ Top
- Abstract
- Introduction
- Materials & Methods
- Results
- ▲ Discussion
- References
- 1. Alm, R. A., P. Guerry, and T. J. Trust. 1993. Distribution and polymorphism of the flagellin

- genes among isolates of Campylobacter coli and Campylobacter jejuni. J. Bacteriol. 175:3051-3057 [Abstract].
- 2. Altschul, S. F., W. Gish, W. Miller, E. W. Myers, and D. J. Lipman. 1990. Basic local alignment search tool. J. Mol. Biol. 215:403-410[Medline].
- 3. Chen, G.-F., and M. Inouye. 1994. Role of the AGA/AGG codons, the rarest codons in global gene expression in *Escherichia coli*. Genes Dev. 8:2641-2652[Abstract].
- 4. Chou, Q., M. Russell, D. E. Birch, J. Raymond, and W. Bloch. 1992. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplification. Nucleic Acids Res. 20:1717-1723 [Abstract].
- 5. Clouthier, S. C. 1995. Ph.D. thesis. University of Victoria, Victoria, Canada.
- 6. Clouthier, S. C., S. K. Collinson, and W. W. Kay. 1994. Unique fimbriae-like structures encoded by *sefD* of the SEF14 fimbrial gene cluster of *Salmonella enteritidis*. Mol. Microbiol. 12:893-903 [Medline].
- 7. Clouthier, S. C., K.-H. Müller, J. L. Doran, S. K. Collinson, and W. W. Kay. 1993. Characterization of three fimbrial genes, sefABC, of Salmonella enteritidis. J. Bacteriol. 175:2523-2533[Abstract].
- 8. Collinson, S. K., S.-L. Liu, S. C. Clouthier, P. A. Banser, J. L. Doran, K. E. Sanderson, and W. W. Kay. 1996. The location of four fimbrin-encoding genes, agfA, fimA, sefA, and sefD, on the Salmonella enteritidis and/or S. typhimurium XbaI-BlnI genomic restriction maps. Gene 169:75-80 [Medline].
- 9. Collinson, S. K., P. C. Doig, J. L. Doran, S. C. Clouthier, T. J. Trust, and W. W. Kay. 1993. Thin aggregative fimbriae mediate binding of *Salmonella enteritidis* to fibronectin. J. Bacteriol. 175:12-18[Abstract].
- 10. Collinson, S. K., L. Emödy, K.-H. Müller, T. J. Trust, and W. W. Kay. 1991. Purification and characterization of thin, aggregative fimbriae from *Salmonella enteritidis*. J. Bacteriol. 173:4773-4781[Medline].
- 11. Doran, J. L., S. K. Collinson, S. C. Clouthier, T. A. Cebula, W. H. Koch, J. Burian, P. A. Banser, E. C. D. Todd, and W. W. Kay. 1996. Diagnostic potential of sefA DNA probes to Salmonella enteritidis and certain other O-serogroup D1 Salmonella serovars. Mol. Cell. Probes 10:233-246[Medline].
- 12. Doran, J. L., S. K. Collinson, C. M. Kay, P. A. Banser, J. Burian, C. K. Munro, S. H. Lee, J. M. Somers, E. C. D. Todd, and W. W. Kay. 1994. fimA and tct based DNA diagnostics for Salmonella. Mol. Cell. Probes 8:291-310[Medline].
- 13. Evans, D. G., D. J. Evans, Jr., and W. Tjoa. 1977. Hemagglutination of human group A erythrocytes by enterotoxigenic *Escherichia coli* isolated from adults with diarrhea: correlation with colonization factor. Infect. Immun. 18:330-337[Medline].
- 14. Feutrier, J., W. W. Kay, and T. J. Trust. 1986. Purification and characterization of fimbriae from Salmonella enteritidis. J. Bacteriol. 168:221-227[Medline].
- 15. Fourney, R. M., J. Miyakoshi, R. S. Kay III, and M. C. Paterson. 1992. Northern blotting: efficient RNA staining and transfer. Focus 10:5-7.
- 16. Fournier, M. J., and H. Ozeki. 1985. Structure and organization of the transfer ribonucleic acid genes of *Escherichia coli* K-12. Microbiol. Rev. 49:379-397.
- 17. Gally, D. L., J. Leathart, and I. C. Blomfield. 1996. Interaction of FimB and FimE with the *fim* switch that controls the phase variation of type 1 fimbriae in *Escherichia coli* K-12. Mol. Microbiol. 21:725-738[Medline].
- 18. Garcia, G. M., P. K. Mar, D. A. Mullin, J. R. Walker, and N. E. Prather. 1986. The E. coli dnaY gene encodes an arginine transfer RNA. Cell 45:453-459[Medline].

- Gauss, D. H., and M. Sprinzl. 1983. compilation of tRNA sequences. Nucleic Acids Res. 11:1-53
 [Medline].
 - 20. Hacker, J., G. Blum-Oehler, I. Mühldorfer, and H. Tschäpe. 1997. Pathogenicity islands of virulent bacteria: structure, function and impact on microbial evolution. Mol. Microbiol. 23:1089-1097[Medline].
 - 21. **Hawley, D. K., and W. R. McClure.** 1983. Compilation and analysis of *Escherichia coli* promoter DNA sequences. Nucleic Acids Res. 11:2237-2255[Abstract].
 - 22. **Ikemura**, T. 1981. Correlation between the abundance of *Escherichia coli* transfer RNAs and the occurrence of the respective codons in its protein genes: a proposal for synonymous codon choice that is optimal for the *E. coli* translational system. J. Mol. Biol. **151:**389-409[Medline].
 - 23. **Ikemura**, **T.** 1981. Correlation between the abundance of *Escherichia coli* transfer RNAs and the occurrence of the respective codons in its protein genes. J. Mol. Biol. **146:**1-21[Medline].
 - 24. **Klemm, P.** 1986. Two regulatory *fim* genes, *fimB* and *fimE*, control the phase variation of type 1 fimbriae in *Escherichia coli*. EMBO J. 5:1389-1393[Abstract].
- 25. Lindsey, D. F., D. A. Mullin, and J. R. Walker. 1989. Characterization of the cryptic lambdoid prophage DLP12 of *Escherichia coli* and overlap of the DLP12 integrase gene with the tRNA gene argU. J. Bacteriol. 171:6197-6205[Medline].
- 26. Marck, C. 1988. "DNA Strider": a "C" program for the fast analysis of DNA and protein sequences on the Apple Macintosh family of computers. Nucleic Acids Res. 16:1829-1836[Abstract].
- 27. McClain, M. S., I. C. Blomfield, and B. I. Eisenstein. 1991. Roles of *fimB* and *fimE* in site-specific DNA inversion associated with phase variation of type 1 fimbriae in *Escherichia coli*. J. Bacteriol. 173:5308-5314[Medline].
- 28. McCormick, J. R., J. M. Zengel, and L. Lindahl. 1991. Intermediates in the degradation of mRNA from the lactose operon of *Escherichia coli*. Nucleic Acids Res. 19:2767-2776[Abstract].
- 29. Morschhauser, J., V. Vetter, L. Emody, and J. Hacker. 1994. Adhesin regulatory genes within large, unstable DNA regions of pathogenic *Escherichia coli*: cross-talk between different adhesin gene clusters. Mol. Microbiol. 11:555-566[Medline].
- 30. Müller, K.-H., S. K. Collinson, T. J. Trust, and W. W. Kay. 1991. Type 1 fimbriae of Salmonella enteritidis. J. Bacteriol. 173:4765-4772[Medline].
- 31. Mullin, D. A., G. M. Garcia, and J. R. Walker. 1984. An *E. coli* DNA fragment 118 base pairs in length provides *dnaY*⁺ complementing activity. Cell 37:669-674[Medline].
- 32. Newman, J. V., R. L. Burghoff, L. Pallesen, K. A. Krogfelt, C. S. Kristensen, D. C. Laux, and P. S. Cohen. 1994. Stimulation of *Escherichia coli* F-18Col⁻ type-1 fimbriae synthesis by *leuX*. FEMS Microbiol. Lett. 122:281-287[Medline].
- 33. Reiter, W.-D., P. Palm, and S. Yeats. 1989. Transfer RNA genes frequently serve as integration sites for prokaryotic genetic elements. Nucleic Acids Res. 17:1907-1914[Abstract].
- 34. Rich, A., and U. L. RajBhandary. 1976. Transfer RNA: molecular structure, sequence, and properties. Annu. Rev. Biochem. 45:805-860[Medline].
- 35. Ritter, A., D. L. Gally, P. B. Olsen, U. Dobrindt, A. Friedrich, P. Klemm, and J. Hacker. 1997. The Pai-associated *leuX* specific tRNA^{Leu} affects type 1 fimbriation in pathogenic *Escherichia coli* by control of FimB recombinase expression. Mol. Microbiol. 25:871-882[Medline].
- 36. Rosner, J. L. 1972. Formation, induction and curing of bacteriophage P1 lysogens. Virology 48:679[Medline].
- 37. Saier, M. H., Jr. 1995. Differential codon usage: a safeguard against inappropriate expression of specialized genes? FEBS Lett. 362:1-4[Medline].
- 38. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. . Molecular cloning: a laboratory manual,

- 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
- 39. Swenson, D. L., and S. Clegg. 1994. Salmonella fimbriae, p. 105-113. In P. Klemm (ed.), Fimbriae: adhesion, biogenesis, genetics and vaccines. CRC Press, London, United Kingdom.
- Swenson, D. L., K.-J. Kim, E. W. Six, and S. Clegg. 1994. The gene *fimU* affects expression of Salmonella typhimurium type 1 fimbriae and is related to the Escherichia coli tRNA gene argU. Mol. Gen. Genet. 244:216-218[Medline].
 - 41. Swenson, D. L., and S. Clegg. 1992. Identification of ancillary fim genes affecting fimA expression in Salmonella typhimurium. J. Bacteriol. 174:7697-7704[Abstract].
 - 42. **Travers, A. A.** 1984. Conserved features of coordinately regulated *E. coli* promoters. Nucleic Acids Res. 12:2605-2618[Abstract].
 - 43. Travers, A. A. 1980. Promoter sequence for stringent control of bacterial ribonucleic acid synthesis. J. Bacteriol. 141:973-976[Medline].

J Bacteriol, February 1998, p. 840-845, Vol. 180, No. 4 0021-9193/98/\$04.00+0

Copyright © 1998, American Society for Microbiology. All rights reserved.

This article has been cited by other articles:

- Edwards, R. A., Matlock, B. C., Heffernan, B. J., Maloy, S. R. (2001). Genomic analysis and growth-phase-dependent regulation of the SEF14 fimbriae of Salmonella enterica serovar Enteritidis. *Microbiology* 147: 2705-2715 [Abstract] [Full Text]
- Tinker, J. K., Hancox, L. S., Clegg, S. (2001). FimW Is a Negative Regulator Affecting Type 1 Fimbrial Expression in Salmonella enterica Serovar Typhimurium. *J. Bacteriol*. 183: 435-442 [Abstract] [Full Text]
- Tinker, J. K., Clegg, S. (2000). Characterization of FimY as a Coactivator of Type 1 Fimbrial Expression in Salmonella enterica Serovar Typhimurium. *Infect. Immun.* 68: 3305-3313 [Abstract] [Full Text]
- Julio, S. M., Heithoff, D. M., Mahan, M. J. (2000). ssrA (tmRNA) Plays a Role in Salmonella enterica Serovar Typhimurium Pathogenesis. *J. Bacteriol.* 182: 1558-1563 [Abstract] [Full Text]

- ▶ Abstract of this Article
- Reprint (PDF) Version of this Article
- Similar articles found in:
 - JB Online
 - <u>PubMed</u>
- PubMed Citation
- ▶ This Article has been cited by:
- ▶ Search Medline for articles by: Clouthier, S. C. || Kay, W. W.
- Alert me when:
 - new articles cite this article
- Download to Citation Manager
- ▶ Books from ASM Press

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Appl. Environ. Microbiol.

Infect. Immun.
J. Virol.

Eukaryot. Cell

Mol. Cell. Biol.

Microbiol. Mol. Biol. Rev.

ALL ASM JOURNALS